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ABSTRACT 
Poly(ADP-ribose) polymerase (PADPRP) is a nuclear enzyme with a well documented 
role in DNA repair. Inhibitors of P ADPRP, (e.g. 3' substituted benzamides) potentiate the 
cytotoxicity of a wide range of antitumour drugs. The results presented in this thesis 
represent, to the best of my knowledge, the first comprehensive and quantitative 
assessment of the ability of a range of P ADPRP inhibitors to modulate the cellular 
responses to damaging agents. Two novel PADPRP inhibitors, 8-hydroxy-~-methyl 
quinazolin-4(3H)-one (NU1025) and 3,4 dihydro-5-methoxyisoquinolin-1-(2H)-one (PD 
128763) were compared with two "classical" PADPRP inhibitors, 3-aminobenzamide 
(3AB) and benzamide (BZ). The relative potencies for 3AB, BZ, NU1025 and PD 
128763 as PADPRP inhibitors in vitro were 1.0, ~1.0, ~43 and ~53 respectively. All 
compounds potentiated the growth inhibition and cytotoxicity of the monofunctional 
alkylating agent temozolomide (TM) in L1210 cells. For example, 10/-lM NUI025 and 
PD 128763 gave dose enhancement factors (DEF) of ~2 at 100/0 survival, whereas ImM 
3AB and 0.5mM BZ where required to give similar DEF values. Cellular NADl- levels 
were depleted up to 50% by 1-2mM TM and this depletion was completely prevented by 
coincubation with 50-100JlM PD 128763 and 1-3mM 3AB. TM induced DNA single 
strand break levels were increased in a concentration dependent manner by the P ADPRP 
inhibitors. Overall, the relative potencies for ability of the compounds to potentiate TM 
induced growth inhibition, cytotoxicity and DNA single strand breaks showed good 
correlation with those determined in an in vitro inhibition study, with both NU 1 025 and 
PD 128763 exhibiting ~60 fold increased inhibitory activity as compared to 3AB. The 
P ADPRP inhibitors per se did not effect the growth or survival of the L 121 0 cells, nor 
increase DNA strand breakage. 
NAD+ is the substrate for PADPRP. A L1210 cell line made resistant to tiazofurin (TZ) 
utilising a step wise selection protocol \\'as sho\\'n to he deficient in nicotinamiJc 
mononucleotide adenyl transferase (N:v1NAT) , the final enzyme required for :-;AD-
biosynthesis. The consequences of a reduced NMNAT activity «3% of the parental line ) 
and an ~40% reduction in intracellular NAD+ levels were determined. The resistant cells 
showed an ~3 fold increased sensitivity to TM as compared to the parental cells. Upon 
coincubation with increasing concentrations of NU 1 025 in the presence of a fixed 
concentration of TM, growth inhibition was potentiated ~ 70 fold in the resistant cells but 
only ~ 1 0 fold in the parental cell line, demonstrating the reduced level of competition 
between NAD+ and NUI025 for PADPRP. However, DNA single strand breaks were 
increased in the resistant compared to the parental cell line only when NU 1025 was 
coincubated with TM. In contrast, in the presence of the PADPRP inhibitors alone, 
equivalent growth inhibitory effects were observed in each of the cell lines, suggesting 
inhibition of PADPRP was not the cytotoxic effector. The -400/0 NAD+ depletion 
observed could therefore suggest, that NAD+ levels in the resistant cells were reduced to, 
or near to the KmNAD+ for PADPRP. 
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CHAPTER 1 INTRODUCTION 
1.1 CELLULAR NAD+ METABOLISM 
1.1.1 Introduction 
In mammals, the synthesis of the pyridine nucleotide, nicotinamide adenine dinucleotide 
(NAD+) occurs via three pathways, a de novo pathway in addition to two salyage 
pathways (see Figure 1.1). The de novo synthesis occurs solely in the liver and kidney 
cells, and utilises the essential amino acid, tryptophan. The tryptophan is degraded to 
quinolinate, which then accepts a phosphoribosyl group from PRPP to form nicotinate 
mononucleotide. This reaction is catalysed by quinolinate phosphoribosyl transferase. The 
AMP moiety from A TP is then linked to nicotinate mononucleotide by means of a 
pyrophosphate linkage to form nicotinate adenine dinucleotide. This is catalysed by NAD+ 
pyrophosphorylase [EC.2.7.7.1], which is also referred to as nicotinamide mononucleotide 
adenylyl transferase (NMNAT), and will be thus designated in this thesis. The final step 
of the pathway converts the nicotinate adenine dinucleotide to NAD+ via a transamidation 
reaction with glutamine acting as the NH2 donor. 
The first salvage pathway involves the phosphoribosylation of nicotinate (niacin/vitamin 
B3) to nicotinate mononucleotide via nicotinate phosphoribosyl transferase, which is then 
converted to NAD+ as described above. The second salvage pathway originates with 
nicotinamide. Following phosphoribosylation, the nicotinamide mononucleotide (NMN) 
formed is converted directly to NAD+ by the transfer of an AMP moiety from A TP. This 
reaction, catalysed by NMNAT, was identified in 1950 by Kornberg and co-workers. 
Mammalian cells in both in vitro and in rivo situations utilise nicotinamide salvage as 
their main source for NAD+ biosynthesis (Olsson et ai, 1993). In mammals only liver anJ 
kidney cells are capable of utilising the de novo pathway (Ikeda et ai, 1965). However, 
a diet lacking any of the three starting compounds, tryptophan, niacin or nicotinamide 
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Figure 1.1: The biosynthetic pathways of NAD+ and NADP+ 
(Voet & Voet, 1990). 
leads to the deficiency disorder. pellagra with symptoms including dennatosis, especially 
in areas exposed to the sun, and in cases of profound deficiency, encephalopathy 
resembling the Wemicke-Korsakoff syndrome (disorder of the CNS caused by abusive 
alcohol intake and nutritional depletion resulting in paralysis of the eye muscles. the 
inability to stand and an eventual derangement of mental functions) (Hendricks. 1991). 
Initially, the function of NAD+ was exclusively considered to be as an electron carrier 
in the metabolic reactions of the cell, particularly oxidative phosphorylation. These 
reactions are all situated in the cytoplasm and mitochondria. Consequently. the 
identification of NMNAT as a nuclear enzyme denoted the possibility of additional roles 
for NAD+, with over 90% of the total activity located in the nucleus (Hogeboom & 
Schneider, 1952). The rate of NAD+ synthesis and degradation was calculated utilising 
a double-label pulse-chase technique. C4C] Adenine and [3H] nicotinic acid were used to 
label the pyridine nucleotides, but as NAD+ breakdown occurred faster than that of the 
ATP pool, the overall rate of loss of [14C] adenine from the NAD+ was calculated as a 
balance between the rate of NAD+ breakdown and the rate of re-entry of C4C] adenine 
from the ATP pool. The rate of NAD+ synthesis was found to be -25-fold greater than 
that required to maintain exponential cell growth (Haines et aI, 1969; Rechsteiner et aI, 
1975). However, a compensatory rate of NAD+ bio-degradation was observed, and 
estimations have indicated that 95% of the NAD+ synthesised replaces that catabolized, 
with only 5% required to maintain the pool size required for growth (Rechsteiner et aI, 
1976). 
1.1.2 NAD+ metabolism and the role of Poly(ADP-ribose) Polymerase. 
Poly(ADP-ribose) polymerase (PADPRP) [EC 2.4.2.30] is a nuclear enzyme that utilises 
NAD+ as its substrate to form homopolymers of ADP-ribose (see Sections 1.2 and 1.5 for 
detailed literature reviews on PADPRP enzymology and function). The activation of 
PADPRP via DNA strand breaks reduces the half-life of the (ADP-ribose) polymer from 
2 
minutes to seconds with a concomitant increase in the consumption of the cellular ~AD· 
pool. In fact, PADPRP activity is considered the major cellular function responsible for 
the high rate ofNAD+ degradation. Therefore, the positive correlation between N!\r\.-\ T 
activity and the cellular NAD+ content (Haines, 1969), coupled together with the 
activation of P ADPRP and the subsequent decrease in the NAD- levels, indicates the 
biosynthesis and degradation of cellular NAD+ to be a unique nuclear process. with 
control over the cellular NAD+ supply. The post-translational modification of nuclear 
proteins by (ADP-ribose) polymers has been observed to modulate their actiyity or 
function (see Section 1.2.6). A report by Ruggieri and colleagues (1988), who purified 
NMNAT from yeast, suggested that a possible modification of the NMNA T by 
poly(ADP-ribose) resulted in an inhibition of enzyme activity. Utilising fast protein liquid 
chromatography (FPLC) on a highly purified NMNAT preparation, three protein peaks 
were isolated in addition to the enzymatically active peak. Each of the three peaks 
contained 3-4 moles of adenine derivatives, and were proposed as inactive modified forms 
of the NMNAT. Although the existence of P ADPRP has yet to be substantiated in yeast, 
Ruggieri showed an incorporation of [3H] adenine into acid precipitable material that was 
prevented in the presence of the P ADPRP inhibitor, benzamide (BZ). 
1.2 POLY(ADP-RIBOSE) POLYMERASE 
1.2.1 General introduction 
Poly(ADP-ribose) polymerase, (PADPRP), (EC.2.4.2.30), is a unique enzyme found in 
the nuclei of eukaryotic cells, although several terminally differentiated cells were found 
to lack P ADPRP activity, including mature granulocytes (Ikai et ai, 1980a & b), mature 
erythrocytes (N ishizuka et ai 1967) and intestinal epithelial cells (Porteous & Pearson, 
1982). Initially in 1956, Roitt demonstrated that after the treatment of ascites tumour cells 
with a cytotoxic agent, glycolysis was inhibited with a concomitant increase in the 
catabolism ofNAD+. This was inexplainable by NADase action alone. Several years later 
in the course of RNA polymerase research, :"landel and co-workers (Chambon c{ al. 
1963) detected the presence of a new polymer formed from the adenYlic moiety of A TP. 
. . 
synthesised by an enzyme dependent on DNA. and in response to added N~l~. Thl? 
polymer was at first thought to be poly (A), but later evidence indicated a novel polymer 
consisting of ADP-ribose units. The utilisation of radiolabelled NMN and ATP shO\\"ed 
that both the ribose and phosphate groups of NMN. as well as the adenylic moiety of 
ATP were incorporated into the polymer. Both NMN and ATP are precursors for N:\O " 
The addition of unlabelled N AD+ reduced the incorporation of NMN and A TP indicating 
NAD+ to be the substrate for PADPRP (Chambon et aI, 1966). 
PADPRP is dependent upon, and activated by, breaks in the DNA strands (Janakideveh 
& Koh, 1974; Miller, 1975; Halldorsson et al. 1978; Benjamin & Gill. 1980). The 
activation of PADPRP results in the formation of (ADP-ribose) homopolymers that are 
covalently added to itself (automodification), and to proteins involved in nuclear 
organisation and biosynthetic reactions, e.g. histone proteins, topoisomerase I. DNA ligase 
II, RNA polymerase (heteromodification) (see Section 1.2.6 for details). This post-
translational modification is totally dependent on breaks in double stranded DNA. An 
increased activation of PADPRP, represented by an increase in poly(ADP-ribose) 
synthesis was observed after treatment of DNA with DNase I (Janakidevi & Koh. 1974: 
Miller, 1975). Gill et af (1974), then showed the nucleotide sequence of the DNA to have 
little or no importance, but that the shearing of the DNA increased the activity of 
PAD PRP, approximately in proportion to the number of strand breaks. The effectiveness 
of different break ends was analysed utilising purified calf-thymus PADPRP in the 
presence of either covalently closed plasmid, or plasmid digested with restriction enzymes 
producing different end structures. It was found that double strand breaks with flush ends 
were most effective at initiating (ADP-ribose) polymer synthesis, followed by breaks with 
3'overhangs, then breaks with 5'overhangs and single stranded breaks (Benjamin & Gill. 
1980). 
P ADPRP function appears to be an important regulatory mechanism of the cell. 
Therefore this Chapter will aim to review the literature characterising the structure of 
both the P ADPRP and its polymer, and provide an account of the proposed roles the 
enzyme plays within the cell. 
1.2.2 Cellular distribution of P ADPRP 
P ADPRP is a basic, non-histone protein comprised of a single polypeptide chain. and 
is tightly associated with the chromatin. Early evidence implicated P ADPRP with 
transcriptionally active regions of the chromatin (Mullins et ai, 1977) and (ADP-ribose) 
polymer has since been located in these regions, although not exclusively (Hough & 
Smulson, 1984). The basic repeat unit of chromatin is the nucleosome, consisting of 
~ 200bp of DNA, in association with an octomeric core of histone proteins 
(H2A,H2B,H3,H4)2· The length of DNA wrapped around the core particle is 140bp with 
the remainder comprising the "linker DNA", joining the nucleosomes together. 8-10 
nucleosomes are organised into the subsequent level of the higher ordered chromatin 
structure (Stratling et ai, 1978). Histone HI is located at the site of DNA entry/exit into 
the core structure. Interaction of histone HI with both the linker DNA (C-terminus) and 
the core histones (N-terminus) provides possible intemucleosomal crosslinks which 
stabilise higher ordered chromatin structure (see Figure 1.2) (Worcel & Benyajati, 1977). 
PADPRP is located in the intemucleosomal linker region (Mullins et ai, 1977; Butt et 
ai, 1978; Giri et ai, 1978). In the absence of DNA breaks, P ADPRP was observed to bind 
to superhelical DNA. The binding of P ADPRP to two distinct DNA strands results in the 
formation of looped structures (Gradwohl et ai, 1987). Under such circumstances, 
P ADPRP could compete for the same binding sites as histone HI but upon introduction 
of a break, histone HI, due to preferential poly(ADP-ribosyl)ation would detach from the' 
chromatin. so allowing PADPRP access to these binding sites. ThC' migration rate of a 
5 
139bp fragment of plasmid DNA, containing a single strand break was found to be 
retarded in comparison to an intact fragment. Visualisation of the break-containin 
'-' 
fragments by electron microscope identified "V"-like structures. The intact fragment 
.showed no curvature. Incubation of P ADPRP with the nicked fragments isualised the 
P ADPRP bound to the "V" shaped conformation, corresponding to the position of the 
break (Le Cam et aI, 1994). 
Figure 1.2 A model to show the role of the three domains of histone HI in nucleosome 
and higher order chromatin structure (Boulikas, 1993) 
Higher order chromatin structure also influences P ADPRP activity. Enzyme acti ity 
increased until a structure containing 8 nucleosomes was reached then, any further 
increase in the number of nucleosomes resulted in a decreased P ADPRP acti ity (Butt el 
aI, 1978). The increasing compactness of the chromatin structur rna constrain th ace 
of P ADPRP to the acceptor proteins. 
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Chromatin structure is an important component of P ADPRP activity and will b~ 
discussed further in Sections I.2.5b and 1.5. 
1.2.3 Structural analysis of P ADPRP 
1.2.3a Introduction 
With the advent of molecular biology techniques, a detailed analysis of the structure and 
function of PADPRP at the molecular level has been achieved. A full length eDNA for 
the human PADPRP, of 3.6-3. 7Kb, was initially cloned by Alkatib et al (1987) utilising 
immunologically detected poly(ADP-ribose) polymerase from a human hepatoma ,,-gtll 
genomic expression library. The expression of the cDNA identified a nucleotide sequence 
possessing a single, 3042 base, open reading frame (Cherney et ai, 1987; Uchida et ai, 
1987). This translates into a protein consisting of 1014 amino acids with a predicted 
molecular weight of 1 13KDa. The modern biochemical technique for the overproduction 
and large-scale purification of PADPRP utilises a bacculovirus expression system in 
insect cells. The co-transfection of a strong bacculoviral promoter of the AcNPV 
bacculovirus to express P ADPRP cDNA, together with the plasmid p VL 1392, which 
allows the higher expression of foreign protein, into Sf9 cells, resulted in the large scale 
synthesis of PADPRP (Giner et ai, 1992). 
The PADPRP gene is 43Kb in length and is divided into 23 exons (Potvin et ai, 1993). 
Chromosomal mapping initially located the active P ADPRP gene to chromosome 1 with 
pseudogenes (i.e. non-translated DNA), present on chromosomes 13 and I·t (Cherney et 
ai, 1987). Fluorescence in situ mapping confirmed these chromosome locations with 
specific assignments of the P ADPRP gene to 1 q42 and the pseudogenes to 13q34 and 
14q24 (Baumgartner et aI, 1992). The P ADPRP gene is considered a member of the 
"housekeeping" genes which are continuously expressed in most tissue. rhe 
characterisation of the 5'flanking region of the PADPRP gene revealed conscncJ 
sequences homologous with the 5' regions of other housekeeping genes (Ogura ('/ ai, 
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1990; Potvin et ai, 1993; Oei et ai, 1994) including multiple transcriptional initiation 
sites, CCAA T and T AA T promoters located approximately 500bp upstream of the 
initiation CAP site, and two potential palindromic sequences which Oei et al (1994) 
postulated would facilitate transcriptional activation and could also be involved in 
transcriptional autoregulation. 
Kameshita et al (1984), first demonstrated the presence of three functional domains 
within the PADPRP protein. Using specific protease digestion of the purified protein. a 
46KDa NH2-terminal domain possessing DNA binding properties was isolated, together 
with a 54KDa NAD+ binding domain, located at the COOH-terrninus of the protein. 
Separating the two domains was a 22KDa domain associated with auto(ADP-ribosyl)ation 
(see Figure 1.3). 
Initial sequence alignment studies indicated PADPRP to be a sub-family member of the 
DNAINAD binding proteins. 3D protein predictions suggested the presence of conserved 
structural motifs in each of the domains. These will be described in the following 
Sections. 
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Figure 1.3 Schematic representation of:- A. the three functional domains of P ADPRP; 
and B. the primary structure of the Zn + fingers (Molinete et aI, 1993). 
1.2.3b The DNA binding domain 
Energy dispersive X-ray fluorescence determined that P ADPRP contained two molecules 
of Zn2+ (Mazen et aI, 1989). Analyses utilising radiolabelled Zn2+ and Western blots 
together with the examination of the PADPRP sequence, identified two Zn2+-finger 
structures in the 29KDa region closest to the amino terminal (see Figure 1.3). A 
molecule of Zn2+ bound to each finger was essential for activity (Mazen et al 1989). Zn2.f 
fingers are DNA sequence motifs used for recognition and binding to the DNA. Utilising 
ite-directed mutagenesis and footprint analysis, the finger structures were obs rved to 
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bind differentially to single and double stranded DNA breaks (Gradwohl et al. 1990~ 
Ikejima et ai, 1990), with a symmetrical protection pattern of 7±1 nucleotides around a 
single break. This was suggestive of P ADPRP dimerisation. There was no recognition of 
specific sequences by the P ADPRP Zn2+ fingers as observed with other described finger 
structures, e.g. transcription factor IlIa (Menissier-de Murcia et al. 1989). Other obserYeJ 
structural differences of the Zn2+ fingers for P ADPRP were, the unusual ligand binding 
of the Zn2+ to the amino acids, and the formation of larger finger structures, both of 
which could be related to the different recognition system. i.e. DNA strand breaks. 
Downstream of this 29KDa region, two lysine rich clusters and a helix-tum-helix motif, 
suggestive of DNA binding, have been located (Ikejima et al. 1990). Non-specific 
interactions between the DNA and such sequences could conceivably keep any 
unactivated P ADPRP associated with the DNA. 
A further structure elucidated in the DNA binding domain was a bipartite nuclear 
location signal (NLS), consisting of two basic amino acid clusters (Schreiber et ai, 1992) 
(see Figure 1.3). NLS directs proteins involved in the management of the nucleus from 
the cytoplasm, where they are translated, back to the nucleus. 
1.2.3c The NAD+ binding domain 
This 54KDa domain possesses four autonomous catalytic activities, initiation and 
elongation of the polymer. a branching activity plus a glycohydrolaselNADase associated 
activity (Thibodeau et ai, 1989; Simonin et ai, 1993b). The domain shows a high level 
of interspecies sequence conservation, and initial alignment studies proposed the presence 
of an NTP-binding motif, GKG (Huppi et ai, 1989; Thibodeau et ai, 1989). Recent 
evidence has suggested a sequence homology between PADPRP and the NAD+ dependent 
amino acid dehydrogenase enzymes (AADH) (Simonin et al. 1990). Site-directed 
mutagenesis of PADPRP demonstrated that the residue. lysines93 and a potential p-a-p 
fold located at the domain terminal to be essential for activity (Simonin et ai. 1990 & 
1993a), both in accordance with the AADH enzymes. The crystal of the NAD+ -binding 
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Figure 1.4 Schematic diagram to show the possible dimerisation models of P ADPRP 
(Uchida et ai, 1993b). 
1.2.4 The poly(ADP-ribose) polymer 
1.2.4a Substrate specificity 
Unlike the majority ~f NAD+ -dependent enzymes, P ADPRP utilises the pyridine 
dinucleotide, NAD+ as a substrate, rather than for the transfer of electrons. The adenosine 
diphosphate ribose moiety ofNAD+ is used to form the homopolymer. poly(ADP-ribose), 
Other analogues of NAD+, e.g. NADP(H) and desamido NAD+ are unable to be 
substituted. and aNAD+ acts as a potent inhibitor of the enzyme (PNAD+ is the naturally 
12 
occuring form). 
The physiological concentration of NAD+ within the cell is generally between 100-
1000/-lM (Shall, 1984). The estimated K",NAD for PADPRP is -50/-lM (Ueda et ai, 1982). 
but as DNA and protein acceptor interactions must be considered. accurate determinations 
prove difficult. 
1.2.4b Research techniques for the characterisation of (ADP-ribose) polymer 
The characterisation of poly(ADP-ribose) in intact cells is complicated by the inability 
ofNAD+ to permeate the cell membrane, and although (ADP-ribose) polymer is classified 
as the third nucleic acid, the natural content in most tissues has been calculated to be just 
3-30ng/mg DNA (Minaga et ai, 1979). This led to the utilisation of labelled NAD+ e.g. 
[
32p] NAD+, [Adenine 14C]NAD+, to characterise (ADP-ribose) polymer formed in an in 
vitro situation (Miwa et ai, 1979; Ikejima et ai, 1987; Naegelli et ai, 1989; Keith et ai, 
1990; Naegelli & Althaus, 1991), or the use of chloroacetaldehyde, which when incubated 
with the nucleosides of hydrolysed polymer (see later in this Section) created the unique 
fluorescent compound 1,N'-ethenoribosyl-adenosine (Sims et ai, 1982; Sims et ai, 1983; 
Jacobson et ai, 1983; Alvarez-Gonzalez & Althaus, 1989). Wielckens et al (1982) also 
utilised [2,8,5,-3H] ATP as an in vitro label of (ADP-ribose) polymer. However, [3H] 
adenosine and [3H] adenine were utilised in in vivo labelling procedures by Tanuma & 
Johnson (1983) and Alvarez-Gonzalez & Jacobson (1987) respectively. A problem 
encountered with in vivo labelling of the NAD+ pool, was the achievement of a 
sufficiently high specific activity, and the selectivity of labelling, as the adenine 
derivative used could also be incorporated into RNA and DNA, which then contaminated 
the (ADP-ribose)n. The separation of the polymer from such contaminants was performed 
using dihydroxyboryl affinity chromatography (Wielckens et ai, 1981). Utilising 
dihydroxyboronate biorex 70 resin, a mixed resin of boron ate and carboxylate groups, the 
(ADP-ribose) polymers are selectively bound due to the presence of vicinal 1,2 cis-diol 
groups on the ribose moiety. DNA and RNA possess just a single hydroxyl group. and 
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hence are unable to bind. Polymers are removed by labilisation of the cyclic boronate 
ester bonds, which allows charge repulsion between the carboxylic groups in the resin and 
the phosphate groups on the polymer. 
Hydrolysis of the purified (ADP-ribose) polymer with snake venom phosphodiesterase 
yields three products; AMP, which is the terminal residue of the polymer chain. PR-
AMP, which forms the internal polymeric residues, and (PR)2 AMP is the residue located 
at the branch points of the polymer (Miwa et ai, 1979) (see Figure 1.5). A further 
assessment of the PR-AMP fraction can be performed using alkaline phosphatase. creating 
ribosyl adenosine (reviewed in Shall, 1984) . 
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Figure 1.5 The hydrolysis products of poly(ADP-ribose) resulting from treatment with 
phosphodiesterase (de Murcia et al. 1991). 
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Several techniques have been used to assess the quantity of each hydrolate fraction. 
thereby determining the initial polymer level. High pressure liquid chromatography 
(HPLC) is used for the quantification of both radiolabelled and fluorescent residues 
(Jacobson et ai, 1983; Sims et ai, 1982; Sims et ai. 1983; Alvarez-Gonzalez & Jacobson. 
1987; Naegelli et ai, 1989; Naegelli & Althaus, 1991; Kiehlbauch et aI, 1993). Poly-
acrylamide gel electrophoresis provides an excellent, high resolution. anal)1ical tool for 
determining the sizes of the fractionated polymer (Panzeter & Althaus, 1990). The small 
fragments are observed well resolved, but multibranched polymers fail to enter the gel. 
However, their extraction from the gel allows further characterisation (Alvarez-Gonzalez 
& Jacobson, 1987; Naegelli et ai, 1989; Naegelli & Althaus, 1991: Kiehlbauch et al. 
1993). 
1.2.4c Formation and structure of the ADP-ribose polymer 
The first ADP-ribose residue of the polymer is bound covalently to an acceptor protein 
e.g. PADPRP, histone HI, via an alkali labile ester bond, formed between the terminal 
ribose residue and a carboxyl group of the protein, usually a glutamate or lysine residue. 
The generation of a linear polymer of ADP-ribose units ensues, linked via a( l' -2") 
glycosidic bonds (see Figure 1.6). The structure formed resembles the secondary helical 
structure of single stranded DNA (Minaga & Kun, 1983). Branch points within the 
polymer, linked by 1 111_2" glycoside bonds were isolated by Miwa et ai (1979), with an 
estimated frequency of one branch point every 40-50 ADP-ribose residues (Alvarez-
Gonzalez & Jacobson, 1987; Keith et ai, 1990). Overall, polymers containing up to 200 
residues with multiple branch points have been isolated in vitro and in cultured cell 
systems (Alvarez-Gonzalez & Jacobson, 1987; Kiehlbauch et ai, 1993). The size of the 
polymer formed is dependent upon the experimental conditions. as is the polymer half-
life. Alvarez-Gonzalez & Althaus (1989) monitored the degradation pattern ofpoly(ADP-
ribose) by poly(ADP-ribose) glycohydrolase [EC.3.2.1.-] (see Section 1.2.5e) in intact 
cells, utilising the PADPRP inhibitor. 3-aminobenzarnide to prevent additional polymer 
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Figure 1.6: The chemistry of poly(ADP-ribose), and the enzymes involved in its 
synthesis and degradation (Boulikas, 1993). 
synthesis. Polymer levels were determined utilising the fluorescent derivative protocol 
(see Section 1.2.5b). The degradation of (ADP-ribose) polymer was observed to be 
biphasic. The initial 60% of the polymer degraded with a tl/2 of 6 minutes, and the 
remaining polymer had a t1/2 of 7.7 hours. Treatment of intact cells with an alkylating 
agent, e.g. MNNG or UV irradiation, reduced the tll2 to less than 1 minute, although the 
dose administered was found to affect the rate of degradation. The greater the polymer 
synthesis, the faster the initial catabolism (see Section 1.2.5e)(Alvarez-Gonzalez & 
Althaus, 1989). 
1.2.4d Polymer elongation 
Two possible modes of polymer elongation have been proposed (see Figure 1.7): 
1. Proximal addition would involve the transfer of an existing polymer, bound to a site 
on the PADPRP, to an ADP-ribose moiety bound at an adjacent site. Alternation between 
the two sites would result in polymer elongation (Ikejima et ai, 1987). This proposal 
suggests an intramolecular reaction, with only completed polymer chains being transferred 
to the acceptor proteins. 2. Polymerisation via the distal mechanism requires the addition 
of ADP-ribose residues to the l' -OH terminal ribose residue of a polymer chain attached 
to the acceptor protein. An intermolecular reaction, with two enzyme molecules forming 
the polymer simultaneously has been proposed. 
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Figure 1.7 Two possible mechanisms of poly(ADP-ribose) chain elongation (Ikejima et 
ai, 1987). 
1.2.4e Polymer size patterns 
NaegeUi et al reported in 1989, that in a reconstituted in vitro system, specific polymer 
patterns were formed processively in both the auto- and heteromodification reactions. 
Identification procedures involved the purification by boronate affinity chromatography, 
followed by digestion with snake venom phosphodiesterase, and either HPLC or PAGE 
separation (see Section 1.2.5b). The histone proteins, already known to be ADP-
ribosylated, were now identified as possessing individual patterns of polymerisation. Also, 
observations indicated. that the configuration of polymer formed during the 
automodification of purified P ADPRP to be dissimilar to that found when in the presence 
of histone (automodification reaction - polymer sizes ranged from 15-18 residues up to 
>45 residues, the histone proteins - polymer sizes ranged from 5 residues to >45 residues, 
\\lith most observed between 25-45 residues). The most potent regulator was histone HI 
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which appeared to modulate the termination reaction (Naegelli & Althaus. 1991). These 
elegant experiments raise questions concerning the role of histones in the regulation and 
modification of PADPRP. 
1.2.4f Degradation of poly(ADP-ribose) 
The rapid turnover of poly(ADP-ribose) recorded within the cell, especially after DNA. 
damage, requires the consecutive action of poly(ADP-ribose) gycohydrolase and A.DP-
ribosyl protein lyase. 
PolyCADP-ribose) glycohydrolase 
Poly(ADP-ribose) glycohydrolase is a 71KDa, monomeric protein (Uchida et ai, 1993a) 
which is the major enzyme involved in the degradation of poly(ADP-ribose) (Hatakeyama 
et ai, 1986). The enzyme hydrolyses the ribosyl-ribose bonds, from the adenosine 
terminus of both the linear and branched portions of the polymer, in an exoglycosydic 
manner (see Figure 1.8) (Miwa et ai, 1974). Monomers of ADP-ribose are released from 
the distal terminus. Endoglycosidic degradation occurs on large, branched polymers 
(Braun et ai, 1994; Brochu et ai, 1994). Known inhibitors include ADP-ribose, cyclic 
3'5" monophosphate, histones (Tavassoli et ai, 1983), and the recently identified potent 
inhibitors, the nobotanins B, E and K (Tsai et ai, 1992; Aoki et ai, 1993). 
A biphasic mode of action for the glycohydrolase has been suggested (Wielckens et ai, 
1982; Hatakeyama et ai, 1986) with ADP-ribose monomers liberated in a processive 
manner by the sequential degradation of the polymer branches. Degradation of the 
remaining oligomer core was distributive, i.e. collective degradation of the polymers. 
However, Braun et al (1994) recently demonstrated three degradative mechanisms:- 1. 
endoglycosidic cleavage, 2. endoglycosidic cleavage with exoglycosidic, processive 
degradation, and 3. exoglycosidic distributive degradation. The secondary structure 0 f the 
polymer, which occurs after the linkage of -9 ADP-ribose units could influence the 
glycohydrolase activity. In "itro studies demonstrated that large polymers, generally 
associated with automodified PADPRP. were preferentially degraded. with a K", 100-fo1J 
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lower than the ~ calculated for the oligomers (Hatakeyama et aI, 1986). 
ADP-ribosyl protein lyase 
ADP-ribosyl protein lyase specifically cleaves the proximal ADP-ribose unit attached to 
the acceptor protein. This forms the rate determining step of ADP-ribosylation turnover 
reactions (Ueda et ai, 1985) (see Figure 1.8). 
ADP-ribosyl Protein 
Lyase 
Figure 1.8 Mode of poly(ADP-ribose) degradation (Ueda et ai, 1985). 
1.2.5 Acceptors of PoJy(ADP-ribose) 
1.2.5a Introduction 
The major acceptor for the (ADP-ribose) polymer is PADPRP itself, as was described 
in Section 1.2.4d. However, a large number of nuclear proteins have been identified in 
vitro as acceptors of the ADP-ribose polymer, with several also characterised in intact 
cells. Caution is required in extrapolating from in vitro to intact cell data, otherwise a 
distinct impression could occur that any nuclear protein possessed the potential to be 
modified. 
The modified proteins, are either structurally or enzymatically connected with the 
biochemical processes suggested for P ADPRP. and are capable of interacting with the 
DNA. ADP-ribosylation increases the molecular weight and the charge of the protein 
which could enormously influence both the conformation of the protein and its cellular 
activity. As has been described. the main acceptor for poly(ADP-ribose) is PADPRP itself 
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I.2.Sb Histone 
Poly(ADP-ribosyl)ation of all histone proteins has been observed in .... ·itro (Thi \ Ian & 
Shall, 1982; Huletsky et ai, 1989; Thibeault et ai, 1992) but only histone HI and H2B 
are known to be modified in vivo (Adamietz & Rudolph, 1984). Histone HI is the second 
major acceptor of ADP-ribose polymers, and upon modification, a decondensation of the 
nucleosomal structure was observed utilising electron microscopy (Poirier et al. 1982b; 
Neidergang et ai, 1985; De Murcia et ai, 1986). Subsequent treatment with poly(ADP-
ribose) glycohydrolase resulted in the rapid renaturation of nucleosomal structure, which 
suggested that histone HI did not dissociate entirely from the nucleosomes (Poirier et ai, 
1982; Aubin et ai, 1983; De Murcia et ai, 1986). The dimerisation of histone HI, linked 
by an ADP-ribose polymer was initially thought to be formed during hypermodification. 
However, as the action of glycohydrolase is exoglycosidic, this concept becomes highly 
doubtful, and a more conceivable proposal would involve the repulsion of modified 
histone HI due to an increased negative charge (De Murcia et ai, 1986). In vitro evidence 
has suggested that after HI modification, H2A and H2B become the main acceptors 
(Adamietz & Rudolph, 1984). Antibody studies have shown a destabilisation of core 
histones after modification and this may also sterically hinder recondensation (Mathis & 
Althaus, 1987; Huletsky et ai, 1989; Thibeault et ai, 1992). 
The effect of poly(ADP-ribosyl)ated histones has been predicted as an early event of the 
DNA metabolic processes to allow enzymes access to damaged sites on DNA 
(Neidergang et ai, 1985). The implications of histone modification within the DNA repair 
context will be discussed in Section 1.5. 
I.2.Se Nuclear matrix 
The nuclear matrix consists of a network of proteinaceous fibres, and is thought to 
provide the structural framework for interphase nuclei. Experimental evidence has 
indicated the dynamic involvement of the matrix in chromatin replication, repair and 
transcription (Pardoll et ai, 1980). 
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A number of groups, utilising both in vitro and intact cell techniques, have identified a 
large range of nuclear proteins modified by poly(ADP-ribose) (Weisierka-Gadek & 
Sauermann, 1985; Singh et ai, 1985; Adolph & Song, 1985a & b; Adolph, 1987; 
Cardenas-Corona et ai, 1987; Pedraza-Reyes & Alvarez-Gonzalez, 1990). The 
modification was preventable in the presence of P ADPRP inhibitors. In all cases. 
modified proteins between 60-70KDa were observed, and Pedraza-Reyes & Ah'arez-
Gonzalez, 1990) suggested these to be the lamins. The lamins are the most abundant 
proteins found in the nuclear matrix. The use of 3'dNAD-, an analogue of NAD+ 
recognised by P ADPRP, but from which oligomers of only four residues can be formed, 
demonstrated covalent interactions between the lamins and poly(ADP-ribose) (Pedraza-
Reyes & Alvarez-Gonzalez, 1990). 
1.2.Sd High mobility group proteins (HMG proteins) 
HMG proteins are basic, low molecular weight proteins that are loosely associated with 
the chromatin. Several in vitro reports of HMG-proteins modified by poly(ADP-
ribosyl)ation have been published (Poirier et ai, 1982a; Tanuma et ai, 1983). An intact 
cell study, showed a small fraction of HMG proteins to be ADP-ribosylated. with 
different levels of modification for each protein type. P ADPRP inhibitors prevented this 
modification (Tanuma & Johnson, 1983a). The association ofHMG proteins with actively 
transcribed genes has been suggested, especially HMG 14 & 17, thought to be responsible 
for the DNase I sensitivity of active chromatin (Einck & Bustin 1985). 
1.2.Se Topoisomerase I 
The topoisomerases are ubiquitous nuclear enzymes of eukaryotes that catalyse the 
concerted breakage and rejoining of phosphodiester bonds within the DNA, so altering 
topological conformation (reviewed in Wang, 1987). 
In 1983, Jongstra-Bilen et ai, and Ferro et at. individually published evidence to show 
the co-purification of a topoisomerase I with calf-thymus PADPRP. The activity of the 
topoisomerase \vas inhibited in the presence of NAD+. and in this inhibited state was 
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found to be modified by ADP-ribose polymers (Jongstra-Bilen et al. 1983; Ferro et lit. 
1983). Purified topoisomerase I also acts as an acceptor for polymer resulting in an 
inhibition of activity (Ferro & Olivera, 1984). Observations suggested complex formation 
is reversibly inhibited with a repulsion reaction similar to the automodification of 
P ADPRP. In vivo data supportive of such a theory indicates topoisomerase bound to 
chromatin containing PADPRP to be inhibited (Kasid et al. 1989). The co-purification 
and modification of the topoisomerase I could indicate a dual existence and function with 
P ADPRP. Interestingly, the physiological roles suggested for topoisomerase I include 
DNA replication, DNA repair and recombination (reviewed in Wang, 1985). Sister 
chromatid exchanges were observed to increase when inhibitors of P ADPRP were present 
(see Section 1.2.7c). The frequency of topoisomerase I within the chromatin has been 
estimated as 1 enzyme moleculell 0-20 nucleosomes, a similar value to that predicted for 
PADPRP. Topoisomerase I has also been located bound to the polymer acceptors, HMG 
17 and histone HI, which results in a stimulation of topoisomerase activity (Kasid et ai, 
1989). 
An inhibition of to poi some rase II activity by poly(ADP-ribosyl)ation was shown in vitro 
(Darby et ai, 1985). Topoisomerase II is implicated in the organisation of higher ordered 
chromatin structure. Inhibition of this topoisomerase may be required during periods of 
chromatin relaxation, e.g. after DNA damage. 
1.2.Sf Ca2+lMi+ dependent endonuclease 
Endonucleases are nuclear enzymes which hydrolyse phosphodiester bonds within the 
DNA. Evidence has suggested a role for eukaryotic endonucleases in DNA synthesis 
(Burzio & Koide, 1973). 
In 1975, Yoshihara isolated a Ca2+ IMg2+ -dependent endonuclease activity using a purified 
enzyme system. Activity of the endonuclease appeared to be inhibited by poly(ADP-
ribosyl)ation with endonuclease activity partially restored upon incubation with snak~ 
venom phosphodiesterase (see Section 1.~.5b) (Yoshihara et ai, 1975). DNA binding 
..,.., 
proteins were found in crude preparations of the enzyme. that were capable of stimulating 
endonuclease activity but which also acted as acceptors for poly(ADP-ribose) (Tanaka et 
ai, 1984). Inhibition of the DNA binding protein activity via ADP-ribosylation would be 
observed as an inhibition of endonuclease activity. Conceivably. by inhibiting Ca2+nlg>-
dependent endonuclease activity, especially during periods of DNA damage, extensive 
degradation of the DNA could be prevented, e.g. as occurs during apoptosis (see Section 
1.4.7c). 
1.2.Sg RNA polymerase II 
RNA polymerase II is located in the nUcleoplasm and synthesises precursor mRNA and 
small nuclear RNA. Transcription is initiated more readily on a nicked than an intact 
DNA template in vitro, but in the presence of PADPRP. transcription was inhibited 
(Slattery et ai, 1983). A possible competition between the two enzymes for the DNA 
binding sites was proposed (Slattery et ai, 1983). Taniguchi, in an in \'itro study, 
observed RNA polymerase II from wheatgerm to be modified by ADP-ribose polymers 
(Taniguchi et ai, 1985). The presence of a random nick suppressor especially during 
cellular stress, e.g. DNA damage, may prevent the production of unwanted transcripts. 
1.2.Sh DNA Ligases 
In mammalian cells, three distinct DNA ligases have been isolated (Tomkinson et ai, 
1991). All three enzymes catalyse the formation of phosphodiester bonds, in an A TP 
dependent reaction sequence, at breaks in the DNA backbone. DNA ligase I has been 
implicated in the replication process, but physiological roles for DNA ligases II & III 
have yet to be fully elucidated. Evidence suggests an involvement in repair replication 
and/or recombination events (Higashitani et ai, 1990). 
Yoshihara et al (1985), showed DNA ligase II to be modified in vitro by (ADP-ribose) 
polymer, which resulted in the inhibition of enzyme activity. Intact cell data suggested 
DNA ligase II activity to be modulated by poly(ADP-ribosyl)ation (Creissen & ShalL 
1982). DNA ligase I was not ADP-ribosylated in vitro (Yoshihara et al 1985). The 
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modification of DNA ligase II activity within the DNA repair mechanism \\ill be 
considered in Section 1.5. The effect of P ADPRP activity on DNA ligase III is at present 
unknown. Preliminary suggestions have associated the enzyme with recombination, a 
mechanism P ADPRP is identified with. Therefore DNA ligase III could possibly be 
controlled via ADP-ribosylation. 
1.2.Si SV 40 Large T antigen 
The large T antigen (T Ag) is the multifunctional early protein of the SV 40 tumour 
virus, involved in the initiation of DNA replication, regulation of gene transcription and 
control of transformation. Post-translational modification reactions are thought to permit 
the many functions of this single protein. Both phosphorylation and acetylation ha\'e 
previously been identified. In 1981, Goldman first showed T Ag to be poly(ADP-
ribosyl)ated both in vitro and in intact cells (Goldman et ai. 1981). Utilising 
immunofractionation with anti -pol y( AD P -ri bose )-sepharose, mini chromosomal DN A from 
SV 40 cells containing replicative intermediate DNA was observed to bind with greater 
affinity than mature DNA (Baksi et ai, 1987). Modification ofT Ag by poly(ADP-ribose) 
polymers could possibly cause repulsion from the DNA thereby slowing the number of 
initiated replication cycles. 
The Herpes simplex virus early protein, ICP4 has recently been shown to be modified 
by ADP-ribose polymers (Blaho et ai, 1992). This protein is also phosphorylated, so 
perhaps post-translational modifications as a means of regulation have been adopted by 
many VIruses. 
1.2.Sj Terminal dNTP transferase, DNA polymerase a and DNA polymerase (J. 
Yoshihara and colleagues (1985), also showed, using an in ,'itro poly(ADP-ribosyl)ation 
system the suppression of activity of terminal dNTP transferase activity, the enzyme 
responsible for addition of nucleotidyl units to the ends of polynucleotide chains, ~md 
both DNA polymerases a and ~, enzymes involved in DNA replication and repair. i\1ild 
alkaline treatment, which hydrolyses the ester-linkag~ between the (ADP-ribose) polymer 
and the protein acceptor restored enzyme activity. 
1.2.6 Role of P ADPRP within the cell 
1.2.6a Introduction 
The physiological role for the polymerisationJdegradation reactions performed by 
PADPRP and poly(ADP-ribose) glycohydrolase has yet to be clearly defined. A vast body 
of evidence unquestionably implicates P ADPRP in the DNA repair process and this "'ill 
be reviewed in Sections 1.4.6 and 1.5, but other associations including DNA replication, 
recombination and differentiation have been postulated. In the following paragraphs the 
possible role of P ADPRP in these cellular mechanisms will be discussed. The use of 
chemical inhibitors of P ADPRP played an important role towards identifying the 
functions of PADPRP. However, the inhibitors used, e.g. nicotinamide, benzamide, 3-
aminobenzamide (see Section 1.3) are of low potency towards PADPRP, and lack 
specificity. A partial inhibition of PADPRP activity, or the modification of other 
metabolic processes within the cell could therefore limit the interpretation of the results. 
1.2.6b DNA replication & cellular proliferation 
Both the synthesis and activity of PADPRP appear to be regulated throughout the cell 
cycle. The activity of P ADPRP rose steadily through G 1, peaking in mid-S phase 
(Kidwell & Mage, 1976; Leduc et ai, 1988), which correlated with an increased synthesis 
of the enzyme (Leduc et ai, 1988). Upon co-incubation with a PADPRP inhibitor. a 
transient inhibition of G liS was observed followed, by an S phase delay. A requirement 
for PADPRP activity prior to entry into S phase may be necessary. PADPRP enzyme 
levels were also elevated during the G21M phase of the cycle, although the increase was 
insufficient to account for the increased level of activity observed (Leduc el aI, 1988). 
Alterations in the levels of poly(ADP-ribosyl)ated proteins upon the transition from 
interphase to metaphase has also been recorded (Adolph, 1987). Contradictory evidence 
characterising the involvement of PADPRP in cellular proliferation exists within the 
literature. Similar P ADPRP activities were obseIyed in both proliferating and non-
proliferating rat liver tissue (Hilz & Kittler, 1971; Hilz et aI, 1972), but in lymphocytes 
stimulated with the mitogen, phytohaemoglutanin (PHA), PADPRP activity \vas increased 
(Rochette-Egly et aI, 1980). Co-incubation with the P ADPRP inhibitors. 3-
aminobenzarnide (3AB) or benzamide (BZ), prior to the addition of PHA inhibited the 
PHA stimulated DNA synthesis, cellular proliferation, and PADPRP activity, suggesting 
that PADPRP is involved in the initiation procedure for DNA synthesis (Ittel et al. 1983). 
Also, in Novikoff hepatoma cells (Burzio et aI, 1972) and leukaemic cells (Burzio et al. 
1975) P ADPRP activity was higher than in the corresponding normal cells. Some of these 
apparent differences could be accounted for by different experimental conditions. 
Overall, P ADPRP function is proposed as being indirectly involved in an early event of 
DNA replication and proliferation. A comparison of the P ADPRP and the DNA 
replication activities, utilising specific inhibitors, e.g. 3AB and aphidicolin which 
specifically inhibits DNA polymerase a, showed them to be individual processes with no 
dependence on each other (Berger et aI, 1978). This was further verified using cells 
which exhibited temperature sensitive DNA synthesis. PADPRP activity was increased 
at the non-permissive temperature and expression of the mutant cells induced secondary 
effects of histone modification plus chromatin decondensation (Savard et aI, 1981). The 
relaxation of the chromatin structure due to histone, nonhistone and HMG protein 
modification is a well documented event (see Sections 1.2.5b-d). and could increase the 
access of replication enzymes to their substrate. Electron microscopy showed the DNA 
that co-purifies with P ADPRP contained a high proportion of replication forks (De 
Murcia et aI, 1983) with PADPRP located in their vicinity. FUrd, which causes an 
accumulation of short replicative intermediates (Yingnian et aI, 1989) and DNase L which 
fragments the DNA (Smulson et aI, 1975) resulted in the stimulation of PADPRP 
activity. During replication. gaps exist at the replication fork, and at 10kb intervals due 
to newly synthesised DNA intermediates. In 1985. Lonn & Lonn observed that in the 
26 
presence of 3AB, ligation of replicon intermediates was inhibited (Lonn & Lonn. 1985). 
This could be due to a condensed chromatin structure. so access of ligase to DNA is 
prevented, or a direct modification of the enzyme, thereby altering its activity. 
1.2.6c Recombination 
Recombination is the exchange of genetic material between two separate segments of 
chromosomal DNA, extrachromosomal DNA, or between chromosomal and 
extrachromosomal DNA. In recent years, recombination has received mounting attention, 
as the techniques for studying the integration of transfected DNA sequences with 
chromosomal DNA have advanced. This has made possible the study of gene structure 
and function by construction of "knock-out genes" and the use of gene therapy to correct 
human genetic disorders. A problem experienced is that in eukaryotic systems, the foreign 
DNA becomes incorporated at random sites, by processes involving illegitimate 
recombination (Thomas et ai, 1986). An involvement of P ADPRP in this random 
integration process has been observed (Farzaneh et ai, 1988; Waldman & Waldman, 
1990). The uptake and integration of trans fee ted DNA into a host genome is a multi-stage 
process, but the inhibition of P ADPRP activity decreased the integration of the donor 
DNA. At this point of the procedure, strand breaks are induced and subsequently 
religated. Such findings could implicate P ADPRP in eukaryotic recombinational events. 
Perhaps chromatin decondensation, resulting in an exposure of the DNA strands could act 
as sites for the intergration reactions. 
A well documented involvement ofPADPRP activity in eukaryotic recombination is that 
of sister chromatid exchange (SCE) (Utakoji et ai, 1979; Oikawa et ai, 1980; Hori, 1981: 
Morgan & Cleaver, 1982; Schwartz et al. 1983). SCE involves the transfer of 
homologous DNA sequences between paired sister chromatids. Recombinational repair 
(see Section 1.3) could provide a significance purpose for SCEs. Initially. SCE 
experiments were used to assess proposed mutagenic and carcinogenic agents, as they 
increase SCE frequencies. llowever, the non-mutagenic, non-carcinogenic PADPRP 
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inhibitor, nicotinamide was observed to induce SCEs (Utakoji et ai, 1979). A number of 
theories were suggested for its involvement. Nicotinamide is an acceptor of the -CH3 
group from s-adenosyl methionine, therefore if nicotinamide concentrations increase. the 
S-adenosyl-methionine pool would be reduced, which could in turn lead to the 
hypomethylation of intracellular macromolecules. The hypomethylation of DNA would 
lead to an increased gene expression, and an increased frequency of recombination 
(Utakoji et ai, 1979). Also, a decrease in the poly(ADP-ribosyl)ation of a Ca2+ IMg2+_ 
dependent endonuclease was proposed. This would increase DNA strand break levels, 
thereby increasing recombination sites. SCEs occur spontaneously but are also induced 
by agents damaging the DNA. 5-bromodeoxyuridine (BrdUrd), used to label the DNA in 
experiments to assess SCE levels could be recognised as repairable damage. Inhibition 
of PADPRP, a component of the repair process (see Section 1.5) could increase the half-
life of the strand breaks formed, thereby increasing the opportunity for SCEs. Further 
studies revealed BZ, 3AB and nicotinamide deprivation also increased the level of SeEs 
following DNA damage, and this was correlated with P ADPRP inhibitory ability (Oikawa 
et ai, 1980; Hori, 1981; Morgan & Cleaver, 1982; Schwartz et ai, 1983). Previous 
suggestions have associated the role of PADPRP with chromatin stability rather than a 
direct involvement in DNA replication or repair. The inhibition of PADPRP, especially 
in the repair process, could lead to replication on a damaged template with a persistence 
of strand breaks. This would extend the availability of the template for recombination. 
1.2.6d Differentiation 
Cellular differentiation involves the induction of specialised functions, e.g. haemoglobin 
production in erythrocytes. Differential gene expression has been proposed as the 
mechanism for the transformation. 
Induction of differentiation in 10 chick myoblasts and human peripheral blood 
lymphocytes by mitogenic stimuli \Vas accompanied by an increased frequency of DNA 
strand breaks (Farzaneh ct al. 1982: Johnstone & Williams, 1982). The repair processes 
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within the cells were judged efficient, as breaks induced by the alkylating agent. dimethyl 
sulphate (DMS) or gamma-irradiation were proficiently repaired (Farzaneh et al. 1987b). 
Differentiation could therefore require the presence of DNA breaks for the selectiye 
expression of genes. Protein factors are known to regulate differentiation. The 
differentiation inducing protein MGI-2 (myeloid differentiating factor(DF)) was obsen'ed 
to bind to double stranded DNA, but not single stranded DNA (Weisinger & Sachs. 
1983), and the purified form induced single strand breaks into a supercoiled SV 40 
(Weisinger et ai, 1986). This in vivo nicking of the DNA could initiate the required gene 
expressIOn. 
Due to the presence of breaks in the DNA structure, a role, albeit contentious one, was 
proposed for PADPRP in differentiation processes (Farzaneh et ai, 1982; Johnstone & 
Williams, 1982). Nevertheless, one point of agreement does appear to be the involvement 
of the enzyme in an initial event of the process. PADPRP inhibitors have been utilised 
to elucidate the role of PADPRP, although again, the results are somewhat contradictory. 
This could be partially due to the different cell lines and experimental conditions used. 
When mitogen stimulated human lymphocytes (Johnstone & Williams, 1982), cultured 
hepatocytes (Althaus et ai, 1982) or the mitogen stimulated human promyelocytic 
lymphocyte, HL60 cell line (Farzaneh et ai, 1987a) were prior incubated with 3AB, BZ 
or nicotinamide, all of which are inhibitors of PADPRP, induction of differentiation was 
prevented. Conversely, Grosso & Pitot (1984) saw an increased level of differentiation 
in an HL60 cell line after treatment with 10mM 3AB, but at this concentration of 3AB, 
cellular metabolic effects unrelated to PADPRP inhibition become apparent (see Section 
1.3.2). Durkacz et ai (1992), showed utilising a range of PADPRP inhibitors, the 
induction of melanogenesis in murine melanoma cell line. In a nicotinamide deprived 
system the induction of differentiation was also prevented (Farzaneh et ai, 1982) 
- , 
conceivably indicating a causal relationship between the induction of differentiation and 
PADPRP activity as nicotinamide is a precursor for NAD+, the substrate for PADPRP. 
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Differentiation is a complex process that requires alterations in gene expression and 
transcription. In addition to increased differentiation, Grosso & Pitot (1984) found that 
the expression of c-myc in HL60 cells was reduced to -half of control levels follo\ving 
either 3AB or theophylline treatment. c-myc expression is inversely correlated to the 
differentiation state of the cell. The ability of P ADPRP inhibitors to induce loss of c-myc 
expression as promyelocytes were differentiated to granulocytes was also obseryed by 
Shima et al (1989). The up-regulation of metallothionein gene expression was observed 
in the presence of the P ADPRP inhibitor 3AB, and this correlated with reduced levels of 
poly(ADP-ribosyl)ated chromatin proteins, HMG 14 and 17 and histone HI. The reduced 
polymer levels were proposed to allow increased access of the RNA polymerase II to the 
metallotionein promotor (Tanuma et ai, 1987). 
1.2.7 Mono- and cyclic- (ADP-ribosyl)ation reactions 
1.2.7a Mono(ADP-ribosyl)ation 
Mono(ADP-ribosyl)ation is a post-translational modification involving the transfer of a 
single ADP-ribose moiety of NAD+ to an acceptor amino acid, catalysed by specific 
ADP-ribosyl transferases (ADPRT). Arginine, cysteine, dipthamide, which is a modified 
histidine residue, and asparagine have all been identified as acceptors for the ADP-ribose 
group. The mono(ADP-ribosyl)ation reaction does not serve as the precursor for 
poly(ADP-ribosyl)ation, as the former reaction involves the modification of side-chain 
N atoms to produce N-glycosides, whereas in contrast, the latter initiates from a carboxyl 
group to form an O-glycoside (Ueda & Hayaishi, 1985). In fact, mono(ADP-ribosyl)ation 
reactions predominate over poly(ADP-ribosyl)ation approximately 10 fold in mammalian 
cells (Hilz et ai, 1982). 
The bacterial toxins were initially identified as ADPRTs. and consequently are the best 
characterised. The diptheria toxin targets a dipthamide residue present in elongation 
factor-2 protein (EF-2) (Honjo el al. 1968). required for polypeptide chain elongation on 
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ribosomes in eukaryotic cells. ADP-ribosylation therefore inhibits protein synthesis and 
ultimately leads to cell death. The arginine-specific ADPRTs, for example, cholera toxin, 
were found to modify the a subunit of the GTP binding protein G
s 
(Cassel & Pfeuffer, 
1978; Gill & Meren, 1978). A signal from a hormone/receptor complex causes GTP to 
displace GDP on the Gs protein. This results in the dissociation of Gs-a-GTP. which 
subsequently binds to adenylate cyclase, the enzyme responsible for the production of the 
second messenger, cAMP. The hydrolysis ofGTP stops further signal transduction. When 
the Gs-a is ADP-ribosylated, GTPase activity is inhibited resulting in a permanent state 
of activation (Moss & Vaughan, 1979). 
The important identification of an endogenous arginine:ADPRT in turkey erythrocytes 
(Moss & Vaughan, 1979), with the capability to activate adenylate cyclase in the presence 
ofNAD+ suggested a possible physiological role for ADPRTs in signal transduction. This 
suggested the bacterial toxins were exploiting physiological regulatory mechanisms. 
However, in the endogenous situation a reversible post-translational modification was 
postulated to prevent cell destruction (Tsuchiya & Shimoyama, 1994). As well as the 
identification of numerous endogenous ADPRTs, many of which involve GTP binding 
proteins, ADPRT hydrolases have been identified which catalyse the removal of the ADP-
ribose group (Tsuchiya & Shimoyama, 1994; Takada et ai, 1994). 
1.2.7b Cyclic(ADP-ribosyl)ation 
In 1987, Lee & colleagues identified a novel form of ADPR, cyclic ADPR (cADPR) 
(Clapper et ai, 1987). cADPR functions as a messenger in the mobilisation of intracellular 
Ca2+ stores, in a mechanism distinct from the highly characterised IP 3 route (Berridge & 
Irvine, 1989). Identified as effecting Ca2+ release in sea urchin egg micro somes (Clapper 
et ai, 1987; Lee et ai, 1989), this function has been characterised in mammalian cells 
(Koshiyama et ai, 1991; Takasawa et ai, 1993a). 
cADPR is formed from NAD+ by the linking of the N at position 1 of the adenine ring 
to the terminal ribose of NAD+. so displacing nicotinamide (Kim ef ai, 1993). 
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Surprisingly, the NAD+ glycohydrolases (NADases), the initial enzymes to be 
characterised that converted NAD+ to ADPR, for which a function has failed to be 
elucidated, were found to possess both the cyclase and hydrolase activities for NAD+ 
(Kim et aI, 1993). 
A further exciting development was the identification that a human leukocyte antigen 
CD38, expressed on the plasma membrane of the cell, possessed both cyclase and 
hydrolytic activities for cADPR (Takasawa et aI, 1993b). 
1.3 INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE 
1.3.1 Introduction 
Inhibitors of P ADPRP have played an important role in the elucidation of the 
physiological function of P ADPRP. A large number of compounds have been shown to 
inhibit PADPRP to varying degrees (see Section l.3.2), with the majority acting 
competitively with the enzyme substrate, NAD+. Most of the inhibitors lack potency, 
exhibit a low solubility in aqueous solution, and are implicated in other non-specific 
reactions, e.g. NAD+ metabolism. In recent years, a number of groups have developed 
novel PADPRP inhibitors with the aim of increasing the potency and specificity towards 
PADPRP. This Section will review both the early and novel PADPRP inhibitors and 
discuss their effects on cellular metabolism. 
1.3.2 The classical P ADPRP inhibitors 
Nicotinamide was the first compound to be identified as an inhibitor of PADPRP 
(Fujimura et aI, 1967; Clark et aI, 1971). Preiss then observed that select, metabolically 
unrelated pyrimidine derivatives, e.g. thymine, thymidine, 5-bromo-2' -deoxy uridine. and 
the nicotinamide analogue, 5-methylnicotinamide, could also inhibit the activity of 
PADPRP (Preiss ('/ ai, 1971). Thymidine and deoxythymidine \\"ere more potent PADPRP 
inhibitors than cytidine, deoxycytidine or uraciL suggesting the base was of greater 
importance than the sugar. Similarities between the pyridine and pyrimidine ring 
structures suggested these compounds compete for the nicotinamide binding site of 
PADPRP. The sugar was considered to be of some relevance as cytosine arabinoside was 
, -
completely ineffective (Berger, 1978). Inhibition was competitive for both classes of 
inhibitor, but the involvement of the compounds in other cellular processes questioned 
their observed biological effects as being attributable to the inhibition of PAD PRP. 
Nicotinamide is a precursor for the biosynthesis of NAD+ (see Figure 1.1), but also 
inhibits tRNA methylase especially in malignant cells (Buch et ai, 1972), forms I-methyl 
nicotinamide, so decreasing the S-adenosyl methionine pool (Utakoji et ai, 1979), and 
decreases PRPP pools (Leiber et ai, 1973) due to increased rates of NAD+ synthesis, 
which then can result in a depletion of nucleotide biosynthesis. Thymidine has been used 
to prevent cell cycle progression (Tanuma et ai, 1979) and is known to inhibit DNA 
synthesis due to the depletion of dCTP (Meuth et ai, 1976). The administration of high 
concentrations of thymidine results in the formation of a large intracellular dTTP pool 
which produces a feedback inhibition of CDP reduction, thereby causing a dCTP 
deficiency. 
A number of purine based compounds, including the methylated xanthines, and to a 
certain extent the cytokinins, also exhibit inhibition of PADPRP, by competition for the 
adenine element of the NAD+ binding site (Berger et ai, 1978). However, these 
compounds are also potent inhibitors of cAMP phosphodiesterase, the enzyme responsible 
for the degradation of cAMP. cAMP acts as the second messenger in the action of some 
hormones, e.g. glucagon, and therefore affects the regulation of a wide range of metabolic 
processes. Therefore, attributing PADPRP related effects derived from the use of these 
inhibitors in intact cells must be regarded with extreme caution. 
The principal PADPRP inhibitors that have been used experimentally are the )-
substituted benzamides developed by Purnell & Whish (1980) (see Figure 1.9). 
Benzamide is an analogue of nicotinamide, and was initially demonstrated to be a potent 
PADPRP inhibitor by Shall in 1975. The lack of nitrogen in the ring structure of 
benzamide was not essential for activity but this increased the specificity of the in \'ivo 
PADPRP inhibition, as NAD+ biosynthetic enzymes fail to recognise it as a substrate. The 
3-substituted benzamides all act competitively, and show an increased potency relatiye 
to nicotinamide. However, the cell contains other NAD+ consuming enzymes, e.g. 
mono(ADP-ribosyl) transferases (see Section 1.2.8a), and NAD+ glycohydrolases, \\hich 
could also be inhibited by such competitive inhibitors. Rankin et at (1989) evaluated the 
selectivity of the 3-substituted benzamides for PADPRP inhibition. Benzamide was the 
most potent inhibitor tested with an I C50 of - 31-lM against PAD PRP, but when the 
concentration was raised to -4mM, a panel of mono(ADP-ribosyl) transferases were also 
inhibited. 
The elucidation of a physiological role for PADPRP, especially in DNA repair has been 
investigated primarily using 3-aminobenzamide. However, the specificity of PADPRP 
inhibition by the benzamides came into question when data was published showing 
benzamide and its analogues inhibited the enzyme S-adenosyl methionine:nicotinamide 
methyltransferase, both in liver homogenates and intact rat kidney cells (Johnson, 1981). 
Milam and colleagues (1984, 1986), then indicated that incubation of lymphoid cells with 
the benzamides caused a disruption of glucose metabolism, and DNA synthesis, via 
effects on de novo purine and pyrimidine metabolism. Therefore caution was advised in 
the interpretation ofPADPRP dysfunction studies using these compounds. However. these 
results were concluded from a series of indirect metabolic assays, i.e. the level of DNA 
synthesis from eH]thymidine, [3H]methionine and C4C]glucose incorporation was 
determined in the presence of a benzamide analogue, rather than the determination of the 
cellular dNTP levels which would have offered a more definitive answer to the effects 
of the benzamides on nucleotide metabolism. Hunting et at (1985), utilising the PADPRP 
inhibitors 3AB, 3AAB and 3meBZ, showed that PADPRP inhibition had no significant 
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Figure 1.9: Chemical structures of PADPRP inhibitors. 
effects on dNTP pool sizes, either in the absence or presence of D"\,:-\ damage. HO\\-e\-er. 
'1" [14C]C 14 utl ISIng lonnate and [ C]glycine, the label incorporated into ATP and GTP \\"as 
depleted following an incubation of the L 121 0 cells with 5mM 3AB, whereas when 
C4C]hypoxanthine was used, control levels were maintained. This indicated the PADPRP 
inhibitor had a possible effect on either de novo purine synthesis or folate metabolism. 
The cytotoxicity of the anti-metabolite, 6-mercaptopurine was enhanced when co-
incubated with 3AB and this correlated with an increased PRPP leveL indicative of an 
effect on de novo purine synthesis (Moses et ai, 1990). When a co-treatment \vith 5FU 
and 3AB was considered, the cytotoxicity of 5FU was enhanced although there was a lack 
of effect on both the cellular NAD+ and the strand break frequency, effects commonly 
associated with PADPRP inhibition (Willmore & Durkacz, 1993). However, it was 
observed that 3AB increased the incorporation of FU into DNA by an increased 
anabolism of the base analogue. Nevertheless, Snyder (1984) found a total lack of effect 
on the purine dNTP pools following an incubation of human fibroblasts with 3AB. 
A comparison of the potential of the benzamides to inhibit (ADP-ribose) polymer 
formation following MNNG treatment in an in vitro and an intact cell situation were in 
excellent agreement (BZ: in vitro IC50 = 3.3~M, in vivo IC50 = 3.5~M; 3AB: both in vitro 
and in vivo IC50 = 5.4~M) (Rankin et ai, 1989). The intact cell data for nicotinamide and 
thymidine (Rankin et ai, 1989) exhibited a 3-5 fold higher IC50 concentration requirement 
than observed for the inhibition in vitro. This could possibly indicate a discrepancy 
between the intracellular NAD+ concentration and that used in the in vitro cell assay, as 
the inhibitors compete with the NAD+ for the active site of the P ADPRP. Other possible 
influences include membrane transport effects, compartmentalisation within the cell or 
metabolism of the compound. 
1.3.3 Development of novel P ADPRP inhibitors 
Although the 3-substituted benzamides displayed increased potency as inhibitors of 
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PAOPRP compared to nicotinamide and thymidine. problems \\-ith hydrophobicity. a lack 
of specificity and low potency towards the enzyme still remained. In 1990. Sestili L'I al 
published a detailed analysis of the optimal substituted benzamide structure required for 
PAOPRP inhibition. An unsubstituted carboxamide moiety proyed essential for actiyity. 
A simple model for the binding of the nicotinamide moiety of NAO+ to the actiYe site 
of P AOPRP is shown in Figure 1.10a. The benzamides are also thought to bind to this 
site with the 3'-substituted group positioned within the nucleoside-binding domain. 
Banasik also observed that all P ADPRP inhibitors that possessed a carbonyl group 
showed inhibitory activity and that potency was increased when the carbonyl was built 
into a second ring (Banasik et ai, 1992). The orientation of the amide with respect to the 
3'substituted position was optimal for activity (see Figure 1.10), and by restricting the 
rotation of the amide by an ethane/ethene bridge. inhibitory activity was increased (Suto 
et ai, 1991). From such an analysis, a series of 5'substituted dihydroisoquinolinones were 
developed. They retain structural features analogous to nicotinamide and are extremely 
potent inhibitors ofPAOPRP. The compound, 3.4 dihydro-5-methoxyisoquinolin-l-(2H)-
one (PO 128763) (see Figure 1.9), was observed to potentiate radiation induced lethality 
(Arundel-Suto et ai, 1991) and the cytotoxicity of monofunctional alkylating agents 
(Sebolt-Leopold & Scavone, 1992), with an -10-fold decrease in the concentration of PD 
128763 (0.5mM PO 128763) as compared to 3AB (5mM), and exhibiting an approximate 
60-fold decrease in the inhibition of PAOPRP activity compared to 3AB in an in )'itro 
P ADPRP assay. 
The molecular electrostatic potential (MEP) records the electrostacity of a compound. 
A correlation was observed between the MEP and the ability to inhibit PADPRP. This 
was utilised to assess the inhibitory ability of novel benzamide structures (Sestili et al. 
1990). Compounds with an amide group present in the 3'substituted position, but 
rotationally restricted in an aromatic ring \\ere predicted to haye PADPRP inhibitory 
actiyity. 
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A development programme between the Cancer Research Unit and Chemistry 
Department, both of the University of Newcastle, is currently investigating a number of 
novel structures involving restriction of the 3'substituted position. The compound. 8-
hydroxy-2-methylquinazolin-4(3H)-one, NU1025 (see Figure 1.9) has proved to be -(10-
fold more potent than 3AB as a P ADPRP inhibitor, and is equipotent with PD 128763 
(Data shown in Chapter 3). The requirement for at least one free -NH group was 
demonstrated (see Diagram l.10b), as when the H (marked X) was replaced \\ith a 
methyl group the inhibitory activity of the compound was reduced from 920/0 to 11 % at 
a concentration of 1 O~M (Griffin et ai, 1995 in press). The biological consequences of 
the PADPRP inhibition by NU1025 will be discussed in detail in this thesis. 
As the potency of the P ADPRP inhibitors increases, their potential to be introduced into 
the clinics as biomodulators becomes more valid. Intact cell work (as described herein) 
together with in vivo studies will have to be performed to fully assess the specificity of 
these novel inhibitors and any possible toxic effects. Overall these compounds may prove 
valuable implements in the fight against resistance to anticancer drugs. 
1.4 DNA REP AIR MECHANISMS 
1.4.1 Introduction 
The best understood role for P ADPRP is the involvement in DNA repair, therefore an 
overview of DNA damage and repair mechanisms was considered essential for this thesis. 
Mutations in somatic cells, estimated at a frequency of 10-9_10- 12 mutations/nucleotide'cell 
generation, have been implicated with the ageing process, cell injury and carcinogenesis. 
This Section will initially aim to review the types of lesions formed from both 
spontaneous and environmental damage, their involvement in the mutagenic and 
carcinogenic processes and the mechanisms employed by the cell to repair them. Finally. 
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the repair mechanisms with which P ADPRP has been associated will be discussed in 
detail. 
1.4.2 Spontaneous DNA damage. 
1.4.2a Replication errors 
Semi-conservative replication is probably the main source of base substitutions, deletions. 
and mispaired bases. An estimated 1 error/l 00 nucleotides has been predicted, but the 
association of DNA polymerase with a proof-reading ability. i.e. 3'-5'exonuclease action. 
and the affiliation with accessory proteins, e.g. single strand binding protein, increases 
the fidelity of replication. 
1.4.2b Depurination of bases 
In vivo, DNA exists in the fully hydrated, structural B-form (Lindahl, 1993). 
Consequently, hydrolytic depurination by the protonation of the base. followed by the 
direct cleavage of the glycosyl bond is likely to be a frequent alteration. A turnover of 
2000-10000 purine residues/day has been predicted (Lindahl & Nyberg. 1972), a figure 
100X greater than that for depyrimidination. The rapid initiation of base excision repair 
(see Section 1.4.7) ensures the DNA integrity is maintained prior to the ensuing cycle of 
replication, thereby preventing possible mutations. 
1.4.2c Deamination of bases 
Cytosine, adenine and guanine can be deaminated to uracil, hypoxanthine and xanthine. 
respectively, due to the presence of an exocyclic amide group. Deamination results when 
the amide group spontaneously dissociates during pH and temperature dependent reactions 
of the DNA (Lindahl, 1993). The main deamination reaction found is cytosine ~ uracil. 
Uracil DNA glycosylase acts rapidly to excise the uracil residues, therefore few mutations 
arise (see Section 1 A. 7). 
Methylation of cytosine forms the analogue, 5 methyl cytosine (SmC) which is also a 
. . 
target for deanlination reactions. Approximately 30/0 of all the cytosine in the cell exists 
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as 5mC, with -700/0 of all CpG sites methylated. Methylation at epG sites is important 
in the regulation of gene expression. with the patterns of methylation under stringent 
- ~ 
control (Holliday & Grigg, 1993). The deamination of 5mC results in the formation of 
thymine which can lead to C:G ~ T:A transitions during replication. Mismatch repair 
must be employed to correct this error (i.e. the T:G mismatch). This is a slower form of 
repair (see Section 1.4.5c), and so coupled with the slightly increased frequency of Sme 
deamination as compared to cytosine deamination (Lindahl & Nyberg, 1974: \\'ang et al. 
1982; Lindahl, 1993), 5mC becomes a preferred target for spontaneous mutation. 
1.4.2d Base oxidation 
A large number of metabolic reactions lead to the generation of active oxygen species. 
A wide spectrum of lesions form during oxidative damage to the DNA, including 8-
hydroxyguanosine, planar lesions, e.g. cytosine glycols. and lesions causing major helical 
distortion, e.g. 8'5 cyclopurine deoxyribonucleosides. The majority are excised from the 
DNA by DNA glycosylase enzymes. The major mutagenic lesion is 8-hydroxy guanosine 
which forms a mispair with adenosine (Shibutani et ai, 1991). 
1.4.2e Base methylation 
The one-carbon donor of intermediatory metabolism, S-adenosyl methionine, is capable 
of a weak alkylating action towards the bases of the DNA (Rydberg & Lindahl, 1982; 
Barrows & Magee. 1982). The main lesions formed are 7-methyl guanine (7mG) and 3-
methyl adenine (3mA). Due to a lack of base mispairing during replication 7mG has no 
effect on the genetic sequence. and is chemically degraded over a period of days. 
However, 3mA is a cytotoxic lesion which can block DNA replication. An estimation of 
600 3mA lesions/day has been recorded (Rydberg & Lindahl, 1982). but the presence of 
an efficient 3-methyl adenine glycosylase ensures their efficient excision. 
1.4.3 Environmental damage 
Ionizing radiation and ultradolet radiation (UV) are the two components of thL 
electromagnetic spectrum known to have carcinogenic potential. 
1.4.3a Ionising radiation 
Ionising radiation interacts with molecular species to disrupt chemical bonds. \\"ith the 
three major reactive radicals formed being the hydroxyl radical OH, a solvated electron. 
e-
aq 
and the hydrogen radical, H+ (Ward, 1975). Although these are short lived, interaction 
with the DNA leads to base alteration and the formation of strand breaks, by 
phosphodiester bond cleavage. All four bases are subject to damage, with the major form 
being the saturation of the C5=C6 bond of thymine to form the corresponding glycols and 
hydrates which in E.coli are excised by the specific thymine hydrate (TH) DNA 
glycosylase (Friedberg, 1984). The secondary structure of the DNA assists in minimising 
the level of damage, especially the bases, which gain protection due to their central 
location within the hydrophobic helix. Abundant free radical scavenger molecules, e.g. 
cysteine and glutathione, compete for the radicals formed, decreasing further the possible 
detrimental effects of IR on the DNA (Ward, 1975). 
1.4.3b UV radiation 
UV radiation incites molecules into a short lived "excited state" that renders them 
reactive. Interaction with aquated DNA promotes the formation of pyrimidine dimers 
between adjacent thymine bases, that become covalently linked to form a stable 
cyclobutyl ring, or cytosine residues which form the alkali labile pyrimidine-pyrimidine 
lesion, from C6 of one base to C4 of the second (6,4 photoproduct) (Lippke et ai, 1981). 
UV radiation can also induce, but to a lesser extent, the stable thymine glycol (Demple 
& Linn, 1980), the major lesion associated with ionizing radiation. A number of minor 
lesions have been identified, including pyrimidine hydrates, but their short half-life 
indicates rapid repair and the lack of a significant role in vivo (Kittler & Loeber, 1977). 
Intercalating compounds, e.g. psoralen can absorb UV radiation, so initiating the 
formation of thymine-thymine dimers (Pathak et ai, 1974). The presence of this lesion 
can result in the arrest of DNA replication. 
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1.4.4 Chemical damage 
1.4.4a Aromatic amines & polycyclic hydrocarbons. 
Many substances encountered during every day life can Increase the risk of 
carcinogenesis. Two highly studied chemical groups are the Aromatic amines e.g. N-2 
acetyl 2 aminofluorene (AAF) and the Polycyclic hydrocarbons, e.g. benzo(a)pyrene. 
Both are present in a number of industrial substances, with benzo(a)pyrene also found in 
coal tar, cigarette smoke and exhaust fumes. They are metabolically activated, principally 
in the liver, by the cytochrome P-450-dependent mono-oxygenases, located in the 
endoplasmic reticulum of the cells. The activated metabolites alkylate the Cg position or 
the 2-amino group of guanine, to form "bulky" lesions repairable via nucleotide excision 
repair (Kreik, 1972; Weinstein et ai, 1976) (see Section 1.4.5c). The latter adduct is a 
minor product of the interaction of AAF metabolites with the DNA, but the principle 
lesion formed in the dihydrodiol-epoxide intermediate ofbenzo(a)pyrene. The persistence 
of this lesion is implicated in the initiation of carcinogenesis. 
1.4.4b Chemotherapeutic agents 
Ironically, compounds which damage DNA and are potentially mutagenic are exploited 
for cancer therapy. A vast number of chemotherapeutic agents have been identified and 
these can be broadly divided into two classes:- 1) Direct acting agents interact directly, 
or following metabolic activation via the P-450 enzyme complex, with the DNA resulting 
in the formation of a large variety of DNA lesions e.g. mono- and bi-functional alkylating 
agents (e.g. MNNG and BCNU respectively), cisplatin and several of the antibiotics, e.g. 
actinomycin D. 
2) Anti-metabolites interfere with the biosynthesis of DNA and result in the in the 
incorporation of incorrect bases during DNA synthesis, e.g. methotrexate, 5-flurouraciL 
6-mercaptopurine. 
The nun1ber of chemotherapeutic agents and all the respective modes of action are too 
extensive to be discussed within the scope of this thesis. Because of the focus of this 
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thesis, only the alkylating agents will be reviewed. 
1.4.4c Alkylating agents 
Alkylating agents were the first class of cytotoxic drug to be utilised in the clinic. They 
interact with all biological molecules, especially the DNA bases, due to an electrophilic 
reactive species that forms covalent links with nucleophilic groups, e.g. -NH." p, -OH. 
Alky lating agents can be either mono-functional (one reactive site) or bi -functional (two 
reactive sites), and interact with numerous potential sites on the DNA bases. Generally. 
the most modified sites are 06alkyl guanine, N7alkyl guanine and N3alkyl adenine. but 
steric effects of the DNA are a major determining factor. The physiological configuration 
of DNA is the B form, so due to positions in the major groove, the N7 and 0 6 residues 
of guanine, are easily accessed by the alkylators (Friedberg. 1984). The principle 
mutagenic lesion formed is 06methyl guanine which mispairs with thymine during 
replication, so leading to a GC:TA transitions. 
A clinically relevant group of alkylating agents with a particular pertinence to this thesis 
are the imidazotetrazines. These are a novel group of synthetic compounds that possess 
a NNN cyclic linkage, which under alkaline conditions is hydrolysed to form the active, 
corresponding linear alkyl triazenes (Stevens et ai, 1987; Tisdale, 1988). Mitozolomide, 
is activated to a chloroethylating species that forms crosslinks with the DNA. Promising 
results from Phase I clinical trials were obtained (Newlands et ai, 1985) and 
mitozolomide was entered into Phase II trials. However, the minor antitumour activity 
towards small cell lung cancer and malignant melanoma was accompanied by severe 
myelosuppression, which halted the further clinical useage. Temozolomide (TM) is a 3-
methyl substituted analogue of mitozolomide that is unable to form DNA crosslinks, but 
retains antitumour activity. Under alkaline conditions TM is chemically degraded to the 
alkylating agent, MTIC (Stevens et ai, 1987; Tsang et ai, 1991) (see Figure 1.11). 
The metabolically activated linear triazene, dacarbazine (DTIC) gave disappointing 
results in the clinic, possibly due to interpatient variations in the level of metabolising 
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enzymes. A similar mechanism of cytotoxicity for DTIC and TM has been suggested. but 
as TM is chemically degraded, improved clinical results were anticipated. Due to low 
toxicities in the preclinical screens, TM was selected for entrance into a Phase I clinical 
trial. Clinical activity was observed in malignant melanoma, mycosis fungoides and high 
grade gliomas, with only a limited myelosuppression (Newlands et ai, 1992). Phase II 
trials are at present ongoing (Woll et ai, 1995). 
Figure 1.11 Pathway of decomposition of temozolomide (Tsang et ai 1991). 
Cells treated with TM show increased levels of alkali labile sites in the DNA that 
correlate with the removal of 7meG (70% of total lesions) and 3meA (9% of total 
lesions) (Hepburn & Tisdale 1991). The lesion 06meG. was also observed and correlated 
with cytotoxicity, but the level of sensitivity was decreased in those cells with high 0 6 
methyl guanine methyl DNA transferase (MGMT) levels (see Section 1.4.5b). Howe\'t~r. 
upon co-incubation of such cells with an inhibitor of MGMT. the sensitivity to TM was 
increased (Tisdale, 1988~ Hepburn & Tisdale. 1991: Baer et ai, 1993). 
Terminal differentiation in TM treated cells has been observed (Tisdale, 1988: Zuccetti 
c/ ai, 1989~ Tsang et ai. 1991) but the mechanism of action has still to be elucidated. An 
increased expression of the haemoglobin gene \\'as correlated \\'ith its hypomethylation. 
in TM treated K562 cells (Tisdale, 1988) but the methylation patterns of the globin gen~s 
or the oncogenes, c-myc or ras treated with TM remained unaltered (Zucchetti et al. 
1989). 
1.4.5 Carcinogenesis 
The term "cancer" is the general term used for a malignant tumour. A tumour is initiated 
due to the ability of a cell to prevail over the normal growth regulatory mechanisms, 
resulting in the formation of a clone of cells. This then competes for the space and 
nutrients of the adjacent tissues. The potential to invade other areas of the body. I.e. 
metastasis, is the extremely pernicious feature that signifies malignancy. 
Carcinogenesis is defined as "a multistage process driven by carcinogen induced genetic 
and epigenetic damage in susceptible cells that gain a selective growth advantage and 
undergo clonal expansion as a result of the activation of proto-oncogenes and/or 
deactivation of tumour-suppressor genes" (Harris, 1991) (see Figure l.12). 
The initial postulate for the induction of carcinogenesis consisted of two phases:-
1. Initiation - is the exposure of a cell to a chemical, physical or microbial carcinogen. 
or spontaneous endogenous damage that results in an irreversible genetic change, leading 
to the suppression of regulated growth. 
2. Promotion - is the increased proliferative state which promotes the possibility of 
further genetic damage, e.g. mutation or amplification of proto-oncogenes or deactivation 
of tumour-suppressor genes, thereby increasing the risk of malignant development. 
The majority of cancers originate from initial mutagenic events. However, most 
genotoxic agents exhibit a threshold dose below which tumours do not develop, due to 
the activation of the cellular repair mechanisms that correct the defects imposed on the 
genome. If these repair processes become saturated or are defective in any way. the errors 
in the DNA persist and are replicated leading to the fixation of the mutations and 
induction of carcinogenesis (Loeb, 1989). tvlutagenesis is only part of the carcinogenesis 
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Figure 1.12 Schematic representation of the sources for multiple mutations in cancer 
(Loeb, 1994). 
process, and this is highlighted by the fact that some compounds are carcinogenic. but not 
mutagenic (Clayson, 1989; Grasso el ai, 1991). These compounds, e.g. the antibiotic. 
sulphonamide, activate endogenous mitogens, e.g. growth factors, thereby increasing the 
proliferative capacity of the cell and so the chance of replicative errors (Shaw & Jones, 
1994). 
Many genes in normal mammalian cells are homologous to viral genes whose products 
are involved in the transformation of the normal cell to a malignant state. Such genes are 
termed "protooncogenes", and many encode for proteins involved in the control of cell 
proliferation and differentiation, e.g. the ras family proteins possess GTPase activity and 
are considered the intermediatary signal between the cell surface receptor and the 
adenylate cyclase second messenger; c-src is a protein tyrosine kinase involved in 
phosphorylation cascades. Protooncogenes are endogenously found in low levels. but once 
a cell has been transformed, e.g. by amplification of the protooncogene, chromosome 
translocations. or when under viral transcriptional control, the oncogene subsequently 
ructions at high levels. Over activation may then lead to inappropriate activity. e.g. 
amplified or continuous signals, increased kinase activity, which would thereby alter 
cellular activities. In contrast. tumour suppressor genes. e.g. p53 (see Section 1.4. 7b). 
when inappropriately inacth'ated cause dysregulation of growth and differentiation 
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(reviewed in Harris, 1991). 
Following the mutation of genes whose products sustain genome stability, e.g, proteins 
involved in DNA replication, repair, recombination, the cell has a reduced ability to 
overcome any further genomic damage. Thus, the probability of preventing the induction 
of carcinogenesis, following subsequent mutational events would be significantly 
decreased. Definitive evidence for such a mutator phenotype has been observed in colonic 
cancer cells (Parsons et ai, 1993; Ionov et ai, 1993). In families suffering from hereditary 
nonpolyposis colorectal cancer (HNPCC), an increased hypervariability in the CA 
microsatellite repeat regions, known mutation hotspots (Schlotterer & Tautz, 1992), has 
been observed. A mutation in the gene homologous to mut S, the bacterial gene 
responsible for methyl directed mismatch repair was also identified in HNPCC patients 
(Modrich, 1991), and a lack of functional mismatch repair has been observed in extracts 
from colon cancer cells (Leach et ai, 1993). Together, these pieces of evidence provide 
a logical reasoning for the microsatellite instability. Mismatch repair corrects single-base 
substitutions, deletions, additions, frame shifts and small sequence rearrangements (see 
Section 1.3.5c), so increasing the accuracy of replication 10-400 fold. The CA repeats are 
usually considered "junk" DNA, but a possible function could be in the prevention of non 
homologous recombination (Radman & Wagner, 1993). Many cancer cells show an 
increased rate of non homologous recombination, so perhaps instability of microsatellite 
DNA will be identified in other forms of cancer. 
1.4.6 Mechanisms of DNA repair 
1.4.6a Introduction 
The persistence of DNA damage, especially during DNA replication results in an 
increased risk of carcinogenesis. Therefore, in response to the damage, the cell initiates 
repair mechanisms that restore the genetic integrity prior to replication, thus protecting 
the cell from mutagenesis and c\'cntual carcinogenesis. 
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The repair processes are broadly divided into two main classes 1) Direct repair and ~) 
Excision repair. 
1.4.6b Direct repair 
Direct repair involves the removal of the DNA lesion without the loss of material and 
leaves the DNA intact. Two examples of this form of repair are enzYmatic 
photoreactivation and the repair of 0 6 alkyl guanine lesions. The former involves the 
activation of the light absorbing DNA photolyase to remove cyclobutane pyrimidine 
dimers that have the potential to inhibit DNA replication (Sancar & Sancar, 1988). 
06alkyl guanine lesions are mutagenic, causing GC~AT transitions. A repair mechanism 
has evolved that utilises the protein, 06methyl guanine methyl DNA transferase (MGMT) 
[EC 2.1.1.63] which stoichiometrically transfers the methyl group from the guanine 
residue to a S-methyl cysteine residue within itself (Demple & Karran. 1983: Pegg, 
1990). This results in the restoration of the guanine residue in the DNA, but the MGMT 
protein is not regenerated, and for this reason has been termed a "suicide enzyme". 
The mammalian MGMT gene has recently been cloned (Hayakawa et ai, 1990; Rydberg 
et ai, 1990). The preferred substrate is 06me G, although longer alkyl groups, e.g. propyL 
butyl, and branched structures also act as substrates, but with a decreased affinity (Pegg. 
1984). The human MGMT level ranges from a low expression in the brain and mammary 
gland to high levels in the liver and spleen (Pegg, 1990). These differences in the rate of 
06me G repair confer a tissue dependent susceptibility to tumour promotion. 
1.4.6c Excision repair 
During excision repair. the damaged bases/nucleotides are excised from the DNA by 
specialised enzymes. The DNA integrity is then restored by the action of DNA 
polymerases and DNA ligase. The concepts of excision repair were initially conceived 
in 1964 (Boyce & Howard-Flanders, 1964~ Setlow & Carrier, 1964). and two major 
excision mechanisms. base and nucleotide excision haye been identified in all liying 
organisms. However, mismatch repair, which corrects base mispairs, and recombinational 
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repair that is essential for the repair of crosslinked DNA. have also been distinguished 
and will be briefly discussed later in this Section. 
Base excision repair (BER) 
The multi-enzyme process of BER (see Figure 1.13) has been characterised most fully 
in E coli, but significant advances towards elucidating the mammalian process are being 
made. 
The initial event of BER is the hydrolysis of the N-glycosidic bond that links the 
modified or damaged base to the sugar/phosphate backbone. This reaction is catalysed by 
DNA glycosylase enzymes, each enzyme having specificity for a single type of base. The 
DNA glycosylases are ubiquitous globular enzymes, ranging from 20-50KDa with no 
requirement for cofactors (Friedberg, 1984; Lindahl, 1990). In E coli, six DNA 
glycosylase enzymes have been isolated to date. The sequence analysis of four of the 
enzymes showed no homology and lacked characteristic DNA binding motifs, e.g. Zn2+-
fingers, helix-turn-helix (Sakumi et ai, 1986; Varshney et ai, 1988). The characterised 
enzymes are:-
Uracil DNA glycosylase removes the misincorporated and deaminated base, uracil. 
Encoded by the ung gene in E coli the survival of ung- mutants indicate this to be non-
essential (Duncan, 1985). Hypoxanthine DNA glycosylase removes the product of adenine 
deamination. 3methyl adenine (3meA) DNA glycosylase is important for the removal of 
alkylation damage. In Ecoli two forms of the enzyme exist, TagI, encoded by the tag 
gene shows specificity for 3meA (Riazuddin & Lindahl, 1978), and TagH encoded by the 
AlkI gene. TagH, recognises a broader range of lesions mainly located in the minor 
groove, including 3meG, 7meG, 7meA, Q 2meT, Q 2meC plus the ethyl derivatives. As the 
minor groove is usually unmethylated (Friedberg, 1984). TagH has been proposed to 
"patrol" the domain. Formamidopyrimidine DNA glycohvdrolase encoded by the fpg 
gene (Boiteux ('/ aI, 1987), removes the C5=C6 pyrimidine lesions resulting from ionizing 
and oxidative interactions. Pyrimidine dimer DNA Glvcosylase removes pyrimidine 
dimers and associated lesions with the concerted action of an AP endonuclease. :\11 these 
enzymes are also found in mammalian cells with the exception of the pyrimidin~ dimer 
DNA glycosylase. Also, only a single 3meA DNA glycosylase has been identified with 
specificity for both 3meA and 7meG. In murine plasmocytoma cells a further D\::\ 
glycosylase has been identified that removes hydroxymethyluracil. a product of ionizin!.! 
radiation and oxidative damage (Hollstein et ai, 1984). 
After removal of the base, the lability of the apurinic/apyrimidinic (AP) phosphodiester 
bonds is increased. Spontaneous hydrolysis via a ~-elimination reaction can result. but 
the tl/2 of 40-100 hours is limiting (Lindahl & Andersson, 1972). Located in all organisms 
are special nucleases that specifically hydrolyse these bonds. Again, the nucleases of 
E. coli are the most intensively studied with the identification of several functional 
enzymes although, as many are minor enzymes, they are unlikely to be of biological 
significance. The main nuclease is exonuclease III encoded by the xth gene. The initial 
identification of a 3'~5'exonuclease action gave the enzyme its name, although the 
endonuclease activity is the main enzymic function (Weiss & Grossman, 1987). Catalysis 
of the phosphodiester bond occurs 5' to the AP site producing 3'OH and S'P termini 
(Gossard & Verly, 1978). The second most prevalent endonuclease is the inducible, 
endonuclease IV which shares characteristics with the endonuclease enzymes found in 
yeast (Johnson & Demple, 1988), drosophila (Kelley et ai, 1989), and human cells (Kane 
& Linn, 1981). It also cleaves 5' to the damaged base, usually as a result of oxidative 
damage. The mammalian AP endonucleases have been characterised from many sources, 
including HeLa cells, human fibroblasts and placenta (Linn, 1982). The placental AP 
endonuclease is capable of incising at either the 3' or the 5' sites but not both. 
Until recently the BER mechanism had a "missing link", as following 5' incision there 
remained a base-less deoxyribosephosphate residue attached to the 5' termini. Due to 
obstruction hy the residue, the DNA polymerase I of E coli was shown to promote strand 
displacement synthesis rather than nick-translation. thercfor~ increasing the possihility of 
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Figure 1.13: DNA base excision repair pathway for the removal 
of danlaged bases and AP sites (Franklin & Lindahl, 1988), 
inaccurate replication (Mosbaugh & Linn, 1982). InitiallY. an enzyme activinr was 
- - -
identified in E coli with the ability to remove this incomplete nucleotide (Franklin & 
LindahL 1988). A similar enzyme activity has been isolated in mammalian cell extracts 
(Franklin & Lindahl, 1988). Recently this action has been identified as a function of the 
DNA exonuclease, encoded by the Ecoli reel protein involved in the recombinational 
repair pathway and mismatch repair (Dianov et aI, 1994). 
Nucleotide excision repair (NER) 
NER is the most versatile of all the cellular repair mechanisms with a vast array of DNA 
lesions corrected, e.g. UV dimers, photoproducts, chemical lesions.( e.g. metabolites of 
aromatic amines and benzo(a)pyrene), cisplatin adducts and even oxidative damage 
(Huang et aI, 1994). Such adaptability within a single procedure is partially due to the 
creation of distortions in the DNA helix by the "bulky" adducts, that are then recognised 
by the repair enzymes. However. the multitude of specialised proteins that work 
collectively as an excinuclease complex to remove the damaged sites must also offer 
versatility. 
The initial process of NER was elucidated in E coli, and this has been used as a 
simplified basis for the determination of the eukaryotic system. Elucidation of the 
eukaryotic NER pathway (see Figure 1.14) has advanced significantly only in the last 
three years. Cleaver initially identified patients suffering from the genetic disorder. 
Xeroderma pigmentosum (XP) which confers sensitivity to UV irradiation, to be deficient 
in the incision step of the NER mechanism. Complementation analysis identified seven 
different groups, indicating the involvement of at least seven proteins in the recognition 
and incision of damage (Cleaver, 1983). Recently. the cloning of the yeast (Prakash et 
aI, 1993) and human repair genes (Van Duain et al. 1986; Tanaka et al. 1990; \\'eeda et 
al. 1990; Legerski & Peterson. 1992: Weber ef al. 1990; Thompson et aI, 199.+: Scherly' 
eI al. 1993: MacInnes et aI, 1993) has been the factor responsible for establishing the role 
of each protein. and the inter-protein relationships within the NER process. A high degree 
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of evolutionary conservation between the yeast (RAD) and human (XPIERCC) repair 
genes has been established. Initially. in eukaryotes the damage recognition protein 
RAD14IXPA (Robins et ai, 1991; Guzder et ai, 1994) binds to a XPFIERCC4:ERCCl 
heterodimer (Li et ai, 1994; Park & Sancar, 1994) and to the replication protein. HSSB. 
which binds to the damaged site. Protein subunits. RAD3IXPBlERCC2 and 
RAD25/SSL2IXPB/ERCC3, which possess helicase activities are recruited to the damaged 
site by the RAD 14IXP A. The RAD4IXPC protein is subsequently installed at the damage 
site, either through an attraction to, or a loose association with, the TFIIH (Sancar, 1994). 
The presence of the helicases presumably opens up the helix structure as in the 
prokaryotic system. This conformational change allows the RAD2IXPG (Habraken et ai, 
1993; 0' Donovan et ai, 1994) and RAD 1 lRAD 1 0 complexIXPF (Tomkinson et ai, 1993: 
Sung et ai, 1993), both of which possess nuclease ability. to make a dual incision at the 
3' side (O'Donovan et ai, 1994) and the 5' side (Bardwell et ai, 1994) of the lesion. 
respectively. The excision of the oligonucleotide and the removal of the repair proteins 
is facilitated by the proliferating cell nuclear antigen (PCNA) (Shivji et ai, 1992), and the 
ensuing "gap" is infilled by either DNA polymerase 8 or E prior to DNA ligation. 
A scanning method for the recognition of damaged sites has been proposed whereby the 
protein(s) would "track" along the helix until a distortion was encountered (Gruskin & 
Lloyd, 1988a,b; Dowd & Lloyd, 1990). 
Recently, the most significant finding was that NER is divided into two sub-pathways: 
1) Transcription coupled repair: removes lesions that block ongoing transcription and 
therefore requiring urgent elimination (Bohr et ai, 1985). 
2) Genome overall repair: removes lesions from the bulk of the non-transcribed DNA. 
Initially, transcription and repair were considered to be individual processes. The 
observation of preferential repair of the transcribed DHFR gene in CHO cells (Bohr et 
ai, 1985) challenged this theory and further investigations highlighted the possibility that 
this phenomenon is common to all organisms (Madhani et al. 1986: t-.1cllon cl ai. 198h: 
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Mellon & Hanawalt, 1989). The stalled RNA polymerase was initially considered as the 
signal that attracted the repair enzymes to the damaged site. However. an in\"estigation 
of E. coli transcription coupled NER found that on encountering a blocking lesion, the 
RNA polymerase I complex, recruited a transcriptional repair coupling factor (TRCF). 
encoded by the mfd gene (Selby et ai, 1991). The TRCF once bound to the complex. 
altered the conformation of the RNA polymerase, resulting in the release of both the 
enzyme and the truncated mRNA. The TRCF which possesses sequence homology with 
UvrB, remained bound to the DNA and attracted the UvrA protein so initiating repair of 
the damaged site (Selby & Sancar, 1993). The elucidation of the events in the eukaryotic 
transcription coupled NER has identified the proteins RAD 1 and RAD 1 0 associate to 
form a DNA endonuclease with a preference for single stranded DNA (Sung et al. 1993: 
Tomkinson et ai, 1993) and that the RAD2IXPGlERCC5 and RAD4IXPC interact 
specifically with the factor b/TFIIH (Freidberg et ai, 1994). The known components of 
the factor b/TRIIH, i.e. RAD25IXPBlERCC3 and RAD3IXPDlERCC2 are of dual 
function which suggests the complex functions as a single unit in both transcription and 
repaIr. 
Repair synthesis 
Following DNA InCISIOn at the damaged site, exonucleases and DNA polymerase 
enzymes act at repair patch sites. DNA strand breaks associated with the repair of 
ionising radiation or small adducts formed by the action of alkylating agents, induce short 
patch repair of 1-4 nucleotides. 
The mammalian DNA polymerases lack associated exonuclease activity, therefore 
independent enzymes are affiliated. Several 5'-3' acting exonucleases have been isolated. 
DNase IV shows a preference for double stranded DNA substrates with 5'-phosphate or 
hydroxyl termini. Although DNase IV shows a resemblance to the polymerase I of E.cnli 
it lacks polymerising activity (Friedberg. 1985). l\H) exonucleases have been found in 
Human placenta - Human placental correxonuclease and DNase VII. The correxonuclease 
is specific for single stranded DNA and can initiate hydrolysis of 30-40 nucleotides from 
either the 5' or 3' termini (Friedberg, 1985). DNase VII is also specific for single 
stranded DNA but liberates short nucleotides exclusively from the 5' terminus (Friedberg. 
1985). In Novikoffhepatoma cells and HeLa cells, DNase V was isolated with specificity 
for double stranded substrates (Friedberg, 1985). The repair synthesis is executed by the 
DNA polymerases a and ~, both of which show a preference for "gapped" 01\:\ 
(Friedberg, 1985). Polymerase ~ shows greater versatility than polymerase a, which is 
only poorly processive; i.e. dissociation from the DNA occurs following the addition of 
-11 nucleotides. The polymerase ~ will initiate synthesis from nicks or 1 nucleotide gaps 
in addition to resynthesising gaps of up to 50 nucleotides. However. reports have 
indicated that if one of the enzymes became rate limiting, then remaining enzyme activity 
increases to compensate (Friedberg, 1985). 
The re-establishment of strand continuity is the final step in the excision repair process. 
DNA ligase catalyses the final phosphodiester bond between the 5'phosphate and the 
3'hydroxyl groups in an ATP dependent reaction. Although DNA ligase I catalyses the 
bond formation in DNA replication, the distinct ligase II has been associated with the 
repair process, especially short patch repair (Friedberg, 1985). 
Mismatch repair 
Mismatch repair is a post-replicative repair process identified in bacteria, yeast and 
higher eukaryotes. Two major forms of the process have been distinguished in E.coli. 
"long patch repair" and "short patch repair". The most versatile of the two is long patch 
repair which corrects mispairs from all replication errors, except C:C, and recognises 
mispaired bases in the early intermediates of homologous recombinations (Rayssiguier el 
aI, 1989). 
The process most fully characterised is that found in E. coli (see Figure 1.15), with 
initiation dependent upon the presence of an unmethylated DNA daughter strand. i.e. 
hemi-mcthylated DNA at d(GATC) sites. The MutH protein. a Mg~' -dependent 
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endonuclease, incises at the hemi-methylated d(GATC) 5' to the G residue (\Velsh L'l al. 
1987). This activity is dependent upon the protein, MutS binding to a mispaired base. 
which then complexes with the protein, MutL that aligns the mispair with a 
complementary sequence. The MutS, Land H proteins are highly conseryed. with 
homologous genes identified in yeast and humans. The excision of the mismatch (up to 
1 Kb) is bi-directional and therefore requires either a 5' acting or a 3' acting exonuclease. 
e.g. exonuclease VII (Chase & Richardson, 1974) or exonuclease I (Lahue & ~lodrich. 
1989) respectively. A DNA helicase action (MutDlUvrD) is required to provide the single 
stranded substrate for these exonucleases. 
The initial evidence that identified a eukaryotic mismatch repair process was the 
recognition of hemimethylated cytosine in CpG sites as the strand target. As previously 
described in Section 1.4.4 of a mutated mismatch repair process has been identified in 
HNPCC together with a hypervariability of microsatellite DNA that induces a mutator 
phenotype, which destabilises the genome and so increases the probability of cancer 
development. 
A recently identified phenotype in mammalian cells confers a "tolerance" towards the 
cytotoxicity of unrepaired methylated bases, especially Q6meG (reviewed in Karran, 
1994). These lesions remain mutagenic and evidence suggests tolerance is derived due to 
a mutated mismatch repair process. Mismatch repair removes incorrect Q6meG or 
thymidine bases. However, removal of thymidine instigates a futile mismatch repair cycle, 
as thymidine is repeatedly reinserted as "correct" opposite Q6meG. Tolerent cells could 
avert such a futile cycle thereby preventing further risk of damage or even death due to 
persistent strand breaks and the prolonged stalling of the replication complex. 
Recombinational repair 
Both DNA crosslinking agents. e.g. cisplatin, UV irradiation, nitrogen mustards, and 
agents which induce DNA double strand breaks, e.g. UV irradiation, X-irradiation, cause 
an increase in recombinational events. Both types of DNA damage, due to the destruction 
of the two DNA strands, lack a complementary sequence from which to initiate D:\A 
repaIr. 
The double strand break repair model predicts that the ends of a double strand "gap" 
created from the double strand break, interact by alignment with the second unbroken. 
homologous duplex present in the genome and utilises its sequence as the template 
required to repair the "gap". This represents a "gene conversion" as information is 
transferred from one duplex to its homologous counterpart (Deng & Nickoloff, 1994). 
Jessberger & Berg (1991) developed an in vitro system to identify the proteins involyed 
in the mammalian recombinational repair system. Utilising extracts derived from calf-
thymus nuclei a high molecular weight complex, termed RC-l was identified. This was 
found to catalyse the recombinational repair of double strand gaps and deletions in DNA 
by gene conversion as well as cross over events. Co-purified with the RC-l complex was 
DNA polymerase E, a DNA ligase thought to be mammalian DNA ligase III. and several 
nuclease activities, e.g. 3'-5'exonuclease. 5'-3'exonuclease, double stranded endonuclease. 
Crosslinks formed between the two DNA strands utilise a combination of nucleotide 
excision repair and recombinational repair. As for most of the repair pathways, the 
mechanism of action is most characterised in E.co/i. The (A)BC excinuclease incises on 
both sides of the crosslink, but in just one of the strands. The protein RecA, which binds 
to single stranded DNA invades the damaged duplex, so displacing the excised oligomer. 
However, the excised oligomer remains bound by the crosslink to the second DNA strand. 
The (A)BC excinuclease then excises this in a manner similar to that of a mono adduct 
so causing its release. The resulting gap is infilled by the action of polymerase L helicase 
II and ligase (Friedberg, 1985: Sancar & Sancar, 1988). 
104.7 Inducible responses in DNA damaged cells. 
104.701 Introduction 
A cdl responds to DNA damage with an induction of gene transcription and protein 
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synthesis, a transient arrest of cell cycle progressIOn, and at least with some D?\A 
damaging agents, apoptosis, the controlled cell death mechanism may be actiyated. Such 
cellular responses are suggestive of a sensor mechanism for the detection of D\:A 
damage, the level of damage incurred and the survival capability of the cell. PADPRP 
has been proposed as a possible candidate for such a detection system (de Murcia & 
Menissier de Murcia. The abundance and localisation of PADPRP, the specificity for 
activation by breaks in the DNA and the rapid half-life of the polymer make this an 
excellent candidate. This Section will briefly review the mechanisms induced by the cell 
in response to DNA damage and the possible involvement of PADPRP. 
1.4.7b Cell cycle checkpoints and the p53 inducible response following DNA damage. 
The cell cycle is a highly regulated process with each phase controlled by a series of 
cyclin dependent kinases (CDKs) which drive the cell through successive checkpoints. 
Mammalian cells contain a broad range of CDKs, with CDK2 acting at S-phase and 
CDKI required for mitosis. PCNA, a cofactor of DNA polymerase 8, involved in DNA 
replication and NER repair synthesis is found complexed with many of the early CDKs. 
The inhibition of the CDKs by interphase checkpoint proteins, regulates the transcription 
rates, degradation and phosphorylation status of the CDKs which restricts the progression 
through the cycle until each phase is complete. These inhibitors could also provide the 
mechanism for blocking the proliferation of quiescent or senescent cells, although a loss 
of function could lead to uncontrolled cell growth and tumour formation (reviewed in: 
Hunter, 1993; Pines, 1994). 
The cell responds to DNA damage with an induction of specific genes and an arrest of 
the cell cycle at the G/S and G/M phases (Little, 1968; Kastan et al. 1992). This 
provides a period for repair, and so presumably prevents the replication and propagation 
of mutagenic lesions which could lead to genomic instability and tumourigenesis. The 
prokin product of the protooncogene p53 was identified as haying a pivotal role in the 
G/S checkpoint control following damage to the DNA (see Figure 1.16) (Kastan <-'I ai, 
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1991; Kuerbitz et ai, 1992). Mutations in the p53 gene are found in 500/0 of all tumours 
(Marx, 1994), with many exhibiting a lack of the G 1 arrest following y irradiation. The 
survival of a knockoutp53 mouse indicated p53 to be non-essential for cell yiability and 
development, although a high susceptibility to tumours in the young adult knockout 
mouse indicated a possible requirement for p53 in the maintenance of genomic stability 
(Donehower et ai, 1992). 
The formation of both single and double stranded breaks in the DNA are the proposed 
trigger for the observed transient increase of the p53 protein following DNA damage 
(Nelson & Castan, 1994). However, the lack of induced gene transcription or protein 
synthesis indicated a post-translational stabilisation mechanism. p53 is a trans-activating 
transcription factor that binds to specific p53 motifs in the promoters of targeted genes 
or the TAT A box binding protein, to influence the expression of proteins involved in the 
regulation of the G 1 arrest (see Figure l.16) (Kern et ai, 1991; Kern et ai, 1992). 
Transcription of the protein p21 wafl/sd\lIcip\ is stimulated by p53 and inhibits the cycling of 
the cell by at least two independent pathways:- 1) The activity of several of the early 
CDKs, i.e. cyclin A-CDK2, cyclin E-CDK2 and cyclin D-CDK2, are inhibited both in 
vitro and in vivo by the binding of p21 (Xiong et ai, 1993), 2) p21 bound to PCNA 
inhibits the activation of DNA polymerase 8 (Waga et ai, 1994). Similarly, the 
transcription of Gadd45, a member of the "growth arrest and damage inducible" family 
of genes was found to be dependent upon p53 stabilisation. A role in DNA repair was 
identified when complexes of Gadd45 were found associated with PCNA in the absence 
of CDKs. and an inducible repair-like response was observed (Smith et al, 1994). 
Following DNA damage. immunostaining techniques identified a redistribution ofPCNA. 
perhaps indicative of a switch from replication to repair (Hall et ai, 1993). 
The expression of mdm2 mRNA is also induced by p53 (see Figure 1.16) (Barak et ai. 
1993). Mdm2 protein binds and complexes to p53 causing the inhibition of transcriptional 
acti\'ities and consequently the G) arrest (Zaubem1an el aI, 1993; Oliner et al. 1993). In 
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cycling cells, a balance was proposed between mdm2 and p53 for the entrance of the cell 
into S phase (Barak et ai, 1993; Otto & Deppert, 1993). The complex. transcription 
factor-like structure of mdm2 would suggest a role in the regulation of gene expression, 
in addition to a simple inhibitory binding function (Picksley & Lane, 1993). 
The G/M phase arrest following DNA damage or incomplete DNA replication has been 
characterised most fully in yeast, although homologies to human genes suggest the 
existence of O2 checkpoint arrest in humans. The arrest of cell division following DNA 
damage is under the control of the RAD9 gene, although it is not essential for the repair 
process (Weinert & Hartwell, 1988). RAD9 could therefore be an equivalent to p53, 
scanning the DNA for signs of damage, especially double strand DNA breaks. 
Observations suggest just a single double strand DNA break is sufficient to activate the 
O/M checkpoint (Sandell & Zakian, 1993). A number of other proteins have been 
identified that also prevent mitosis including RAD 17, RAD24 and MEC 1, MEC2 and 
MEC3 (Hartwell & Kastan, 1994). Interestingly, the phosphorylation of cyclin B-CDK2 
complexes results in the inhibition of a negative feedback pathway, which prevents the 
cells with damaged or incompletely replicated DNA from entering into mitosis (EI-Deiry 
et ai, 1993; Harper et ai, 1993). 
1.4.7 c Apoptosis 
Apoptosis is the programmed death of a cell, which performs an important role III 
embryogenesis and development (Wylie et ai, 1981a). However, numerous DNA 
damaging agents have been found to induce apoptosis (reviewed in: Wyllie et ai, 1981 b, 
Kauffmann el ai, 1993). Several distinct morphological features distinguish apoptosis. 
including the loss of cell-cell interactions. the condensation of the nucleus into 
heterochromatin masses, nuclear fragmentation, and the "budding off' of apoptotic bodies. 
which are subsequently phagocytosed by macrophages prior to lysis (Dive & Hickman. 
1991). 
A considerable number of factors involved in the apoptotic process have been identified. 
although their functions have still to be fully elucidated. An intlux of Ca2+ into cells 
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destined for apoptosis has been observed, which may act as a second messenger. 
signalling the action of further components of the process (McConkey et ai, 1989; 
Tenniswood et ai, 1992). The endonuclease responsible for the oligonucleosomal DNA 
fragmentation observed exhibits a dependency on Ca2+ IMg2+ (Wyllie et ai. 1981 a). A 
possible candidate for the apoptotic endonuclease could be the Ca2+ IMg2+ dependent 
endonuclease activity modulated by P ADPRP (see 1.2.6f). 
The accumulation of p5J was found to result not only in the arrest of the GIl S phase 
transition. but also in an increased frequency of apoptosis (see Figure 1.18) (Lo\\l? c/ aI, 
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1993). However, the effect of p53 on apoptosis appears connected with the function of 
the proto-oncogene c-myc (Hermeking & Eick, 1994). This is a protein-kinase C regulated 
gene, previously implicated in the positive regulation of cell proliferation (Hickman el 
ai, 1992). The levels of c-myc decrease during apoptosis (Hickman et al. 1992). In 
normal cells, damage results in either the delayed continuance of the cell cycle or 
apoptosis, but in cells expressing a mutant p53, only cell proliferation is obseryed. One 
proposal indicates that c-myc, usually found at increased levels in comparison to p53 
attempts to over-rule the p53 0 1 arrest but this results in the p53 stimulation of apoptosis 
(Hermeking & Eick, 1994). Uncontrolled cell growth, with a high predisposition to 
tumourigenesis results from a lack of apoptosis. This is observed in tumours exhibiting 
an increased expression of the bcl-2 gene, known to inhibit apoptosis (Reed, 1994) 
1.4.7d The role of P ADPRP in apoptosis 
Several possible mechanisms for the involvement of P ADPRP in the apoptotic process 
have been proposed, including the modulation of cellular NAD+ (see later discussion) 
(Sims et ai, 1982; Sims et ai, 1983; Nosseri et al. 1994), the poly(ADP-ribosyl)ation of 
crucial proteins involved in the apoptotic process (Darby et ai, 1985) and the 
decondensation of the chromatin due to (ADP-ribose) polymer modifications which would 
then allow access of endonucleases to the DNA (Realini & Althaus, 1992). Howe\cr. 
specific inhibitors of P ADPRP. e.g. 3AB, nicotinamide, thymidine, have given conflicting 
results, with some indicating a decrease in the presence of TNF growth factor and VP 16 
(Agarwal et ai, 1988; Tanizawa et ai, 1989), and others an increase in the level of 
apoptosis induced by nitro so-compounds (Rice et al. 1993). 
Associated with apoptosis is a depletion of the intracellular NAD+ concentration. 
PADPRP activation in the presence of DNA strand breaks results in a rapid loss of 
cellular NAD+ due to the formation of the polymer, (ADP-ribose). This could represent 
a mechanism for damage determination. Previously postulated by Berger & colleagues. 
the "suicide hypothesis" described. that in extreme instances of DNA damage. N:\IY 
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levels would be seriously reduced so resulting in an impaired purIne nucleotide 
metabolism. The resulting limited DNA, RNA and protein synthesis would lead to the 
eventual death of the cell (Sims et ai, 1982: Sims et aI, 1983). Such a mechanism 
provides a link between excessive damage and cell death. Recently, in cells undergoing 
apoptosis, P ADPRP was found to be proteolytically cleaved into an 85KDa fragment and 
a 25KDa fragment, the latter containing the Zn2+ -fingers (Kaufmann et aI, 1993 ~ Lazebnik 
et ai, 1994). Utilising a specific inhibitor of PADPRP, the cleavage was shown to occur 
subsequent to the NAD+ depletion (Kaufmann et aI, 1993). PADPRP activation would 
ensue in response to the initial damage, but could also be activated for a second time due 
to the endonucleolytic fragmentation during apoptosis. Therefore, the cleavage of 
PADPRP may prevent attempts to repair this damage. Interestingly, the PADPRP 
inhibitors failed to arrest both PADPRP cleavage and endonuclease induced fragmentation 
suggesting that PADPRP activation does not actively participate in apoptosis, but is a 
passive response (Kaufmann et aI, 1993). 
1.5 THE ROLE OF P ADPRP IN DNA REP AIR 
1.5.1 Historical perspective 
In 1956, Roitt observed a depletion in the intracellular NAD+ concentration following 
treatment of tumours with alkylating agents. The mechanism of depletion was unknown. 
but further research indicated the decrease to be dependent on the concentration (Schein 
('/ ai, 1973) and potential cytotoxicity of the agent used (Harrap & Furness, 1973). An 
initial theory proposed that non-specific damage to the plasma membrane resulted in the 
loss of NAD+ through "leaky membranes" (Harrap & Furness, 1973). Ho\\~\"t?r. 
subsequent evidence showed the retainment of cell viability following the NAD! 
depletion. with the eventual replenishment of the NAD+ level (Skidmore et al. 1979). 
1'\\'0 further theories were then generated:- 1) the biosynthesis of the NAD' is decreased 
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or 2) the degradation of the NAD+ is increased, mediated by PADPRP activity. 
The involvement of PADPRP function in this depletion of~AD~ was initially recognised 
by Juarez-Salinas and colleagues (1979). The induction of DNA damage by treatment 
with the alkylating agent, MNNG, was correlated with a vast increase in the level of 
poly(ADP-ribose) polymer and a concomitant decrease in the NAD+ level. As damage to 
the DNA initiates the cellular repair mechanisms, activating P ADPRP which utilises 
NAD+ as its substrate, these results suggested an involvement of PADPRP in the repair 
process. Substantiation for the theory was provided when the NAD+ depletion was 
prevented in a concentration dependent manner following co-incubation of the alkylating 
agent, MNU with 5-methylnicotinamide, theophylline, theobromine and thymidine, which 
had been demonstrated to be inhibitors of PADPRP (Skidmore et ai, 1979). The 
degradation of NAD+ in the cell could occur via the action of P ADPRP or the enzyme, 
NAD+ glycohydrolase [EC 3.2.2.6]. Following DNA damage, the level of glycohydrolase 
activity remained constant, and therefore was not accountable for the alterations in 
cellular NAD+ concentration (Skidmore et ai, 1979). P ADPRP had been shown to be 
activated by breaks in the DNA (Janakideveh & Koh, 1974; Miller, 1975; Halldorsson 
et ai, 1978; Benjamin & Gill, 1980), and cytotoxic drugs or y radiation were known to 
lead to DNA strand scissions. Then in 1980, Durkacz and coworkers presented the first 
evidence to indicate the involvement of PADPRP in the cellular recovery from DNA 
damage (Durkacz et ai, 1980). The utilization of alkaline sucrose density gradient 
centrifugation as a measure of the integrity of the DNA revealed that upon co-incubation 
of the alkylating agent, DMS, with the PADPRP inhibitor. 3AB, a persistence of the 
DNA strand breaks occurred, indicating a retardation of the excision repair process. The 
repair of strand breaks occurred over the same time frame as the observed increase in 
polymer synthesis. The role of PADPRP in repair was further corroborated by the 
increased cytotoxicity of the DNA damaging agent when coincubated with non-toxic 
concentrations of the PADPRP inhibitor, or following nutritional deprivation of 
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nicotinamide. The effect on cytotoxicity enhancement and D~A increased strand break 
levels is not simply confined to 3AB and the alkylating agent, DMS. Table 1.1 proyides 
an overview of the effects that a wide variety of P ADPRP inhibitors haye on numerous 
DNA damaging agents. The cytotoxicity of monofunctional alkylating agents, e.g. !\l~IS. 
DMS, and bifunctional alkylating agents, e.g. BCND, melphalan, together with oxidising 
agents, e.g. H20 2, bleomycin, and antimetabolites, e.g. 5FU. hmdUrd. was enhanced when 
in the presence of several differing P ADPRP inhibitors, e.g. 3AB, 3-MBZ, 5meNic, 
3AAB, 6AN. Furthermore, where determined, a concomitant increase in DNA strand 
break frequency was observed. The majority of these agents result in DNA base 
modifications or direct DNA strand breaks. The co-incubation of 3AB with UV 
irradiation gave conflicting results. James & Lehmann (1982) were unable to show 
potentiation of UV cytotoxicity, and there was no effect on DNA strand break levels. 
However, Hunting & Gowans (1987), did observe increased DNA break levels when UV 
irradiated cells were co-incubated with 5mM 3AB. These observations will be discussed 
in greater detail in Section 1.5.2. 
The mechanism of enhanced cytotoxicity in the presence of the P ADPRP inhibitors was 
investigated by analysis of cell cycle perturbations. Das et al (1984), found that a co-
treatment of MMS with 3AB resulted in a progression of cells into the G2 phase of the 
cell cycle, with an ensuing block in the G2 phase. To further characterise this effect 
Boorstein & Pardee (1984), utilised a synchronised cell population, and at the entrance 
into each phase of the cell cycle cells were treated with MMS and 3AB, then assessed 
for cell survival. Cells in Go exhibited little sensitivity towards 3AB until advancement 
into S phase, when the sensitivity was increased. However, towards completion of S 
phase, 3AB sensitivity began to decrease. The lethal effect of 3AB in MMS treated cells 
was considered due to the traverse of the DNA damaged cell population through S phase. 
A transient inhibition of DNA repair of cells in Go was proposed to lack lethality. but 
following traverse into S phase. the lack of repair was proposed to conyert non-lethal 
TABLE 1.1 
DAMAGING PADPRP CYTOTOXICITY BREAK 
AGENT INHIBITOR FREQUENCY 
BCNU 1mM 6AN enhanced ]\;Uo 
Berger et ai, 1982 
DMS 5mM 3AB enhanced increased 
'Y irradiation 5mM 3AB 
no effect no effect 
UV irradiation 5mM 3AB 
no effect no effect 
James & Lehmann, 
1982 
melphalan 5mM 3AB enhanced NfD 
Brown et ai, 1984 
streptozotocin 2mM 5MeNic enhanced N/D 
Nduka & Shall, 1984 
MMS 4mM 3AB enhanced increased 
Boorstein & Pardee, 
1984 
MNNG ImM 3-MBZ enhanced NfD 
Jacobson et ai, 1984 
X-rays 4mM 3AB enhanced increased 
Lunec et ai, 1984 
BrdUrd + UV 20mM 3AB enhanced N/D 
Ben-Hur el ai, 1985 
bleomycin 3-MBZ enhanced increased 
Huet & Laval, 1985 
11 20 2 5mi\1 3AB enhanced increased 
Cantoni c/ al. 1986 
CV irradiation 5mM 3AB \:'0 increased 
Hunting & Gowans, 
1987 
hmdUrd 4mM 3AB enhanced 
Boorstein et ai, 1987 NID 
6-thioguanine 3.25mM 3AB enhanced no effect 
Moses et ai, 1988 
MTIC 1mM 3AAB enhanced increased 
Lunn & Harris, 1988 
5FU 3mM 3AB enhanced no effect 
5FdUrd 3mM 3AB reduced increased 
Willmore & Durkacz, 
1993 
·N/D: Not determined 
lesions to lethal ones as the DNA was replicated. Structural damage to the D~A. resulting 
from incubation with DNA damaging agents. e.g. M\lS, was suggested to result in a G:; 
phase arrest, and this was amplified in the presence of 3AB. Jacobson et al (1985a). also 
observed a G2 phase arrest with MNNG treated cells in the presence of the PA.DPRP 
inhibitor, 3-MBZ. A requirement for PADPRP activation was proposed for the successful 
progression of the cell cycle in DNA damaged cells. 
1.5.2 In which of the repair processes is P ADPRP involved? 
The unique activation of P ADPRP by breaks in the DNA strands greatly determines the 
involvement of the enzyme in the repair process. This immediately excludes an 
involvement in direct repair, e.g. as carried out by MGMT, as the DNA strand integrity 
is maintained. The involvement for P ADPRP in excision repair has only recently been 
clarified. Evidence indicated that the rate of the two excision repair processes was 
governed by different reactions:- in BER, ligation of the break determined the rate of 
repair, but in NER it was the incision step (James & Lehmann, 1982). This is due to their 
different mechanisms of action. In BER, abundant and constitutive DNA glycosylase and 
AP endonuclease enzymes remove damaged bases and rapidly incise the DNA 
respectively. so creating a surge of breaks. However. a low break frequency exists in 
NER as the excinuclease complex must assemble prior to excision of the damaged site. 
This complex then would mask the DNA strand breaks from the PADPRP. These two 
pathways repair different lesions, with BER removing alkylation, and at least a proportion 
of oxidation and gamma-radiation damage and the NER process handling the bulky 
chemical lesions and the dimers formed from UV -radiation. However. the involvement 
of P ADPRP in the repair of UV damage has been a contentious subject for several years. 
Conflicting reports have been published. McCurry & Jacobson (1981) and Berger et al 
(1979) showed PADPRP activity and ADP-ribose polymer synthesis was increased 1.5-:;-
fold following UV -radiation respectively. James & Lehmann (1982) failed to obscrn~ 
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enhancement of cytotoxicity when UV damaged cells were co-incubated with 5m\f 3A.B. 
As a 50 fold increase in PADPRP activation was observed by alkylation damage. the 
break frequency appeared to determine the extent of enzyme activation. Recently Satoh 
et al (1993) utilised E.coli endonuclease III, an analogous enzyme to TH DN.\ 
glycosylase to remove the minor UV lesion, the pyrimidine hydrate from plasmid DNA, 
thereby leaving only the bulky pyrimidine dimers and 6-4 photoproducts. F ollo\ving 
repurification of the plasmids, the treated cell extracts showed no induction of PADPRP 
activity. The conclusion reached therefore was that the small increase in PADPRP activity 
following UV -radiation was due to the BER of the minor UV -induced lesion. This theory 
conforms with the effect of P ADPRP inhibition on other forms of chemical damage. The 
bifunctional alkylating agents, melphalan, BCNU, and cyclophosphamide form crosslinks 
with the DNA due to the presence of two chloroethylating groups. The P ADPRP 
inhibitor, 6-aminonicotinamide potentiated the cytotoxicity of BCNU (Berger et ai, 1982). 
However, although BCNU primarily crosslinks the DNA, initially, just one arm of the 
crosslink is formed which could possibly be a target for BER. Oxidising agents lead to 
the formation of a wide spectrum of lesions in the DNA, with most excised via DNA 
glycosylase action. However, certain lesions, e.g. 8'5'cyclopurine deoxyribonucleosides, 
would be removed by the NER process because their "bulky" conformations would lead 
to helical distortions. Overall, the general consensus is that PADPRP plays a specific role 
in the BER process. 
By the same argument one could predict that PADPRP would not be involved in the 
mismatch repair process. Incision would again be rate limiting and masked by the binding 
of the mismatch repair complex of enzymes and proteins. 
1.5.3 At which stage of excision repair is P ADPRP involved? 
The excision repair process can be divided into three characteristic sections:- 1) incision 
at the site of damage 2) gap formation & polymerisation (repair synthesis. or unscl'duled 
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DNA synthesis (UDS) and 3) ligation of the final phosphodiester bond (for a more 
detailed account see Section 1.4.5c). P ADPRP is activated in response to breaks in the 
DNA strands with the effect of PADPRP inhibitors delaying the rejoining of strand 
breaks rather than completely preventing their repair. This could indicate a lack of total 
inhibition ofPADPRP explainable by the competitive nature of the inhibitors, or a failure 
to achieve sufficiently high intracellular concentrations. Alternatively the PADPRP 
inhibitors could alter the kinetics of strand break repair (Durkacz et af. 1980). At anyone 
time the number of breaks observed represents a dynamic balance between the level of 
strand break formation and the rate of break ligation. The effect of the P ADPRP 
inhibitors on repair synthesis will be considered separately in the following subsection. 
Generally, the function of PADPRP in the repair process is considered to be in the 
regulation of ligation. Following treatment of cells with an alkylating agent the level of 
breaks increases. An increase in the activity of P ADPRP that facillitates ligation would 
thereby increase the rate of strand rejoining and so augment cell survival (James and 
Lehmann, 1982). Creissen & Shall (1982) observed an increased activity of ligase II in 
the presence of DNA strand breaks which was repressed in the presence of inhibitors of 
PADPRP. Ligase activity was estimated by the amount of 32p labelled 5'-phosphate in 
nicked DNA that became inaccessible to alkaline phosphatase due to religation of the 
break. Partially purified extracts from in vivo DMS treated cells exhibited a five fold 
enhancement of ligase II activity, but a co-treatment with 3AB resulted in a return to the 
basal activity. The activity of ligase I was unchanged. The modification by (ADP-ribose) 
polymer of the ligase II itself, or a closely associated protein was postulated. However, 
Yoshihara eI af (1985) utilising a reconstituted poly(ADP-ribosyl)ating enzyme system 
found the activity of ligase II to be inhibited when poly(ADP-ribosyl)ated. which 
suggested an alternative interpretation was required. An early report showed the activity 
of partially purified DNA ligase to be suppressed when in the presence of histone proteins 
(Zimmermann & Levin, 1975). Ohashi and colleagues (1983). utilising DNAlhistonc and 
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reconstituted chromatin systems also found an inhibition of DNA ligase actiyity \\'hen in 
the presence of histone proteins. However. the addition of (ADP-ribose) polymer or 
activated purified PADPRP, resulted in the reactivation of the ligase actiyity. To explain 
the results Ohashi proposed two possible mechanisms. The neutralisation of the negatiyely 
charged histones by poly(ADP-ribose) could result in the decondensation of the 
chromatin, allowing access of ligase II to DNA, or the (ADP-ribose) polymer could 
facilitate the localisation of the ligase at sites of DNA damage due to the observed high 
affinity of the ligase for the (ADP-ribose) polymer. 
1.5.4 The effect of P ADPRP on repair synthesis 
The effect ofPADPRP inhibitors on "gap-filling" of the excised site has been intensi\'eiy 
studied in a number of cells following alkylation or radiation damage (Berger el al. 1979; 
Berger & Sikorski, 1980; Althaus, 1980; Durkacz el ai, 1981 a; Miwa el ai, 1981; James 
& Lehmann, 1982; Sims et ai, 1982 & 1983). In each case an increase in repair synthesis 
was observed. Both Durkacz et al (1981a) and James & Lehmann (1982) showed 
concentration dependent increases in the level of repair synthesis following exposure to 
the damaging agent, DMS but that this plateaued at high concentrations. Cleaver (1985) 
proposed that the number of lesions repairable at anyone time was limited by the cellular 
concentration of repair enzymes. However, the level of repair synthesis was maintained 
during a co-incubation of the lower range of damaging agent concentrations and the 
P ADPRP inhibitors, but at the higher concentrations of DNA damaging agent, the levels, 
rather than reaching a plateau, continued to increase (Durkacz et ai, 1981; James & 
I.ehmann, 1982). This increase was dependent upon the potency of the compound as an 
inhibitor of PADPRP (Miwa ef al 1981, Sims el al 1982). Therefore, until an extreme 
levd of danlage to the DNA occurred, PADPRP appeared to play no part in the 
polymerisation step of excision repair. Miwa et al (1981) proposed two possible theories 
to explain the effect of the inhibitors of PADPRP on repair synthesis following DNA 
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damage:-
1) The suppression of the ligase activity due to PADPRP inhibition (Creissen & Shall. 
1982) induces a persistence of the strand breaks. The delayed religation leads to a loss 
of control over polymerisation, with the correction finish point not recognised, thereby 
resulting in a longer chain of repair synthesis. 
2) A Ca2+/Mg2+-dependent endonuclease activated by PADPRP inhibition (see Section 
1.2.6f) increases the number of breaks induced into the DNA at anyone time so initiating 
extra sites for the polymerisation reaction. 
Berger and colleagues presented a third theory (Sims et ai, 1982 & 1983). Following low 
levels of DNA damage the NAD+ and A TP reserves are maintained, with a continuance 
of DNA repair synthesis. However, after extreme damage to the DNA, PADPRP 
activation could seriously reduce the cellular NAD+ concentration, which in turn could 
deplete the ATP reserves of the cell and thereby affect DNA, RNA and protein synthesis. 
As ATP is an essential co-factor of ligase, and the final phosphodiester bond of repair 
synthesis is catalysed by the action of ligase, then repair synthesis would also be limited 
as demonstrated by the plateau in the rate of repair synthesis at high levels of DNA 
damge. The use of PADPRP inhibitors would preserve the NAD+ levels and consequently 
the ATP supply, which would enable the dose dependent increase in repair synthesis to 
continue. 
The patch size formed during repair synthesis was assessed in an aim to identify which 
of these mechanism was involved. An increase in repair patch size would indicate the 
first and most supported hypothesis, but a constant sized patch would point to the second 
hypothesis. Cleaver (1985) incubated C4C] dThd labelled cells in the presence of BrdUrd. 
elf] dThd and HU after treatment with the DNA damaging agent, MMS before cleaving 
the DNA with miccrococcal nuclease to reduce the DNA size. The incorporation of eHl 
Thd into the C4C] labelled parental DNA would indicate repair synthesis. Ilo\vever. 
BrdUrd labelling was also utilised to distinguish further bet\\"een repair and 
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semiconservative replication according to the density of the strands. Utilising isopynic 
gradients, repair synthesis was observed to increase in the presence of 3AB, but there was 
no alteration in the density of the DNA fragments, that would have indicated an increase 
in the patch size. Therefore, Cleaver (1985) reported that the increase in repair synthesis 
did not correlate with an increased repair patch size and declared the endonuclease theory 
to be the most plausible. The proffered explanation was that by inhibiting P ADPRP. the 
activity of a Ca2+/Mg2+ dependent endonuclease normally dormant due to (ADP-ribose) 
polymer modification would be increased, thereby raising the number of breaks 
introduced into the DNA (see Figure 1.17). At low concentrations of the P ADPRP 
inhibitors repair synthesis would manage slight increases in DNA strand break levels. 
However, at higher P ADPRP inhibitor concentrations, Ca2+ IMg2+ -dependent endonuclease 
activity would be increased, thereby a maximal rate of repair synthesis would be 
observed, and consequently the number of repair patches would be increased. 
However, Ruffer & Morgan (1992) were unable to validate this theory. They utilised a 
technique which electroporated restriction enzymes, which induce double stranded DNA 
breaks, into human cells containing the shuttle vector pHAZE, in the presence or absence 
of 3AB. A lacZ target gene within the vector possessed sites of action for the enzymes. 
Previously. a dramatic increase in the level of chromosome abberations was observed 
following treatment with restriction enzymes in the presence of 3AB (Chung et ai, 1991). 
Utilising the restriction fragment length polymorphisms (RFLP) technique, mutations due 
to abberations at the restriction sites could be mapped. Mutations would result from 
possible recombination events at the sites of restriction enzyme incision, with the loss of 
the recognition sequence for the restriction enzyme. An increase in non-specific nuclease 
action, e.g. Ca2+ IMg2+ -dependent endonuclease, due to the inhibition of PADPRP could 
be determined, as the restriction fragment pattern of recovered plasmids would bc altered 
due to mutation outside of the known restriction sites. However, the results showed no 
significant differences bet\\Cl'Il mutation rates of the untreated or th~ 3AB-treated cdls 
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thereby indicating the absence of non-specific endonuclease activity. 
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Figure 1.17 Pathway by which inhibition of poly(ADP-ribose) synthesis by 3AB may 
lead to a non-specific attack on DNA by endogenous nucleases after exposure to DNA-
damaging agents (Cleaver & Morgan, 1985). 
1.5.5 Topoisomerase I 
Topoisomerase I relaxes supercoiled DNA prior to DNA replication and repair (see 
Section 1.2.6e). Compounds that inhibit topoisomerase I, e.g. camptothecin and topotecan, 
are cytotoxic towards cells due to stabilisation of the topoisomerase I:DNA complex 
which prevents further activity (laxel et aI, 1991; Mattern et aI, 1991). However, these 
inhibitors have an essential requirement for active topoisomerase I. As previously stated 
in Section 1.2.6e. poly(ADP-ribosyl)ation of topoisomerase I resulted in the reversible 
impediment of enzyme:DNA complex formation with the inhibition of enzyme acti\'ity 
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(Ferro & Olivera, 1984; Kasid et al. 1989). Under such conditions, the effect of the 
topoisomerase I inhibitors would be diminished, with a reduction of the cytotoxic 
potential. However, Mattern et al (1987) observed that if cells were treated \\-ith an 
inhibitor of PADPRP, e.g. 3AB, prior to the administration of the topoisomerase I 
inhibitor, the topoisomerase I would not be modified by (ADP-ribose) polymers, and a 
greater proportion of active topoisomerase enzymes would be present to form cleayabl~ 
complexes. This was supported by the observation that 3AB was able to potentiate 
camptothecin cytotoxicity (Mattern et ai, 1987). 
The (ADP-ribosyl)ation of topoisomerase I in the vicinity of DNA strand breaks has 
been postulated as part of the mechanism to aid the temporary shutdown of DNA 
replication (longstra-Bilen et ai, 1983). 
1.5.6 Modulation of chromatin structure by poly(ADP-ribose) polymer. 
Several reports in the literature have related the modulation of the chromatin structure. 
resulting from PADPRP activation (see Section 1.2.6b) to an early event in excision 
repair. P ADPRP is activated in response to DNA breaks formed during BER. An (ADP-
ribose) affinity column was utilised to separate oligonucleosomes modified by polymer 
from the bulk chromatin taken from cells treated in vivo with an alkylating agent. The 
modified regions were observed to be preferentially located adjacent to breaks in the 
DNA (Thraves et ai, 1985). Both auto- & hetero-modification reactions occur following 
activation of PADPRP, with extensive modification of histone HI resulting in the 
relaxation of the chromatin structure (Poirier et ai, 1982b; Aubin et ai, 1983; Niedergang 
('/ al. 1985: De Murcia ct al. 1986). Modification of just 100/0 of the histone HI proteins 
has been estimated to induce the relaxed state (Thoma & Koller. 1981). Subsequent 
modification of thc core histones by ADP-ribose polymer would then destabilise the 
DNA/protcin interactions at the nucleosomal level of the chromatin organisation. An 
antibody approach was used to assess the disruptiyc effect of the (.\DP-ri hose) polymcr 
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on the chromatin structure. Antibodies directed against epitopes on the surface of the 
histone proteins showed an altered response following P ADPRP activation, indicativc of 
local rearrangement (Thibeault et ai, 1992). Most of the in vitro systems designed to 
study PADPRP induced chromatin rearrangements fail to emulate the in l'ivo situation, 
with PADPRP and PADPR glycohydrolase acting concurrently. However, an in vitro 
procedure devised by Thomassin et al (1992), showed that in a high polymer turnoycr 
situation i.e. a high glycohydrolase activity similar to that found in intact cells. there was 
an overall reduction in the polymer content with the polymer distribution altered. A 
reduced level of automodification of P ADPRP itself was observed with the percentage 
of polymer bound to the histone HI and core histones increased. The increase in negative 
charge resulting from ADP-ribosylation would decrease the affinity of the histones for 
the DNA, resulting in the dissociation of the chromatin solenoid. This relaxation of the 
chromatin structure in the vicinity of a DNA break has been proposed to facilitate the 
access of repair enzymes to the damaged site. Substantiation for the theory was observed 
as the activity of DNA polymerase a (Niedergang et ai, 1985) increased following the 
ADP-ribosylation of polynucleosomes. The chromatin rearrangement hypothesis would 
also support the involvement of DNA ligase activity as local chromatin disruption would 
facilitate a secondary effect on repair reactions. Mathis and Althaus (1986, 1990) 
discovered that the P ADPRP associated structural alterations of the chromatin were 
coupled with the repair of damage to the DNA and that the repair patches were located 
in the free-DNA domains. Following depletion of the chromatin-bound ADP-ribose 
polymers though. an inhibition of the excision repair process was observed. 
As previously described in Section 1.2.5d, specific polymer patterns of the histone 
proteins have been associated with the regulation of the P ADPRP reaction during DNA 
repair (Naegelli & Althaus, 1991; Malanga & Althaus, 1994). The ability of the histones 
to modulate the polymer configuration indicated the possible presence of non-covalent 
interactions bct\\cen the histones and the polymers. Panzeter & Althaus (1992) 
72 
acknowledged the existence of such bonding with a hierarchy of preferential interactions:-
branched polymer > long linear polymers > short linear polymers. In "ivo data, using 
mammalian cell extracts, found that the histones \\-ere exclusively capable of binding 
noncovalently to the polymer and interestingly, the histone domains involyed in these 
interactions were identical to those involved in chromatin condensation e.g. histone HI 
bound via the C-carboxy terminal, whereas histones H3 and H4 utilised the N-terminal 
(Panzeter et ai, 1993). The histone shuttle mechanism, proposed by Althaus and 
associates describes an elegant reaction pathway for the involvement ofpoly(ADP-ribose) 
metabolism and the modulation of chromatin in response to DNA damage (Realini & 
Althaus, 1992) (see Figure 1.18). P ADPRP, targeted by breaks in the DNA, is activated 
which results in the extensive automodification of the enzyme. The presence of polymer. 
especially large branched structures, attract the histone proteins which bind non-covalently 
to the polymer upon dissociation from the DNA. This renders the DNA free for the 
action of repair enzymes. Finally, degradation of the polymer by PADPR glycohydrolase 
eliminates the binding sites for the histones causing the reassembly of the nucleosomal 
structure with the DNA. 
1 6f.,jolymerase ~~~1 
glyco-
hydrolase 
J ,. 
~ 
-0 
Figure 1.18 A schematic representation of the poly(ADP-ribosyl)ation-dependent histone 
shuttle on DNA. 
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1.5.7 New advances in the quest to identify the function of P ADPRP in repair. 
Recent advances in molecular technology have enabled P ADPRP research to enter new 
avenues. 
The development of mutant cells with a reduced P ADPRP activity has provided a means 
to bypass the use of PADPRP inhibitors and the possible involvement of secondary 
effects on the cell metabolism. A replica-plating mutagen treatment was used, and the 
CHO colonies were subsequently screened using a [32p]NAD+ permeable cell-screening 
assay for reduced PADPRP activity (MacLaren et ai, 1990). Initially, two mutant CHO 
lines were characterised, P ADR-1 and P ADR-2, both of which possessed just 50% of the 
parental PADPRP activity, but maintained a similar growth rate. The sensitivity to the 
DNA methylating agent, ethyl methane sulphonate (EMS) was found to be increased 1.3-
fold in the PADR-1 line as compared to the parental CHO cells (MacLaren et ai, 1990). 
P ADR-1 was subsequently utilised for a second mutagen treatment. P ADR-9 was isolated 
and found to exhibit just 17% of the parental P ADPRP activity but again maintained a 
similar growth rate (Witmer et ai, 1994). The sensitivity towards EMS was further 
increased in the PADR-9 cells to 2.8-fold. A direct correlation between the reduced 
PADPRP activity in the mutant cells and the increased sensitivity to cell kill by alkylating 
agents was observed. 
The depletion of endogenous P ADPRP in HeLa cells by the transfection of an antisense 
RNApADPRP plasmid construct showed P ADPRP activity to be decreased -800/0, and the 
levels of PADPRP protein reduced by -90%. Assessment with deoxyribonuclease I 
showed PADPRP depleted chromatin to have an altered structure. Following treatment 
with MMS, PADPRP depleted HeLa cells exhibited a decreased survival as the cells were 
unable to initiate DNA strand break rejoining. However, normal PADPRP levels were 
restored after 8-16 hours. and at later times repair was found to be re-established. The 
concentration of P ADPRP present was considered in excess for DNA repair or 
replication, but it was postulated that the excess le\'els were required for maintenance of 
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chromatin structure (Ding et ai, 1992 & 1994; Ding & Smulson, 1994). The effect of 
antisense construct expression was then investigated in the repair of either UV or nitrogen 
mustard damage in the essential gene, DHFR. Antisense cells were only deficient in the 
repair of alkylation damage, adding support to the participation of PADPRP only in gene-
specific BER of alkylation damage. This was verified further as cells expressing the 
antisense constructs showed an increased sensitivity to the nitrogen mustard in a 
clonogenic survival assay, and so indicated the requirement for the repair of essential 
genes in cellular survival (Stevnsner et ai, 1994). 
The development of a cell free system to assay DNA repair showed P ADPRP to possess 
an inhibitory effect on repair. The cell free system involved the incubation of a y 
irradiated plasmid containing one single strand break/molecule together with soluble cell 
extracts of cultured cells supplemented with Mg2+, dNTPs, NAD+, ATP and a 
regenerating A TP system. Repair was measured by the amount of plasmid converted to 
covalently closed circular DNA. The effect of each component suspected of an 
involvement in the repair process was investigated by its selective elimination from the 
assay. In the absence of PADPRP, repair occurred equally efficiently in the absence or 
presence of NAD+, but following the addition of purified P ADPRP to the system, an 
NAD+ requirement was essential to release the P ADPRP molecule bound to the strand 
break to allow strand rejoining to occur. The presence of a PADPRP inhibitor also 
aggravated the situation by the delayed release of the P ADPRP. However. this system 
would indicate PADPRP was not essential for DNA repair. A structural role in the 
chromatin was again proposed, or a possible signalling role due to the P ADPRP binding 
to the DNA strand break ends thereby signalling to the cell to arrest and so preventing 
lesions replicating (Satoh & Lindahl, 1992; Satoh et ai, 1993). Similar results \\cre 
obtained when the innovative technique of overexpressing recombinant DNA binding 
domain (DBD) polypeptides of PADPRP in CV -1 cells was performed (Molinete ('I ai, 
1993). Following MNNG treatment a trans-dominant inhibition of endogenous PADPRP 
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was observed due to the binding of the DBD to the strand breaks. Once bound. release 
of the DBD could not be effected due to the lack of the domains required for the 
automodification reaction. This is a similar situation to the presence of P/\OPRP but 
absence of NAD+ in the cell-free system. 
Recently, the most exciting revelation was the survival ofa "PADPRP knock-out mouse" 
indicating P ADPRP to be non-essential for cell viability and organism deyeiopment 
(Wang et ai, 1995). Mice devoid of the P ADPRP gene would remove the possible 
secondary reactions and side-effects of the PADPRP inhibitors and experimental 
techniques previously used. A genetical approach utilised mice with a disrupted P ADPRP 
gene and homologous recombination. Embryonic stem cells were used and mice 
heterozygous for P ADPRP i.e. chimeras were crossed to give homozygous P ADPRP 
negative mice. After 5-6 months, -30% of the mice developed severe skin disease, and 
this was increased with age. The level of DNA repair in PADPRP deficient embryonic 
fibroblasts (-/-) and control fibroblasts containing PADPRP (+/+) was assessed by:- (1) 
the measurement of the restoration of in vitro damaged SV 40 CAT plasmid expression 
levels, which had been transfected into the P ADPRP deficient and control fibroblasts. 12 
hours after transfection, CAT expression levels from both groups of cells containing the 
damaged plasmids were decreased, as compared to undamaged controls. However, 28 
hours later. control values were reattained, but comparable rates of repair were observed 
in both the -/- and +/+ fibroblasts, indicative of similar repair efficiencies. (2) The 
incorporation of [3H] thymidine into replication arrested -/- and +/+ fibroblasts, treated 
with either MNNG or UV irradiation was measured to analyse the rate of UDS. Both cell 
lines showed comparable concentration dependent increases in [3H] thymidine 
incorporation, indicating PADPRP not to be required for either BER (MNNG treatment) 
or NER (UV treatment). This would again support the results from the cell-free system. 
PADPRP was postulated to be important component in the response to environmental 
stress. and target molecules. e.g. p5~. eyelins were proposed to require ,\DP-ribosylation 
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In response to such external stresses. However. the long tenn effect of PADPRP 
deficiency has yet to be established. The efficiency of the repair processes is considered 
to decline with the age of the organism, with an increased probability of mutation and 
the development of tumours. 
1.6 AIMS 
15 years ago, a concept for utilising P ADPRP inhibitors as resistance modifiers in the 
treatment of leukaemia was proposed (Durkacz et aI, 1980). This emanated from the 
ability of these inhibitors, e.g. 3AB, nicotinamide, to potentiate the cytotoxicity of DNA 
damaging agents which activated the BER mechanism. However. due to a lack of potency 
and specificity towards PADPRP, and problems with insolubility, this idea has failed to 
be realised. The recent development of novel P ADPRP inhibitors with greatly enhanced 
potency (-60 fold greater than 3AB) has again raised the possibility for clinical 
development. Before entrance onto a clinical trial, extensive in vitro and intact cell studies 
must be performed. One of the aims of this thesis was to ascertain if the inhibitory ability 
of two novel compounds, NUI025 and PO 128763, both of which exhibit -60 fold 
increased P ADPRP inhibition when compared to 3AB in vitro, showed the same increased 
potency when cellular responses to DNA damage were analysed. The two "classically" 
used inhibitors, 3AB and BZ were used as comparisons. The clinically relevant, 
monofuctional alkylating agent, TM was utilised as the DNA damaging agent, and a 
series of growth inhibition, cytotoxicity and NAD+ studies were the biological endpoints 
chosen. 
Upon examination of the PADPRP inhibitor literature, it was apparent that a 
comprehensive study to analyse the PADPRP inhibitor concentration range required to 
effect an increase in the single strand break frequency or cytotoxicity. following damage 
to the DNA. was missing. The majority of studies concentrated only on the llse of a 
single. high concentration of the PADPRP inhibitor together with varying doses of the 
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damaging agent. Due to the availability of P ADPRP inhibitors \\-ith differing le\els of 
potency. a study of changes in single strand break levels. to determine such concentration 
ranges was initiated, again utilising the clinically relevant T~1. 
A further aim attempted to discover if disturbances to the intracellular N.-'\O-
concentration resulted in an alteration of the PADPRP activity, following DNA damage. 
NAD+ is the substrate for PADPRP, therefore alterations to the metabolism of NAD+ 
could be an important regulator of PADPRP activity. A cell line, deficient in the final 
metabolic enzyme of NAD\ NMNAT, was isolated and characterised (in comparison to 
the parental cell line <5% NMNAT activity and -500/0 lower NAD+ le\els were obseryed) 
before being used to assess the effect low NAD+ levels and low biosynthetic capacity of 
NAD+ had on the activity of PADPRP in DNA damaged cells. 
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CHAPTER 2 : MATERIALS AND METHODS 
2.1 MATERIALS 
Chemicals/reagents 
3-Aminobenzamide was purchased from Pfaltz & Bauer. Phase Separations, Deesside. 
UK~ Coomassie protein assay reagent was bought from Pierce, Rockford, Illinois 61105. 
USA~ trypan blue was purchased from NBL, U.K, and SeaKem ME agarose was acquired 
from FMC Bioproducts, Rockland, ME 04841, USA. Adenosine 5' -triphosphate (ATP). 
p-nicotinamide adenine dinucleotide (PNAD+), p-nicotinamide mononucleotide (PNMN). 
benzamide (BZ), dithiothreitol (DTT), 3-[4,5-dimethylthiazol-2-yl]-2.5 
diphenyltetrazolium bromide (MTT), phenazine methosulphate (PMS) and triethanolamine 
were purchased from Sigma Chemical Company. St.Louis, MO, USA. 
All remaining chemicals, unless otherwise stated were of Anal R grade and purchased 
from Sigma or BDH, Dorset, UK. 
Enzymes 
Alcohol dehydrogenase (ADH) and Proteinase K were both purchased from Boehringer 
Mannheim Biochemica, Mannheim, Germany. 
Radiolabel 
[2- 14C]Thymidine, specific activity = 52mCi/mMol, [methyl-3H]thymidine, specific 
activity = 41 mCi/mMol and e2p] NAD\ specific activity = 1000Ci/mMoi were bought 
from Amersham International, Amersham, UK. 
Tissue culture supplies 
The constituents of the tissue culture medium were obtained from Gibco BRL Life 
Technologies Ltd, Paisley, UK. Foetal calf serum (FCS) was bought from Globepharm 
Ltd, Esher. Surrey. UK. Dulbecco's phosphate buffered salts (modified) without Ca2+ and 
Mg~+ (Dul A) and sterile NaOH \\"ere purchased from ICN Flow, leN Biomedicals inc .. 
I rvinc. llK. Tissue culture plastic ware (25cm2 & 80cm~ flasks. 60x 15 dishes. 6-wdl 
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multi-dishes) was obtained from NUNC. Denmark. Acrodiscs (2JlM pore size) were 
obtained from Gelman Sciences, USA for filter sterilisation. 
2.2 PREPARATION OF THE STOCK DRUG SOLUTIONS 
Both 8-carbamoyl-3-methylimidazo-[5, 1-d]-1 ,2,3,5,-tetrazin-4-(3H)-one (temozolomide. 
TM) (kindly supplied by Professor M.F.G.Stevens, Cancer Research Laboratories, 
University of Nottingham) and 5-(3,3-methyl-1-triazeno) imidazole-4-carboxamide 
(MTIC) (synthesised in the Chemistry Department, Newcastle University) were prepared 
to stock concentrations of 100mM in DMSO and stored aliquoted at _20DC. 2-~-D­
ribofuranosylthiazole-4-carboxamide)(tiazofurin, TZ) (generously donated by Dr V. 
Narayanan, National Cancer Institute, Bethesda, MD) was made to a stock concentration 
of 200mM in sterile water, filter sterilised and stored in volumes of 500J.l1, at _20DC. 
30mM stocks of 3AB and BZ were prepared fresh in medium for each experiment. Prior 
to use, the stocks were filter sterilized and the required concentrations of the compounds 
were prepared by dilution into medium. Stocks of 8-hydroxy-2-methylquinazolin-4[3H]-
one, NUI025 (synthesised in the Chemistry Department, University of Newcastle upon 
Tyne) and 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one, PD 128763 (a gift from Dr 
W.R.Leopold, Parke Davis Pharmaceutical Division, Warner Lambert Company, Ann 
Arbor, MI 48105) were made at a concentration of 200mM in DMSO and stored frozen 
in aliquots at _20DC. Dilutions of NU1025 and PD 128763 were prepared into DMSO. 
The volume of DMSO-dissolved drug, added to the cell suspensions, was such that the 
DMSO content was kept constant and did NOT exceed 1 % in the medium. Treatment of 
cells with DMSO alone results in a concentration-dependent inhibition of cell growth. At 
10/0, the growth was reduced to approximately 700/0 of control cell growth. In experiments 
where drug-treated cells were exposed to DMSO, control cells were also given an 
equivalent volume of DMSO. 
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2.3 TISSUE CULTURE 
The murine leukaemic cell line, L 121 0, (obtained from European Collection of :\nimal 
Cell Cultures, U.K.) was maintained as a suspension culture in RP\H-1640 containing 
10% FCS, 10mM glutamine, 18mM HEPES buffer, IlmM sodium bicarbonate and 100 
Units/ml penicillin, 100~g/ml streptomycin. The medium was adjusted to pH 7.2 with 1 ~1 
sterile NaOH. The cells, maintained in tissue culture flasks with the lids loosened to allo\\" 
gas exchange, were routinely subcultured to keep the density between 5xl03-
8xl05cells/ml, otherwise cell growth slowed due to the presence of old and dead cells. 
The cells, which doubled each 12-13 hours, were incubated in a Heraeus incubator at 
37°C, 50/0 CO2• For experimental procedures, cells in the exponential growth phase were 
used. 
2.4 ROUTINE TEST FOR MYCOPLASMA 
Mycoplasma are a genus of bacteria that are a common contaminant of cell cultures, and 
which can produce various abnormal changes within the cell. The growth of the cell is 
not necessarily affected, thereby detection is difficult. 
Utilising the fluorescent stain, Hoechst 33258 which specifically binds to DNA, the cells 
were routinely tested for mycoplasma (Chen 1977). L1210 cells were cocultured for 3 
days in RPMI medium with an adhesive cell line, e.g. CHO-Kl (Chinese hamster ovary) 
grown on to glass coverslips. Contaminated L 1210 cells would lead to the cross-
contamination of the adhesive line. When the CHO-Kl cells were approximately 50% 
confluent they were "fixed" using Carnoy's fixative (3:1, methanol:acetic acid) stained 
and then visualised using an UV microscope. Mycoplasma are identified as small 
morphologically uniform fluorescent bodies located in the extranuclear and intercellular 
space. The L 1210 cells tested negati\'e for mycoplasma at all times. 
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2.5 CALCULATION OF CELL DENSITY 
The haemocytometer (Neubauer, UK) was used to determine the cell density. A thick 
glass coverslip was positioned over two mirrored counting chambers found in the centre 
of the glass slide, so producing Newton' s ring interference patterns. Each chamber is 
divided into 9 x I mm2 squares and with the coverslip in place, the depth of the chamber 
is O.Imm. The volume of the square is calculated as shown:-
(lmm x Imm) x O.Imm = O.lmm3 (=10-4ml) 
The counting chambers were filled by capillary action using a pasteur pipette which was 
touched against the edge of the coverslip. Cells were counted in either the centre or -+ 
corner squares, with cells touching the upper and right hand perimeter lines ignored and 
those touching the lower and bottom lines counted. At least 100 cells were counted for 
each determination. 
2.6 CRYOGENIC STORAGE OF THE LI210 CELLS 
Stocks ofL1210 cells for long term storage were preserved in liquid N2. Upon reduction 
of the temperature, ice crystals form within the cell. The presence of DMSO in the freeze 
media helps to prevent the formation of ice. and by freezing the cells slowly, but by 
thawing rapidly, damage can be kept to a minimum. 
Freeze-down protocol 
L 121 0 cells of a known cell density were centrifuged for 5 min at 400g. 20DC (MSE 
Mistral 3000, Fisons, U.K.). The cell pellet was resuspended into an appropriate volume 
(approximately 106 cells/ml) of the freeze medium (RPM! medium containing 10% 
DMSO). To ensure sterility, the DMSO was filter sterilised into the medium immediately 
before use. The cells were stored in cryotubes (NUNC) in Iml aliquots. and for the initial 
24 hour maintained at _BODC. They were then transferred to the liquid N2 stores. 
Revival protocol 
An aliquot of cells taken from the liquid N2 was thawed quickly by plunging the 
\..)"') 
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cryotube into a waterbath at 37°C. The cells were then added to 9ml medium and 
centrifuged as above to remove traces of the DMSO. before being resuspended into fresh 
medium. After a 24 hour incubation the cells were again pelleted and fresh medium 
added. 
2.7 ISOLATION OF DRUG-RESISTANT Ll210 CELLS 
L 121 0 cells resistant to tiazofurin (TZ) were selected using a step wise selection protocol 
(Jayaram et al 1993). In the parental L1210 cells, TZ has an IC50 of 2.7f.lM (as 
determined using a growth inhibition analysis, see Section 2.9). The L 121 0 cells were 
subcultured as described above but a concentration of TZ equal to the I C50 was added to 
the medium. The TZ concentration was maintained for several weeks with routine 
subculturing until the growth rate had resumed that of the parent cell line. The 
concentration of TZ was then raised at intervals, with the cells allowed time for a similar 
adjustment between each new concentration. A final concentration of 2mM TZ was 
achieved after approximately 3 months, representing a -1000 fold increase in the I C50 
value (see Figure 6.2). 
The resistant L 121 0 cells were then cloned to ensure that a cell line was obtained which 
represented a homogeneous population derived from a single cell. The technique for 
colony formation was as described in Section 2.9. A known number of the cells were 
seeded into the soft agar in tubes that contained TZ to a final concentration of 2mM. The 
cells were then left for 7 days to allow for the development of colonies, at which point 
the contents of the tube were transferred to plastic tissue culture dishes, and single 
colonies extracted using the tips of sterile glass pipettes. The colonies were placl?d into 
individual wells of a 96 well plate containing IOOf.l1 medium and agitated to cause 
dispersal into single cells. From this point. only a single cell suspension was taken to be 
subcultured as described in Section 2.3. This cell line was designated TZR (for tiazo furin 
resistant). Resistance was stable over a 3 month period in the absence of selection. but 
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to guarantee against a possible reversion to sensitivity, the cells \vere grown in 2m~1 TZ 
for a single passage every 4 weeks. Experiments were carried out using the cloned 
resistant cells, after they had been grown in the absence of TZ for at least two passages. 
TZ is phosphorylated to tiazafurin 5' -monophosphate (TRMP) which is then converted 
to the active metabolite, thiazole-4-carboxamide dinucleotide (TAD). an analogue of 
NAD+ (Cooney et al 1982). TAD is unable to efflux from the cell. Thus it was 
considered necessary to grow the TZR cells in the absence of TZ for several generations 
prior to experimentation to ensure the loss of cellular metabolites of TZ by dilution. 
2.8 POLY(ADP-RIBOSE) POLYMERASE ASSAY 
The permeabilised cell assay for the measurement of P ADPRP activity was as described 
by Halldorsson et ai, 1978. The principle of the procedure involves the introduction of 
"holes" into the cell membrane through which the labelled NAD+ can pass freely. 
Together, the hypotonic buffer and the ice-cold conditions result in osmotic and cold 
shock permeabilisation of the cells. 
In the presence of a blunt ended oligomer to activate the enzyme, the labelled NAD+. 
in an active poly(ADP-ribosyl)ation system is rapidly incorporated into acid-insoluble 
(ADP-ribose) polymer. The ability of compounds to actively inhibit PADPRP can be 
assessed by their inclusion into the reaction mixture. 
Preparation of the permeabilised cells 
L 121 0 cells were seeded to give a final cell number of 8x 107 cells in 100mi on the day 
of the experiment. After the cell number was determined by haemocytometer count, the 
cells were washed once in ice cold Dul A and the pellet resuspended into ice cold 
hypotonic buffer (9mM Hepes, 4.50/0 dextran, 4.5mM MgCl~. adjusted to pH 7.8 with 
NaOH/HCL stored at +4°C. DTT was added to a final concentration of 5mM from a 
100mM stock solution prior to use) to a density of 3xl07cells/ml. Following a 30 minute 
incubation, 9 volumes of ice-cold isotonic buffer was added (40mtvl Hepes. 130mM KCL 
84 
40/0 dextran, 2mM EGTA, 2.3mM MgCI2• 225mM sucrose. adjusted to pH 7.8 with 
NaOHlHCI, stored at +4°C). DTT was added to a final concentration of 2.5m:"! from a 
1 OOmM stock solution prior to use. The extent of permeabilisation was determined using 
'-
a trypan blue exclusion haemocytometer count. The permeabilised cells (ideally >950/0) 
take up the blue dye whereas intact cells exclude the dye. Once resuspended into the 
isotonic buffer, and kept on ice, the cells remain useable for up to 1 hour. 
Preparation of the NAD+ 
A stock solution of approximately 6mM NAD+ was prepared in sterile water. The 
absolute concentration of this stock was determined from the measurement of the optical 
density (OD) of a 100 fold dilution at 260nm, using a UV lamp and quartz cuvettes. 
Based on this data, a working NAD+ stock solution of 600~M was prepared (£=18000. 
see Section 2.14) to which a small volume (2-5~1), depending on the current specific 
activity of [32p] NAD+ (-1 O~Ci/~I), was added. 
Poly(ADP-ribose) polymerase assay 
The components of the reaction mixture, 5~1 palindromic (CGGAATTCCG) 
oligonucleotide (200j.lg/ml in 10mM Tris-HCI, pH 7.8), 50~1 600~M NAD+ containing 
e2p] NAD+, 8~1 drug dissolved in DMSO (a final concentration of 2%) (prepared at 50X 
required final concentration), 37~1 H20 were added to 15ml conical bottomed tubes 
(NUNC) and positioned in a shaking water bath at 26°C. Each drug concentration was 
performed in quadruplicate. 
The previously prepared cell suspension was warmed for 7 minute, before being mixed 
thoroughly with an Eppendorf repeat dispenser. To each of the reaction tubes. 300~1 cell 
suspension was added at 5 second intervals, mixing the tube contents after each addition. 
Each tube was allowed a 5 minute incubation before the addition of 2ml of ice cold TCA 
(10% w/v TCA, 10% w/v Na pyrophosphate). Assay blanks (To), which correct for non-
specific binding of the C2pJ NAD+ to the filter (see next Section) \vere prepared hy 
addition of the TCA to the reaction mixture before the cells \H?re added, thereby 
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preventing initiation of the reaction. All the tubes were left on ice for a 1 hour incubation 
period. 
Utilising a Millipore filtration apparatus (Millipore Corporation, Bedford, Mass. USA). 
GFIC (25mm) microfibre filters (Whatman International Ltd, Kent. UK) were placed 
rough side upwards onto the filter holder, after being moistened with the 10% TCA. The 
funnel assembly was secured tightly on top and the contents of the tubes added to 
indi vidual funnels. Each was rinsed with TCA (1 % w/v TCA, 1 % w/v N a pyrophosphate) 
6 times, under gentle suction pressure. The filters were then removed, and pinned onto 
a foil covered card with a yellow Gilson tip beneath to prevent them sticking before 
being oven dried. The filters were placed into scintillation vials (20ml, Packard 
Instrument Company, USA) containing 10mi scintillation fluid (Wallac Scintillation 
Products, Finland), the vials capped and then shaken. Four standards (S) containing 10J.lI 
of the 600J.lM NAD+ + r2p] NAD+ solution were prepared and 10mi scintillant added. 
All of the vials were counted on the ~ scintillation counter (Wallac Scintillation Products) 
for 2 minute. 
Calculation of the results 
Initially the number of counts which represented 1 pMol NAD+ was calculated. The mean 
of the four standards (SM) was utilised: SM = number of counts/pMol NAD+ 
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The pMol NAD+ is representative of the level of (ADP-ribose) polymer formed. 
Therefore, the pMol NAD+ present in each of the samples (P) after a 5 minute incubation 
was calculated. 
First. the mean of To, TOM was determined and subtracted from each of the sample 
counts, thereby removing non specific background counts: P - TOM = Po 
The values of Po obtained were then divided by the number of counts representitiYe of 
1 pmol NAD+ (C) to give: 
Po = pMol NAO' in each sample Cs 
-C 
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As the volume of cells added to each sample was 300~L Cs represents the pMol NAD-
in 300~1 of the cell suspension. To determine the pMol NAD- in Iml of cell suspension. 
Cs was mUltiplied by 3.33. A cell count taken prior to the experiment. was then utilised 
to allow the presentation of the final result as: 
pMol NAD+ incorporated /1 06cells/5 minute 
The ability of a compound to inhibit P ADPRP was expressed as a percentage inhibition 
of control: 
1 - (+Inhibitor) x 100% = % inhibition 
control 
However, in certain cases the PADPRP activity was expressed as: 
pMol NAD+ /mg protein. 
In this case, a sample of the permeabilised cells was removed for protein estimation (see 
Section 2.15). 
2.9 DETERMINATION OF THE CELL GROWTH RATE 
The number of parental and TZR L 121 0 cells were determined utilising a coulter counter 
(Coulter Electronics Ltd, UK), which is an electronic counting machine. The cells, 
suspended in an electrolyte. are drawn through a small orifice, across which a current 
flows between two immersed electrodes. As each cell enters the aperture, it displaces its 
own volume of the electrolyte and so modulates the basic impedance of the current. This 
is detected as a voltage pulse that is proportional in height to the volume displaced, and 
therefore also to the magnitude of the particle size. The pulses in voltage are monitored 
and a rapid, accurate determination of the cell number is obtained. The counter settings 
used were, a lower threshold (T L) of 11 ~m and an upper threshold (T u) of 20Jlm (the 
threshold settings determine the size range of the particles which are to be counted) 
The cells, seeded at 1 xl 04/ml into :24-well multi-dishes. \n~rc incubated, and at 24 hour 
intervals the cells were pipetted up and down using a Gilson pipette, to ensure a single 
cell suspension, and the number in quadruplicate wells was determined. The results. 
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plotted as the cell number against time (hours) enabled the doubling time of the cells to 
be calculated. 
2.10 GROWTH INHIBITION ASSAY 
Growth inhibition assays are a measure of the cytostatic effect of a drug, or 
combinations of drugs, on the growth rate of cells. L1210 cells were seeded as described 
in Section 2.9 and incubated for a 24 hour period prior to the addition of drug 
combinations (see Figure legends for details of the concentrations and combinations 
used). In experiments in which PADPRP inhibitors were utilised in conjunction \\ith 
drugs, e.g. temozolomide (TM), the inhibitors were added first. 
For each required drug concentration, triplicate wells were prepared, along with three 
wells designated for the day zero cell count (No), which were counted immediately after 
drug addition. Following a 48 hour incubation, the treated (NT) and untreated (Nd cells 
were counted as described in Section 2.10, and results expressed as the growth of the 
treated cells as a percentage of control cell growth utilising the following equation:-
(NT - No) x 100% = % growth inhibition 
(Nc - No) 
The growth inhibition in experiments utilising cells treated with drug combinations were 
calculated using a control treated with either TM or inhibitor alone (see Figure legends 
for details). 
2.11 CLONOGENIC ASSAY 
A colony forming assay was used to determine cell survival after treatment with 
cytotoxic drugs (Sebolt-Leopold & Scavone 1992). Only cells that maintain their viability 
are able to proliferate and so enter through the 5-6 doublings required to produce a 
visible colony. 
L 121 0 cells were seeded into 25cm~ flasks from a suspenSlOn of between 6-
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7.5xl05cells/ml to gIve a final cell number of 3xl05cells/flask. The cells were then 
incubated for between 5-6 hour. The dosing schedules were as described in the Figure 
legends. In the experiments using either BZ or 3AB. the initial volume of cell suspension 
in the flasks was 4ml, and this was made up to 5ml with inhibitor to give the required 
concentration. Dilutions of stock NUI025 and PD 128763 were prepared and added to 
5ml of cell suspension directly, in 50).l1 quantities. 
Following a 16 hour or 24 hour incubation (see Figure legends), the cells were 
suspended thoroughly, to ensure a single cell suspension and then counted by 
haemocytometer. For each individual flask, a minimum of 80-1 00 cells were counted. The 
cells were then diluted up to 1000-fold (3xl0 fold serial dilutions) into RPMI medium 
and the number of cells to be seeded determined. Set volumes of cells were added to 
plastic tissue culture tubes, e.g. 200).lllOoox, 400).lllOoox, 800).lllOoox, 160).l11Oox etc, to give 
a cell number that would produce a countable number of colonies, e.g. between 50-200 
colonies. The volume was then made up to 1 ml with medium, and to each tube 5ml of 
the previously prepared agarose/medium (see below) was added. The tube contents were 
mixed and then incubated for 7 days to allow for colony formation. 
Preparation of the agarose 
0.12g of SeaKem ME agarose was boiled in 10ml Dul A, until dissolved. This procedure 
also ensured sterility. The agarose was then added to growth medium, prewarmed to 37°C 
to give a final volume of 100ml, and this was kept at 37°C until required. 
Determination of colony formation 
For each experiment MTT was freshly prepared to a concentration of 0.5mg/ml using 
sterile \vater and then stored \\Tapped in foil at +4°C until use. to protect from the light. 
1 ml MTT was aliquoted into labelled plastic tissue culture dishes. The agarose containing 
89 
the colonies was then added (gentle transfer from the tube to the plate does not disrupt 
the integrity of the colonies) in a flow hood to maintain sterility and the colonies were 
incubated overnight at 37°C, 5% CO2 to allow for the development of colour. Formation 
of colour is due to the tetrazolium compound of the MTT being reduced by the 
mitochondrial reductases in the cells, so forming a blue formazan product. Colonies \\·ere 
counted by eye using a gridded light box, with magnifying lens, as an aid and the results 
were calculated as follows:-
Initially the Colony Forming Efficiency, CFE for each plate was calculated:-
number of colonies counted x 100% = CFE 
number of cells seeded 
Then, the treated samples were expressed as a % of the control to give the % survival:-
CFEtreated X 100% = % survival 
CFEcontro' 
The control CFE was routinely above 95%. 
2.12 DNA STRAND BREAK ASSAY 
Alkaline elution, as described by Kohn et al (1981), is a technique that utilises 
polycarbonate filters to separate single strands of DNA on the basis of size. The filters, 
rather than adsorbing the DNA, impede the passage of the longer DNA fragments, and 
so the rate of elution of the DNA from the filter is relative to the size of the DNA strand. 
Thus, the elution rate is proportional to the DNA strand break frequency. Adaptations of 
the technique enable the measurement of single strand and double strand breaks, alkal i 
labile sites, DNA-protein cross links and DNA inter strand crosslinks. The sensiti\'ity of 
the assay has been previously calculated to be 1 DNA lesionll07 nucleotides. Assay 
precision was increased by the coelution of the treated samples with an internal standard 
(see below and Section 4.J). The internal standard defines a corrected time scale so 
eliminating intersample differences. 
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Preparation of the filters 
Polycarbonate filters (Whatman International Ltd, UK), moistened in ice-cold phosphate 
buffered saline (PBS) (Gibco), pH 7.2 were placed shiny side up onto 16x25mm 
polyethylene filtration funnels (Millipore Corporation, USA). A rubber gasket was then 
centralised over the filter to prevent leakage of the system, and a filtration funnel top 
screwed on tightly. Subsequently, they were covered in foil, to pre\'ent the induction of 
light induced breaks in the DNA strands, and then placed onto a numbered stand. Two 
volumes of 2.5ml PBS was passed through the filters, and then to each a 50ml syringe 
(Becton Dickinson, Ireland) was connected. 15ml PBS was added and the filters were 
allowed to drip freely. Any of the filters that did not drip had the airlock freed by 
sucking out the trapped air with a 5ml Gilson. In each of the barrels - 10ml PBS was 
left, in readiness for the cell additions and the apparatus was stored at +4()C. 
Sample preparation 
Sample and internal standard cells were seeded at 2. 5x 1 04cells/ml into 80cm2 flasks at 
40ml/flask and incubated for 24hr. The sample and internal standard cells were labelled 
with C4C]thymidine (0.016j.!Ci/ml) and [3H]thymidine (O.Ij.!Cillml), respectively, for 
24hr. Any unincorporated label was removed by centrifuging the cell suspension at 400g 
for 5 minutes at 20°C. and the cells were resuspended in fresh medium. A further 
incubation of approximately 4 hours ensured that the label was chased into the high 
molecular weight DNA. 
After the sample cells had been ali quoted into 6 well multi dishes, 2ml/well, they were 
treated with varying drug combinations (see Figure legends for the details). The cells 
were then harvested by centrifugation, as described above and resuspended in 2ml ice-
cold PBS. The internal standard cells were resuspended in 10ml of PBS before being 
irradiated with 300 cGray (see Section 4.3 for the rationale for use of an internal 
standard). (The majority of these irradiations were performed using a Marconi X ray 
machine, but due to changes in circumstances, the final experimental series were carried 
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out using a Gammacell 1000 elite, Nordian International Inc., Canada). All the aboyc' 
procedures, from the point of harvesting the cells until the lysis of the cells (see below). 
were carried out in the dark and on ice as this prevented any further light induced strand 
breakage and stopped repair processes within the cells. 
Elution protocol 
The sample cells were loaded onto previously prepared filters. and an equal number of 
internal standard cells, as determined by haemocytometer count, added to each. The cells 
were washed with 2mllysis buffer (69mM SDS, 2SmM EDTA. adjusted to pH 10 using 
1 M NaOH), then the clips on the filtration funnels were fastened and the cells treated for 
Ihr with I.Sml lysis buffer containing proteinase K (O.Smg/ml). before being washed 
twice with 20mM EDT A, pH 10. The filtration funnels were then attached to the 
appropriate tubes on a fraction collector and the syringes connected. To each, 2Sml of 
elution buffer (2mM EDTA-acid form, SM tetrapropylammonium hydroxide. adjusted to 
pH 12.2 using the tetrapropylammonium hydroxide) was added, and all were covered to 
prevent the entrance of light. The fraction collector (2211 Superfrac, Pharmacia LKB 
Technology, Sweden) was then programmed for 12 hours, 90 minutes for each of 8 
fractions and the pump (202U/AA, Watson-Marlow. UK) started. This utilized solvent 
resistant manifold tubing (Watson-Marlow) and was set at a slow and constant speed, 
operating at 0.033ml/min. The fractions were delivered to the fraction collector via 
polythene tubing (1.0mm internal diameter, Pharmacia LKB Technology) and collected 
into scintillation vials containing ISml liquid scintillation cocktail. After 12 hours, the 
pump was continued for a further 20 minutes to collect into fraction 9 any sample 
remaining in the tubes. The tubing was then disconnected from the filtration funnels and 
O.4mM NaOH pumped through for another 20 minutes to flush the system of any 
remaining counts. At this point the filtration funnels \\"ere dismantled and the filters 
placed on the bottom of fresh scintillation vials. To each, O.4ml 1M Hel was added. the 
yials capped and then baked for 1 hour at 60°C to depurinate the DNA. 2.5ml O.4mM 
92 
NaOH was then added, the vials shaken and left at room temperature for 1 hour. This 
resulted in the conversion of the apurinic sites to strand breaks, thereby the DNA was 
fragmented and released from the filter. 15ml of scintillation fluid was added to each vial. 
This vial allows computation of the counts retained by the filter. All of the vials were 
then capped, shaken and placed in racks onto a 1410 scintillation counter (Wallac 
Scintillation Products). The levels of 3H (fraction of internal standard DNA) and 14C 
fraction of sample DNA) present in each of the vials was determined using a 1 minute 
dual label count. 
Calculation of the results 
For each sample, the total amount of either 3H or 14C (T) initially placed onto the filter 
was calculated by addition of counts from each of the 10 fractions (9 "fractions" + a vial 
containing the filter). Then, using cumulative addition, the number of counts remaining 
on the filter after each fraction had eluted (R) was determined:-
where V = the number of counts in the vial 
T - (V I + V 2) = R2 
T - (V I + V 2 + V 3) = R3········ 
This was converted to the fraction of counts remaining using the following equation:-
RI / T = Fraction of counts remaining after viall 
" " " 2 
R / T = 3 " " " 3 ....... . 
To aid the computation of the results, the computer software programme, Quatropro 4.0 
(Borland) was utilised. The calculated data was plotted as the fraction of C4C]-dThd 
remaining on the filter against the fraction of eH] Thd using a double log scale to form 
an elution profile. Example profiles are given in Figures 4.5 & 4.6. To summarise the 
data, the relatin~ elution (R.E.) value was calculated. R.E. represents the ratio of the rate 
of elution of the DNA after treatment compared to untreated control. Initially. utilising 
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the software programme, "Graphpad Inplot tm" (San Diego, CA. USA) the relative 
retention (R.R.) values of each elution profile were determined by regression analysis. 
R.R. is the fraction of sample DNA retained on the filter when 500/0 of the internal 
standard DNA has eluted. The following equation was subsequently used to give the R.E. 
values:- R.E. = (log.R.R. sampl~ DNA) - (log.R.R. control DNA) 
R.R.l 1.0 
R.R.2 -------
z 
...... 
< 
R R 3 -----=---• . C=J 
~ 
z 
o 
• 
0.1 I 
1.0 FRACTION 3 HRETAINED 0.1 
I 
I 
INTERNAL STANDARD DNA ELUTED 
Figure 2.1 Method for calculation of the relative retention values. 
2.13 DETERMINATION OF CELLULAR NAD+ LEVELS 
The cellular NAD+ concentration in L 121 0 cells was determined utilising a colourimetric, 
enzyme cycling assay. For assay principles see "Measurement of the cellular NAD''', 
Sample preparation 
L 121 0 cells were seeded into 25cm2 flasks at a density of 1.5x 1 05cells/mL 10ml'flask, 
and were incubated overnight before being exposed to drug combinations (see '·igure 
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legends for details). All drug treatments were performed in triplicate. The cells. after 
being harvested and washed once with Dul A, were repelleted and resuspended into 1 ml 
500/0 v/v ethanol. At this stage of the protocol the cell samples could be stored at -20"C. 
Each sample was sonicated (MSE Soniprep 150. Fissons) on ice for 3xl0 second bursts 
at an amplitude of 15. A 200JlI aliquot of this suspension was then transferred to a fresh 
1.5ml Eppendorf (Starsted Ltd, UK) and stored at -20De to await protein estimation. The 
remaining sample was centrifuged for 10 minutes at 17000g using a microfuge (Biofuge 
15, Heraeus Sepatech GmbH, Germany) and the supernatant was carefully decanted from 
the pellet and stored, also at -20De, for NAD assays. 
Determination of NAD+ concentration 
The protocol was performed as described by Nisselbaum & Green (1969). The assay is 
termed a "cycling assay" due to the following reaction sequence:-
ETHANOL ETHANAL 
"--ADH~ 
NAD+ ~ ~NADH 
PMS/MTT REDUCED PMS/MTT OXlDISED 
(GREEN) (YELLOW) 
The alcohol dehydrogenase (AD H) reduces the ethanol and NAD+ to gIve the 
corresponding aldehyde and NADH. The NADH is then chemically oxidised by the PMS 
and MTT, with the reduction of MTT resulting in a colour change as described in Section 
2.11. The colour change from yellow to green is monitored spectroscopically and is 
proportional to the NAD+ concentration. Each assay is standardised using NAD+ of a 
known concentration. All the reagents are present in vast excess oyer the NAD+. 
A 100mM Triethanolan1ine He1 buffer, pH 7.4, containing 2.7% ethanol. was prepared 
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usmg a 500mM triethanolamine stock that had been dissolyed in distilled water. 
autoc1aved and stored at +4°e. MTT (12.1mM) and PMS (2.6mM) were freshly prepared 
in distilled water, for each experiment, and due to light sensitivity were covered in foil 
for protection. The ADH (which comes as a solution) (30mg/ml) was diluted 3 fold \\-ith 
distilled water. All the reagents were maintained on ice until required. 
The components of the cocktail, (53mM triethanolamine (1.7ml). 0.83mM PMS (lml), 
0.19mM MTT (0.05ml), O.lmg ADH (O.lml)), were added to giYe a final volume of 
2.85ml in 4.5ml cuvettes and warmed to 37°e, prior to the addition of the NAD+ sample. 
Construction of the standard curve 
The concentration of NAD+ present in the prepared cell extracts was determined by 
reference to a standard NAD+ curve. A stock solution ofNAD+ was prepared at O.lmg/ml 
in sterile water and stored aliquoted at -20oe. To determine the absolute concentration of 
this stock, a 10 fold dilution was made with the triethanolamine buffer and the 
absorbance at 260nm recorded, utilising the UV lamp and quartz cuvettes. The Beer 
Lambert law is used to determine the absolute concentration of the 0.01mg/ml NAD 
stock:-
A = E.C.£ 
where A = absorbance of the NAD stock, E = molar extinction coefficient (NAD = 
18000), c = unknown concentration and £ = pathlength (cm). The pMoles NAD/ml for 
each point on the standard curve can be calculated. 
Based on these data, a working NAD+ standard of 0.0 1 mg/ml was prepared using the 
sample buffer. Prior to the addition of NAD+, up to 300111 of 50% ethanol was added to 
each cuvette (4.5ml, Fisons) to maintain a constant volume. The reaction was initiated 
by NAD+ addition and the cuvettes were inverted several times to ensure thorough mixing 
before being placed into a PU 8610 UV NIS kinetics spectrophotometer (PYE Unicam 
Ltd, UK). The spectrophotometer, used in the "kinetics mode", was heated using a cell 
temperatun: controller (PYE Unicam Ltd) to 37°C. and the change in absorbance at 
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556nm monitored over a period of 5 minute, at intervals of 1 minute. A "blank", 
containing the reaction cocktail minus the NAD+ was utilised for each standard curye. 
Similarly, for the samples, 300JlI of cell extract was added to the cocktail, mixed and 
the change in absorbance recorded as described for the standard curve. For each set of 
samples a separate blank containing 300JlI 50% ethanol was included. 
Calculation of Results 
For each standard/sample the absorbance readings were recorded over 5 cycles as 
described above. The blank of each cycle was subtracted from the standard/sample 
reading and the amended absorbances were then entered into the following equations:-
(S Abs3 - S Abs2) = A Abs ........ 
Where s = standard/sample and ~Abs = the change in absorbance. The mean change in 
absorbance over a one minute interval was then calculated (~AbsM) . 
Construction of the standard curve 
The NAO+ concentration of triplicates of the prepared solution, calculated as shown 
above were plotted against the change in absorbtion. An example curve demonstrating a 
linear relationship is shown in Figure 2.2. 
Determination of the NAD+ concentration in the cell extracts 
To aid the computation of results the computer programme, Quatropro was utilized. The 
gradient of the standard curve was calculated by linear regression and this value was 
termed the x-coefficient. The NAO+ concentration of each sample was then determined 
by:-
X coefficient 
The NAO+ concentration was then multiplied by the appropriate dilution factor to give 
the final result in pMoles NAO+ Iml cell extract. 
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Figure 2.2: A. Example NAD+standard curve. 
Each point is representative of triplicate 
samples + I - SE. B. NAD+ absorbance over a 
5 minute incubation period, - 604pMoles 
NAO+ Iml. - 1208pMoles NAD+/ml. 
The NAD+ concentration was then divided by the protein concentration of the sample 
(see Section 2.15) to give:-pmoles NAD+/mg protein 
2.14 DETERMINATION OF CELLULAR NMNAT LEVELS 
The final reaction in the biosynthesis of cellular NAD+ is catalysed by nicotinamide 
mononucleotide adenyl transferase (NMNAT):-
NMN + ATP ~ NAD+ + PP j 
A methodology for assaying NMNAT in murine tumour tissue has been published 
(Ahluwalia et ai, 1984). A 20 minute incubation of tissue extract with exogenous NMN 
and ATP formed NAD+. Following termination of the reaction, the concentration of 
NADH present in the assay mixture was determined by measurement of the absorbance 
at 340nm. The NAD+ that had formed was subsequently reduced to NADH during a 30 
minute incubation in the presence of ADH. The absorbance at 340nm was then 
reevaluated and the difference between the absorbtion readings was equivalent to the 
NMNAT activity, described as: 
The amount of enzyme that cayalyses the transformation of 
1 mol NMN to 1 mol NAD+ Isecond. 
Initial trials for the conversion of the above methodology for use with tissue culture cells 
exhibited poor sensitivity, even when lxl07cells per sample were used. Due to the 
formation ofNAD+ during the first incubation period of the NMNAT assay, I developed 
a method that coupled together the beginning reactions of the NMNA T assay with the 
enzymic cycling NAD+ assay (described in Section 2.13). The increase in sensitivity of 
the coupled assay was determined using the molar extinction coefficient for NADH at 
340nm, (£ = 6220). Utilising the Beer Lambert law. the NADH concentration required 
to give an optical density (OD) unit of 0.1. was calculated to be 16/-lM. Ho\\c\'er. 
utilising the NAD+ standard curve shown in Figure 2.2. a change in absorbance of 0.1 00 
required -950pMoks NAI), Iml in the coupled colourimetric assay, representing a 
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concentration of -I J.lM, and an -16 fold increase in sensitivity. 
Cell extract preparation 
Treated or untreated L1210 cells, (see Figure legends for details of the concentrations) 
were counted by haemocytometer, and samples containing Ixl07cells prepared (-20mls 
cell suspension at 6xl05cells/ml). The following procedures were performed on ice to 
prevent enzyme activity. The cells were washed once in ice cold Dul A and the pellet was 
resuspended into O.5ml resuspension buffer (20mM Tris-HCI, ImM DTT (the DTT was 
added prior to use from a IOOmM stock) adjusted to pH 7.4 using HCI) before being 
transferred to labelled Eppendorfs. The cells were then sonicated for 20 seconds at an 
amplitude of 15, which resulted in the total disruption of the cell integrity as observed 
by the light microscope. In this respect, the cell extract differes from Ahluwalia el al 
(1984), as this is a whole cell extract as opposed to a nuclear suspension. 
Assay protocol 
To previously prepared assay buffer (0.2mM nicotinamide, 25mM glycyl glycine, 7.5mM 
MgCI2, stored frozen in 20ml aliquots), ATP was added to a final concentration of 3mM, 
together with either IOmM glycyl glycine buffer pH 7.6, or NMN, to final concentrations 
of O.lmM and 8mM, respectively. These buffers were termed "_" and "+", respectively. 
0.5ml of the prepared assay buffer was ali quoted into fresh Eppendorfs. For each sample, 
an Eppendorf containing the "_" assay buffer and an Eppendorf containing the "+" assay 
buffer was required. The cell extract contains modest quantities of both NMN and NAD+, 
of which the NMN would be converted to NAD+ during the reaction time, which would 
subsequently be measured spectroscopically. So, to determine the activity of the NMNAT 
due solely to added NMN, a "blank" containing no NMN, ie "-" was prepared for each 
sample. To each of the Eppendorfs ("_" and "+"), 200J.lI of the cell extract was added, and 
the reaction initiated by incubating in a water bath for 30 min, at 37°C. The remaining 
cdl sample was stored at -20°C to await protein quantification. The reaction was 
terminated by plunging the \. ppendorfs into a boiling water bath for 1 minute before 
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centrifuging at 3000g for 5 minutes using the microfuge. 500111 of the supernatant was 
transferred to fresh Eppendorfs before being stored at _20DC until assaying of the ~AD-. 
The NAD+ assay was as described in Section 2.13 with minor modifications. 150111 of cdl 
extract was added to the cocktail, together with 150111 50% ethanol. The ethanol is an 
essential component of the cycling reaction, therefore its presence was maintained in the 
cocktail. 
Expression of the results 
The results were calculated as previously described in Section 2.13. The concentration 
of NAD+ formed in 1 minute ([NAD+h), due solely to the added NMN was calculated 
as follows:-
([NAD+]+NMN - [NAD+1NMN) = [NAD+]F 
30 minute 
Any dilutions made throughout the assay were taken into account by multiplying the 
[NAD+h value with the dilution factor, to give the final NAD+ concentration. The 
quantity of NAD+ formed in 1 minute was then divided by the protein concentration to 
give activity of the NMNAT, expressed as:-
pMoles NAD+ formed/mg protein/min 
2.15 ESTIMATION OF PROTEIN CONCENTRATION 
The protocol utilised was based on the Bradford method (Bradford 1976). Previous to 
this, assays that determined protein concentration were described in the literature as 
insensitive and suffering from interference with a wide range of compounds, e.g. EDT A, 
Tris. The Bradford method eliminates the majority of these disadvantages and can be used 
to screen large numbers of samples. The assay utilises Coomassie blue, existing in two 
colour forms, red and blue. The red dye, on binding to the protein, results in the 
formation of a blue protein dye complex, and due to the high extinction coefficient of this 
complex and its stability over 1 hr, the assay is highly sensitive and does not require 
critical timing. As the assay is slightly non linear, due to overlap of the two d\ e 
100 
~ 
s 
c: 
L.() 
O'J 
L.() 
"--'" 
~ 
u 
z 
<r: 
III 
~ 
0 
ifJ. 
III 
<r: 
0.6 
• 
• 
0.3 
• / 
• / 
0.0 
0.00 0.25 0.50 
mg PROTEIN/ml 
Figure 2.3: Example protein standard curve. 
Each point represents the mean of triplicate 
samples + / - SE. 
spectrums, a standard curve is constructed for each assay. but this problem decreases as 
complex formation increases. 
The standard protein samples were prepared over a concentration range of 0.0625 _ 
0.5mg/ml from a BSA stock at 2mg/ml using the sample buffer (50% ethanol or the 
resuspension buffer for the NAD and NMNAT assays respectively. see Sections 1.13 and 
2.14). 
50J.lI of the prepared standards and 2.5ml Coomassie protein assay reagent (the bottle 
was inverted several times to ensure the contents were well mixed) were added to each 
tube. The tube contents, after being thoroughly vortexed were transferred to 1.6ml plastic 
cuvettes (Fisons) and the absorbance at 595nm measured using the spectrophotometer. A 
blank consisting of only the buffer and Coomasie reagent was used with each run. For 
the unknown samples, the protocol was as described for the standards, although dilutions 
were performed as required, if the protein present was too concentrated. 
Calculation of results. 
The absorbance of the blank was subtracted from the sample absorbance to give the 
corrected reading. A standard curve (see Figure 2.3 for an example standard curve) was 
constructed with protein concentration plotted against the absorbance reading, again using 
the linear regression analysis function on Quatropro, and the concentration of protein in 
the samples determined by division of the x coefficient. Any dilutions made were taken 
into account by multiplying the determined protein concentration with the dilution factor. 
2.16 STATISTICAL ANALYSES 
Mean (x): The experiments presented in this thesis were performed. generally in triplicate 
and the mean was used to calculate the representative value. The definition of the mean 
is:- The sum of the observations, i.e. sample repeats (x) divided by the total number of 
observations (n). x = l:xln 
Standard de"iation (S): Th~ amount of scatter of each observation from the mean is 
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expressed as the DEVIATION from the mean distribution. Howe\'er. the square of the 
deviation must be calculated (sum of squares). as when the average deviation is calculated 
this is equal to zero, due to the influence of the sign, i.e. + or -. An average of the square 
deviation is determined by division by n-l (degrees of freedom), rather than n. as an 
estimation of the scatter from the original population is required. This yalue is the 
S 2 = L( x - 'XY / n-l 
Due to the units of S2, the square root of the variance is calculated to glye the 
ST ANDARD DEVIATION (S). This has the same units as the initial observations. 
S = ..JS2 
Standard error of the mean (SE): is an estimate of the standard deviation calculated 
if repeated samples from the same population were taken for analysis. 
SE = S / ..In 
Conventionally, SE is used when the concern is with precision of the estimates, whereas 
S is utilised when the variability of the population or distibutions requires consideration. 
F or the experimental data presented in this thesis, SE was utilised to express the error on 
the data. 
Regression: demonstrates how one variable. y is related to changes in another variable. 
x and is a criterion for judging the line of best fit through experimental data points. The 
deviations of the points from the line in the y direction represents the variability of y not 
explained by x. The chosen line of best fit makes the sum of the deviations around the 
line a minimum. This gives the METHOD OF LEAST SQUARES. The equation of the 
least squares linear regression line is: 
Y = a + bX 
The slope of the line, b is calculated: 
L(x -x)(y - 50) / L(x - X)2 
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and the line must pass through the mean of the data, x and y. Regression analysis \vas 
utilised in calculating the NAD+ and protein standard curves (see Chapter 3 and 6). the 
R.R. values from the alkaline elution profiles (see Chapter 4, 5 and 6) and the regression 
analysis for the increase in DNA single strand break levels following TM treatment in the 
presence of increasing concentrations of PD 128763 (see Chapter 5). 
Non linear regression: fits a particular equation to the data points to give the line of best 
fit. A sigmoid curve analysis with the resulting curve smoothed was utilised to calculate 
ICso and DEF 10 values in growth and clonogenic survival curves (see Chapter 3). 
Graphpad Inplot tm, San Diego, CA software package was used for these calculations. 
Student's two tailed, unpaired t test: A significance test asks whether the difference 
observed between two values was small enough to have occurred by chance. 
A t distribution is the mean of a sample with a normal distribution but unknown 
variance. Normal distribution is assumed but this varies according to the associated 
degrees of freedom i.e. n-1. t distributions are utilised for the analysis of small 
populations. 
t = x - Jl I -1(S2 In) 
where Jl = population mean. 
"Two tailed" allows for the possibility of the difference being greater or lesser than the 
given value. "Unpaired" is the comparison of two independent groups of data. The 
variability between subjects is of importance as well as the mean difference between the 
groups. 
A two tailed. unpaired student" s t test \vas used to determine whether the values 
calculated for the DNA single strand break level in TM alone treated cells was 
significantly different to the DNA single strand break level due to TM + specified 
concentrations of a PADPRP inhibitor (see Chapter 5). and also to determine whether the 
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difference between NMNAT activity III control or TM treated L 121 0 cells \vas 
significantly different (see Chapter 6) 
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CHAPTER 3 : EFFECT OF THE PADPRP INHIBITORS O~ T'I 
INDUCED GROWTH INHIBITION, CYTOTOXICITY AND 
NAD+ DEPLETION. 
3.1 INTRODUCTION 
Most of the treatments for cancer rely on the use of chemotherapeutic drugs that 
interfere with proliferation of tumour cells. Unfortunately, this activity also affects normal 
tissue cells, resulting in toxicity, especially in highly proliferative cell populations, e.g. 
lymphocytes, epithelial cells. These toxicities manifest over the period chemotherapy 
treatment is administered and include myelosuppression, mucositis, and damage to critical 
organs such as the kidneys, lungs and the central nervous system. Such toxicities can 
therefore limit both the dose, and frequency of administration of the antineoplastic agent 
which makes for a poorer prognosis. 
A primary goal of cancer research is the discovery of novel compounds that possess 
increased antitumour activity, but lack systemic cellular toxicity. However. a further 
avenue of research is to identify compounds that would attenuate the toxic effects of the 
agents already in clinical usage. Such "chemoprotectants" or "resistance modifying agents" 
would themselves be inherently non-toxic, but raise the therapeutic index. The therapeutic 
index is a measure of the antitumour activity of a chemotherapeutic agent in relation to 
the level of normal tissue damage induced. A good strategy, rather than isolating 
chemoprotectants specific for individual anticancer agents, is to target the common 
mechanisms of action of these agents. One such action is the production of either direct 
or indirect damage to the DNA, with the ensuing stimulation of the cellular DNA repair 
mechanisms. The base excision repair (BER) process recognises damaged and missing 
bases that result from treatment with alkylating and oxidative agents, as well as ionising 
radiation. Inhibition of BER would therefore increase the cytotoxicity of many clinically 
rdc\'ant chemotherapeutic agents, as well as ionising radiation. 
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Resistance is another major problem associated with the clinical use of chemotherapeutic 
agents which could also benefit from the modification of the repair processes. The 
development of resistance, e.g. the multi-drug resistance (mdr) phenotype, thymidylate 
synthase (TS) gene amplification, to the chemotherapeutic agents leads to an associated 
decrease in the level of antitumour activity of the drugs employed. One possible 
mechanism of resistance that has been demonstrated is that cells exhibit an increased 
proficiency to repair damage to the DNA (e.g. Masuda et ai, 1988 and 1990, Institoris 
et ai, 1992). By inhibiting the repair process, the antitumour activity of the agent would 
be restored. Institoris et al (1992) found that P388 leukaemia cells resistant to L~:5,6-
dianhydrogalacticol (DAG) undergo DNA excision repair of the intrastrand crosslinks, 
resulting in the formation of DNA strand breaks. In the presence of BZ, the cytotoxicity 
of DAG was potentiated, and the DNA strand break levels were increased, consistent with 
an inhibitory effect on repair. In the sensitive P388 cell line, DAG cytotoxicity was not 
potentiated by BZ and showed no evidence for DNA strand break formation. 
PADPRP is involved in BER (see Section 1.5). The potential for inhibitors of PADPRP 
to act as resistance modifying agents was initially suggested by Durkacz et al. in 1980, 
for use in the treatment of human leukaemia. In the presence of 3AB. the cytotoxicity of 
the alkylating agent DMS was enhanced 4-fold. Subsequent reports in the literature have 
shown this potentiation of cytotoxicity to occur with other alkylating agents (e.g. Nduka 
et ai, 1980, Lunn & Harris, 1988), oxidising agents (e.g. Huet & Laval, 1985) and 
ionising radiation (e.g. Lunec et ai, 1984), in the presence of several P ADPRP inhibitors 
e.g. 3AB, 3AAB, BZ (see Table 1.1). The level of cytotoxic enhancement correlated with 
the potential of the compounds to inhibit PADPRP (Nduka el ai, 1980). A further 
indicator for the PADPRP inhibitors to act as resistance modifiers is that the cellular 
NADl concentration in tumour cells is reported to be reduced in comparison to that found 
in their normal parental counterparts (Jedeikin & Weinhouse. 1955; Branster & Morton, 
1956: Glock & McLean. 1957; Morton. 1958). As NAD+ is the substrate for PAJ)PRP. 
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the potency of P ADPRP inhibitors which act in a competitive manner will be dependent 
on the NAD+ concentration. Therefore, in tumour cells, low NAD+ levels \,·ould creatc 
an advantageous situation for the action of the P ADPRP inhibitors. Solid tumours ha\·c 
been predicted as containing up to 10-200/0 hypoxic cells, which exhibit an increased 
reductive potential, i.e. the NADH:NAD+ ratio is increased (Kennedy et ai. 1980). NADH 
also acts as a potent inhibitor of PADPRP, with a ~ comparable to that of 3AB, of 5J.lI\1 
(Ueda et ai, 1982). Together, the increased cytotoxicity due to the inhibition of repair. 
with the reduced cellular NAD+ pool in the tumour cells could lead to an increase of the 
therapeutic index for many of the antineoplastic agents used clinically when used in 
conjunction with PADPRP inhibitors. However, a major problem for exploiting this 
potential was the lack of potent P ADPRP inhibitors with specificity towards the enzyme. 
The nicotinamide analogues, i.e. benzamide and the 3'-substituted benzamides, especially 
at high concentrations, were found to affect other metabolic processes, e.g. glucose and 
purine metabolism (Milam & Cleaver, 1984). Therefore, a number of programmes were 
recently initiated with the aim of developing novel P ADPRP inhibitors that exhibited 
increased potency, and that could eventually be entered into clinical trials (Suto et ai, 
1 991 ~ Banasik e t ai, 1992, Griffin e t ai, in press). 
3.2 AIMS 
A vital assessment of any novel compound that possesses the potential to inhibit a 
metabolic reaction is the ability of that compound to act in an intact cell situation. The 
initial in "itro screening of possible compounds utilises purified enzymes or conditions 
that allow the facilitated access of the compound to its target, e.g. in the case of 
PADPRP, a permeabilised cell assay. This type of study solely provides a measure of the 
maximum inhibitory potential of the compound. The cellular int1ux and eftlu:\ rates, the 
cellular concentrations achieved. the interactions with cellular components other than the 
intended target. and the intracellular metabolism of the compound are all important 
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considerations that will influence the inhibitory potential of a novel compound. Therefore. 
intact cell studies which will take into account such reactions, are an essential step in the 
progress of a compound into clinical trials. 
The aim of this initial Results Chapter was to assess the ability of the two no\'el 
compounds, 8-hydroxy-2-methylquinazolin-4[3H]-one (NU1025) and 3.4-dih\'dro-5-
methoxy-I[2H]-isoquinolinone (PD 128763) to act as PADPRP inhibitors in intact cells. 
A comparative study with the classical inhibitors, 3-aminobenzamide (3AB) and 
benzamide (BZ) was carried out. 
PD 128763 was the lead compound in a series of 5'substituted dihydroisoquinolinones 
developed by Leopold and colleagues, which was shown to exhibit a 60-fold increase in 
potency towards PADPRP as compared to 3AB (Suto et ai, 1991). 500JlM PD 128763 
in combination with the monofunctional alkyating agent streptozotocin, exhibited a 7-fold 
potentiation of streptozotocin cytotoxicity in L 121 0 cells, whereas a similar study utilising 
5mM 3AB produced only a 2.5 fold enhancement (Sebolt-Leopold & Scavone, 1992). 
Due to the structural similarities of NUI025 and PD 128763 (see Figure 1.9) a 
comparable level of potency was anticipated. 
The activation of PADPRP in response to DNA damage induced by monofunctional 
alkylating agents is extensively reported in the literature. Therefore, the biological 
endpoints chosen for the comparative study assessed the cytotoxicity of the clinically 
relevant monofunctional alkyating agent TM in L1210 cells (see Section 1.4.3a) via both 
growth inhibition studies (see Section 2.10), and clonogenic survival assays (see Section 
:2.11). The effects of an incubation with the P ADPRP inhibitors alone, or in coincubation 
with TM were considered. An indirect measure of PADPRP inhibitory ability was also 
utilised in the study, with measurement of ability of the P ADPRP inhibitor to prc\'cnt the 
TM induced NAD+ depletion. 
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3.3 THE IN VITRO INHIBITION OF PADPRP 
The data presented in Figure 3.1, reproduced with the kind permission of J.K. Porteous 
and K.J. Bowman (Cancer Research Unit, The University of Newcastle Upon Tyne) 
displays the percentage inhibition of P ADPRP activity versus the concentration of the 
PADPRP inhibitors, 3AB, BZ, NUI025 and PD 128763, as determined utilising an in 
vitro permeabilised cell assay (see Section 2.8). Each compound inhibited the actiyity of 
PADPRP in a concentration-dependent manner (see Figure 3.1). and as predicted from 
their similar structural forms, PD 128763 and NUl 025 exhibited comparable potency. The 
concentrations of the compounds required to inhibit the activity of P ADPRP by 50% 
(lCso) are shown in Table 3.1, together with their potencies in relation to 3AB. (The 
relative potency of 3AB has been set as 1). The relative potencies calculated for 3AB and 
PD 128763 are in excellent agreement with those established by Suto et ai, (1991). Both 
NUI025 and PD 128763 were found to be more than an order of magnitude more potent 
than 3AB and BZ, i.e. the ICso values for NUI025 and PD 128763 were 0.44/-lM and 
0.36/-lM respectively, which represent an -43 and -53 fold increase in potency as 
compared to 3AB (lCso = 19.1/-lM). Therefore the increased level of potency exhibited 
by NU 1 025 and PD 128763 against P ADPRP would indicate a potential for use as 
c hemoprotectants/resistance modifiers. 
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TABLE 3.1 
INHIBITOR IC50 VALUE ± SE RELATIVE POTENCY 
3AB 19.1 JlM ± 6.9JlM 1.0 
BZ 13.7JlM ± 6.9JlM -1.0 
NUI025 0.44JlM ± 0.13JlM -43 
PD 128763 0.36JlM ± O.OIJlM -53 
Table 3.1: Permeabilised L1210 cells were incubated with increasing concentrations of 
the P ADPRP inhibitors, and P ADPRP activity was measured as a 010 of untreated control. 
PADPRP was activated utilising a blunt ended oligomer. The IC50 values were calculated 
utilising the non-linear regression analysis of "Graphpad Inplot tm. San Diego, CAli 
software and are the average of at least three independent experiments ± SE. 
3.4 THE EFFECT OF THE PADPRP INHIBITORS PER SE ON L1210 CELL 
GROWTH AND SURVIVAL. 
An effective resistance modifier should lack inherent cellular toxicity. The literature 
indicates that both 3AB and BZ, over the concentration range required to enhance the 
cytotoxicity of DNA damaging agents, i.e. up to 5mM, exhibited little or no effect 
themselves on cell survival (James & Lehmann, 1982; Brown et aI, 1984; Huet & Laval, 
1985; Boorstein ef al. 1987: Moses et al. 1988). Therefore, a study was required that 
determined whether the two novel compounds were themselves cytotoxic to cells and how 
they compared to 3AB and BZ. 
Initially the cytostatic effect of all four compounds was investigated. Figure 3. 2 shows 
that the growth of L 1210 cells over a 48 hour incubation with each of the PADPRP 
inhibitors was inhibited in a concentration dependent manner. Cell gro\\"th \vas inhibited 
bv 500/0 at concentrations of 0.41 mM NU 1 025 and 0.45mM PD 128763. \vhereas 6. 7m\ 1 
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3AB and 2.5mM BZ were required to produce similar levels of grO\\th inhibition. This 
represents a 20-fold reduction in the concentrations of NUI025 and PO 128763 as 
compared to 3AB, and a 5-fold decrease in concentration compared to that of BZ. The 
ICso values are summarised in Table 3.2. 
The subsequent analysis performed assessed the cytotoxic effects of the four PADPRP 
inhibitors on L1210 cell survival. The exposure time for the clonogenic assays was oyer 
a 24 hour period, as opposed to the 48 hour incubation for the growth inhibition 
evaluation. Figure 3.3 reveals biphasic survival curves for 3AB, BZ and NUI025. The 
initial shoulder observed indicates that the lower concentrations of inhibitors had little 
effect on the cloning ability of the L 1210 cells. However. the steady increase in the 
concentration, initiated a concentration dependent decrease in cell survival. In the 
presence of PO 128763, the survival curve appeared to lack the initial shoulder and cell 
survival was immediately concentration dependent. 
A biphasic curve would indicate that as the concentration of the PAOPRP inhibitors 
increases initially, there is little or no cytotoxic effect, but the attainment of a critical 
concentration initiates a reduction of cellular survival. 
The calculated LOso values (the dose required to reduce survival to 500/0 of control) for 
3AB, BZ, NUI025 and PO 128763 were 14.9mM ± 1.0. 5.7mM ± 1.5, 1.6mM ± 0.08 
and 0.99mM ± 0.18 respectively with the same order of relative potencies as observed 
for the growth inhibition and in vitro PAOPRP activity studies (see Table 3.2). However. 
the LOso values were increased 2-fold when compared to the IC50 values calculated for 
the cytostatic effect of 3AB, BZ and PO 128763 on L1210 cells. 
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TABLE 3.2 
INHIBITOR GROWTH RELATIVE CYTOTOXICITY RELATIYE 
INHIBITION POTENCY LD50 (mM) POTENCY 
IC50 (mM) 
3AB 6.7 ± 0.2 1.0 14.9 ± 1.0 l.0 
BZ 2.5 ± 0.3 -3 5.7 ± 1.5 -3 
NU1025 0.41 ± 0.06 -16 1.6 ± 0.08 -9 
PD 128763 0.45 ± 0.01 -15 0.99 ± 0.18 -15 
Table 3.2: Comparison of IC50 and LD50 values resulting from 48 and 24 hour continuous 
exposures of L1210 cells to increasing concentrations of the PADPRP inhibitors 
respectively. Both the IC50 and LD50 values were calculated utilising the "smooth curve" 
function on the non linear regression analysis of "Graphpad Inplot tm". The values 
represent the mean of at least three independent experiments ± SE. 
3.5 THE CYTOSTATIC AND CYTOTOXIC EFFECT OF TM ON Ll210 CELLS. 
The active biological species of TM is the monofunctional linear triazene, MTIC. TM 
is chemically degraded in biological mileau to MTIC, which then methylates the bases 
of the DNA, e.g. 3meA, 7meG and 06meG, via a methyl diazonium ion. 
A 48 hour continuous exposure of L 121 0 cells to an increasing concentration of TM 
resulted in a concentration dependent inhibition of cell growth (see Figure 3.4) with an 
I ('50 value of 361 ~M ± 25~M. Over a similar TM dose-range, but with just a 16 hour 
continuous incubation period, the cytotoxic effect on L 121 0 cells also increased (see 
Figure 3.4). The LD50 was calculated as 251~M ± 13~M. 
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3.6 CHEMOPOTENTIATION OF TM CYTOTOXICITY BY INHIBITORS 
OF PADPRP 
3.6.1 The effect of a fixed dose of TM on the growth inhibitory effect of the 
PADPRP inhibitors on L12l0 cells. 
The growth inhibition, of L 121 0 cells, following a 48 hour exposure to a fixed dose of 
TM in the presence of increasing concentrations of P ADPRP inhibitors was investigated. 
Two criteria were essential when considering the TM concentration to be used:- (1) the 
concentration should show only moderate growth inhibition itself, and (2) the 
concentration should induce a biologically measurable level of DNA damage, thereby 
allowing subsequent comparisons with DNA strand break analyses. A TM dose of 100J-lM 
was chosen, which itself reduced the cell growth by -26% (see Figure 3.4), and for this 
series of experiments the growth inhibition due to the TM alone was as used as the 
control (i.e. normalised to 100% survival). 
All four of the PADPRP inhibitors inhibited cell growth when co-incubated with 100J-lM 
TM (see Figure 3.5). An analysis of the growth curves in Table 3.3A and B shows that 
in the presence of 100J-lM TM, the concentrations of NU1025 and PD 128763 required 
to inhibit cell growth by 50% were reduced from 0.41mM to 0.04mM, and 0.45 to 0.023 
respectively, representing a 10-20-fold decrease in the inhibitor concentration. However, 
the difference between the IC50 concentrations of 3AB and BZ alone, or in association 
with the TM was only 2-3 fold, with values of 6.7mM to 2.5mM for 3AB, and 2.5mM 
to 0.84mM for BZ respectively. This represents a much closer overlap of the growth 
inhibitory effects between both of these inhibitors alone, and in the presence of TM. 
However. a statistical analysis, utilising a two-tailed, unpaired students T test showed the 
difference between the inhibitor alone, and in the presence of 100J-lM TM to be 
significant for each of the four inhibitors (P values: 3AB, <0.0001; BZ, 0.0184; NU 1 025, 
0.0056; PD 128763, <0.0001). 
11 ~ 
.....J 
0 
~ 
E-t 
Z 
0 
u 
~ 
0 
~ 
~ 
U) 
~ 
::c: 
E-t 
~ 
0 
~ 
0 
.....J 
0 
~ 
E-t 
Z 
0 
u 
~ 
0 
~ 
~ 
U) 
~ 
::c: 
E-t 
~ 
0 
~ 
0 
100 
10 
1 
0 
100 
10 
1 
0.0 
5 
[3AB] mM 
.~ 
0.5 
[NUI025] mM 
T 
J..-
10 
T 
1 
1.0 
100 
~" 
~ 
, ~----. 
o~~ 
g~~~T 
10 0 
...L 
1 
0.0 2.5 5.0 
[BZJ mM 
100 
• 
10 
1-------0 
1 
0.0 0.5 1.0 
[PD 128763J mM 
Figure 3.5: The growth inhibitory effect of a 48 hour continuous 
exposure to an increasing concentration of the PADPRP 
inhibitors in the absence • , or presence 0 of 100j.LM TM, 
The points represent the mean of at least nine individually dosed 
samples, taken from three independent experiments. 
100 100 ~.-------------------
10 
1 
100 
10 
1 
0.0 0.3 
[3AB]/IC 50 3AB 
0.6 
10 
1 
100 
10 
1 
0.0 
\ 
0.3 
[BZ]/IC 50BZ 
0.6 
o 123 o 1 2 3 
[NU1025]/IC50 NU1025 [PD 128763]/IC50 PD 128763 
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TABLE 3.3A 
INHIBITOR ICso (mM) ± SE [INHIBITOR](m~1) / 
INHIBITOR ALONE ICso INHIBITOR 
3AB 6.7 ± 0.2 0.37 ± 0.01 
BZ 2.5 ± 0.3 0.21 ± 0.03 
NU1025 0.41 ± 0.06 0.93 ± 0.05 
PO 128763 0.45 ± 0.01 1.2 ± 0.05 
TABLE 3.3B 
INHIBITOR ICso (mM) ± SE ([INHIBITOR](mM) + 
INHIBITOR + 1 OO~M TM 1 OO~M TM) / I Cso INHmITOR 
3AB 2.5 ± 0.1 0.121 ± 0.009 
BZ 0.84 ± 0.12 0.062 ± 0.005 
NU1025 0.04 ± 0.003 0.106 ± 0.007 
PO 128763 0.023 ± 0.002 0.057 ± 0.001 
Tables 3.3A and 3.3B: L1210 cells were continuously exposed for 48 hours to increasing 
concentrations of the P AOPRP inhibitors, in the absence or presence of a fixed 
concentration of TM, and the level of growth inhibition assessed. The ICso values were 
calculated utilising the smooth curve analysis of "Graphpad Inplot tm". and are the 
average of three independent experiments ± SE. The ratio: [inhibitor](mM) +/- TM / IC'ili 
'h'b' was also calculated by smooth curve analysis utilising the inhibitor IC'i() values 
In ( (tor 
determined in the in vitro PADPRP assay (see Section 3.3 and Table 3.1). 
Further analysis of the data, resulting from the division of the inhibitor concentration by 
the inhibitor ICso , as calculated in the in vitro P ADPRP assay (see Chapter 2, Section 2.8 
and Chapter 3, Section 3.3) provides an indication as to whether each inhibitor acts on 
the same target. Table 3.3A reveals that following division by the inhibitor IC so the 
difference between the ratios for the different inhibitors is reduced to -5 fold as opposed 
to -20 fold when the ICso concentrations are compared, (e.g. [PD 128763]IICso = 1.2 ± 
0.05; [3AB]/ICso = 0.37; whereas ICso PD 128763 = 0.45 ± O.OlmM; ICso 3AB = 6.7 ± 
O.2mM). When the cells were co-treated with 100J.lM TM the values for the ratios were 
reduced even further from -120 fold to -2 fold, (e.g. ICso 3AB = 2.5 ± 0.1: ICso PD 
128763 = 0.023 ± 0.002 whereas ([3AB] + TM)IICso = 0.121 ± 0.009; ([PD 128763] + 
TM)/ICso = 0.057 ± 0.001). The similarity between the ratio values for each of the four 
inhibitors in the presence or absence of TM would suggest that the four inhibitors act on 
the same cellular target. 
3.6.2 The growth inhibitory effect of increasing concentrations of TM In the 
presence of fixed concentrations of the PADPRP inhibitors on Ll210 cells. 
I n Section 3.5, a dose-dependent decrease of L 121 0 cell growth following a 48 hour 
continuous exposure to TM was presented. Subsequently, the ability of the PADPRP 
inhibitors to potentiate this growth inhibition was investigated. The concentrations of 
inhibitor involved caused minor growth delays themselves but this was corrected for by 
normalising the growth in the presence of inhibitor alone to 100%. 
A 48 hour continuous exposure to an increasing concentration of TM in the presence of 
fixed doses of each of the four P ADPRP inhibitors potentiated the inhibition of cell 
growth in a concentration dependent manner (see Figure 3.6). The determined ICso values 
are shown in Table 3.4, together with the enhancement factor, which represents, the ratio 
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Figure 3.6 The growth inhibitory effect of a 48 hour continuous 
exposure to an increasing concentrationof TM alone • , or in the 
presence of fixed concentrations of the PADPRP inhibitors. A. .. 
ImM 3AB, ~ 5mM 3AB. B ... 0.3mM BZ, ~ 3mM BZ. C ... 10J,lM 
NU 1 025, ~ 100J,lM NU 1 025. D. .. 10J,lM PD 128763, ~ 50J,lM PD 128763 
The points represent the mean of at least nine individually dosed 
samples, taken from three independent experiments. 
of the concentration of TM alone which reduces growth to 50% of control. diYided by 
the concentration of TM that inhibits growth by 50% when coincubated with a fixed 
concentration of PAD PRP inhibitor. The enhancement factor \\"as calculated using the Ie 50 
value of TM alone of 361J-lM (averaged from 14 individual experiments). 
An -100 and -30 fold decrease in the concentration of NUl 025 was required to exhibit 
a corresponding cytostatic effect as observed for 3AB and BZ respectively, during a co-
incubation with TM, e.g. 1 mM 3AB and 10J-lM NU 1 025 both showed enhancement 
factors -2. However, a 2-fold lower concentration of PD 128763 (50J-lM, EF = -6.7) 
gave an an almost 2-fold higher enhancement as compared to NU1025 (lOOJ-lM, EF = 
-4.1). 
TABLE 3.4 
INHIBITOR CONCENTRA TION IC50J-lM ± SE ENHANCEMENT 
FACTOR 
3AB ImM* 177.6 ± 3.9 -2 
5mM 147.4 ± 5.2 -2.5 
BZ 0.3mM# 250.1 -1.4 
3mM 114.6 ±2l.3 -3.1 
NUI025 10J-lM* 223.2 ± 5.5 -l.6 
100J-lM 87.9±9.1 -4.1 
PD 128763 10J-lM 140.5 ± 3.2 -2.6 
50J-lM 53.6 ± 3.2 -6.7 
Table 3.4: L 121 0 cells were incubated continuously for 48 hours with increasing 
concentrations of TM in the presence of fixed concentrations of the PADPRP inhibitors, 
and the lcn~l of growth as compared to control cell growth assessed. The IC50 values \\Cfe 
calculated utilising the smooth curve analysis as described for Table 3.2. The yalues were 
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averaged from three independent experiments ± SE. unless otherwise indicated. 
* ICso value determined from two individual experiments. # Single experiment. 
3.6.3 The cytotoxic effect of an increasing concentration of TM in the presence of 
fixed concentrations of the P ADPRP inhibitors on Ll210 cells. 
Figure 3.7 shows that in the presence of fixed doses of all four of the PADPRP 
inhibitors, the dose-dependent cytotoxicity of TM was enhanced. The magnitude of the 
potentiation was observed to increase as the concentration of each inhibitor was raised. 
Both NUI025 and PD 128763 at concentrations of just 10~M exhibited significant 
potentiation of TM cytotoxicity, with concentrations of 50~M and 1 OO~M showing a 
maximal effect (see Graphs C & D, Figure 3.7). In comparison, 1-5mM 3AB and 1-3mM 
BZ was required to potentiate TM cytotoxicity to a similar extent (see Graphs A and B, 
Figure 3.7). 
Potentiation of TM cytotoxicity was quantified utilising dose enhancement factor values 
calculated at a survival of 100/0 (DEFIO). DEFIO values are defined as a ratio of the 
concentration of TM alone that reduces cell survival to 10%. divided by the dose of 'I'M 
that exhibits 10% survival when co-incubated with a fixed dose of a P ADPRP inhibitor. 
Table 3.5 shows the DEF 10 values for each of the four inhibitors. As the concentration 
of the inhibitor increased, so too did the DEF 10 values. 
10~M NUI025 and PD 128763 resulted in similar DEFIO values of 2, but these 
concentrations were decreased 100 and 50-fold in comparison to the concentrations of 
3AB and BZ required respectively for a similar DEF IO, e.g. ImM for 3AB. This 
represents a similar concentration difference to that which was observed in the gro\\1h 
inhibition results (see Section 3.6.2). The DEFIO values therefore give an excellent 
measure of potency of the compounds against the activity of PAD PRP, with the same 
order of potency as in the in l'itro PADPRP activity (see Section 3.3) and gro\\th 
inhibition studies (see Section 3.6.1 <md :1.6.2). 
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Figure 3.7: The cytotoxic effects of a 16 hour continuous exposure to 
increasing concentrations of TM alone • ,or in the presence of a 
fixed concentration of PADPRP inhibitors. A. 0 1mM 3AB, .. 5mM 
3AB. B. 0 1mM BZ, .. 3mM BZ. C. 0 lOfLM NUI025, 6, 50ILM NUI025, 
• 100J.lM NUI025. D. 0 lOILM PD 128763. 6 50ILM PD 128763, 
• 100ILM PD 128763. 
The points represent the mean of at least three independent 
experiments. 
TABLE 3.5 
INHIBITOR CONCENTRATION DEFIO ± SE 
3AB 1mM 2.4 ± 0.3 
5mM 4.1 ± 0.4 
BZ 1mM 4.0 ± 0.7 
3mM 6.9 ± 0.2 
NUI025 10JlM 2.0 ± 0.2 
50JlM 4.0 ± 0.5 
100JlM 5.1±0.7 
PD 128763 10JlM 2.0 ± 0.1 
50JlM 6.0 ± 0.5 
100JlM 7.1±0.4 
Table 3.5: L1210 cells were continuously exposed for 16 hours to increasing 
concentrations of TM in the presence of fixed concentrations of the P ADPRP inhibitors, 
and cell survival was determined by colony formation. The DEF 10 values were calculated 
utilising a smooth curve analysis as described in Table 3.2. Each value is calculated from 
3 independent experiments. 
3.7 CELLULAR NAD+ STUDIES 
3.7.1 The effect of TM on cellular NAD+ levels 
Some of the work described in this Section was carried out by S. Jones and J .K. 
Porteous. Cancer Research Unit The University of Newcastle Upon Tyne. and has been 
included because of its relevance to the research presented in this thesis. 
PADPRP is activated in response to DNA strand breaks with the resulting formation of 
the homopolymer. (ADP-ribose). Cellular NAD' is the substrate for PADPRP \\ith the 
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ADP-ribose moiety utilised for the polymer formation. Therefore. the extent of depletion 
of the cellular NAD+ pool following DNA damage gives an indication of PADPRP 
activation. 
In the previous Sections, the cytostatic and cytotoxic effects of TM on L 121 0 cells \\"as 
demonstrated. As the concentration of TM increased, growth was inhibited and cell 
survival decreased. TM related DNA damage activates cellular repair processes, \\"ith the 
consequential activation of PADPRP. The magnitude of activation can be indirectly 
determined by measuring cellular NAD+ pool modifications. Hence. following a 4 hour 
incubation of L 121 0 cells in the presence of increasing concentrations of TM, the N AD+ 
levels were recorded. Over this period, -95% of the TM will have degraded to the active 
MTIC. Figure 3.8B shows that NAD+ levels were depleted in a concentration dependent 
manner, and that a -60% depletion was observed with a concentration of 2mM TM. 
However, this represented a -10 fold higher TM concentration required in comparison 
to the doses of TM required to achieve significant growth inhibition e.g. ICso = 361 f.lM 
and cytotoxicity e.g. LDso = 251 f.lM (see Section 3.5). 
An important determination was the effect of time on the depletion of the cellular NAD+ 
levels following an incubation with TM. Previous data in the literature reports that, 
following administration of fixed doses of the mono-functional alkylating agents, MNU 
and DMS, there was a rapid depletion of the cellular NAD+ within 2 hours. The extent 
of the depletion was concentration dependent. However, following a 14 hour incubation. 
control NAD+ levels were recovered at each concentration, apart from those which 
reduced the NAD+ to less than 10% of control (Skidmore et aI, 1979; Durkacz et al. 
1980). A possible explanation proposed is that in circumstances of extreme damage to the 
cell, the severe NAD+ depletion would act as a suicide mechanism, arresting ATP 
synthesis and thus halting metabolic processes essential for the existence of the cell, e.g. 
DNA replication, glucose metabolism, (Sims c( al. 1982,1983). 
As the above agents act immediately, e.g. MNU has a tl2 of 10 minutes (Skidmore cI 
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Figure 3.8: The effect of TM and the PADPRP inhibitors on the 
cellular NAD levels in L1210 cells. A. The effect of • lmM TM 
or 0 2mM TM over 6 hours. B. Cells were treated with an 
increasing concentration of TM for 4 hours. C. The effect of 
increasing doses of • PD 128763 and 6 3AB on the NAD levels 
in cells treated with 2mM TM for a 4 hour incubation. The 
graphs are representative examples, with the points shown being 
the mean of triplicate samples, taken from a single experiment. 
aI, 1979), whereas TM has a prolonged active period of up to 6 hours, it was of interest 
to determine how the NAD+ pool size varied with time after T\ 1 treatment. 1 m\ 1 and 
2mM TM, which reduced the cellular NAD- levels by ~40~ 0 and -60% respectiYely 
following a 4 hour continuous incubation (see Figure 3.8B) were incubated for various 
times with the L 1210 cells. The NAD+ was depleted in a time dependent manner for both 
TM doses, with a 50% NAD+ loss only observed following a 6 hour incubation with 
2mM TM. However, this reduction remained concentration dependent (see Figure 3.8A). 
The active metabolite of TM is MTIC, which has a half life of -4 minutes (REF) and 
so represents the effect of a more direct acting DNA damaging agent. A comparison of 
the effect of MTIC on NAD+ levels was therefore carried out. Initially, the effect of an 
increasing concentration of MTI C on the growth of the L 121 0 cells was assessed to 
determine a suitable concentration range for use in an NAD+ study. Figure 3.9 shows that 
after a continuous 48 hour exposure to concentrations of MTIC between 0-1 OOO~M, 
L 121 0 cell growth was inhibited in a concentration dependent manner, with an I Cso of 
154 ± 2~M. 
The intracellular NAD+ level of L 121 0 cells treated for either a 2 or 4 hour continuous 
exposure to MTIC were depleted in a concentration dependent manner with a 500/0 
depletion of the NAD+ observed after just a 2 hour incubation with ImM MTIC 
(5178pMoles NAD+ Img protein depleted to 2496pMoles NAD+ Img protein) (see Figure 
3.10A). However, Figure 3.1 OA also shows that after a 4 hour exposure to increasing 
concentrations of MTIC the NAD+ levels were beginning to recover, with NAD+ levels 
being higher than the 2 hour levels over the entire concentration range of MTIC. 
To investigate further the effect of time on the MTIC induced NAD+ depletion, L 121 0 
cells were incubated with 1 mM MTIC for increasing incubation periods of up to 6 hours. 
Figure 3.10B shows that after just a 30 minute incubation. the NAD+- was maximally 
depleted to -60% of controL and that over the subsequent incubation times of 1-6 hours 
the NAO+ levels were reco\Tred in a time-dependent manner. By 6 hours the intracellular 
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NAD+ level had almost returned to control values. 
3.7.2 The effect of a co-exposure to TM and a P ADPRP inhibitor on the cellular 
NAD+ pool in Ll210 cells 
The prevention of NAD+ depletion by inhibitors of P ADPRP provides evidence that the 
decrease in intracellular NAD+ is due to increased PADPRP activity. Previous 
publications have shown, that prevention of the NAD+ depletion was dependent on the 
concentration of the damaging agent, and both the potency and concentration of the 
inhibitor (Skidmore et ai, 1979; James & Lehmann, 1985). Therefore, in view of the 
enhanced cytostatic effects and cytotoxicity of TM in the presence of NUl 025 and PD 
128763 as compared to 3AB and BZ, the ability of the novel inhibitor PD 128763. 
compared to 3AB, to prevent the NAD+ depletion was investigated. L 121 0 cells were 
incubated for 4 hours in the presence of 2mM TM in the presence of increasing 
concentrations of either 3AB or PD 128763, representative examples of a classical and 
a novel inhibitor. Both inhibitors abrogated the depletion of NAD+ in a concentration 
dependent manner as shown in Figure 3.8C. However, whilst a concentration of -1 OO~M 
PD 128763 completely prevented the NAD+ depletion, a concentration of -1 mM was 
required by 3AB to emulate this effect. 
3.8 DISCUSSION 
Overall, the results presented in this Chapter clearly demonstrate that the two novel 
compounds, NU1025 developed by the Drug Development Initiative at this University. 
and PD 128763 formulated by Leopold and colleagues at the Parke-Davis Division of the 
Warner Lambert Pharmaceutical Company, act as potent inhibitors of the enzyme. 
PADPRP, both in in vitro and in intact cells. When compared in an in "itro PADPRP 
assay to two of the classically used PADPRP inhibitors, 3AB and BZ. a -50-fold increase 
in potency was observed. The ability of the compolmds to retain inhibitory activity on 
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transfer from an in vitro situation to the intact cell was of extreme importance. in "iew 
of their anticipated use as resistance modifying agents in the clinic. 
A major criterion for a compound to act as a resistance modifer requires that inherent 
cellular toxicity is low. Therefore, the effect of the P ADPRP inhibitors per Sl.! was 
determined utilising both growth inhibition and cytotoxicity studies (see Section 3.4). 
Each of the inhibitors reduced cell growth and cell survival in a concentration dependent 
manner. However, in both studies, the concentrations ofNUI025 and PD 128763 required 
to reduce the cell growth and cell survival by 50% were -15-fold and -5-fold lower than 
required by 3AB and BZ. These data correlated to some extent with the relative potencies 
of the four inhibitors against in vitro PADPRP activity (see Table 3.1 and Table 3.2). 
Cytostasis, i.e. growth inhibition following administration of PADPRP inhibitors, has 
been reported to result in a G liS phase cell cycle arrest (Schwartz et ai, 1983; Moses et 
ai, 1988). One of the roles proposed for PADPRP is as an early event in DNA 
replication. The synthesis of the (ADP-ribose) polymer was suggested to relax the 
chromatin structure thereby facilitating the access of replisomes to DNA. The inhibition 
of this process could possibly retard replication, and subsequently be manifested as a 
growth delay of the cell cycle. However, evidence suggested this cell cycle delay to be 
a transient effect, with the eventual resumption of normal growth patterns (Kidwell et ai. 
1982). If so, the survival of cells treated with the P ADPRP inhibitors should not be 
reduced. 
Previous data in the literature found no evidence to imply inhibition of endogenous 
PADPRP activity as responsible for cytostatic effects. Hunting et ai utilised a growth 
inhibition analysis to compare the cellular effects of several PADPRP inhibitors. They 
found no correlation between the extent of delayed growth and the relative potencies of 
the compounds as inhibitors of PADPRP. e.g. at concentrations exhibiting comparable 
potencies against PADPRP in L 121 0 cells. 1 mM 3AAB was not gro\\1h inhibitory. 5mM 
3AB sho\ved a slight inhibition of growth (80% of control). but 5mM 3meBZ was 
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extremely growth inhibitory (10% of control) (Hunting et ai, 1985). Recently. the 
existence of a knock-outPADPRP mouse has shown P ADPRP to be nonessential for cell 
survival and proliferation (Heller et ai, 1995). The results presented in this Chapter \\"ould 
also support a nonessential role for P ADPRP due to the lack of cytotoxicity at the 
concentrations which result in a cytostatic effect, e.g. at 0.5mM NUI025, gro\\1h \\3S 
inhibited by 60% of control (see Figure 3.3), but 100% cell survival was observed 
following a 24 hour exposure (see Figure 3.2). 
The work of Cleaver and colleagues proposed that P ADPRP inhibitors affected other 
metabolic reactions. Perturbations of glucose and de novo purine & pyrimidine 
biosynthesis became apparent following the administration of high concentrations of the 
PADPRP inhibitors, e.g. 10mM 3AB (Milam and Cleaver, 1984). The data presented 
shows a cytotoxic effect of the inhibitors only at the higher concentrations, e.g. 20mM 
3AB and 2mM PD 128763 as compared to the concentrations used in the potentiation of 
cytotoxicity studies, e.g. 5mM 3AB and 50J.!M PD 128763. The cytotoxic effects could 
be due to the secondary effects of the P ADPRP inhibitors on other metabolic processes 
as described above, and are unlikely to be due to inhibition of PADPRP. Lautier et al 
(1994) found ADP-ribose polymer synthesis was inhibited by -90% in intact cells 
following treatment with the oxidising agent xanthine-xanthine oxidase, in the presence 
of 100J.!M BZ. Therefore, the high P ADPRP inhibitor concentrations required to effect 
cell kill. e.g. 10mM BZ, would be highly unlikely to be because of PADPRP targetting. 
The ability of the four compounds to potentiate TM induced growth inhibition and 
cytotoxicity was used as a measure of inhibitor potency. The effect TM alone had on the 
growth and survival of the L 121 0 cells was initially determined. Different periods of 
exposure were utilised in the two assays, i.e. 48 and 16 hour continuous exposures were 
used in the growth inhibition and cell survival assays respectively. but very similar I C50 
<md LD50 values \vere calculated, 361 ± 25J.!M and 251 ± 13J.!M respectively. The half 
life of TM in "ilro, in human plasma (Stevens et aI, 1987) and in murine lymphoma cells 
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(Tsang et aI, 1991) was determined as -40 minutes and -50 minutes respectiyely. Trv! 
is therefore a relatively slow acting agent with damage induced over an extended period 
of time. It can be calculated using the murine tl :1 of 50 minutes that a period of 6 hours 
is required for 99% of the TM to have degraded to MTIC. The MTIC subsequently 
decomposes to the methyldiazonium ion with a half life of -4 minutes. The different 
incubation times of 48 hours and 16 hours used for the growth inhibition and survival 
protocols, respectively would both encompass the complete period of TM decomposition, 
and therefore the similarity between the IC50 and LD50 values is not surprising. 
Both L 121 0 cell growth and survival was decreased in a concentration dependent manner 
in the presence of TM. DNA damage results in a transient cessation of DNA synthesis 
due to the cell cycle arrest at G/S and G/M boundaries, which consequently retards the 
growth of the cell (Little, 1968, Kastan et aI, 1992). With minimal damage to the DNA, 
e.g. at low concentrations of TM, the efficient repair processes of the cell would rapidly 
repair the lesions with the subsequent continuation of cell growth. However, base 
methylation encompasses a broad spectrum of lesions with reportedly different tl'2 repair 
rates. The efficient activity of 3meA glycosylase ensures the fast excision of this modified 
base (half-life -3-8 hours), whereas 7meG although actively removed has a half life of 
-40 hours. As 7meG basepairs normally with cytosine, it is not considered to be a 
cytotoxic lesion. However, 3meA is considered lethal to the cell as it blocks DNA 
replication. Hence, the persistence of such lesions could result in an increased growth 
delay with eventual cell death. The lesion initially considered as lethal was Q6meG. 
QhmeG is removed by MGMT but the levels of this enzyme vary between different cells. 
L 121 0 cells have little or no MGMT present (unpublished result - C.E. Arris, Cancer 
research Unit, The University of Newcastle-Upon-Tyne) and this is demonstrated by the 
increased sensitivity of L 121 0 cells to I'M as compared to other cell lines (Hepburn & 
Tisdale, 1991). QOmeG also forms basepairs in the DNA, but lethality occurs due to its 
removal via the mismatch repair process (Karran & Bigami. 1992). The position of the 
cell in the cycle at the time of damage would also be of importance. as once a cdl is 
committed to divide it must complete the cycle. In such cases, a damaged template \\"ould 
be replicated during S phase. With the subsequent increase in the TM concentration, the 
number of modified bases would be extensively raised, saturating the repair mechanisms. 
resulting in extensive growth delays and intensifying the cytotoxic effects. 
The effect of increasing concentrations of the P ADPRP inhibitors when coincubated \vith 
a fixed concentration of TM (lOO!J.M) on the effect on L 121 0 cell growth was 
determined. Each inhibitor potentiated the growth inhibitory effects of the TM In a 
concentration dependent manner. However, the concentrations ofNU 1 025 and PD 128763 
required to potentiate growth inhibition to a similar level as 3AB were reduced -60 and 
-110 fold. This gave the same order of relative potency as was observed for the in "itro 
PADPRP inhibition study (see Section 3.3). The PADPRP inhibitors, 3AB and BZ have 
been shown to inhibit PADPRP competitively with k j values of 2.6!J.M and I.O!J.M 
respectively (Purnell et ai, 1985). The novel compounds, NU1025 and PD 128763, were 
also shown to inhibit PADPRP in a competitive manner (unpublished results, lK. 
Porteous, Cancer Research Unit, The University of Newcastle Upon Tyne). These 
experiments therefore provide an indirect measure of the potential of these compounds 
to inhibit P ADPRP in intact cells. The induction of DNA damage resulting from an 
incubation of TM will mobilise cellular repair mechanisms. Excision of the damaged 
bases creates breaks in the DNA which is the stimulus for P ADPRP activation. Inhibition 
of PADPRP is quantitated in these experiments by the potency of the inhibitors as 
potentiators of TM induced growth inhibition. 
Growth inhibition experiments were again utilised to determine the effect fixed 
concentrations of the PADPRP inhibitors had on an increasing concentration ofTM. Each 
inhibitor potentiated the growth inhibitory effects of TM in a concentration dependent 
manner. However. the relative abilities of BZ, NUl 025 and PD 128763 to potentiate the 
growth inhibitory activity of TM in relation to 3AB were -2. -80 and -130 respectively" 
Again, these data correlate extremely well with the ability of the compounds to inhibit 
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in vitro PADPRP activity (see Section 3.3). where the relative potencies ofBZ, ~UI02:, 
and PD 128763 in relation to 3AB, were -I, -43, and -53 respectively (see Table 3.1). 
Again, the process of repair induced by the TM related DNA damage will be impaired 
in the presence of the P ADPRP inhibitors. A number of studies have shown that the 
inhibition of P ADPRP in the presence of DNA damage results in a prolonged G2 phase 
arrest (Das et al 1984, Boorstein & Pardee 1984, Jacobson et al 1985a). Thus. gro\\1h 
inhibition mediated by P ADPRP inhibitors in the presence of TM presumably reflects 
inhibition of DNA repair and extended growth arrest. 
Cytotoxicity of TM was also potentiated by fixed concentrations of the P ADPRP 
inhibitors in a concentration-dependent manner. The relative potencies of the inhibitors 
in relation to 3AB were -5, -100 and -140 for BZ, NUI025 and PD 128763 
respectively. These again exhibit a reasonable correlation with the relative potencies 
calculated in the in vitro PADPRP inhibition assay (see Section 3.3). The results 
calculated for PD 128763 are also in excellent agreement with those obtained by Sebolt-
Leopold and colleagues. Utilising the monofunctional alkylating agent, streptozotocin in 
conjunction with 500~M PD 128763 they observed a 7 fold increase in the cytotoxicity 
(Sebolt-Leopold & Scavone 1992). However, it appears that they vastly underestimated 
the inhibitory potential of their novel compound. The present study indicates 50-100j.1M 
PD 128763 in the presence of TM results in the maximum decline of cell survival, and 
that at a dose of 10j.1M, a significant level of potentiation is recorded. However, 
dissimilar concentration dependent effects of the P ADPRP inhibitors may arise with the 
use of different damaging agents, and different cell lines (For example, cell lines with 
lower NAD+ concentrations would be predicted to be sensitive to lower concentrations 
of PADPRP inhibitor, because of their competitive nature (see Chapter 6». 
for a compound to act as an effective resistance modifier it must potentiate the 
cytotoxicity of the danlaging agent with little or no inherent toxicity of its own. 5m7'-.1 
lAB gave a DEFIO of 4 whereas a maximum enhancement value of 7 was observed 
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using 100~lM PO 128763. In comparison, toxicity due to a 24 hour exposure to 5m~1 
3AB alone reduced the cell survival by -8% whereas at 10mM 3AB, suryiyal was 
reduced by 340/0 (see Figure 3.2). Similarly, although maximum potentiation of Ti\l 
cytotoxicity was apparent at 3mM BZ, alone this reduced cell survival by 34%. Ho\\'eyer. 
the concentrations of NU 1025 and PO 128763 which resulted in a maximum enhancement 
ofTM cytotoxicity, i.e. 50-100~M, (see Figure 3.7) showed a negligible effect, i.e. <50/0 
reduction in cell survival after a 24 hour incubation (see Figure 3.2). Therefore. NUI025 
and PO 128763, exhibited increased potency towards PADPRP, with less toxic effect per 
se compared to 3AB and BZ, and are thus potential candidates for resistance modifying 
agents. 
The depletion of NAO+ associated with PAOPRP activation is utilised as an indirect 
measure of the enzyme activity. Therefore, the effect increasing concentrations of TM 
had on the intracellular NAO+ concentration was determined. The NAO+ was found to be 
depleted in a concentration and time dependent manner, with a 500/0 NAO+ depletion 
observed at a concentration of 2mM TM following a 6 hour incubation. However, this 
was an -10-fold greater TM concentration than that required to achieve significant growth 
inhibition and cytotoxic effects. Therefore, hyperlethal concentrations of TM must be 
utilised to obtain a measurable level of NAO+ depletion. As the induction of TM related 
DNA damage occurs over a 6 hour period, so the break formation due to the action of 
constitutive repair enzymes, i.e. AP endonucleases, will be prolonged, rather than the 
immediate saturation of breaks characteristic of the more direct acting agents. A 
continuous, but steady depletion of the cellular NAO+ might therefore be expected as 
opposed to the massive decline following administration of agents such as OMS and 
MNU. This theory was illustrated by a direct incubation with MTIC. the active metabolite 
of 'I'M. An ~50% depletion of NAO+ was achieved using ImM MTIC following just a 
1 hour incubation. and by 6 hours the NAO+ levels had almost reattained those of control 
(see Figure 3.8A & B). Unfortunately the TM data only covers a 6 hour period. therefore 
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it would be of interest to follow the NAD+ effects at increased times to determine 
whether the control levels are also reattained over a prolonged incubation. The ability of 
inhibitors of P ADPRP to abrogate the NAD+ depletion provides further evidence that 
PADPRP is responsible for the decrease in NAD+. Both the classical and the noyel 
PADPRP inhibitors, 3AB and PD 128763 prevented the NAD+ depletion in a 
concentration dependent manner, as had been previously shown by Skidmore et al (1979) 
and James & Lehmann (1985). However, the concentration of PD 128763 required to 
completely prevent the NAD+ depletion was -10 fold less than that of 3AB. This again 
shows the increased potential of the novel inhibitor, PD 128763 to inhibit PADPRP, with 
the concentrations required to abolish NAD+ depletion analogous to those required to 
potentiate growth inhibition and cytotoxicity in TM treated cells. It should be noted that 
there was apparently only an -10 fold difference between the concentrations of 3AB and 
PD 128763 required to abrogate the NAD+ depletion, whereas 50-100 fold differences in 
concentration were observed in the growth inhibition and cytotoxicity studies. However. 
these concentration dependent effects spanned only a 2 fold depletion in NAD+ levels, 
and hence cannot be expected to show accurate concentration differences. 
Overall, a comparable level of enhanced potency was recorded for both NU 1 025 and PD 
128763 in each of the biological endpoints chosen, with the relative potencies of the four 
inhibitors correlating well with in vitro PADPRP inhibition. However, the concentration 
ranges required to exert significant biological effects for each of the four PADPRP 
inhibitors in the in vivo studies were found to differ -25-200 fold, in comparison to the 
I C50 concentrations determined in the in vitro assays. In the intact cell, the influx and 
efflux rate of the inhibitor, its possible metabolism once inside the cell, and reactions 
\vith acceptors other than PADPRP must be accounted for. Differences in the intracellular 
NAD+ concentration between the in "itro and the intact cell studies could also account 
for discrepencies in I C50 yalues. As the inhibitors act in a competitive manner. a higher 
NAD i concentration. e.g. 500-1 OOO~M. would require increased concentrations of the 
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inhibitors to effect a similar level of PADPRP inhibition as in vitro (e.g. a concentration 
of 75JlM NAD+ was used in the poly(ADP-ribose) polymerase assay). GiYen these 
limitations, overall, there was an excellent correlation of potency as P ADPRP inhibitors 
in vitro, and potency as potentiators of growth inhibition and cytotoxicity following DNA 
damage in intact cells, both of which have been ascribed to P ADPRP inhibition. 
The potency of NU1025 and PD 128763 when co-incubated with the DNA damaging 
agent TM in growth inhibition and cytotoxicity studies was observed to be increased 
-100-fold as compared to 3AB. There was a slight increase in the potency of PD 128763 
as compared to NU 1 025 in intact cells, although the difference in potency in the in vitro 
assay against PADPRP was not significant (PD 128763 ICso = 0.36JlM ± 0.01 JlM; 
NU1025 ICso = 0.44JlM ± 0.13JlM). However, both of the novel compounds, NU1025 
and PD 128763, exhibit an excellent potential to become candidates as resistance 
modifing agents for in vivo studies, prior to entrance into clinical trials. 
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CHAPTER 4 : EFFECT OF THE PADPRP INHIBITORS ON TI\I 
INDUCED DNA STRAND BREAK LEVELS. 
4.1 INTRODUCTION 
Prior to 1966, attempts to quantify DNA strand break levels were unsuccessfuL as 
shearing forces which occurred during DNA extraction introduced large numbers of 
artefactual DNA strand breaks. However, in 1966, McGrath & Williams introduced the 
technique "alkaline sucrose gradient analysis". Cells were lysed onto the top of the 
alkaline gradient prior to centrifugation, with the alkali causing the denaturation of DNA 
degradative enzymes and also effecting the release of the DNA in single strand form. The 
molecular weight of the DNA was proportional to the rate of sedimentation during 
centrifugation. Although the gentle lysis technique and use of centrifugal force minimised 
the shearing effect on the DNA, the technique proved insensitive to low levels of DNA 
damage. Alkaline elution, developed by Kohn et al (1981), exhibited a greater level of 
sensitivity and was more amenable to quantitative analysis compared to alkaline sucrose 
density gradients. It utilises filters that act as mechanical sieves to discriminate between 
different sized fragments of DNA. DNA is eluted in single strand form using a highly 
alkaline solution (i.e. pH 12.2), and the presence of single strand breaks is recorded as 
an increase in the rate of elution (see Materials and Methods for further details). The 
"nucleoid technique" also allowed for an increased level of sensitivity, but due to neutral 
conditions, differentiated between breaks formed as a result of enzymic incision, and 
those resulting from alkali labile sites (Cook & Brazell, 1975). Nucleoids form in the 
presence of high salt concentrations and nonionic detergents. They consist of the cellular 
DNA, present as large numbers of independent supercoiled loops. but lack most of the 
nuclear proteins. Upon introduction of a DNA strand break, supercoiling is relieved 
resulting in a slower rate of sedimentation. Hence, the loss and recovery of DNA 
supercoiling is followed hy changes in the sedimentation rate through a neutral sucrose 
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gradient. Bimboin & Jevcak (1981) developed a modified "alkali induced D1\:-\. 
unwinding assay" which circumvented the requirement for the physical separation of 
single and double stranded DNA on hydroxyapatite columns. The dye, ethidium bromide. 
was utilised as a direct probe of the DNA structure. as it binds selectively to duplex 
double stranded regions contained within single stranded DNA stabilised by alkali 
treatment. Most recently, a "comet assay" was developed that analyses the effect of DNA 
strand breaks in a single cell utilising gel electrophoresis for separation. Only direct DNA 
strand breaks or those introduced via enzymatic action are measured (Ostling & 
Johannson, 1984). 
Studies to assess the DNA strand break levels in cells cotreated with DNA damaging 
agents and P ADPRP inhibitors have been performed by numerous groups utilising most 
of the techniques described above (e.g. Durkacz et ai, 1980; Durkacz et ai, 1981 b; James 
& Lehmann, 1982; Cleaver et ai, 1983; Huet & Laval, 1985; Cleaver et ai, 1985; Cantoni 
et ai, 1986; Hunting & Gowans, 1988; Lunn & Harris, 1988; Moses et ai, 1988). 
However, most of the investigations used only a single, high dose of the chosen PADPRP 
inhibitor nearly always 3AB, e.g. 3-5mM, and concentrated on the effect this had on the 
level of DNA single strand breaks when used in conjunction with an increasing 
concentration of the damaging agent (see Chapter 1, Table 1.1 for examples). A couple 
of reports touched briefly on the effect increasing concentrations of 3AB had on DNA 
single strand break levels, when in the presence of a damaging agent. Cantoni et al 
(1986), in an experiment to identify the optimum dose of 3AB to utilise in their 
investigation into the effects of P ADPRP inhibition on DNA strand break rejoining in 
H20 2 treated cells, showed 3AB (0.5-5mM) to inhibit the rejoining of H20 2 induced DNA 
strand breaks in a concentration dependent manner. In the presence of 0.5mM and 5mM 
3AB the relative number of Il,O, induced breaks rejoined during a 15 minute post 
, - -
incubation was 95% and 700/0 respectively. A more comprehensive study was reported 
by Clean~r el al (1985). They used a single dose of the alkylating agent. MMS, together 
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with a range of 3AB concentrations. The single strand break frequency \\-as obseryed to 
actually decrease at the low concentrations of 3AB (0.05-1mM). \\ith an increased 
frequency seen only at 2mM and above. However, in general the literature is completely 
lacking both a comprehensive and quantitative dose dependent analysis of the P ADPRP 
inhibitors, compared to their inhibitory potency. on the DNA single strand break le\'el in 
DNA damaged cells. In the previous Chapter, co incubation of the alkylating agent. Tl\l 
together with P ADPRP inhibitors resulted in the potentiation of TM induced cytotoxicity. 
Durkacz et al (1980), determined the effect of coincubating the monofunctional alkylating 
agent, DMS with 3AB on the level of DNA damage. Utilising alkaline sucrose density 
gradients, low molecular weight species of DNA persisted for up to 40 minutes after the 
removal of the DMS, with only intermediate molecular weight DNA recovered by 80 
minutes, indicative of an impaired repair process. This increased break frequency, in the 
presence of PADPRP inhibition was correlated with the cocytotoxic effect. Coincubation 
ofDMS with 3-5mM 3AB resulted in a 4 fold increase in cytotoxicity. with a significant 
increase in the DNA strand break levels over a 90 minute period (Durkacz et ai, 1980; 
James & Lehmann, 1982). This correlation has been reproduced utilising a number of 
different damaging agents and inhibitors of PADPRP (see Chapter 1. Table l.1). 
However, a coexposure to UV radiation in the presence of 3AB showed no effect on 
either the enhancement of cytotoxicity or the level of DNA single strand breaks (James 
& Lehmann, 1982; Cleaver et ai, 1983), confirming the subsequent proposed involvement 
of P ADPRP in BER as opposed to NER (Satoh et ai, 1993). 
4.2 AIMS 
The aim of this second results Chapter was to determine whether the two noyel 
compounds, NU 1 025 and PD 128763, previously observed to inhibit PADPRP in \'itro 
with a ~60 fold increased level of potency as compared to 3AB and BZ, also resulted in 
an increased DNA single strand break level follo\ving treatment with a 
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chemotherapeutically relevant alkylating agent that promotes BER. If this were the case. 
did the concentrations required correlate with their increased potency as PA.DPRP 
inhibitors? This was achieved by performing a quantitative evaluation of a range of 
P ADPRP inhibitor concentrations required to increase the DNA single strand break leyels. 
when used to treat the cells in the presence of a DNA damaging agent. 
To allow a comparison of these results with the cytotoxicity data, TM was again utilised 
as the damaging agent. TM is degraded in biological milieu to the direct methylating 
agent, MTIC with the subsequent formation of the modified bases, 3meA, 7meG and 
Q6meG (for further details see Chapter 1, Section 1.4.3b) (Tisdale, 1988; Hepburn ct al. 
1991). The action of specific glycosylase enzymes removes the damaged bases to leave 
AP sites which are subsequently cleaved to create DNA single strand breaks. The 
technique of alkaline elution was used to quantify the level of single strand breaks (Kohn 
el ai, 1981). However, the AP sites generated are extremely alkali labile and breaks 
formed at the AP sites are identified by a convex curvature of the elution curves, as 
compared to the near linear curves observed with X irradiation, and have a distinct 
dependence on the pH range (Kohn et ai, 1981). This was taken into account when 
examining the alkaline elution profiles obtained following TM treatment. 
4.3 CHOICE AND JUSTIFICATION OF INTERNAL STANDARD 
CONCENTRA TION 
Coelution of internal standard cells with the treated sample cells defines a corrected time 
scale for the assay (Kohn et ai, 1981). This increases the precision of elution by reducing 
intersample variations (see Chapter 2. Section 2.12). 
The elution of internal standard cells requires the introduction of defined levels of breaks 
into the DNA. X irradiation is the most widely employed method, with breaks introduced 
directly into the DNA strands. A suitable dose of X rays for use on the internal standard 
cells. and which was utilised in subsequent experiments, was determined. [14C] Thd 
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Figure!.1: Representative alkaline elution 
profiles of X- ilTadiated cells . 
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labelled Ll210 cells were exposed to increasing doses of X rays, prior to elution of DNA, 
The elution rates were plotted against time. Figure 4.1 shows the slopes of the elution 
profiles increased in a dose dependent manner. Each dose exhibited a linear elution 
profile. The X ray dose chosen to irradiate the internal sample cells was 300 rads, as the 
fraction of 14C retained on the filter after completion of the elution was -0.1. 
4.4 THE EFFECT OF TM ON THE DNA STRAND BREAK FREQUENCY 
Previously, TM was observed to increase the inhibition ofL1210 cell growth as well as 
significantly reduce cell survival in a concentration dependent manner (see Chapter 3). 
The effect of the TM treatment on the level of single strand breaks was therefore 
determined, and the correlation with cytostatic and cytotoxic effects assessed. 
Initially, the effect of two concentrations of TM on the DNA single strand break leveL 
over a period of 24 hours was investigated. The two doses chosen, 200/J.M and 1000/J.M 
TM, reduced cell survival to approximately 50% and 1 % respectively. The results 
presented in Figure 4.2 are in the "relative elution" (R.E.) format. R.E. is a ratio of. "the 
increase in the rate of DNA elution observed with the treated cells as compared to 
untreated controls, at the point when 50% of the internal standard DNA has eluted" (see 
Chapter 2, Section 2.12) (Fornace & Little, 1977). In the presence of both TM 
concentrations an increase in R.E. values was observed up to 4-6 hours, whereas over the 
subsequent incubation periods the R.E decreased, approaching control (undamaged) levels 
by 24 hours. This pattern was concentration dependent, with the effect produced by 
1000/J.M TM -3 fold greater than that observed for 200/J.M TM. The R.E. value obtained 
at anyone time represents a balance between the level of single strand break formation 
and break religation. Over the initial 6 hours, the rate of single strand break formation 
would appear to he in excess over the rate of ligation. 1000/J.M TM treatment caused 
significantly more single strand breaks than was observed with 200JlM TM, with the 
majority formed during the first two hours. The R.E., after an incubation of 1 hour \\'as 
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rapidly increasing in the presence of both 200~M and 1000~M Ttvl (see Figure -+.2). 
Therefore, L 121 0 cells were incubated for 1 hour to determine the effect an increasing 
concentration of TM had on the frequency of single strand DNA breaks. Figure -+.3:-\ 
shows the elution rates increased in a concentration dependent manner. At the lower Tr-..1 
concentrations, i.e. 200-400~M TM, the elution profiles appeared slightly conyexed. 
suggestive of alkali labile sites produced by glycosylase action at sites of base 
methylation producing AP sites. However, as the dose increased, i.e. 800-1 OOO~M Tr-..l, 
the profiles assumed linearity. The R.E. plot of the data is shown in Figure -+.3B, and 
demonstrates a near linear relationship between the dose of TM and the R.E. value. This 
suggests the damaging effect of the TM on the DNA is related to the formation of the 
single strand breaks. 
4.5 THE EFFECT OF THE PADPRP INHIBITORS PER SE ON THE DNA 
STRAND BREAK FREQUENCY. 
Previously, the four inhibitors ofPADPRP. 3AB, BZ, NU1025 and PD 128763 were all 
reported to lack intrinsic toxicity at the doses utilised in the chemopotentiation 
experiments, e.g. 1-5mM 3AB and 10-100~M NU1025. Only as the concentrations were 
significantly raised did a cytotoxic effect become apparent, e.g. 10mM 3AB and 2mM 
NU1025 reduced survival by 34% and 55% respectively. Similarly, an important analysis 
prior to utilising TM in conjunction with the inhibitors, was to assess the effect of the 
inhibitors alone on DNA strand break frequency. 
Following a 24 hour continuous exposure to high concentrations of the inhibitors, that 
had showed signs of cytostatic and cytotoxic effects, on the L1210 cells. i.e. 10mM 3AB. 
10mM BZ, 1 mM NU 1 025 and 1 mM PD 128763, there was no observed increase in the 
frequency of single strand breaks in comparison to untreated control cells, as shown in 
Figure 4.4. 
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Figure 4.4: Alkaline elution profiles depicting 
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4.6 A COMPARISON OF THE ABILITY OF P ADPRP INHIBITORS TO RETARD 
SINGLE STRAND BREAK REP AIR. 
4.6.1 The effect of the P ADPRP inhibitors on a fixed level of TM induced D:\A 
damage. 
The effect of the PADPRP inhibitors, 3AB, BZ, NUI025 and PD 128763 on the leyel 
of DNA single strand breaks following TM induced DNA damage was determined, and 
the results compared to their potency as P ADPRP inhibitors. A quantitative evaluation 
of the DNA single strand break levels was performed over increasing concentrations of 
the inhibitors. 
To allow an accurate comparison, the same starting level of TM induced DNA damage 
was required. Utilising the alkaline elution profile shown in Figure 4.3 a concentration 
of 150J.lM TM was chosen, as this itself resulted in a significant measurable level of 
single strand breaks, but allowed the possible potentiation effects of the PADPRP 
inhibitors on DNA single strand break levels to be observed. 
L 121 0 cells were incubated for 1 hour with 150J.lM TM alone, or in the presence of 
increasing concentrations of the P ADPRP inhibitors, prior to alkaline elution of the DNA. 
Figures 4.5 & 4.6 demonstrate a dose dependent increase in the rate of elution as the 
concentration of each of the P ADPRP inhibitors was increased. Cantoni et of (1986) had 
previously observed a similar concentration dependent increase in single strand break 
frequency by 3AB in the presence of a fixed concentration of H20 2, as had Cleaver et af 
(1985) using the monofunctional alkylating agent, MMS. 
The effect of the 1 hour incubation with TM alone gave rise to profiles with a slight 
convex nature, suggestive of the presence of alkali labile sites. In the presence of low 
doses of the inhibitors the convex shaped profiles were retained, whereas on attaining the 
higher inhibitor concentrations, the profiles became linear. e.g. 1 mM and 3mM BZ 
produced con\'cx curves, but at 10mM and 20mM BZ the profiles were linear (see Figure 
4.5B). A comparison of the inhibitor concentrations that resulted in the production of 
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linear profiles showed both 3AB and BZ required concentrations of 3-10m",1 whereas 
NU1025 and PD 128763 only needed 0.3-1mM. 
The translation of the data presented in the profiles in Figures 4.5 & 4.6 to the R.E. 
values (see Figure 4.7) represents more clearly the effect the PADPRP inhibitor 
concentration had on DNA single strand break frequency. The R.E. data was calculated 
utilising the TM alone as the control, and therefore can be extrapolated back to zero. 
representing a zero inhibitor concentration. A large difference was observed between the 
concentrations of the two novel inhibitors and the "classical" PADPRP inhibitors, 3AB 
and BZ, required to enhance the single strand break level. An arbitrary R.E. value was 
selected of 0.125 as this gave readings on all four of the inhibitor curves, and the 
concentration of each inhibitor required to raise the level of single strand breaks to this 
degree was determined. The concentrations thus calculated are presented in Table 4.1:-
TABLE 4.1 
INHIBITOR [INHIBITOR]o.125 POTENCY AS POTENCY AS 
(DNA strand breaks) COMPARED TO IN VITRO 
3AB PADPRP 
(DNA strand breaks) INHIBITORS 
, 
3AB 12.0mM 1.0 1.0 
BZ 5.3mM -2 ~2 
NUI025 0.18mM -70 -43 
PD 128763 0.12mM -100 -53 
Table 4.1: An assessment of the PADPRP inhibitor concentrations required to increase 
the level of DNA single strand breaks. resulting from treatment \vith 150JlM TM. by a 
similar magnitude. An arbitary R.E. \'alue of 0.125 was utilised. The \'alues were 
calculated from the a\'eraged data presented in Figure 4.7. \ 
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As shown, -70 & -100 fold reductions in the concentrations ofNUI025 and PD 128763 
respectively were required to exhibit the equivalent single strand break frequency as 3AB. 
Only a -2 fold difference was observed between the potencies of 3AB and BZ. These 
figures correlate well with the relative potencies obtained from the IC50 values calculated 
for PADPRP inhibition in vitro, also presented in Table 4.1 (see Chapter 3, Table 3.1). 
However, the inhibitor concentrations required to inhibit P ADPRP in vitro, compared to 
those required to raise the DNA single strand break level to the R.E of 0.125 differ by 
several hundred fold. A concentration of 0.44j.lM NUI025 was sufficient to inhibit 
PADPRP activity in vitro by 50%, but a concentration of 200j.lM NUI025 was required 
before an effect on DNA single strand break levels was observed. However, a direct 
comparison between the intact cells and the permeabilised cell system is not possible, and 
the reasons for this will be discussed in Section 4.8. 
4.6.2 The schedule dependency of the TM and P ADPRP inhibitors. 
The experiments described in the previous Subsection involved a 1 hour coincubation 
of the cells with a fixed dose of 150j.lM TM with increasing concentrations of PADPRP 
inhibitors. The results obtained demonstrated an increase in the level of single strand 
breaks. However, as TM and inhibitors were present simultaneously, an interaction of the 
two compounds, non-specific to P ADPRP could be responsible for the observed effects. 
Therefore, an experiment was performed utilising NU 1 025 as the P ADPRP inhibitor. One 
set of cells was treated simultaneously with TM and NUI025 for the 1 hour incubation 
as described previously. However, a second set of cells was incubated for 1 hour in the 
presence of 150j.lM TM, the TM was then removed, and the cells incubated for a further 
hour in fresh medium containing the increasing concentrations of NUI025. Figure 4.8 
shows the results of the two dosing schedules on R.E. values. The R.E. profiles obtained 
for both the coincubation and pretreatment studies increased in a concentration dependent 
manner, confirming there to be no interaction between the TM and the P ADPRP 
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inhibitor. However, it should be pointed out that these results were derived from a single 
experiment, and the large errors in the high dose values would suggest further studies 
would be required to substantiate these observations. 
4.6.3 The effect of PADPRP inhibition on the DNA single strand break levels 
resulting from fixed doses of TM. 
3AB, in relation to the two novel P ADPRP inhibitors, exhibited a much reduced level 
of potency as a P ADPRP inhibitor as exemplified by the very high concentrations 
required to raise the single strand break frequency, i.e. -70 fold increase in the 
concentration of 3AB was required as compared to NUl025, to produce a similar effect 
on DNA strand break frequency (see Figure 4.7). The potential of 3AB to increase the 
level of DNA single strand breaks was assessed utilising an increased concentration of 
TM which raised the initial break level. The TM concentration used was 250I-lM, and this 
was co-incubated with increasing concentrations of 3AB. Figure 4.9 indicates a raised 
frequency of single strand breaks when 250l-lM TM was used as opposed to l50l-lM TM. 
At both TM concentrations the DNA single strand break levels were increased when 
coincubated with increasing concentrations of 3AB. A slightly reduced 3AB concentration 
was apparently required to initiate the increased strand break frequency. 5mM 3AB was 
required in the presence of l50l-lM TM whereas only 3mM 3AB was necessary if 250l-lM 
was utilised. However, as the data presented in Figure 4.9 was derived from a single 
experiment, further studies would be required for validation. A comparison of the effect 
of an increased TM concentration in the presence of one of the more potent P ADPRP 
inhibitors to observe the effect on DNA strand break frequency would be of interest. 
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4.7 THE EFFECT OF TIME ON THE ABILITY OF THE PADPRP INHIBITORS 
TO INCREASE THE SINGLE STRAND BREAK FREQUENCY FOLLOWING T:\I 
TREATMENT. 
The effect of the P ADPRP inhibitors on TM induced single strand breaks oyer a 24 hour 
period was investigated. A fixed dose of TM was coincubated for increasing periods of 
time in the presence of fixed concentration of P ADPRP inhibitors. The effect of a fixed 
TM dose alone over time was presented in Figure 4.2 It was important that the dose of 
TM chosen for these experiments induced a significant level of damage into the DNA, 
but allowed for the observation of possible potentiation effects of the P ADPRP inhibitors. 
A TM concentration of 200JlM was chosen, as this produced a measurable level of single 
strand breaks as recorded by an increased rate of elution but was approximately 3 fold 
lower than that observed with a high TM concentration, e.g. 1000JlM (see Figure 4.2). 
For the study, just two of the four PADPRP inhibitors were assessed. 3AB and NUI025 
represented a classical and a novel P ADPRP inhibitor respectively, thereby allowing the 
." 
potency of the inhibitors over time to be compared. The concentrations of the two 
inhibitors used were 5mM 3AB and 300JlM NUI025. Both resulted in the increased 
frequency of single strand breaks after just a 1 hour incubation with 150JlM (see Figure 
4.3). The cytotoxicity studies (see Chapter 3, Figure 3.6) gave -60/0 survival following 
200JlM TM + 5mM 3AB. However, as shown, maximal potentiation of TM cytotoxicity 
was observed with 50-100JlM NUI025, giving -3% survival at 200JlM TM. The 
concentration of NUI025 utilised in this time course study was 300JlM, as this gave a 
significant effect on the single strand break levels over a 1 hour incubation. 
Both of the PADPRP inhibitors increased the R.E. values of the TM treated DNA over 
the whole 24 hour period, as observed in the R.E. plots of Figure 4.10, indicating an 
increased frequency of single strand breaks. There was a -3 fold increase in this level 
when the rate obtained in the presence of 300JlM NU 1 025 was compared to that of 5mi\1 
3AB. Howen~r, with both inhibitors, the DNA single strand break levels after an 
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incubation of 24 hours had fallen to nearly that of TM alone. 
4.8 DISCUSSION 
This Chapter investigated the effect that the clinically relevant alkylating agent, TM, had 
on DNA single strand break levels in L1210 cells, in the presence and absence of the four 
PADPRP inhibitors 3AB, BZ, NUI025, and PD 128763. The PADPRP inhibitor 
concentration range over which the level of TM induced DNA single strand breaks was 
raised was determined. 
TM, through its active metabolite, MTIC, methylates DNA bases, e.g. 3meA, 7meG, 
Q6meG. The BER of these lesions results either in the formation of DNA single strand 
breaks due to the action of AP endonucleases (see Chapter 1, Section 1.4.5c), or, as in 
the case of Q6meG, breaks form due to the mismatch repair of incorrect bases paired 
opposite the Q6meG. As the concentration of TM was increased the level of DNA single 
strand breaks was also observed to increase in a concentration dependent manner (see 
Figure 4.3A), with the peak break level attained after 4-6 hours (see Figure 4.2). By 24 
hours, the level of DNA single strand breaks was similar for untreated controls 
demonstrating that repair had occurred. TM degrades to MTIC with a half-life of ~50 
minutes in murine lymphoma cells (Tsang et ai, 1991) with the MTIC reaching a peak 
after 20-40 minutes. This correlates favourably with the peak elution rate observed 
between 1-4 hours for the TM treated L1210 cells. The subsequent reduction in R.E. 
values (see Figure 4.2) would indicate that the balance between break formation and 
break ligation alters. As the TM degrades, the level of base modification and hence the 
substrate for the AP endonuclease would decrease, thereby resulting in a reduced level 
of enzyme activity. Ligase action would therefore predominate. 
The elution profiles of Figure 4.3A, especially at the lower TM concentrations, e.g. 100-
400J.lM, were found to be of a convex nature. However, as the TM concentration was 
increased the profiles were observed to be more linear. To explain this occurrence, the 
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kinetics for the generation of DNA single strand breaks resulting from AP sites because 
of alkaline lability, and the kinetics of AP-endonuclease induce break formation must 
alter at increased levels of damage, with the latter increasing and/or the former becoming 
rate limiting. However as the peak elution rate correlates well with the degradation protile 
of TM, an increase in the activity of the AP endonuclease would be anticipated. 
An assessment of the effect the four P ADPRP inhibitors alone had on the DNA single 
strand break levels showed there to be no difference as compared to untreated controls 
after a 24 hour continuous exposure to high concentrations of inhibitor. e.g. 10mM 3AB, 
ImM NUI025. The cellular DNA is continuously subject to "spontaneous damage" 
resulting from deamination, depurination, methylation and oxidation reactions within the 
cell (see Chapter 1, Section 1.4.2). The BER process is mainly responsible for the repair 
of these types of damage. Because of the known requirement for P ADPRP function in 
BER, an incubation of cells with P ADPRP inhibitors might be expected to slow this 
repair rate, resulting in the increased levels of single strand breaks. However, no effects 
on the single strand break frequency were observed, indicating the ultimate toxicities of 
the inhibitors were not due to an inhibition of the repair of spontaneous damage. The 
levels of spontaneous damage appear relatively high, (e.g. 2000-10000 depurinations/day), 
but when the number of base pairs in the DNA of a single chromosome is taken into 
consideration e.g. Homo sapiens contains -108 nucleotides, the level of spontaneous 
damage appears rather insignificant (e.g. 1 break per -104 nucleotides). This level of 
damage would be measurable using the alkaline elution technique, whose sensitivity is 
of the order of 1 breakll07 nucleotides (Kohn et aI, 1981). However, the number and 
class of DNA strand breaks introduced by DNA damaging agents, e.g. TM, could be an 
important factor in the contribution of PADPRP inhibition to increased cytotoxicity and 
increases in DNA strand break levels. 
When increasing concentrations of the PADPRP inhibitors were coincubated with a fixed 
concentration of TM. which itself resulted in a significant, measurable level of DNA 
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damage, the DNA single strand break frequency was increased in a concentration 
dependent manner. However, there was a -70-100 fold reduction in the concentrations 
of NU 1025 and PD 128763 required to increase the break level to a similar degree as 
3AB. 
To the best of my knowledge this represents the first comprehensive study to determine 
the concentration dependent effect of the P ADPRP inhibitors on single strand break levels 
in DNA damaged cells. The data presented herein does corroborate the few publications 
that have briefly reported the concentration dependency of the PADPRP inhibitor, 3AB, 
on the level of DNA single strand breaks (Cleaver et aI, 1985: Cantoni et aI, 1986). 
However, in this study, I found the single strand break frequency to increase, albeit very 
slightly from 0.3-5mM 3AB, in the presence of a fixed dose of TM (150JlM) (see Figures 
4.5A and 4.6). Only at 10mM 3AB was there an observable increase in the DNA single 
strand break level (see Figure 4.7). Cleaver et al (1985) had reported a decreased 
frequency of DNA single strand breaks between the concentrations of 0.5-lmM 3AB, 
with an increase observed only at 2mM 3AB and above. As well as demonstrating the 
concentration dependent effect of 3AB, the P ADPRP inhibitors, BZ, NU 1 025 and PD 
128763, were also found to exhibit similar concentration dependent increases in DNA 
single strand break levels. The ability of the inhibitors to increase DNA single strand 
break levels was shown to be in excellent agreement with their potencies as P ADPRP 
inhibitors. The order of relative potency of the four inhibitors towards P ADPRP was as 
observed for the in vitro PADPRP inhibition study (see table 4.1). 
Interestingly, the concentrations of inhibitor required to inhibit PADPRP in vitro were 
-1000 fold less than those required to increase the DNA single strand break levels, e.g. 
3AB, gave an ICso value for in vitro PADPRP inhibition of 19.1 JlM, but a significant 
increase in DNA strand break levels was not observed until a concentration of at least 
5mM 3AB was achieved. However, these values can not be compared in a quantitative 
manner, as the R.E. values are only arbitrary figures. Nevertheless, the dissimilarity 
between the concentrations required to generate the effects could be due to the influence 
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of a number of parameters. Perhaps most importantly. to effect the level of DNA strand 
breaks a greater than 500/0 inhibition of the P ADPRP activity could be required. This 
would result in a requirement for much higher PADPRP inhibitor concentrations .. -\lso. 
the inhibitors rather than entering the cell by simple passive diffusion could require active 
transport into the intact cells (Olsson et ai, 1993), or simply not permeate cell membranes 
sufficiently well. In this respect, efflux of the inhibitors may also contribute to 
concentration variations. Once inside the cell, the inhibitors, due to the amide grouping 
shared with nicotinamide, may bind to other NAD+ dependent proteins, e.g. alcohol 
dehydrogenase, glyceraldehyde dehydrogenase. Also, other nonspecific binding to 
intracellular proteins could occur all of which would reduce the inhibitor concentration 
available to inhibit PADPRP. The intracellular NAD+ concentration in intact cells varies 
between 100-1 OOOJ.lM whereas in the in vitro P ADPRP assay the NAD+ was maintained 
at a constant concentration of 75J.lM. Therefore, due to the competitive nature of the 
P ADPRP inhibitors, cells with high intracellular NAD+ levels would require increased 
concentrations of the inhibitors to effect a similar level of P ADPRP inhibition. Metabolic 
degradation of the inhibitors could also provide an explanation for a reduced intracellular 
inhibitor concentration. 
Satoh & Lindahl (1992) proposed a model for the involvement of P ADPRP in the repair 
process. In DNA damaged cells, P ADPRP binds to DNA single strand breaks, which 
activates the synthesis of poly(ADP-ribose) and results in auto- and hetero-modification. 
Automodified P ADPRP exhibits a reduced affinity for DNA, and its release from the 
strand break allows the access of the repair enzymes to the damaged site. Utilising 
MNNG treated cells transfected with the DBD polypeptide, Molinete et ai (1993) found 
the DBD competed with the endogenous P ADPRP for the DNA single strand breaks. 
However, once the DBD was bound, the lack of automodification prevented its release 
\vith a consequential decrease in repair capacity. The transient inhibition of DNA repair 
by inhibitors of PADPRP can be explained utilising this model. The inhibition of 
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PADPRP would significantly inhibit the automodification reaction. therefore PADPRP 
would remain bound to the damaged site for an increased period, thus preyenting the 
access of the repair enzymes. Inhibitors with increased potency towards PADPRP would 
retard the release from the DNA single strand break to an even greater extent. with this 
manifested as an increased delay of DNA repair. 
The effect two different TM and NUl 025 dosing schedules had on the R.E. profiles was 
considered (see Figure 4.8). Both in the coincubation study, (i.e. 150!J.M TM coincubated 
with increasing concentrations of NUl 025), and the preincubation study, (i.e. L 121 0 cells 
were pre-incubated with 150!J.M TM, prior to incubation with the NU1025), the R.E. 
values were observed to increase as the concentration of NU 1 025 was increased. 
Therefore, the concentration dependent increase in DNA single strand break levels was 
not due to an interaction between the two drugs. Interestingly, the initial DNA single 
strand break levels due to TM alone are extremely comparable in both of the dosing 
schedules, which would suggest an efficient "wash out" of TM. In the preincubation 
study, TM was removed prior to treatment with the NU 1025 concentrations. Therefore, 
if the TM was not effectively removed, or became trapped in the cell, e.g. TM efflux was 
transporter dependent or totally prevented due to complexing with intracellular proteins, 
TM would have been present for a 2 hour period, as opposed to 1 hour in the 
coincubation study. Therefore, a higher initial DNA strand break level due to TM alone 
would have been anticipated. 
Several studies have been published which indicate PADPRP function resulted in the 
reduction of the steady state level of single strand breaks present in the DNA following 
damage. Lehmann & Broughton (1984) utilised alkaline sucrose gradients to analyse the 
effect of a DMS and 3AB cotreatment on the DNA single strand break frequency in 
serum starved cells. These Go arrested cells showed an equivalent DNA single strand 
break frequency to a growing cell population. In the absence of 3AB, high molecular 
weight species were regained as most of the DNA breaks were rejoined. However. upon 
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addition of 3AB the break level rose, with the level of DNA single strand brc3ks 
returning to the initial frequency. Cleaver & Morgan (1983) found that the addition of 
3AB at any time between 6-24 hours after alkylation damage resulted in a similar leyel 
of breaks, as if the coincubation with 3AB had been continuous. With the subsequent 
removal of the inhibitor, the DNA single strand break frequency returned to that obseryed 
in the absence of P ADPRP inhibition (Cleaver & Morgan. 1983; Cantoni et aI, 1986). 
As the concentration of 3AB required to exhibit a similar increased level of DNA single 
strand breaks was,.., 70 fold greater than that of NUl 025. the effect of increasing the level 
of damage was assessed. At both 150JlM TM and 250Jl~1 TM the DNA single strand 
break levels were increased in a concentration dependent manner. However, the increase 
observed at 250JlM TM was greater than that at 150JlM TM and the 3AB concentration 
at which the break level initially rose was slightly reduced. Therefore. the effectiveness 
of the PADPRP inhibitors may be dependent on the level of activation of PADPRP. 
which is itself activated by the level damage to the DNA. For example. the amount of 
P ADPRP required for binding and activation may become rate limiting at higher levels 
of strand breaks. Panzeter et al (1992) proposed the homomodification of P ADPRP, with 
one PADPRP molecule bound to DNA strand break ends, which actively produced 
poly(ADP-ribose) to modify a second acceptor PADPRP molecule. Therefore, less 
inhibition would be required to affect strand break frequencies if PADPRP itself became 
rate limiting for strand breaks. However, this result may be at variance with the results 
presented in Chapter 5, where L1210 cells were treated for increasing incubation periods 
with a fixed dose of 150JlM TM, in the presence of increasing PD 128763 concentrations. 
There was no significant difference in the concentration of PD 128763 that resulted in 
an increased level of DNA single strand breaks, although the initial break levels due to 
TM alone was increased. 
The increased single strand DNA break level resulting from a coincubation of T~ t with 
the PADPRP inhibitors was followed over a 24 hour period. Both 5mM 3AB and 300JlM 
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NU1025, when coincubated with 200JlM TM. led to increased R.E. values over the entire 
24 hour period. However, this DNA strand break increase was 3 fold greater when 
300JlM NU1025 was utilised as opposed to 5mM 3AB. By 24 hours control lcyels were 
nearly reattained. The opinion generally upheld, is that the rate of religation of the single 
strand breaks is the factor modified by P ADPRP in the dynamic process of break 
formation and repair. An increase in the activity of DNA ligase, due to direct or indirect 
modification by P ADPRP is a proposed method by which P ADPRP alters the steady state 
level of the single strand breaks (Creissen & Shall, 1982; Ohashi et aI, 1983) (see 
Chapter 1, Section 1.5.2 for detailed discussion). The inhibition of PADPRP results in 
a shift in the balance of this equilibrium. The increased rate of elution observed with 
NUI025 as opposed to 3AB can be interpreted as an increased ability of this compound 
to inhibit the action of P ADPRP. The increased level of P ADPRP inhibition results in the 
increased upset to the dynamic relationship between break formation and subsequent 
religation. The shape of the elution curves as well as the maximal R.E. value obtained 
(i.e. at 6 hours) in the presence of 3AB and NUl 025 was observed to be similar to that 
of TM alone. By 24 hours, the control levels were almost reattained, although there was 
still a slightly raised level of DNA single strand breaks observed with NU 1 025. 
The results presented in this chapter have clearly demonstrated that all four of the 
PADPRP inhibitors, 3AB, BZ, NUI025 and PD 128763, when incubated in the presence 
of TM, result in an increased frequency of DNA single strand breaks. The concentrations 
of the inhibitors required to increase the DNA single strand break levels in the presence 
of a fixed dose of TM showed an excellent correlation with the level of in vitro PADPRP 
inhibition that was demonstrated in Chapter 3. A 70-100 fold decrease in the 
concentration of the novel compounds was required to increase the single strand break 
frequency to that observed with 3AB. This also gave an excellent correlation with the 
relatiye potencies observed in the growth inhibition and cytotoxicity studies. 
The inhibitors themselves lacked effect on DNA strand break production, thus indicating. 
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that the cytotoxicity of the PADPRP inhibitors observed at high concentrations was not 
explainable by the inhibition of repair of spontaneous damage. The cytotoxicity of D:\A. 
damaging agents in the presence of inhibitors of P ADPRP was reportedly correlated with 
an increase in the level of DNA single strand breaks resulting from the repair of lesions 
in the DNA bases. P ADPRP function was associated with reducing the steady state break 
level, by reducing their half life, and thereby increasing survival. The inhibition of 
PADPRP altered this dynamic balance, and correspondingly decreased the cell survival. 
However, although the inhibitors were shown to potentiate the cytotoxicity of T~1, 
together with a significant increase in the frequency of single strand breaks there was an 
observed lack of correlation between the concentrations over which these two biological 
endpoints occurred:- e.g. at 50JlM PD 128763. maximum potentiation ofTM cytotoxicity 
was observed (Chapter 3, Figure 3.6) but at this concentration there was little or no 
apparent increase in the DNA strand break level (Figure 4.7). The following Chapter will 
aim to investigate this observation more thoroughly with the presentation of comparative 
data. 
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CHAPTER 5 : EVALUATION OF PADPRP I~HIBITOR 
CONCENTRATIONS REQUIRED TO POTENTIATE TM 
INDUCED CYTOTOXICITY AND DNA STRAND BREAK 
LEVELS. 
5.1 INTRODUCTION 
When the results of Chapters 3 and 4 were analysed together, as briefly described in the 
summary of Chapter 4, a discrepancy was observed between the P ADPRP inhibitor 
concentration that resulted in the potentiation of TM cytotoxicity. and the concentrations 
required to increase the single strand break frequency, following TM treatment. As 
described in the previous Chapter, the literature lacks a quantitative and comprehensive 
dose dependent correlation between the effects of the P ADPRP inhibitors on the DNA 
strand breaks, and effects on cytotoxicity. Most of the studies utilised just a single, high 
dose of inhibitor in conjunction with increasing concentrations of the damaging agent. 
Cleaver et al (1985) and Cantoni et al (1986), found that DNA single strand break levels 
resulting from fixed concentrations of MMS and H20 2 respectively, were increased in a 
concentration dependent manner by a co-incubation with 3AB, but this was not correlated 
with the effects on cytotoxicity. The potentiation of cytotoxicity of DNA damaging 
agents, especially those resulting in initiation of BER, by inhibitors of PAD PRP. was 
suggested to correlate with an increase in the DNA single strand break frequency (e.g. 
Durkacz et al. 1980; James & Lehmann, 1982; Huet & Laval, 1985; Cantoni et ai, 1986~ 
Lunn & Harris, 1988). However, a number of studies reported a lack of correlation 
between cytotoxicity and DNA single strand break levels. In 1985, Cleavt:r et al 
published evidence to suggest that the increase in single strand break levels following 
damage to the DNA, were observed only at concentrations of 3AB of 2-5mM or over. 
and that below this there was an apparent decrease in DNA strand break leyd. Howe\'l~r, 
tht: rt:pair replication leyels increased sharply at the lower inhibitor concentrations. so 
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negating the affiliation between repair replication and DNA strand break frequencies 
(Cleaver, 1985). However, different MMS concentrations used in the dosing scheduks 
of these experiments could account for the discrepencies. Recent data, utilising an in l'itro 
cell extract assay which assessed the rejoining ability of a nicked plasmid, found that 
break rejoining was inhibited in a concentration dependent manner in the presence of 
3AB. However, ImM 3AB which only reduced the repair capacity by -700/0 of control 
levels resulted in an 80-90% inhibition of poly(ADP-ribose) polymer formation (Satoh 
et ai, 1994). In fact even in the presence of just 200~M 3AB, a concentration which 
reduced strand rejoining by 20% of control levels, polymer formation was depleted to 80-
90% of that found in control extracts. The 10-20% (ADP-ribose) polymer that was 
formed under such conditions was of a much reduced length, i.e. oligomers of less than 
20 residues (Satoh et ai, 1994). The proposed theory suggested PADPRP acted in a 
negative manner in respect to DNA repair. P ADPRP bound to the DNA single strand 
break ends, required automodification to effect release, thereby allowing the repair 
enzymes entrance to the damaged site. The results indicated that modification by short 
ADP-ribose polymers of less than 20 residues was sufficient to allow chromatin 
decondensation, and therefore repair was inhibited only following complete inactivation 
of PADPRP. 
Jacobson et ai (1985) confirmed the results of Boorstein & Pardee (1984), who had 
shown that the P ADPRP inhibitors caused an increase in the cytotoxicity of DNA 
damaging agents only if the cells traversed the S phase of the cell cycle. When quiescent 
and dividing cells were treated with MNNO in the presence of the PADPRP inhibitor. 3-
MBZ similar increased levels of breaks were observed, and this increased break frequency 
was maintained throughout a 48 hour incubation period (Jacobson et ai, 1985). Ho\\e\er. 
the quiescent cells failed to exhibit an enhancement of cytotoxicity. Such cells are in 0(1' 
and so have an indefinite period of time in which to repair the DNA strand breaks. 
Therefore, the slowing of repair by inhibition of PADPRP actiyity does not increase 
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cytotoxicity. Boorstein & Pardee (1984) also recorded a lack of correlation between the 
level of single strand breaks and the enhanced lethality in quiescent cells, due to S-phase 
dependency of the P ADPRP inhibitors. Such data suggests that the processing of the 
DNA strand breaks by replication renders them lethaL and so results in cytotoxicity. The 
technique of alkaline elution was suggested to measure two subpopulations of DNA single 
strand breaks:- (1) benign repairable, and (2) lethal unrepairable (Boorstein & Pardee, 
1984). The second class was proposed to originate from breaks in the initial class that had 
interfered in replication processes. Inhibition of PADPRP impedes repair. Jacobson et al 
(1985) demonstrated that if the P ADPRP inhibitor was removed prior to the end of the 
48 hour incubation period, then the break level was reduced to that of MNNG alone. but 
if inhibitor was added only after a -36 hours incubation, the break frequency was 
increased. These data would support the theory proposed by Cleaver & Morgan (1983) 
and Lehmann & Broughton (1984), that PADPRP was involved in the regulation of single 
strand, steady state break levels. A further explanation for the discrepancies between 
enhanced lethality and DNA strand break levels would be that P ADPRP was not directly 
involved in the repair process. Due to the raised poly(ADP-ribose) polymer levels at the 
Gland S phases of the cell cycle (Kidwell & Mage, 1976; Leduc et ai, 1988), Jacobson 
et al (1985) postulated P ADPRP was required by DNA damaged cells for the successful 
progression through the cell cycle, either by modulation or stabilisation of the chromatin 
structure. Realini & Althaus (1992) proposed the elegant histone shuttle model, describing 
such a mechanism for the decondensation of the chromatin structure. 
5.2 AIMS 
The aim of this third results Chapter was to further investigate the apparent discrepencies 
between the range of PADPRP inhibitor concentrations required to potentiate T~l 
cytotoxicity (Chapter 3) and the concentrations that resulted in an increased single strand 
break frequency in the DNA ~ Chapter 4). To allo\\' such comparisons, the concentration 
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of TM was maintained at a constant 150IlM. and the concentration range of PD 128763 
and BZ were varied in cytotoxicity studies and DNA strand break analyses for the 
purposes of direct comparison. 
A comparison of TM cytotoxicity and the concentrations of TM that resulted in DNA 
single strand breaks was also assessed, and the results compared with those from the 
combination studies. 
5.3 CONVERSION OF R.E. TO RAD EQUIVALENTS. 
The R.E. value represents, "the increase in DNA elution observed with treated cells as 
compared to untreated controls, at the point when 50% of the internal standard DNA has 
eluted" (see Figure 2.1, for method of calculation). 
Alkaline elution profiles, constructed from exposure to X rays, are almost first order 
with respect to dose, and the linearity of the elution curves signifies a near random 
distribution of the single strand breaks through the DNA (Kohn et at, 1981). This feature 
of X-rays makes them an ideal candidate for use as a standard of break frequency. The 
calculated R.E. values were converted to rad equivalents, and a linear relationship was 
shown between the R.E. and the X-ray dose (r2 = 0.92) (see Figure 5.1), therefore the 
R.E. values directly reflect the DNA single strand break levels. 
The R.E. values for cells (the cells utilised must be the same as those used in X-ray 
exposure) treated with other DNA damaging agents, e.g. alkylating & oxidising agents, 
ionising radiation can then be expressed in rad equivalents, i.e. that is the X-ray dose 
which would produce an equivalent frequency of breaks. 
SA COMPARISON OF CYTOTOXICITY AND DNA STRAND BREAK LEVELS 
IN TM TREATED LI210 CELLS. 
Figure 5.2 shows that the cytotoxicity (Section 3.5). and the frequency of DNA strand 
breaks (Section .f.4) in TM treated LI210 cells are both concentration dependent over a 
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Figure 5.2: Concentration dependent effects 
of • TM induced cytotoxicity and • DNA 
strand break levels in L1210 cells continuously 
exposed for 16 hours and 1 hour respectively. 
The cytotoxicity data points represent the mean 
of at least six independent experiments, whereas 
the DNA strand data was averaged from at least 
six samples, taken from two independently dosed 
experiments. 
similar range of TM doses, i.e. 100-1 OOO!J.M. A 25% increase in cell kill correlates with 
an increase of -125 rad equivalents, and this was raised to -250 rad equivalents when 
a 50% increase in cell kill was observed. 
5.5 CONCENTRATION DEPENDENT EFFECTS OF THE P ADPRP INHIBITORS 
ON TM CYTOTOXICITY AND DNA SINGLE STRAND BREAK LEVELS. 
In Section 3.6.1, the effect of IOO!J.M TM in the presence of increasing concentrations 
of the P ADPRP inhibitors on the growth of L 121 0 cells was determined. For the current 
study, this experimental design was repeated, but in the form of a clonogenic survival 
assay (see Section 2.11) which allowed the percentage increase in cell kill due to 
PADPRP inhibitor treatment to be determined. To permit comparisons with the DNA 
single strand break data, a fixed concentration of 150!J.M TM was used. The DNA strand 
break study was itself extended from that in Section 4.6.1 to include doses of BZ and PD 
128763 over a lower range of concentrations. 
Figure 5.3 clearly demonstrates that, in marked comparison with the effects of TM on 
cell kill and DNA single strand breaks, both BZ and PD 128763 lacked a concentration 
dependent correlation between the potentiation ofTM cytotoxicity and the increased DNA 
single strand break frequency. It is important to mention at this point that the cytotoxicity 
data was calculated using TM alone as the control representing 00/0 cell kill, whereas the 
rad equivalent values were plotted inclusive of the effect TM alone had on the DNA 
single strand break level (i.e. using an untreated control for calculating R.E. values). 
Unlike for TM alone (Figure 5.2), the % increase in cell kill and the increase in DNA 
single strand break levels resulting from a coincubation of either BZ or PD 128763 with 
TM, do not increase over obviously analogous concentration ranges. For each inhibitor, 
the curves representing the increase in cytotoxicity and the increase in DNA single strand 
break level were found to be sigmoidal in the semi log plots used. A sigmoid curyc is 
divided into three phases:- (l) lag phase, (2) exponential phase and (3) plateau phasc. :\s 
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depicted in Figure 5.3, -92% and -91 % increases in cell kill were obseryed on the 
exponential part of the curves for 3mM BZ and 50J.l~ PD 128763 respectiyely. However. 
at these concentrations there was little evidence of any effect on DNA strand break len~ls 
(i.e. the data points remain on the lag phase of the curve). 
In order to numerically portray the concentration dependency of the P ADPRP inhibitors 
on DNA single strand break levels in relation to the % increase in cell kilL Tables 5.1 
and 5.2 were constructed. The DNA single strand break levels were increased as the 
concentration of both BZ and PD 128763 were increased. At concentrations of BZ and 
PD 128763 which gave corresponding -90% increases in cell kill, i.e. 3mM BZ and 
50J.lM PD 128763, the DNA single strand break levels in rad equivalents were 107 ± 12 
and 129 ± 8 respectively. The rad equivalents related to 150J.lM TM alone were 67 ± 7 
and 81 ± 9 respectively (which are not significantly different). Although the DNA single 
strand break increase was calculated as being statistically significant (P values were 
0.0145 and 0.0006 respectively), in relative terms this represents only a small increase 
in break levels, i.e. -600/0 in both cases. This was clearly demonstrated in Figure 5.3, as 
3mM BZ and 50J.lM PD 128763 are positioned on the lag phase of the rad equivalent 
curve whereas the % increase in cell kill at equivalent concentrations are positioned on 
the exponential part of the curve. A 50% cell kill was observed with 20J.lM PD 128763, 
but this only increased DNA single strand break levels by -30% (although due to 
relatively high errors at low levels of strand breaks, this was not computed as 
significantly different from the TM alone levels by the Student's T test). \Vhen the 
inhibitor concentrations were raised further, a concentration dependent increase in the 
DNA strand break frequency was found, giving -4 fold increases by 20000J.lM BZ and 
500J.lM PD 128763. 
For the two inhibitors, the rad equivalent data was plotted against the % cell kill to allow 
the identification of possible correlations and this was compared with the effect of Ti\ 1 
alone (see Figure 5.4). Both BZ and PD 128763 were found to produce an almost total 
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enhancement of cytotoxicity with only a slight corresponding increases in D\: A strand 
breaks. These plots are in contrast to that for TM alone (also Figure 5.4) where the 
cytotoxicity was observed to increase in relation to increases in the DNA single strand 
break levels. However, once the % cell kill reached -80%, there was decrease in the 
gradient of the slope. This increase must be considered in a relative manner. thus. larger 
increases in DNA strand break levels have a lesser effect on cytotoxicity. 
TABLE 5.1 
DRUG TREATMENT % CELL KILL RAD SIGNIFICANCE 
EQUIV ALENTS (P VALUES) 
TM alone 0 81 ± 9 
TM + 10~M PD 128763 21 ± 3 81 ± 14 0.9979 
TM + 20~M PD 128763 48 ± 7 107 ± 11 0.1236 
TM + 50~M PD 128763 91 ± 1 129 ± 8 0.0006 
TM + 1 OO~M PD 128763 97 ± 1 186 ± 10 <0.0001 
TM + 300~M PD 128763 >99 403 ± 27 <0.0001 
TM + 500~M PD 128763 >99 558 ± 31 <0.0001 
Table 5.1: The effect of a 16 hour, or 1 hour continuous incubation with a fixed 
concentration of TM, in the absence or presence of increasing concentrations of PD 
128763 on the % cell kill, and DNA single strand break levels respectively. A two-tailed, 
unpaired students t test was utilised to determine whether. the difference between the rad 
equivalents of TM alone and TM + increasing concentrations of PD 128763 wt?rt? 
significant. The "GraphPad InStat" computer programme \\"as used to aid computation. 
Figures were calculated from at least 3 indiyidually dosed samples. 
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TABLE 5.2 
DRUG % CELL RAD SIG~IFICA~CE 
TREATMENT KILL EQUIV ALENTS (P VALUES) 
TM alone 0 67 ± 7 
TM + 100J.lM BZ 0 46 ± 36 0.2185 
TM + 500J.lM BZ 13 ± 8 61 ± 6 0.6284 
TM + 1000J.lM BZ 54 ± 7 87 ± 10 0.1216 
TM + 3000J.lM BZ 92 ± 2 107 ± 12 0.0145 
TM + 5000J.lM BZ 97 ± 1 76 ± 16 0.5707 
TM + 10000J.lM BZ >99 199 ± 29 0.0008 
TM + 20000J.lM BZ >99 417 ± 32 0.0001 
Table 5.2: The effect of a 16 hour, or 1 hour continuous exposure to a fixed 
concentration of TM, in the absence or presence of increasing concentrations of BZ on 
the % cell kill, and DNA single strand break levels respectively. The statistical analysis 
was as described for Table 5.1. 
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The similar position and the parallel slopes of the curves for the two inhibitors \vould 
suggest a parallel mechanism of action. This is an important observation. as once again 
an -60 fold increase in potency towards PADPRP was observed with PD 128763 as 
compared to BZ (see above: 50JlM PD 128763 as compared to 3mM BZ). 
Tables 5.1 and 5.2 clearly demonstrate an increase in rad equivalents observed as the 
concentration of inhibitor increased, e.g. PD 128763: 10JlM = 81 ± 14 rads, 20JlM = 107 
± 11 rads, 50JlM = 129 ± 8 rads. This may imply. that rather than there being a total 
dissociation between the % increase in cell kill and DNA single strand strand break 
frequency, a modest increase in DNA single strand breaks, e.g. perhaps originating from 
a distinct base modification, is sufficient to account for the increased cytotoxicity (see 
Section 5.6 for further Discussion of this point). 
At present a detailed analysis for the effect of time on the relationship between cell kill 
and DNA strand break levels is lacking. The cytotoxicity data presented above was 
calculated from a 16 hour continuous exposure to the TM and P ADPRP inhibitors, 
whereas just a 1 hour co-incubation was given in the DNA strand break assessment. 
However, preliminary strand break data utilising increased incubation periods of 4 and 
6 hours would indicate the PD 128763 concentration dependent increase in DNA single 
strand break frequency to show similar responses at different time points (see Figure 5.5). 
The only apparent difference between each time point is the initial level of DNA single 
strand breaks. TM is a slow acting agent, with a t1/2 of -50 minute in murine lymphoma 
cells (Tsang et ai, 1991), and Figure 4.2 showed the peak of DNA single strand breaks 
to occur after a 2-4 hour incubation period. Figure 5.5 shows linear plots of the increase 
in single strand break frequency for increasing concentrations of PD 128763 in the 
presence of 150~lM TM at 1, 4, and 6 hour incubation periods. The initial number of 
breaks due to the 150JlM TM alone increases with time, although the difference between 
the 4 and 6 hour incubations is only -50 rad equivalents as opposed to -320 rad 
equivalents between the 1 and 4 hour incubations. This data would again indicate the 
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independently dosed experiments. 
DNA single strand breaks to plateau after a 2-4 hour incubation as obseryed in Figure 
4.2. 
Initially, inspection of the data suggested a "null" effect of the low PO 128763 
concentrations on DNA single strand break levels, but due to large errors. (i.e. between 
10-20% at 10J,lM and 20J,lM PD 128763), a linear relationship was assumed. Interestingly, 
linear regression analysis for each of the three curves gave quite similar rates of increase 
in break level (see Figure 5.5), with the calculated slopes being, 0.38, 0.31 and 0.5 for 
1, 4 and 6 hours respectively. Utilising the linear regression slopes, figures were derived 
for the effect of specific concentrations of inhibitor on rad equivalent values. The data 
is presented in Table 5.3, along with the % increase in DNA single strand break levels 
that these figures yield. Upon analysis of, for example, the 1 hour incubation data only 
slight % increases in the DNA single strand break levels were observed as the 
concentration of PD 128763 was raised, e.g. at 20J,lM PD 128763 there was a -10%) 
increase in the DNA strand break levels, whereas by 50J,lM PD 128763 the % increase 
in DNA strand break levels was just -25%. A notable increase in the DNA single strand 
break level only became apparent at a concentration of 300J,lM PD 128763. Due to the 
considerable errors at the lower concentrations, the linear regression analysis was repeated 
ommiting these values (e.g. 0-50J,lM PD 128763) However, there was no significant 
differences observed, with similar values calculated for the gradients of the curves. 
Table 5.3 also shows the data for the 4 and 6 hour incubations. Significant increases in 
DNA single strand break levels were only observed when 300J,lM PO 128763 was 
utilised. Interestingly, the % increases in DNA strand breaks observed at these later times 
were much smaller than those calculated for the 1 hour incubation. e.g. at 50J,lM PO 
128763, a 1 hour incubation gaye a -250/0 increase whereas just -4% and -6% increases 
were observed at the 4 and 6 hour incubations respectiyely. At 100J,lM PO 128763 a 0/0 
cell kill of> 95% was obseryed, but at the 4 and 6 hour incubations the increase in the 
kyel of DNA single strand breaks was just -8-12% as opposed to -50% at 1 hour. 
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Therefore, the % increases in strand breaks when % cell kill is greater than 90% become 
even more "modest" at later incubation time points. Note ho\\"eyer. that in "absolute" 
terms, these % increases represent larger numbers of breaks because the starting levels 
are higher at these later times (e.g. 50~M PD 128763 at 1 hour: 250/0 increase == -20 rad 
equivalents, 50~M PD 128763 at 4 hour: 4% increase == -16 rad equivalents). 
TABLE 5.3 
PD 128763 1 HOUR 4 HOUR 6 HOUR 
(~M) INCUBATION INCUBATION INCUBATION 
RAD % RAD % RAD % 
EQ. INC. EQ. INC. EQ. INC. 
0 76 - 370 - 425 -
20 84 -10 377 -2 435 -2 
50 95 -25 386 -4 450 -6 
100 114 -50 401 -8 475 -12 
300 189 -150 463 -25 575 -35 
Table 5.3: Effect of time on the PD 128763 related % increase in DNA single strand 
breaks in L 121 0 cells treated with 150~M TM. The data presented is derived from linear 
regression analysis of the data using the "Graphpad Inplot tm. II software programme, and 
values represent, at least, five samples taken from three independently dosed experiments. 
The percentage increases in DNA single strand break levels were calculated utilising the 
following equation:- PD 128763x - control/control x 1000/0. Where X = the concentration 
of PD 128763. 
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5.6 DISCUSSION 
This results Chapter, due to the preliminary stage of the research. and experimental 
limitations because of the accuracy of the data, especially at low levels of D:--: A strand 
breaks, includes a number of perhaps highly contentious theories and interpretations. 
However, it was considered important to include this comparison to allow a full 
interpretation of the results in Chapters 3 and 4. 
Initially, the correlation between the TM concentrations that effected cytotoxicity and 
caused an increase in the DNA single strand break frequency was assessed. Both 
endpoints were observed to increase over a similar range of TM concentrations, 
suggestive that the increased break frequency was related to the increased cytotoxicity. 
TM, degrades to the methylating agent, MTIC which results in base modification (see 
Figure 1.13). To date three such bases have been described, Q6meG, 3meA and 7meG. 
However, the structurally related compound DTIC, has been identified as modifying 12 
different sites on the bases within the DNA (Mitchell & Dolan, 1993), and as both DTIC 
and TM degrade to the active metabolite MTIC, it is likely that TM also exhibits a morc 
varied range of base modifications, which as yet remain unidentified. The mechanism by 
which TM exerts its cytotoxic effect also has yet to be fully defined. Reports have 
suggested Q6meG to be implicated in the cytotoxic event, especially as cells with low 
levels of the Q6meG repair enzyme, MGMT show an increased level of sensitivity to TM 
treatment (Tisdale, 1988; Hepburn & Tisdale, 1991; Baer, 1993). The persistence of 
Q6meG fails to impede the replication fork but allows the continuation of DNA 
replication. However, the base placed opposite Q6meG during replication is T, so giving 
a GC ~ AT transition (Coulondre & Miller, 1977). Q6meG levels have been shown to 
correlate well with the induction of mutations, but correlations with cytotoxicity have 
proved contentious. Whilst Kalamegham et al (1988) found that unrepaired Q6meG was 
correlated with cytotoxicity. probably due to futile cycles of mismatch correction, others 
failed to do so (Nc\\'bold et aI, 1980). The recent identification of the "tolerance" 
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phenotype could possibly provide an explanation for this discrepency (see Chapter l. 
Section 1.4.5c). 
The results presented herein demonstrate TM related cytotoxicity in II 210 cells to be 
correlated with a concentration dependent increase in the DNA single strand break 
frequency, e.g. at a 50% increase in cell kill the increase in rad equivalents was -250. 
and when the cell kill was increased to 75%, the number of rad equivalents had increased 
to ~375. L1210 cells are almost completely lacking MGMT (unpublished data, C.E. Arris, 
Cancer Research Unit, The Universisty of Newcastle upon Tyne), and hence mismatch 
correction would be initiated due to the persistence of Q6meG lesions in the DNA. 
Q6meG repair is a slow repair process, with a complex of enzymes and proteins involved 
formed prior to the strand break formation. However. Hepburn & Tisdale (1991) reported 
that TM treatment also resulted in the formation of the repairable bases, 3meA and 
7meG. 3meA is removed from the DNA by a specific 3meA glycosylase. The rate of 
removal of 3meA (Medcalf & Lawley, 1981) was found to correlate with growth 
inhibitory effects of TM, up to 24 hours after treatment, in cells treated directly with TM 
or in cells transfected with TM damaged DNA (Hepburn & Tisdale, 1991). 3meA is 
considered a lethal lesion as it blocks DNA replication (Lindahl et ai, 1988). Although 
this base modification has yet to be implicated as a cytotoxic effector in eukaryotes, 
Karren et ai, (1980) found 3meA was involved in the cytotoxicity of methylating agents 
in bacteria. Hepburn & Tisdale (1991) found that of the total modified bases in TM 
treated cells, ~ 700/0 were 7meG and just ~ 1 0% 3meA. As 7meG fails to disrupt the 
genetic sequence, a significant role in TM cytotoxicity would be highly improbable 
(Lehmann & Karren, 1981). In summary, TM treatment leads to the formation of subsets 
of lesions, which either fail to produce DNA strand breaks, e.g. Q6meG. or which 
represent just a small percentage of the total lesions present, but may have a greater effect 
on the cytotoxicity than the overall break levels, e.g. 3meA. Thus, although a correlation 
was observed bet\n~en the TM concentrations that effected cytotoxicity. and the DNA 
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single strand break levels, it may be too simplistic to interpret the increased break le\"els 
as being responsible for the increase in cytotoxicity. Overall TM c:10toxicity could be 
a combination of events, only some of which are dependent on strand breaks. all 
interacting to result in the death of the cell. 
The time difference between the incubation periods of the two biological endpoints could 
lead to complications in the interpretation. The cytotoxicity studies were performed 
following a 16 hour continuous exposure to TM whereas the DNA strand break analysis 
utilised just a 1 hour exposure. Due to possible variations in repair kinetics of individual 
lesions, the correlation observed between TM cytotoxicity and DNA single strand break 
levels may be unrepresentative due to the dissimilar incubation periods. Figure 4.2 
showed that the level of DNA single strand breaks in TM treated cells plateaued between 
4-6 hours. However, after only a 1 hour exposure to TM, even a TM concentration of 
200~M gave a significant level of DNA single strand breaks. The effect of increasing 
concentrations of P ADPRP inhibitor in the presence of a fixed concentration of TM was 
then considered (see Figure 5.3). Unlike TM alone, where the increase in strand breaks 
paralleled the increase in cytotoxicity, a discrepency was observed between the 
concentrations of inhibitor required to increase cytotoxicity, and those required to increase 
the DNA single strand break levels (see Figure 5.3). At 3mM BZ and 50/-lM PD 128763 
in the presence of 150/-lM TM, a >90% increase in cell kill was observed, but the 
increase in DNA single strand break frequency although statistically significant remained 
on the lag phase of the curve. Nevertheless, it could still be a possiblity that the increases 
in DNA single strand breaks do account for the increased level of cytotoxcity, e.g. a 50% 
cell kill was observed with 20~M PD 128763, and at this concentration an -30% increase 
in DNA single strand breaks was observed. Figures 5.5 and 5.6, could support this 
proposal. as on linear plots, DNA single strand break levels could be interpreted as 
increasing in a concentration dependent manner. rather than there being a "null" effect 
at the lower PADPRP inhibitor concentrations which cause high degrees of cytotoxicity 
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e.g. 900/0 cell kill. This takes account of the high errors obseryed at the lower inhibitor 
concentrations (e.g.lO-20%). However, the data would suggest that the theory postulated 
-15 years ago, that potentiation of cytotoxicity by P ADPRP inhibitors \\-as directly 
related to the increase in the DNA single strand break level, is at best too simplistic. 
especially when compared to the TM alone data where a good correlation was shown_ 
How has this discrepancy previously failed to be recognised? Cytotoxic mechanisms of 
DNA damaging agents are extremely complex, as previously described, e.g. Q6meG and 
3meA. For the PADPRP inhibitors to cause cytotoxicity due to an altered rate of repair 
of these lesions, then the involvement of P ADPRP in their repair must be considered. The 
direct repair of Q 6meG via MGMT does not introduce breaks into the DNA strands, as 
previously described. However, persistence of the lesion resulting from a lack of the 
MGMT would lead to mismatch repair. This form of repair does result in DNA strand 
breaks with which P ADPRP could interact, but requires the interaction of several 
enzymes/proteins in the form of a complex to incise the DNA strands (see Section 
1.4.5c). The complex could therefore mask the DNA strand breaks from PADPRP, 
thereby preventing its attachment to the strand ends. 3meA is repaired via the BER 
process. A specific 3meA glycosylase removes the modified base from the DNA, 
resulting in the formation of AP sites that are subsequently processed by AP 
endonucleases to form DNA single strand breaks. This reaction sequence activates 
PADPRP only after the generation of the DNA strand breaks and therefore is unlikely to 
modulate the rate of removal of 3meA. Furthermore, the P ADPRP inhibitor 5meNic had 
no effect on the removal of 7meG from the DNA following treatment with MNU 
(Durrant et ai, 1981). However, a 2 fold enhancement of Q 6meG was observed (Durrant 
('/ ai, 1981). The classical inhibitors, e.g. BZ and 3AB were known to be of low potency 
and specificity towards PADPRP. therefore the concentrations of 1-5m~1, which ga\"c 
moderate potentiation of cytotoxicity. but had little or no effect on other metabolic 
reactions were generally used (Durkacz et aI, 1980; James & Lehmann. 1982; Huet <.\: 
Laval. 1985~ Cantoni et al. 1986: Boorstein. 1987: Moses et al. 1988: Lunn & Ilarris. 
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1988) (see Section 4.1, Chapter 4 for a more detailed reyiew of the literature). Howeyer. 
with the availability of novel PADPRP inhibitors, which exhibit increased levels of 
potency towards PADPRP, it was possible to carry out a comparative analysis with the 
"classical" inhibitors to compare the range of inhibitor concentrations that resulted in 
increased cytotoxicity and a raised level of DNA single strand breaks in DNA damaged 
cells. 
PADPRP has previously been proposed as a possible signal which would alert the cell 
to DNA damage. As presented in the introduction to this Chapter. Jacobson et al (1985) 
postulated that raised polymer levels during the Gland S phases of the cell cycle were 
required for correct progression through the cell cycle. However, from the observed 
effects of the P ADPRP inhibitors, P ADPRP may have control over two different 
endpoints. A report by Satoh et al (1994) suggested that the poly(ADP-ribose) polymer 
formed had a dual function, as almost all P ADPRP activity could be suppressed in vitro 
by either 200!-1M 3AB or 50!-1M 2-nitro-6(5H)-phenanthridinone (a novel PADPRP 
inhibitor developed by Banasik et aI, 1992), with little effect on the repair capacity. Short 
polymer chains were all that were required for the repair of damage to the DNA and they 
proposed that the synthesis of long polymer chains was required to prevent homologous 
recombinational events. However, another interpretation for these results, which would 
also support the results presented in this Chapter would suggest that two different 
biological endpoints, cytotoxicity and DNA repair are controlled by modifications to the 
long and short polymer chains respectively. The synthesis of long polymers (up to 200 
residues (Alvarez-Gonzalez & Jacobson, 1987; Kiehlbauch et aI, 1993» could be the 
means by which DNA damage is signalled to the cell. The P ADPRP inhibitors, due to 
their competitive nature, transiently inhibit PADPRP activity in a concentration dependent 
manner, i.e. at the lower inhibitor concentrations PADPRP remains actiYe but at a 
reduced leyel (Sims ('/ aI, 1983). (ADP-ribose) polymers form in a processin? manner 
(Naegelli ('/ aI, 1989) which would account for the concentration-dependent effect 
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observed on the potentiation of cytotoxicity. The poly(ADP-ribose) glycohydrolase is 
responsible for the intracellular breakdown of the polymer. Research has sho\\TI that the 
(ADP-ribose) polymers are degraded in a biphasic manner (\\'ielckens et al. 1981: 
Hatakeyama et ai, 1986) with the long polymers processively degraded in either a 
endoglycosidic or exoglycosidic manner. until short polymers remain (Miwa et ai, 1974: 
Braun et ai, 1994; Brochuet et ai, 1994). The short polymers are subsequently degraded 
in a distributive manner. Therefore, at the lower P ADPRP inhibitor concentrations , 
preferential inhibition of long polymer synthesis could occur. A further possibility could 
be that, different concentrations of P ADPRP inhibitor could inhibit the initiation and 
elongation reactions of poly(ADP-ribose) chain formation. The Km for each of these 
reactions would be an important factor. The overall KmNAD+ for P ADPRP was calculated 
to be ~50JlM (Ueda et ai, 1982), with the cellular NAD+ levels at 300-1000JlM (Shall, 
1984). Due to the low Km, the NAD+ levels must be significantly reduced before any 
effects on the velocity of the reaction are observed, or in the case of the PADPRP 
inhibitors, their concentration must be sufficiently high to compete with the NAD+ 
substrate. To sum up, the presence of low inhibitor concentrations may result only in the 
formation of short polymers. The longer polymers would be required to signal cellular 
processes leading to cell survival. The short polymers suffice for chromatin 
decondensation and repair. therefore much higher inhibitor concentrations would be 
required before an observed inhibition of repair. 
The target of the long poly(ADP-ribose) polymers could be a cellular component(s) 
involved in cell cycle arrest and cell survival. A speculative idea for such a target, 
emanating from the cell cycle literature could be, for example. the nuclear protein, p53. 
Following damage to the DNA e.g. by UV, ionising radiation and chemotherapeutic 
agents, the level of p53 in the cell rises due to a post-translational. stabilisation 
mechanism, which subsequently causes the induction of "damage inducible" gene 
transcription, e.g. p11. which result in a 0 1 cell cycle arrest (see Figure 1.18) (Xiong L'l 
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ai, 1993). The stimulus for p53 stabilisation has been reported as DNA single and doubk 
strand breaks (Nelson & Kastan, 1994). With the cell cycle arrested, DNA replication is 
prevented and the polymers bound to P ADPRP and histones etc. would remain capable 
of chromatin decondensation thereby facilitating the repair process. p53 was also shO\\TI 
to induce expression of the damage inducible Gadd45 gene (Smith et ai, 1994). This was 
found bound to peNA, with an enhancement of DNA repair observed. 
Again, as for the TM alone study, an alternative explanation could be that the different 
incubation periods utilised (16 hour: cytotoxicity studies, 1 hour: DNA strand break 
assay) could possibly explain the observed discrepancy between the concentrations of 
P ADPRP inhibitor required. The initial studies to further investigate the effect of time 
on the range of PADPRP inhibitor concentrations required, would indicate that over a 
period of 1-6 hours the rate of inhibitor dependent increase in break levels was similar 
(see Figure 5.6). However, a more detailed analysis would be required before any serious 
conclusions could be drawn, (although again, this may be limited by the accuracy of the 
techniques employed). 
A completely distinct theory for the difference in concentrations required to inhibit repair 
and enhance cytotoxicity would be that the P ADPRP inhibitors themselves were affecting 
two different cellular targets. Rankin et al (1989) showed that the PADPRP inhibitors 
over a low range of concentrations, e.g. 1-100JlM BZ, inhibited PADPRP, whereas when 
the concentrations were raised, e.g. 1 OOJlM-l OOOOJlM BZ, the mono(ADP-ribose) 
transferases were inhibited. Lautier et ai, (1994) also found poly(ADP-ribose) polymer 
synthesis to be inhibited by -90% in intact cells following treatment of cells with the 
oxidising agent, xanthine-xanthine oxidase in the presence of 100JlM BZ. Howeyer. the 
data presented herein shows only a 50% increase in cell kill at a concentration of 1 m!vl 
BZ. Once again, this may represent either cell line specific effects, or more importantly 
could show dependence on the DNA damaging agent utilised, due to the subsets of 
lesions formed and the period of time oyer which dan1age occurs. Howeyer. the inhibition 
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of mono-(ADP-ribosyl)transferases can not be ruled out and the use of a knockout 
, PADPRP 
mouse cell system would be an elegant method for investigating such a possible 
involvement. 
A generally accepted concept is that the progression of DNA single strand breaks 
through the replication fork accounts for a proportion of the cytotoxic effect of DNA 
damaging agents. However, this proposal suffers from a lack of mechanistic explanation. 
DNA single strand breaks entering onto daughter strands result in the presence of a non-
coding lesion. In E. coli two mechanisms were predicted for overcoming replication blocks 
due to UV dimers, (1) DNA synthesis was reinitiated downstream of the template block, 
so creating discontinuities in the daughter strands which were infilled by a 
recombinational event, and (2) continuance of the replisome past the template lesion 
subsequent to an initial arrest (Friedberg, 1985). Cytotoxicity due to the presence of DNA 
strand breaks in daughter strands of mammalian cells could also be explained using the 
above two theories. Replication could halt at the break, but unlike the situation with the 
UV dimer, the replisome would totally lack a template base from which to code the 
leading/lagging strand, therefore further progression would not be possible. However. if 
the replisome could bypass the DNA break, replication would procede, but the single 
strand DNA break would convert to a double strand DNA break. A recombinational 
repair process would be subsequently required to replace the template base(s). 
Interestingly, Boorstein et at (1992) found that a Chinese hamster cell line V79. resistant 
to HmdUrd, failed to express the HmUra DNA glycosylase. Cytotoxicity to HmUrd \\as 
reduced in the resistant cells as compared to the parental cell line, with the persistence 
of high levels of HmUra suggesting that the substitution of HmUra for thymidine in the 
DNA was not the cytotoxic lesion, but that their subsequent repair was. Further c\'idence 
indicati\'c of the c\'totoxic c\'ent being the presence of DNA strand breaks would be the 
obser\'ed increase in the number of SCEs found in the parental V79. Con\'ersely, Chinese 
h"illlster ovary cells \,"hich overexpress the N-mcthylpurineDNA glycosylase show an 
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increased rate of removal of N-methylpurines from the DNA, but this was not associated 
with an increased level of resistance towards cell kill by the DNA damaging agents. 
MMS and MNNG (Coquerelle et ai, 1995). The level of repair in this cell line \\"ould be 
enhanced, so increasing the numbers of DNA strand breaks. However, levels of seEs 
were increased, and the DNA replication delay was prolonged. In the presence of 
inhibitors of PADPRP, e.g. BZ, 3AB, SCEs were observed to increase (Oikawa et ai. 
1980; Hori, 1981; Morgan & Cleaver, 1982; Schwartz et ai. 1983). The inhibition of 
P ADPRP increases the halflife of DNA strand breaks, so increasing the opportunity for 
SCEs. Recombinational repair of DNA double strand breaks would provide the 
mechanism for the P ADPRP inhibitor dependent production of SCEs. 
In conclusion, whilst the possibility that a small increase in DNA single strand break 
levels accounts for large increases in cytotoxicity, in cells co-treated with a DNA 
damaging agent and a PADPRP inhibitor cannot be excluded, it appears likely that there 
is no direct simple cause-effect relationship. 
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CHAPTER 6: EFFECT OF LOW NMNAT ACTIVITY IN A TZ 
RESISTANT LI210 CELL LINE ON THE CELLULAR 
RESPONSE TO DNA DAMAGE 
Due to the collaborative nature of the project, a number of results presented in this 
Chapter are shown with the kind permission of S. Jones, Cancer Research Unit. The 
University of Newcastle-upon-Tyne. 
6.1 INTRODUCTION 
2-p-D-ribofuranosylthiazole-4-carboxamide (Tiazofurin, TZ) is a C-nucleoside which 
exhibits significant oncolytic activity against a number of rodent and human tumour cell 
lines, e.g. murine leukaemias L1210 and P388, human leukaemia K562, Chinese hamster 
ovary CHO, and murine hepatoma 3924A. TZ was also found to be curative against the 
refractory Lewis lung carcinoma (Robins et aI, 1982). Phase I and II clinical trials of TZ 
have shown a response rate of -50% in the treatment of chronic myelogenous leukaemia 
(Tricot et aI, 1989, Jayaram et aI, 1992). However, a problem encountered with TZ 
treatment is the development of resistance. 
Following treatment with TZ, the concentration of the guanine nucleotide pools, i.e. 
GMP, GTP, dGTP, were found to be decreased, and the activity of inosinate 
monophosphate dehydrogenase (IMPDH) was inhibited (Jayaram et aI, 1982). IMPDH 
is the rate limiting enzyme in the biosynthesis of guanine, which converts IMP to 
xanthine monophosphate (XMP). The active metabolite of TZ was found to be an 
analogue of NAD+, with the thiazole-4-carboxamide moiety of TZ replacing the 
nicotinamide group to form thiazole-4-carboxamide adenine dinucleotide (TAD) (Cooney 
('/ aI, 1982,1983). The anabolism of TAD utilises an enzyme of the NAD+ biosynthetic 
path\\·ay. TZ is initially phosphorylated, by an as yet unidentified kinase to the 
5'monophosphate, which is subsequently anabolised to the dinucleotide by nicotinamide 
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mononucleotide adenylyl transferase (NMNAT) which normally catalys~s the reaction:-
NMN + ATP ~ NAD+ + PP j • TAD inhibits I!\1PDH with a kj of 1-2xlO-7~1 (Jayaram. 
1985), which utilises NAD+ as an obligatory co-factor. The IMPDH reaction procedes by 
a "bi-bi mechanism":- IMP binds to the enzyme followed by NAD-t-. l\ADH is then 
released, followed by the product of the reaction, XMP (Yamada et al. 1988). TAD is 
considered to bind to the NADH site on IMPDH with the formation of an enzym~ : Xi'.IP 
: TAD complex (Weber et aI, 1985, Yamada et aI, 1988). 
The TZ related inhibition of IMPDH, and the subsequent depletion of the guanylate 
pools has been implicated as the cytotoxic mechanism of TZ. The administration of 
guanine prevents TZ induced cytotoxicity (Streeter & Robins, 1983). Both de novo 
synthesis and a salvage mechanism contribute to the guanylate pool. When either guanine 
and hypoxanthine are combined with the precursor PRPP, in the presence of hypoxanthine 
guanine phosphoribosyl transferase (HGPRT), guanylate and IMP are formed respectively. 
TZ does not directly affect this guanylate salvage pathway, but the increased 
concentrations of IMP due to inhibition of IMPDH are thought to result in a 
concentration dependent feedback inhibition of HGPRT (Weber et aI, 1985). An added 
contribution to the high IMP concentrations could be due to activation of AMP deaminase 
following TZ treatment. High GTP concentrations usually repress this enzyme activity, 
which converts AMP to IMP (Weber et aI, 1985). 
Guanidine nucleotides are an important component of many metabolic reactions, e.g. 
RNA and DNA synthesis, the citric acid cycle, protein elongation, signal transduction (G 
proteins, cGMP). Therefore it is not surprising that guanylate depletion contributes to the 
cytotoxicity of TZ. Following TZ treatment, differentiation was observed subsequent to 
the down regulation of the proto-oncogenes, ras (Olah et aI, 1988) and myc (Kharbanda 
el al. 1988). These encode for G proteins which couple membrane receptors to signal 
effector systems. GTPase activity leads to the production of the second messengers. i.e. 
cAMP and diacyl glycerol which subsequently activate regulatory enzymes, e.g. protein 
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kinase C, phospholipase C. When TZ was administered to HL60 cells \\ith the 
prostoglandin PGE2, a reduction in the concentration of cAMP was obser\'ed. Howe\"t~r. 
when PGE2 was substituted with forskolin, a compound that directly stimulates adenylate 
cyclase, the cAMP levels remained as control (Kharbanda et ai, 1990). Also, mono-ADP-
ribosylation by bacterial toxins, e.g. pertussis, cholera, was inhibited by TZ due to a 
depletion of the substrate, as the number of G protein sites occupied was reduced. 
However, the reduction in mono-ADPribosylation could also be explained by depletion 
of the NAD+ concentration due to the presence of TAD (Kharbanda et ai, 1990). 
Prolonged TZ treatment can result in the development of resistance. Therefore. a nun1ber 
of cell lines resistant to TZ have been established, e.g. P388 (Jayaram et ai, 1992), L1210 
(Jayaram, 1985) and K562 (Jayaram et ai, 1993) leukaemias, hepatoma 3924A (Jayaram 
et ai, 1986), and CHO (Kuttan, 1989), using step-wise selection protocols, to examine 
possible resistance mechanisms. A major factor of a TZ resistant phenotype was found 
to be the impaired formation of the active metabolite, TAD, due to a reduction in the 
activity of NMNAT. Residual activities of <10% and <1 % were found in K562 and 
L 121 0 resistant cells respectively. However, each cell line also presented individual 
resistance characteristics. The hepatoma 3924A TZ resistant cells showed a reduced 
uptake of TZ, together with an increase in the guanine salvage pathway (Jayaram et ai, 
1986), and the L1210 cells which also exhibited an increased salvage. and had an 
increased T ADase activity, an enzyme function that was identified as responsible for the 
breakdown of TAD (Jayaram, 1985). 
A wide range of naturally occurring sensitivities to TZ, both in murine and human cell 
lines (Ahluwalia et al. 1984, Jayaram, 1985). have been demonstrated. This appears to 
correlate with the TAD concentration which is regulated by the ratio of NMNA T activity 
(net formation of TAD) : TADase activity (net breakdown of TAD). In the more resistant 
cells the level of breakdown was increased and the level of formation decreased. 
The PJ88 resistant cell line was found to exhibit collateral sensitivity to a variety of 
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cytocidal drugs, including a 5-10 fold increased sensitivity to 5FU as compared to the 
parental line. The reduced NAD+ levels in DNA damaged, TZ resistant cells was 
proposed as a possible factor responsible for such sensitivities. Similar rates of repair of 
X ray induced DNA strand breaks were observed in the TZ sensitive and resistant cells. 
but in the presence of the P ADPRP inhibitor 3AB, the resistant cells failed to repair the 
DNA strand breaks, suggestive of the involvement of P ADPRP. The sensitive cells were 
still capable of strand break repair (Jayaram, 1985). 
The NAD+ biosynthetic enzyme NMNAT, has recently been purified to homogeneity 
from human placenta, utilising a variety of chromatographic procedures (e.g. absorption 
chromatography, FPLC) (Emanuelli et ai, 1992). Previously, the yeast NMNAT enzyme 
had been the most characterised. The mammalian enzyme was characterised as a 
quaternary structure, possessing four apparently identical subunits of 33 KDa each. The 
mechanism of action was Bi-Bi, as for the yeast enzyme, with ~ values for NMN. ATP, 
NAD+ and PP j of 38/-lM, 23/-lM, 67/-lM, and 125/-lM respectively. ADP-ribose was found 
to inhibit the enzyme in a non-competitive manner, although the K j was 950/-lM. 
Therefore, due to the high K j , even under conditions of high ADP-ribose concentrations, 
e.g. damage to the DNA resulting from treatment with alkylating agents leading to the 
formation of ADP-ribose as a breakdown product of ADP-ribose polymer. it would be 
unlikely that ADP-ribose could significantly inhibit NMNAT activity. 
6.2 AIMS 
Characterisation of the TZ resistant phenotype has identified one of the main features 
as being the loss ofNMNAT activity, the enzyme responsible for the formation of TAD. 
The intracellular role of NMNAT involves the final catalytic step in the formation of 
NAD+, and therefore a reduction of NMNAT activity could lead to a depletion of the 
intracellular NAD+ concentration. NAD~ is important for the maintainance of the cellular 
redox potentiaL but ADP-ribosylation reactions, essentially poly(ADP-ribosyl)ation. 
171 
account for the majority of NAD+ catabolism (see Section l.1.1 and 1.1.2). 
P ADPRP is activated in response to breaks in the DNA strands, and has a well 
documented role in the DNA repair process (see Section l.5). The use of P ADPRP 
inhibitors in association with DNA damaging agents, e.g. alkylating agents (see Chapter 
3, Section 3.6), ionising radiation (Lunec et ai, 1984), has been observed to lead to a 
potentiation of cytotoxicity. The competitive inhibition by the PADPRP inhibitor was 
proposed to slow the release of P ADPRP from the DNA strand break end. Subsequently. 
the inaccessibility of the break to DNA repair enzymes would be extended, resulting in 
an increased break level and cytotoxicity. 
However, in some instances the presence of an inhibitor of P ADPRP exhibits a 
protective effect, with an observed decrease in cytotoxicity (e.g. pancreatic islet cells 
treated with nitric oxide (NO) (Kallman et ai, 1992, Heller et al. 1995), NO induced 
neurotoxicity (Zhang et ai, 1994)). NO has been considered as a DNA damaging agent 
due to the formation of nitrite (N02-) which can deaminate purines and pyrimidines. 
Zhang et al (1994) utilising rat brain extracts incubated with increasing concentrations 
of NO found P ADPRP activity was increased upto 3 fold, as cell survival decreased. 
However, in the presence of the P ADPRP inhibitors, BZ, 3AB, and 4AB. neurotoxicity 
was decreased in parallel with their potencies as P ADPRP inhibitors (BZ, 3AB and 4AB 
increased cell survival by -30%, -20%, and -2% respectively). The activation of 
P ADPRP in response to DNA strand breaks results in a massive depletion of cellular 
NAD+ (levels can be reduced to < 10% of control). The transfer of 1 ADP-ribose unit by 
PADPRP consumes 1 molecule ofNAD\ and 4 ATP molecules are subsequently required 
to regenerate the NAD+ from nicotinamide. NAD+ is required in numerous metabolic 
reactions, including the biosynthesis of ATP, the main energy form of the cell. In such 
circumstances, the "suicide" of the cell was predicted (Sims et al. 1982, 1983). A large 
reduction in NMNAT activity could also potentially result in the failure to resynthesise 
NAD+ at the required rate, following NAD+ depletion, and so result in a suicide respons~. 
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However, in the presence of a PADPRP inhibitor, the NAD- levels would be preserved. 
and cytotoxicity could be lowered. 
The results presented in this Chapter utilised a TZ resistant L 121 0 cell line which we 
selected using a step wise selection protocol, and its parental L 121 0 counterpart (WT). 
The following investigations were then perforrned:- (l) The NMNA T activity and the 
intracellular NAD+ concentration of the WT and TZR cell lines was measured to 
characterise the mechanism of resistance to TZ. (2) The survival of the TZR and WT 
L 121 0 cells treated with alkylating agents in the absence or presence of a P ADPRP 
inhibitor was assessed to discover whether low NMNAT activity and consequently low 
NAD+ levels would sensitise cells by reducing PADPRP function or exacerbate NAD' 
depletion. Two hypotheses could be predicted: (i) low NAD+ levels would reduce 
PADPRP activity, and so sensitivity of the P ADPRP inhibitors would increase. (ii) 
reduced NMNAT activity, and low NAD+ levels in a situation of DNA damage could 
result in cell suicide, due to an inability to resynthesise NAD+ at a sufficiently high rate. 
Therefore, P ADPRP inhibitors would be protective. Both hypotheses could also predict 
that a reduced NMNAT activity would lead to increased sensitivity to the alkylating agent 
alone. (3) The effect of alkylation damage on the NAD+ levels in the WT and TZR 
L 121 0 cells was considered, to determine if a reduced. starting concentration of NAD+ 
and/or inability to resynthesise NAD+ at high rates resulted in an altered pattern of NAO+ 
depletion. (4) The NMNAT activity ofWT L12l0 cells exposed for increasing incubation 
periods to fixed concentrations of TM was assessed, as ADP-ribose was postulated as a 
possible, transient regulator of NMNAT activity (Emanuelli et ai, 1992). A number of 
biological endpoints were utilised in the assessment including cytotoxicity studies, DNA 
strand break analysis, and characterisation of the NMNAT activities. 
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6.3 ISOLATION AND CHARACTERISATION OF TZ RESISTANT LI210 CELLS. 
6.3.1 Comparison of WT and TZR cell growth. 
L 121 0 cells resistant to TZ were selected using a step-wise selection protocol as 
described in Chapter 2, Section 2.7. Resistance to TZ was achieved by subculturing the 
L1210 cells in RPMI-medium containing TZ. Initially the IC50 of 2.71lM TZ was used, 
but the TZ concentration was raised at intervals until the cells were capable of gro\\1h 
in 2mM TZ. This represents an -750 fold increase in the concentration of TZ. An 
analysis of the growth rates for the two cell lines found a comparable level of cell 
growth, with both lines exhibiting a doubling rate of -13 hours (see Figure 6.1, A & B). 
Figure 6.2 (presented with permission from S. Jones) shows that a 48 hour incubation 
in the presence of increasing concentrations of TZ caused the growth of the sensitive 
L1210 cells, subsequently referred to as WT, and the TZ resistant L1210 cells, referred 
to as TZR, to decrease in a concentration dependent manner. However, the WT cell line 
had an IC50 to TZ of 2. 711M whereas the TZR cells exhibited an IC50 of> 1 OOOOIlM. This 
represented an -4000 fold increase in resistance to TZ. 
6.3.2 Measurement of NMNAT activity in WT and TZR cell lines. 
The reduced activity of the biosynthetic enzyme, NMNA T was found to be one of the 
main characteristics of TZ resistance in the published TZ resistant cell lines (see Section 
6.1). NMNAT catalyses the reaction: NMN + ATP ~ NAD+ + PP j • Therefore, the 
NMNAT activity of both the WT and the selected TZR cell lines was measured to 
determine whether our TZR L 121 0 line also exhibited a reduction in NMN AT acti vi ty. 
However, in the course of this work I discovered that the published assay for the 
measurement of NMNAT activity lacked sensitivity when transferred from tumour 
samples to tissue culture cells. Therefore, I have coupled together the preparative sections 
of the NMNAT assay with the NAD+ colourimetric cycling assay which increased the 
level of sensitivity -16 fold (see Chapter 2. Sections 2.14 and 2.15). 
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Prior to the determination of NMNAT activity in the \\,1 and TZR cell lines. se\'eral of 
the experimental variables were characterised. Initially. the length of the incubation period 
to determine the level of NMNAT activity was assessed. Figure 6.3 shows that p,\101es 
NAD~ formed/mg protein increased in a linear manner with time. up to 1 hour. An 
incubation period of 30 minutes was utilised for subsequent experiments. The effect NMN 
had on the NAD+ cycling reaction was then assessed. ADH conyerts ethanol to the 
corresponding aldehyde, with the concomitant reduction of NAD+ to NADH. The 
nicotinamide moiety of both NAD+ and NADH forms several interactions with the 
dehydrogenase active site (Holbrook et ai, 1975), therefore the nicotinamide moiety of 
NMN present in the reaction mix could also form possible interactions with the ADH. 
and so interfere in the reaction in the NAD+ assay. However. NMN was found to hayc 
no effect on the rate of change of absorbance over the 5 minute reaction period, either 
in the absence (absorbance values were as control. i.e. -NAD+. results not shown) or 
presence of the natural substrate NAD+ (+NAD+ = ~Abs 0.15, +NAD+ + NMN = ~Abs 
0.14). 
Table 6.1 gives the NMNAT activities for the WT and TZR L 121 0 cells. In the WI 
cells, NMNA T activity was measured at -400 pMoles NAD+ /mg protein/minute, whereas 
the activity of the NMNAT in the TZR cells was -11 pMoles NAD+ /mg protein/minute. 
The activity of the NMNAT in the TZR cells was calculated as < 3% of that in the WI 
cells. 
6.3.3 Measurement of intracellular NAD+ levels in WT and TZR cell lines 
As NMNAT catalyses the final reaction in the anabolism ofNAD+. it was postulated that 
the intracellular NAD+ levels in the TZR cells could be reduced in comparison to the 
NAD+ levels of the WT cells. Utilising the NAD+ colourimetric assay (see Chapter 2. 
Sections 2.1] and 2.15) the intracellular NAD+ content of the TZR cells was measured 
as ] 768 pMoles NAD+ /mg protein. which represented an -400/0 reduction of :\ :\D' as 
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compared to the WT cells. The intracellular NAD+ level for the WT cells \Y3S measured 
at 6070 pMoles NAD+/mg protein (see Table 6.1) (shown with the kind permission of S. 
Jones). 
TABLE 6.1 
CELL LINE NMNAT CELLULAR 
ACTIVITY NAD+ LEVEL 
pMoles NAD+ Img pMoles NAD+ Img protein 
protein/minute 
WT 400.9 ± 27.0 6070±195 
TZR 10.7 ± 3.7 3768±213 
Table 6.1: The extractable NMNAT activity and the intracellular NAD+ levels in WT and 
TZR L 121 0 cells was measured as described in Chapter 2, Sections 2.14 and 2.13, 
respectively. A sample of the cell extract was retained for determination of the protein 
concentrations (see Section 2.15, Chapter 2). The calculated values were averaged from 
three independent experiments ± SE. 
6.4 COMPARISON OF THE GROWTH INHIBITORY EFFECTS OF TM AND 
NUI025 ON WT AND TZR CELLS. 
Data presented with the kind permission of S. Jones. 
6.4.1 Effects of increasing NUI025 concentrations in the absence or presence of a 
fixed TM concentration. 
The ability of the PADPRP inhibitor NUI025 to inhibit the growth of the WT and TZR 
L 1210 cells was assessed. Previously, a 48 hour continuous exposure of L 121 0 cells to 
NU 1 025 was shown to reduce cell growth in a concentration dependent manner (see 
Chapter 3, Section 3.4). Figure 6.4A shows that the growth of the TZR cells following 
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a 48 hour continuous exposure, was also inhibited in a concentration dependent manner. 
with an similar IC50 value compared to the ICso value for the \\'T cells ( \VT, -370~:-d: 
TZR, -368~M). 
The subsequent analysis performed assessed the growth inhibitory effect of a -+8 hour 
continuous coincubation with increasing concentrations of NU 1 025 in the presence of a 
fixed dose of TM on both the WT and TZR cells. 1 OO~M TM was chosen as this allowed 
comparisons with the WT L 121 0 results already presented in Chapter 3. but note that this 
experiment was carried out in parallel for the purpose of a direct comparison. tin the 
subsequent Section 6.4.2 and Figure 6.5. A and B, a 48 hour incubation to TM alone 
resulted in a 3 fold greater inhibition of TZR cell growth as compared to the WT growth. 
However, for the experiments presented in Figure 6.4B the effect of 1 OO~M TM alone 
on cell growth was normalised to 100%.) The growth of both the WT and TZR cell lines 
was inhibited in a concentration-dependent manner (see Figure 6.4B). However, unlike 
the analogous ICso values for NUl 025 alone, growth of the TZR cells was inhibited to 
a greater extent than the WT cells. In the presence of 1 OO~M TM, growth of the WT 
cells was reduced -10-fold from 370~M NUI025 to -35~M, whereas the growth of the 
TZR cells was reduced -70-fold, from -368~M to -6~M. 
6.4.2 Effect of increasing TM concentrations in the absence or presence of NUI025. 
The effect a 48 hour continuous exposure to TM alone had on the growth of WT and 
TZR L 121 0 cells was assessed. Figure 6.5A and B show that in both cell lines growth 
was inhibited in a concentration dependent manner. However the ICso for the WI' cells 
was -385~M TM, whereas that for the TZR cells was -156~M TM, representing an -2.5 
fold decrease in the TM concentration required to inhibit growth to a similar degree. 
In Chapter 3, Section 3.6.2, it was demonstrated that growth inhibition of WT L 1210 
cells treated with increasing concentrations of TM in the presence of fixed concentrations 
of NU 1 025 was potentiated. This increase in the growth inhibition by NU 1 025 \vas 
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concentration dependent. Figure 6.5. A and B, compare the effect increasing 
concentrations of TM, in the presence of fixed concentrations of Nel 025. had on th~ 
growth of WT and TZR LI210 cells. NUI025 potentiated the grov.1h inhibitory effect 
of TM in both cell lines. A 3 fold lower concentration of NU 1 025 was required to reduc~ 
TZR cell growth to a similar level as the WT cells. Table 6.2 shows that 30~~t NUl 025 
resulted in an -2 fold enhancement of growth inhibition in WT cells whereas only 1 O~l\ 1 
NUI025 was required in the TZR cells. However. the difference observed between 50~M 
and 30J.lM NUI025 in the WT and TZR cells respectively was probably not significant. 
A statistical analysis of enhancement factors would be required, but this requires data 
taken from three independent experiments. The data presented in Table 6.2 was compiled 
from just a single experiment, albeit triplicate samples. 
TABLE 6.2 
CELL DOSING GROWTH ENHANCEMENT 
LINE SCHEDULE INHIBITION FACTOR 
ICso 
WT TM 385.4~M 
TM + 30J.lM NUl025 181.9~M -2.0 
TM + 50J.lM NUI025 139.6J.lM -3.0 
TZR TM 1 56.6J.lM 
TM + IOJ.lM NUI025 84.1~M -2.0 
TM + 30J.lM NUI025 65.0J.lM -2.5 
Table 6.2: The effect of a 48 hour continuous exposure to increasing concentrations of 
TM. in the absence or presence of fixed concentrations of NU 1 025, on the growth of \VT 
and TZR L 121 0 cells. The data represents three independently dosed samples from a 
single experiment. 
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6.5 NAD+ LEVELS OF TM TREATED WT Al\D TZR Ll210 CELLS. 
The intracellular NAD- levels of WT and TZR cells treated for a -+ hour continuous 
exposure to increasing concentrations of TM were determined. The NAD~ levels in both 
cell lines was decreased in a concentration dependent manner (see Figure 6.6)(shown \\ith 
permission from S. Jones). The initial NAD+ le\'el of the TZR cells was -60% of that of 
the WT cells (see Table 6.1), but following TM treatment. proportionate NAD+ depletion 
was observed for each TM concentration. For example a 50% NAD+ depletion occured 
with 1 mM TM in both the WT and the TZR cells (TZR = 2222pMoies NAD+ fmg protein 
as compared to control levels of 3778pMoies NAD-fmg protein: \\'T = 3185pMoies 
NAD+/mg protein as compared to control levels of 6111pMoies NAD+fmg protein). 
6.6 STRAND BREAK LEVELS IN DNA DAMAGED WT AND TZR L1210 CELLS. 
6.6.1 Effect of increasing concentrations of TM on the DNA strand break frequency 
in WT and TZR Ll210 cells. 
TM treatment results in DNA damage which is subsequently repaired by the BER 
process with AP endonuclease action leading to the formation of DNA single strand 
breaks. Chapter 4, Section 4.4 showed that R.E. values increased with increasing TM 
concentrations in treated WT cells. Figure 6.7 A shows that the R.E. values for both the 
WT and TZR L 121 0 cells, in a head on comparison, treated with increasing 
concentrations ofTM for an incubation of 1 hour, increased in a concentration dependent 
manner. There was a small, but not significant increase in the R.E. values of the TZR cell 
line compared to WT, indicating that TM treatment caused little or no additional increase 
in the DNA single strand break levels in the TZR cells as compared to the WT cell line. 
6.6.2 The effect of NUI025 on a fixed level of TM induced damage in \\,T and TZR 
L1210 cells. 
The R.E. profiles for both WT and TZR cells coincubated with 150~M Tt-.l in the 
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presence of increasing concentrations of l'\U 1025 are shown in Figure 6.7B. In Charter 
4, Section 4.6.1, when WT Ll210 cells were coincubated with increasing ~UICl~:, 
concentrations in the presence of 150~M TM, a concentration dependent increase in the 
R.E. values was observed. Figure 6.7B shows that the R.E. profile of TZR cells incubated 
with increasing concentrations of NUI025 and 150~M Tl\'1 also increased in a 
concentration dependent manner. However, the rate of increase of DNA single strand 
break levels in the presence of the NUI025 dose was significantly increased at the lower 
concentrations of NU 1025 in the TZR line as compared to the WT cells and this 
difference was maintained at the higher concentrations of NU I 025. This is demonstrated 
by the concentrations ofO.74~M and 0.47~M NUI025 that were required by the WT and 
TZR Ll210 cells respectively to give equivalent arbitrary R.E. values of 0.125. This 
represents an -1.5-fold reduction in the concentration of NUI025 required to gi\'e the 
same level of DNA single strand breaks. 
6.7 THE EFFECT OF TM TREATMENT ON NMNAT ACTIVITY. 
TM treatment results in the formation of DNA single strand breaks due to BER of 
modified bases. The presence of the breaks in the DNA activates P ADPRP which is the 
main consuming reaction of intracellular NAD+. NMNAT, the enzyme responsible for the 
final reaction in the biosynthesis ofNAD+ is a chromatin bound enzyme with a frequency 
of I NMNAT enzyme/1 0-20 nucleosomes (Uhr & Smulson 1982). This is a similar 
frequency as observed for PADPRP. Therefore, because of its similar location to 
PADPRP. it was postulated that NMNAT activity may be up-regulated by some 
mechanism in response to P ADPRP activation in order to increase the rate of NAD+ 
biosynthesis. and so compensate for the NAD+ catabolism during rapid (ADP-ribose) 
polymer formation in response to DNA damage. 
. . 
Initially. the effect that a either 4 or 6 hour continuous exposure to mcreasmg 
concentrations of TM had on NMNAT activity was determined (sec Table 6.~). These 
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times were chosen as the peak level of single strand DNA breaks \\a5 obseryed at 4-6 
hours, and >99% of the TM would have been degraded to MTIC at this time. 
TABLE 6.3 
[TM] 4 HOUR %OF 6 HOUR °0 OF 
~M IlMoles NAD+/mg protein CONTROL IlMoles :-:AD+/mg protein CO:\TROL 
Imin Imin 
0 538.8 ± 10.7 100 692.9 ± 73.6 100 
500 724.1 ± 19.7 134 966.6 ± 41.6 120 
1000 624.7 ± 6.1 116 965.-+ ± 23.-+ 140 
Table 6.3: L1210 cells were treated with TM and the extractable NMNAT activity 
measured, following either a 4 or 6 hour incubation (see Section 2.14. Chapter 2). The 
values represent the average of three independently dosed samples in a single experiment 
± SE. 
At both 4 and 6 hours, at TM concentrations of 0.5 and 1mM there appeared to be an 
increase in the activity ofNMNAT which was calculated as being statistically significant 
utilising a student's paired T test statistical analysis (p values < 0.05). However, the 
degradation period of TM (e.g. -6 hours), and the low level of NAD+ depletion, (e.g. a 
500/0 NAD+ depletion was observed only after 6 hours with 2mM TM. see Chapter 3. 
Section 3) suggested only low level activation of PADPRP. Therefore, the effect of 
MTIC, the more direct acting active metabolite of TM, was considered. MTIC has a half-
life of ~4 minutes with an -50% NAD+ depletion observed after a 30 minute incubation 
with 1 mM MTIC (see Chapter 3, Figure 3.9B). 
A concentration of 1 mM MTIC was chosen for the study. and the effect of time on 
NMNA T activity was determined. L 121 0 cells were incubated for increasing periods of 
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time, up to 24 hours, and the NMNAT activity was determined. A preliminary study 
indicated changes in NMNAT activity occurred at both 6 and 24 hours (control = 599 ± 
40pMoies NAD+fmg protein/minute, 6 hour = 481 ± 18pMoies NAD+fmg proteinlminute, 
24 hour = 858 ± 104pMoies NAD+fmg protein/minute), therefore further studies 
concentrated on these two time points. Table 6.4 shows that after a 6 hour incubation 
with ImM MTIC there was no significant difference in NMNAT activity. Howeyer. after 
24 hours in the presence of ImM MTIC the activity of the NMNAT was increased to 
134% of control. However, using a student's T test analysis this increase was not shown 
to be statistically significant (p value> 0.2). 
TABLE 6.4 
TIME (HOURS) NMNAT ACTIVITY 0/0 OF CONTROL 
pMoles NAD+ fmg 
protein/minute 
0 502.9 ± 27.7 100 
6 479.9 ± 13.7 95 
24 673.6 ± 68.0 134 
Table 6.4: The effect of either 6 or 24 hour continuous exposure to ImM MTIC on the 
extractable NMNA T activity in WT L 121 0 cells. The values were averaged from three 
independent experiments ± SE. 
6.8 DISCUSSION 
PADPRP, when activated in response to breaks in the DNA, catalyses the formation of 
the polymer (ADP-ribose), which covalently modifies itself and other nuclear proteins. 
e.g. chromatin proteins. DNA repair enzymes (see Chapter 1, Section 1.2). The substrate 
for PADPRP is NAD~, and (ADP-ribose) polymer formation accounts for the maJor 
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proportion of NAD+ catabolism. >95% of the intracellular NAD+ is confined to the 
nucleus (Rechsteiner et ai, 1976). 
The results presented in this Chapter have considered the effect of a reduced intracellular 
NAD+ pool and biosynthetic capacity on the ability of PADPRP function in the response 
to DNA damage. Several reports have shown the intracellular NAD+ levels of tumour 
cells to be reduced as compared to somatic cells (Lillian & Jedeikin, 1955: Branster & 
Morton, 1956; Glock & McLean, 1957). Also, solid tumours are known to contain a 
considerable proportion of hypoxic cells, which results in a large shift in the redox 
potential, with the NADH:NAD+ ratios greatly increased (Kennedy et ai, 1980). NADH 
is itself an inhibitor of P ADPRP with a ~ of -5JlM (Ueda et ai, 1982), as compared to 
the k j for 3AB, of -1.8JlM (Purnell & Whish, 1980). Therefore, in the presence of lower 
NAD+ levels PADPRP function would be impaired, resulting in an increased sensitisation 
to DNA damaging agents, which in the presence of a PADPRP inhibitor would be 
potentiated, due to competitive inhibition. 
However, a second situation may well arise due to reduced NMNAT activity. PADPRP 
activation in DNA damaged cells would decrease already low NAD+ levels, but the low 
NMNAT activity would be unable to resynthesise sufficient NAD+, so cell suicide could 
result. A study of P ADPRP function in reduced NAD+ conditions could have significant 
biological implications, e.g. for cancer chemotherapeutic strategies. 
The IC50 for TZ in L1210 cells, as determined by growth inhibition analysis was 2.7~M. 
Several reports in the literature have shown that resistance to TZ occurs due to the 
presence of lower TAD levels, resulting from a reduced NMNAT activity (Jayaram et ai, 
1992; Jay aram , 1985; Jayaram et ai, 1993; Jayaram et ai, 1986). This consequently 
reduces the intracellular NAD+. 
Using a step-wise selection protocol, we selected for TZ resistance in an L 121 0 cell line. 
By growth inhibition analysis, the TZR cell line exhibited a >4000-fold increased 
resistance to TZ as compared to the sensitive WT cells. A comparison of the NAD+ k\"l~ls 
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and the NMNAT activities in the WT and TZR cells showed that the ~AD~ level and 
NMNAT activity in the TZR cells was -60% and <3% respectiyely of that of the \\'T. 
This reduced NMNAT activity compares well with the values published for other TZ 
resistant cell lines (Jayaram, 1985; Jayaram et al. 1993). The growth of the TZR cell line 
correlated extremely well with that of the WT cells. with both cell lines doubling 
approximately every 13 hours. This would suggest that the reduced NMNAT actiyity and 
intracellular NAD+ pool sizes remained compatible with normal cell growth. and indicates 
that intracellular NAD+ levels are in vast excess of requirements under normal growth 
conditions. Rechsteiner et al (1976) estimated that just 5% of the total NAD+ pool was 
required for "unstressed" cell growth. The effect of "stress" in the form of damage to the 
DNA on the growth of TZR cells was then considered. TM results in base modifications 
which are repaired by both BER and mismatch repair processes. BER. due to AP 
endonuclease action results in the formation of DNA single strand breaks which activate 
PADPRP. TM treatment resulted in a concentration dependent inhibition of growth with 
both the WT and TZR cells. However, TZR cell growth was reduced to 500/0 of control 
utilising a 2.5-fold lower concentration of TM than required to reduce WT growth by 
50% (lC50 -156j.lM TM for TZR cells as compared to -385j.lM in the WT cells). In the 
aims of this Chapter, two possible scenarios were postulated to explain the possible 
effects of low NMNAT activity on cell growth and survival. In the presence of a BER 
connected damaging agent, growth inhibition and cytotoxicity in the TZR cells was 
predicted to increase in both scenarios. This Chapter only considers the growth inhibitory 
effects. However, Chapter 3 demonstrated a close correlation between the growth 
inhibition and cytotoxicity studies resulting from TM treatment of L 121 0 cells. In the first 
scenario, it was suggested that lower levels of the substrate, NAD+ (resulting from 10\\' 
NMNA T function). for PADPRP would impair the release of the enzyme from the DNA 
single strand break ends, as (ADP-ribose) polymer formation required for repulsion of 
PADPRP from the DNA would be slowed. Access of the repair enzymes to the damaged 
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site would be subsequently delayed. This would only be a viable theory if the NAD-
levels fell to about the ~NAD+ of the enzyme (-50J.lM. Ueda et ai, 1982), as until that 
point P ADPRP would continue to function at a constant rate. However. below the ~ 
value the NAD+ would become rate limiting, and only then would the activity of 
P ADPRP be slowed. However, the second scenario suggested that if the ~ AD+ 
biosynthetic capacity was reduced, then the activation of P ADPRP in response to DNA 
damage would result in a more rapid "suicidal NAD+ depletion" (Sims et ai, 1982, 1983). 
The P ADPRP inhibitor, NUl 025 was used to identify the actual mechanism of action. If 
the first scenario was correct, then growth inhibition and cytotoxicity would be 
potentiated as P ADPRP inhibition would slow further the release of the enzyme from the 
DNA strand break ends, but if the second scenario was true, then protection against 
growth inhibition and cytotoxicity could be afforded as PADPRP inhibition would 
preserve NAD+ levels. 
Initially the effect of NU I 025 alone was considered. NU I 025 decreased growth of both 
cell lines in a concentration dependent manner. with similar ICso values of -370J.lM 
determined. A possible explanation for the lack of difference between the WT and TZR 
cell lines could be that NU I 025 treatment per se was not specifically targeting P ADPRP, 
and that the growth inhibitory effects observed were due to effects on other metabolic 
reactions. The 3'substituted benzamides have been reported to affect purine metabolism 
(Milam & Cleaver, 1984; Milam et ai, 1986) (see Chapter I, Section 1.3.2, and Chapter 
3, Section 3.8). A structural similarity between the benzamides and NUI025 is the 
presence of a carboxamide moiety, and all the compounds act in a competitive manner. 
Therefore, the possibility exists that NUl 025 could exhibit similar non specific reactions. 
If NUI025 was directly affecting PADPRP, then in the TZR cell line, where NAD! 
concentrations are low, and the capacity for NAD+ biosynthesis is reduced, NUl 025, due 
to its competitive nature, could be expected to have greater inhibitory potential at lower 
concentrations. In fact, this was demonstrated in DNA damaged cells. where lower 
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concentrations ofNUI025 were required in TZR cells compared to \\"T to obtain similar 
effects. The lack of such a differential when NU I 025 growth inhibition per se is 
considered indicates that NUl 025 is not targetting PADPRP at these high concentrations. 
but is exerting some other effect. The cotreatment of both WT and TZR cells \\"ith 
increasing concentrations of TM in the presence of fixed concentrations of ;"';U 1 025 
resulted in the potentiation of growth inhibition. However, a -3 fold lower concentration 
of NUl 025 was required by the TZR cell line to exhibit a similar potentiatory effect as 
observed in the WT cells (see Section 6.4.2 and Figure 6.5). These results would suggest 
the initial scenario to be correct. Due to the competitive nature of the P ADPRP inhibitor 
(utilising a Lineweaver-Burke plot, NUI025 was shown to inhibit PADPRP in a 
competitive manner, lK. Porteous, unpublished results, Cancer Research Unit The 
University of Newcastle Upon Tyne) in reduced NAD+ conditions the PADPRP inhibition 
would be more effective. Therefore, the repulsion of P ADPRP from DNA single strand 
break ends would be slowed further as the inhibition of polymer formation would 
increase. This was further demonstrated when I OO~M TM was incubated with increasing 
concentrations ofNU1025. In the WT cells the IC50 for growth inhibition in the presence 
of TM was reduced -10 fold as compared to NU 1025 alone whereas in the TZR cells an 
-70-fold reduction was observed (see Section 6.4.1). 
Interestingly, the NAD+ depletion in TZR cells treated for a 4 hour continuous exposure 
to increasing concentrations of TM was not relatively different to that of the NAD+ 
depletion observed in TM treated WT cells. Although the initial NAD+ level in the TZR 
cells was -600/0 of that of WT, a proportionate depletion of NAD+ was observed. 
However, when the absolute NAD+ depletion of the two cell lines was compared a 
dissimilarity was found. At a TM concentration of I OOO~M, the NAD+ levels in the \Vl 
cells were reduced -3000pMoles, whereas in the TZR cells an absolute reduction of 
-1500pMoles was observed, representing a -2.5 fold difference. This data would also 
indicate scenario (1) rather than scenario (2) to be more correct. In scenario (1), if the 
NADI concentration fell below the KmNAD+ for PADPRP (-50~M. Ueda et al. 19X:2). 
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P ADPRP function would be slowed, so reducing the level of NAD- utilised. and 
consequently the level of NAD+ depletion, as was observed. 
As TM treatment results in the formation of DNA single strand breaks, the effect an 
increasing TM concentration had on DNA single strand break leyels in the WT and TZR 
cells was determined. The potentiation of cytotoxicity of DNA damaging agents whose 
lesions were repairable via BER, by inhibitors of P ADPRP was suggested to be due to 
an increased level of DNA single strand breaks. However, in Chapter 5 of this thesis. 
evidence for a possible dissociation between the concentration of NU 1 025 required to 
potentiate TM cytotoxicity and that required to increase the level of DNA single strand 
breaks was presented. The effect increasing concentrations of TM had on the level of 
DNA strand breaks in WT and TZR cells would also give support to the alternative 
theories described in the discussion of Chapter 5. The R.E. profiles for WT and TZR cell 
lines showed little or no difference, with DNA single strand breaks increasing in a 
concentration dependent manner. However, a 2.5 fold reduction in TM concentration gave 
the same growth inhibitory effect in TZR cells as for the WT cells. This was interpreted 
as due to a diminished PADPRP activity because the low NAD+ levels were becoming 
rate limiting. Another reasoning (as previously discussed, see Section 5.6, Chapter 5) for 
this result would be that the cytotoxic event of TM treatment is not due solely to DNA 
single strand breaks. When the effect of increasing concentrations of NU 1 025 in the 
presence of 150J.lM TM was considered in both the WT and TZR cells, a concentration 
dependent increase in the R.E. values was observed, but in the TZR line it was enhanced 
-2.5 fold. As NUI025 has been shown to be a competitive inhibitor of PADPRP, the 
decreased competition between the intracellular NAD+ and the NUl 025 for the active site 
of PADPRP, due to the depleted NAD+ levels would result in a further delay of release 
of PADPRP from the break ends and hence increase the effect of NUI025 on strand 
break levels in TZR cells compared to WT. 
The theory postulated in Chapter 5 was that the formation of long (ADP-ribose) 
polymers could act as a system to alert the cell to DNA damage, by targeting a cellular 
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component involved in cell cycle arrest, e.g. p53. The results presented aboye could also 
be interpreted in this light: In a situation of low intracellular 1\AD+ leading to partial 
PADPRP inhibition the formation of long (ADP-ribose) polymers would be especiallY 
affected. However, the production of shorter polymer lengths. still capable of effecting 
repulsion of PADPRP from the DNA would result in the efficient repair of DNA single 
strand breaks. As described, both cell lines exhibited similar R.E. values to TM alone. In 
the presence of NUl 025, the increased effectiveness of the inhibitor due to a lack of 
competition with intracellular NAD+ would inhibit even the formation of the smaller 
polymer lengths, and so DNA single strand break repair would be slowed. 
A functional relationship between the enzymes NMNAT and P ADPRP was considered 
as NMNAT anabolises the NAD\ which in the main is utilised by PADPRP in the 
formation of poly(ADP-ribose). Therefore, it was proposed that PADPRP could signal 
by some means to NMNAT, resulting in an increased level of activity. thereby 
replenishing the intracellular NAD+ pool following DNA damage induced NAD+ 
depletion. Possible mechanisms could include:- direct poly(ADP-ribosyl)ation of 
NMNAT, poly(ADP-ribose) modified chromatin could release the chromatin bound 
NMNAT, thereby activating it, NMNAT gene transcription could be induced by 
poly(ADP-ribosyl)ated chromatin. The NMNAT activity of WT L12l0 cells was 
significantly increased when incubated for either 4 or 6 hours with 0.5-lmM TM. 
However, as a 500/0 NAD+ depletion was only observed following a 6 hour incubation 
with 2mM TM, and the prolonged half-life of TM (-50 minutes in murine cells). the 
damaging agent was changed to MTIC. MTIC degrades with a half-life of -4 minutes and 
a 30 minute incubation with lmM MTIC depletes NAD+ to 50% of control. Preliminary 
evidence suggested effects on NMNA T activity to occur at incubation periods of 6 and 
24 hours. However. further investigation found an effect only at 24 hours, were NMNAT 
activity was increased to 134% of control (see Table 6.4). Improyed experimental design 
could further the invcstigation into the possible association bet\\cen N~1N:\ T and 
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PADPRP activities. Following alkylation damage, NMNAT actiyity could be measured 
at the times when P ADPRP activity was known to be at a high, or when the intracellular 
NAD+ was depleted to a minimum. The effect of co-incubating the cells with an 
alkylating agent and a PADPRP inhibitor, on the activity of NMNA T would provide 
evidence as to whether alterations in NMNAT activity were dependent on PADPRP 
function. 
Uhr & Smulson (1982) calculated that NMNA T enzyme molecules occured at a 
frequency of 1 enzyme/l 0-20 nucleosomes. This was an exceptionally large estimation. 
especially as the NAD+ pool required for redox reactions represented just 5% of the total 
intracellular NAD+ level. They speculated that not all the enzyme molecules were utilised 
at anyone time, but in cases of an increased requirement, e.g. PADPRP activation. the 
reserve NMNAT capacity could be called upon. In the case of the TZR cell lines, with 
reduced capacity for NMNAT activity, the excess NMNAT present in the nucleus could 
well tolerate a loss of > 90% of the NMNA T with little observable effect on the 
biosynthetic capacity for NAD+. 
However, Ruggieri et al (1988) utilising yeast NMNAT suggested that PADPRP was 
capable of modifying the NMNA T so resulting in its inactivation. The identification of 
PADPRP activity in yeast has yet to be substantiated. This result is negated by the ability 
of cells to recover the NAD+ pool. Figure 4.9B clearly demonstrates that after a 6 hour 
exposure to MTIC the NAD+ levels are as for untreated controls whereas a 50% NAD 
depletion was observed after just 30 minutes. The inhibition of NMNAT action by 
PADPRP modification would have negative implications for cell survival. IfNAD' pools 
were not replenished, many essential metabolic processes involving redox reactions would 
be inhibited. 
The data of Ruggieri et al (1988) could support an NAD+ suicide hypothesis. as an 
inhibited NMNAT due to poly(ADP-ribosyl)ation would prevent restoration of the NAD+ 
levels. However. the suicide hypothesis is not a yalid explanation for the results presented 
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herein. The massive NMNA T loss could be interpreted as an analogous situation to the 
inhibition of NMNAT activity. However, Berger et al (1986) did not observe ?\AO-
suicide in L1210 cells treated with MNNG, even when the intracellular NAO+ levels fell 
to just 5% of control levels. Therefore, the hyperlethal doses of TM (e.g. 2m!\1 TM) 
which were required to deplete the NAD+ levels by only 50% of control would fail to 
deplete A TP levels, and so DNA, RNA and protein biosyntheses would continue. with 
the resulting survival of the cell. 
Under normal growth conditions, the main route for the formation of intracellular NAO+ 
is via nicotinamide. The reaction sequence is performed in two steps (see Chapter 1, 
Figure 1.1). The initial reaction catalysed by nicotinamide phosphoribosyl transferase is 
responsible for the formation of NMN from nicotinamide. The second reaction converts 
the NMN to the NAD+. As previously stated this reaction is catalysed by NMNAT. The 
rate determining step of NAO+ formation was found by Berger et al (1987) to be the 
initial reaction. The treatment of a purified T cell preparation with monoclonal antibodies 
to the T3 surface antigen which activates the T-cell receptor complex, and the phorbol 
ester TPA, induce T-cell mitogenesis with a concomitant increases in PADPRP activity 
and pyridine nucleotide metabolism. In TP AlantiT3 stimulated cells both nicotinamide 
phosphoribosyl transferase and NMNA T activities were increased and a comparison of 
the relative activities indicated the former to be the rate determining enzyme. 
The role of NMNAT function in the cellular response to ONA damaging agents could 
vary between different cell lines, e.g. due to a dependency on the relative levels of 
NMNA T, nicotinamide phosphoribosyl transferase, P ADPRP activity and the cellular 
NAD+ levels. For example, in pancreatic islet cells treated with nitric oxide NAO+ suicide 
effects predominate (Radons et ai, 1994). A possible explanation for an increased 
probability that certain cell types enter on to a suicide pathway. could be that such cells 
exist in an arrested state (i.e. Go as opposed to cell cycling). Go arrested cells have been 
reported to contain lower NAO+ levels than cycling cell populations (Sweig\!rt <.'l al. 
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1986). Therefore, these cells would have sufficient time to repair damage to the D;\ A. 
but consequential P ADPRP activity could reduce NAD- leyels below the point at which 
regeneration of the NAD+ pool would be feasible. so leading to the suicide of the cell. 
Radons et al (1994) calculated 0.355pMoles NAD+/1 03 pancreatic islet cells. In the 
presence of a NO donor, NAD+ levels were reduced to -30-40% of control and cells were 
observed to suicide. In an L 1210 study, Berger et al (1986) found that a reduction of 
NAD+ levels to just 50/0 of control did not induce a cell into suicide. However, L 1210 
cells contain -3 fold greater NAD+ concentration than the Islet cells (-1 pMoles NAD+ /1 oj 
cells). 
Overall this Chapter has indicated that cells with reduced NAD+ levels show enhanced 
sensitivity to DNA damage resulting from TM treatment, and enhanced sensitivity to the 
PADPRP inhibitor, NU1025, in potentiating growth inhibition and DNA single strand 
break levels. Therefore, as tumour cells are reported to contain lower NAD+ levels as 
compared to their somatic cell counterparts, and also higher NADINADH ratios, PADPRP 
inhibition would be a good candidate to target in chemotherapeutic regimes. In patients 
treated with TZ who develop a resistance to the drug, the use of TM and an inhibitor of 
P ADPRP could subsequently be administered as the tumour cells would be predicted to 
be sensitised to this combination, based on the results presented in this Chapter. 
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CHAPTER 7 : SUMMARY AND FUTURE DlRECTIO:\S 
7.1 SUMMARY 
Utilising an in vitro PADPRP assay, the novel compounds NUI025 and PD 128763 were 
found to inhibit P ADPRP, with an -50 fold increase in potency as compared to the 
"classical" PADPRP inhibitors, 3AB and BZ. This increased inhibitory activity indicated 
a potential use of NUI025 and/or PD 128763 as resistance modifying agents in the 
treatment of cancer. However, prior to clinical trials, a comprehensive intact cell study 
was required. The data presented in Chapter 3 analysed the effect NUI025 and PD 
128763 had on a number of biological endpoints known to be modulated by PADPRP 
function following DNA damage, e.g. growth inhibition, cytotoxicity studies, and 
intracellular NAD+ levels, and compared them to the "classical" PADPRP inhibitors, 3AB 
and BZ. Overall, an excellent correlation of potency was observed between the in ,'itro 
and intact cell assays, with the relative inhibitor potencies (as compared to 3AB) for the 
intact cell studies, similar to those of the in vitro assay, i.e. 3AB: L BZ:2, NU 1 025 :43, 
and PD 128763:53. The concentrations of PADPRP inhibitor required to potentiate TM 
growth inhibition and cytotoxicity, e.g. 10-50~M NUI025, had little or no effect on the 
growth and cell survival per se. However, a similar concentration range of the PADPRP 
inhibitors abrogated the NAD+ depletion resulting from TM treatment. Taken together, 
these results would suggest both NUI025 and PD 128763 exhibit excellent potential as 
resistance modifying agents and further in vivo studies prior to entrance onto clinical 
trials would be warranted. 
The cytotoxicity of DNA damaging agents in the presence of P ADPRP inhibitors was 
reportedly correlated with an increase in the DNA single strand break levels resulting 
from the repair of lesions in the DNA bases. Chapter 4 assessed the ability of increasing 
concentrations of the PADPRP inhibitors to increase the DNA single strand break levels 
resulting from TM treatment. To the best of my knowledge, this study represents the only 
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comprehensive and quantitative analysis of inhibitor concentration on the DNA strand 
break levels. All four inhibitors increased the DNA single strand breaks in a concentration 
dependent manner when in the presence of TM, with the relative potencies exhibiting an 
excellent correlation with the relative potencies determined for PADPRP inhibition in 
Chapter 3. However, when the concentrations of inhibitor required to enhance cytotoxicity 
were compared with those required to increase the DNA single strand break leyels. a 
discrepency was observed. 3mM BZ and 50J.lM PD 128763 when in the presence of 
150J.lM TM gave a >90% increase in cell kill, but there was little or no effect on DNA 
single strand break levels. The periods of incubation differed between the two biological 
endpoints, but preliminary data suggested increases in DNA strand breaks due to 
P ADPRP inhibition were independent of time. A possible explanation discussed ill 
Chapter 5, proposed that a subset of lesions were responsible for the increased 
cytotoxicity. However, other theories presented in Chapter 5 suggested that PADPRP 
could act as a cellular alarm system in situations of DNA damage, or that PADPRP acted 
upon two different cellular targets over different concentration ranges. In comparison, a 
good correlation between the concentrations of TM required to increase both cytotoxicity 
and DNA single strand break levels was observed, but due to subsets of lesions and 
differing exposure times, the increased cytotoxicity could not be unequivocally related to 
increases in DNA single strand break levels. 
Chapter 6 determined the effect a lower intracellular NAD+ concentrations and reduced 
NAD+ biosynthetic capacity had on the activity of P ADPRP in TM damaged cells in the 
absence or presence of the PADPRP inhibitor. NUI025. A Ll210 cell line was made 
resistant to the IMPDH inhibitor, TZ using a step wise selection protocol. 
Characterisation of this TZR cell showed that NMNAT activity was <3% of the parental 
line. and that the NAD+ levels were reduced by -40%. The growth of TZR cells showed 
an -3 fold increase in sensitivity to TM, and when co-incubated with NUI025, there was 
a dose dependent potentiation of the growth inhibition. However, an -3 fold lower 
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concentration ofNUl025 potentiated growth to a similar extent as in the WT cells. Both 
cell lines showed equal sensitivity to NU1025 alone. DNA single strand break levels 
resulting from TM treatment were equivalent in the WT and TZR cell lines, but a-I. 5 
fold lower concentration of NUl 025 potentiated the DNA single strand breaks in the TZR 
cells to a similar degree as the WT cells. Extrapolating from the data presented in 
Chapter 6, it is possible that a TM and P ADPRP inhibitor regime in patients resistant to 
TZ would offer clinical benefit. 
Finally, the effect of DNA damage on NMNAT activity was assessed. NMNAT is a 
chromatin bound enzyme, as is P ADPRP, and is the final enzyme in the biosynthetic 
pathway of NAD+. The possibility of PADPRP signalling the regulation of NMNA T 
activity was considered. In cells treated with MTIC for 24 hours, the activity ofNMNAT 
was increased to 134% of control. This work is at a preliminary stage and will be 
discussed further in Section 7.2. 
7.2 FUTURE DIRECTIONS 
The most exciting and potentially useful data published in the literature recently was that 
P ADPRP deficient mice are capable of normal development, and survive into adulthood 
(Wang et ai, 1995). This provides an excellent system to identify the in vivo roles of 
PADPRP. However, an animal which is devoid of PADPRP is not analogous to one that 
has an inhibited or mutant enzyme, therefore the use of P ADPRP inhibitors still retains 
a function in elucidating the cellular functions of P ADPRP. This difference was initially 
shown utilising in vitro and intact cell systems. P ADPRP is activated in response to DNA 
strand ends, to which it binds. Poly(ADP-ribose) polymer is the product of activation, and 
this in the main is used to autolhomo-modify PADPRP, which is subsequently repelled 
from the DNA. This mechanism is considered to result in the decondensation of the 
chromatin structure and facillitate access of repair enzymes to the damaged site. Utilising 
an in "itro cell free system, PADPRP was shown to be nonessential to the DNA repair 
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process. The existence of a PADPRP deficient mouse confirmed this observation. In the 
absence of P ADPRP, the repair enzymes have constant access to the damaged sites. 
However, in the presence ofPADPRP, an absolute requirement for NAD- was observed. 
When P ADPRP is bound to a DNA break, until automodification of the enzyme occurs ~ . 
repair is inhibited (Satoh & Lindahl, 1992; Satoh et ai, 1993). \Vhen a recombinant DBD 
polypeptide was introduced into CV -1 cells, a trans-dominant inhibition of repair was also 
observed. This is an analogous system, in that the DBD polypeptide binds to the DNA 
strand break, but due to the lack of domains required for automodification, release of the 
DBD can not occur. Inhibitors of P ADPRP are somewhat analogous in that they cause 
a transient delay of the repair process. Competition between the inhibitor and NAD+. 
slows the automodification reaction and subsequent release of the enzyme. 
P ADPRP knockout mice could be an important tool that would benefit P ADPRP 
research. A major problem associated with use of the P ADPRP inhibitors is their lack of 
specificity. Several reports in the literature have demonstrated the involvement of the 
nicotinamide analogues, e.g. 3AB, BZ, in purine metabolism (see Section 1.3.2. Chapter 
1), and this casts doubt on results obtained. The novel compounds, NU 1 025 and PD 
128763, described in this thesis have yet to be fully characterised for inhibitory activity 
against mono ADP-ribosyl transferases and possible non-specific effects. The exposure 
of cells derived from a P ADPRP deficient mouse to inhibitors of P ADPRP in growth 
and/or cytotoxicity studies, would immediately answer the specificity argument. The 
targeting of reactions secondary to P ADPRP would lead to continued growth inhibition 
and/or reduced survival, however, if the target was solely PADPRP, then no effects 
would be observed. 
Chapter 5 reported a dissociation between the P ADPRP inhibitor concentrations required 
to increase cytotoxicity and those required to increase the level of DNA strand breaks. 
Satoh et al (1994) proposed a dual function for ADP-ribose polymers: short polymers 
«20 residues) were required for repair of damaged DNA. and long polymers were 
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required to to prevent homologous recombinational events. However, the data presented 
in this thesis, i.e. cytotoxicity increased at low inhibitor concentrations, whereas DNA 
repair was only inhibited at high concentrations, could suggest the long polymers Were 
involved in alerting the cell to DNA damage, and the presence of short polymers \yas 
sufficient for repair. An elegant methodology for identifying polymer patterns utilises 
dihydroboronate affinity columns to isolate ADP-ribose polymers, which can be 
subsequently quantified by sequence gel analysis (Wielkens et ai, 1981; Naegelli et al. 
1989; Naegelli & Althaus, 1991, Malanga et ai, 1995). A new methodology utilising a 
silver staining technique, which bypasses the need for radiolabelling the polymer has been 
developed (Malanga et ai, 1995). An analysis of the effects of a range of inhibitor 
concentrations on the synthesis and size distributions of polymers in intact cells would 
be very imformative. For example, do low concentrations of inhibitor decrease the 
average length of the polymers, and how do the concentrations required correlate with 
the concentrations required to enhance cytotoxicity and inhibit DNA repair? 
At present, assessment of the role of P ADPRP in DNA repair utilising the 
knockoutpADPRP mice has been limited, with results from an indirect CAT plasmid assay 
and UDS assay only reported (see Section 1.5.7). Therefore, a direct comparison of 
homologous cell lines, one being proficient (+/+) and the other deficient (-/-) in P ADPRP. 
in the presence and absence of PADPRP inhibitors, utilising a more quantitiative DNA 
repair assay, e.g. alkaline elution, could provide a greater understanding of PADPRP 
function. 
In the discussion of Chapter 5, a possible target for the cellular signal was proposed. p53 
is a trans-activating transcription factor which regulates several genes whose proteins are 
involved in the DNA damage induced G 1 arrest. To investigate such a proposal. 
characterised cell lines for tolerance and p53 status would be required. The a\'ailability 
of an affinity column which would separate ADP-ribose polymers attached to their 
protein acceptors would be extremely advantageous (e.g. Adamietz & Rudolph. 1984). 
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Subsequent characterisation of the separated proteins by western blotting could identify 
p53 or other proteins as the signal target. Rather than covalent modification, nonco\'alent 
bonds between ADP-ribose polymer and p53 could be responsible for the DNA damage 
signal. Panzeter et al (1992) found that histone proteins interacted in a noncovalent 
manner with various sized linear and branched polymers. The domain of histone HI 
responsible for this bonding was found to be that invol\'ed in the induction of higher 
chromatin structure. 
As described in the discussion of Chapter 5, the cytotoxicity of DNA damaging agents 
could be due to single strand breaks formed during repair processes passing through the 
replication fork, so leading to the formation of double strand breaks (see Chapter 5, 
Section 5.6). Neutral elution measures such breaks, and could be utilised to assess the 
level of double strand breaks in both mature and nascent DNA following treatment with 
a DNA damaging agent in the presence and absence of P ADPRP inhibitors. As double 
strand breaks represent a non-coded area of the DNA sequence, recombinational repair 
could be a possible mechanism by which cells could survive. Evaluation of double strand 
break levels over increasing periods of time could provide an indication of repair events. 
The data from the intact cell study presented in this thesis would advocate the initiation 
of in vivo studies to assess the effects of the novel P ADPRP inhibitors on tumour 
regression. The cell line used in this study, i.e. L 121 0 cells, would be a possible starting 
model, but further analyses would require the use of human tumour cells, e.g. the lung 
cancer cell line A549, to be representative of cancers found in the clinics. Nude mice 
would be implanted with the xenografts and co-treatments of TM and NUI025, or PD 
128763 administered. 
A reduction of intracellular NAD+ concentration resulted in an increased sensiti\"ity to 
the DNA damaging agent TM, when in the presence of the PADPRP inhibitor NUI0~5. 
However, the development of TZ resistance in a human cell line would provide a better 
model for preclinical studies. In cells with a lower starting NAO- level, a 500/0 reduction 
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in NAD+ could lower the NAD+ to or below the ~ concentration, and so P ADPRP 
function would be impaired. Increased inhibition by P ADPRP inhibitors would also result 
due to the decreased level of competition. 
The possible interaction between P ADPRP and NMNA T requires futher investigation as 
the results described in Chapter 6, Section 6.7 were at a preliminary stage. NMNA T 
activity was shown to be increased 24 hours after treatment with MTIC. Howeyer, an 
increase in PADPRP activity was observed to occur within a 30 minute incubation (as 
determined by NAD+ depletion analysis, see Chapter 3, Section 3.7.1). Therefore, a 
possible interpretation could be that the upregulation of NMNAT activity was not 
attributable to PADPRP function. Coincubation with a PADPRP inhibitor in these 
experiments would provide an answer to this question. 
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Potentiation of temozolomide-induced cytotoxicity: a comparative study 
of the biological effects of poly(ADP-ribose) polymerase inhibitors 
S Boulton', LC Pemberton2, JK Porteous*, NJ Curtin', RJ Griffin,,2, BT Golding2 and 
BW Durkacz' 
'Cancer Research U~it and 2Department o/Chemistry, The University, Newcastle upon Tyne NE2 4HH, UK. 
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Summary' Four poly(ADP-ribose) polymerase (PADPRP) inhibitors [3-aminobenzamide, benzamide, 3,4-
dihydro-S-methoxyisoquinolin-l(2H)-one (PD 128763) and 8-hydroxy-2-methylquinazolin-4(3H)-one 
(NUI02S») were compared with respect to their effects on a number of biological end points. The following 
parameters were assessed: their ability to inhibit the enzyme in permeabilised Ll210 cells; their ability to 
potentiate the cytotoxicity of temozolomide (including the cytotoxicity of the compounds per se); their ability 
to increase net levels of temozolomide-induced DNA strand breaks and inhibit temozolomide-induced NAD 
depletion. PD 128763 and NUI02S were equipotent as PADPRP inhibitors, and 40- and SO-fold more potent 
than benzamide and 3-aminobenzamide respectively. All the compounds acted in a concentration-dependent 
manner to potentiate the cytotoxicity and increase DNA strand break levels in cells treated with 
temozolomide. There was an excellent correlation between the potency of the compounds as PADPRP 
inhibitors and their effects on cell survival and DNA repair. Temozolomide treatment caused a decrease in 
cellular NAD levels, and this was abolished by the PADPRP inhibitors: In conclusion, the new generation of 
PADPRP inhibitors are at least 50-fold more effective than 3-aminobenzamide as chemopotentiators, and can 
be used at micromolar rather than millimolar concentrations in intact cells. 
Keywords: poly(ADP-ribose) polymerase; temozolomide; DNA repair; NAD; 3-aminobenzamide 
, ' 
Poly(ADP-ribose) 'polymerase (PADPRP, EC 2.4.2.30) is an 
abundant chromatin-bound enzyme which is activated by 
DNA strand breaks. PADPRP function has been implicated 
in a variety of biological processes, including DNA repair 
and cellular survival following DNA damage, recombination 
and regulation of gene expression and development (for 
reviews see Boulikas, 1991; de Murcia and Menissier-de Mur-
cia, 1994). Although the role of PADPRP is best understood 
in DNA repair, this is still an area of contention regarding 
the precise molecular mechanisms involved. Two general 
mechanisms have been proposed, based on accumulated 
evidence. Poly(ADP-ribose) synthesis leads to a dramatic 
structural modification of chromatin, resulting from the 
electrostatic repulsion of the negatively charged covalently 
modified proteins (mainly PADPRP itself and hil'tones) from 
the DNA. This may allow access of repair enzymes to 
damaged sites on DNA (Althaus et 01., 1993). Alternatively, 
unmodified PADPRP binds tightly to free DNA ends, thus 
preventing further processing; upon automodification, PAD-
PRP is released from DNA, allowing gap filling and ligation 
to occur (Satoh and Lindahl, 1992). An additional function 
of poly(ADP-ribose) synthesis may be to modulate directly 
the activity or function of covalently modified acceptor pro-
teins (enzymes, transcription factors). For example, poly 
(ADP-ribosylation) of DNA polymerases, ligase and topo-
isomerase I causes inhibition of these enzymes in vitro (Ferro 
et 01., 1983; Yoshihara et 01., 1985). However, little work has 
been carried out to establish whether these proteins can act 
as acceptors in intact cells. 
A range of PADPRP inhibitors, of" which 3-amino-
benzamide (3AB) has been the most widely used,' was first 
developed by Purnell and Whish (1980). The demonstration 
that they could modulate cellular DNA repair and survival 
responses (Durkacz et 01., '1980) has led to a search for more 
potent inhibitors for use in cancer chemotherapy (Suto et 01., 
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1991; Banasik et aI., 1992). There has been a long-standing 
dispute concerning the specificity of benzamide and .its 
derivatives as PADPRP inhibitors (particularly regarding 
their effects on de novo purine synthesis), and thus about the 
interpretation of the biological data (e.g. Hunting et 01., 
1985; Moses et 01., 1990). Nevertheless, the literature span-
ning 15 years portrays a remarkable consistency regarding 
their effects. Thus, PADPRP inhibitors, at concentrations 
which are not cytotoxic per se, inhibit ADP-ribose polymer 
synthesis in intact cells (Rankin et 01., 1989). They retard the 
rejoining of DNA strand breaks and potentiate the cytotox-
icity of a range of DNA-damaging agents (e.g. Durkacz et 
01., 1980). PADPRP activation by DNA strand breaks causes 
cellular NAD depletion which is abrogated by PADPRP 
inhibitors (Durkacz" et 01., 1980): The increased levels of 
DNA strand breaks obtained in the presence of PADPRP 
inhibitors has been assumed to be a consequence of inhibi-
tion of a late stage in the repair process (e.g. ligation, 
Creissen and Shall, 1982). . 
In more recent years, this scenario of events modulated by 
PADPRP function following DNA damage has been further 
substantiated by molecular, genetic and in vitro approaches 
to PADPRP function. Mutant cell lines which are deficient in 
PADPRP activity have been isolated by a number of 
different techniques (Maclaren et 01., 1990; Chatterjee et al., 
1991; Witmer et al., 1994). These cell lines are typified by 
their hypersensitivity to monofunctional alkylating agents. 
Cell lines transfected with and overproducing the 'DNA 
binding domain' (DBD) of PADPRP, thus inhibiting 
endogenous PADPRP activation, are also hypersensitive to 
monofunctional alkylating agents, and are unable to carry 
out unscheduled DNA synthesis (Molinette et 01., 1993). 
Similar results have been obtained by reducing endogenous 
PADPRP synthesis by the use of antisense olignucleotides to 
PADPRP (Smulson et 01., 1994). Finally, elegant in vitro 
experiments using crude cell extracts which can carry out 
DNA repair have established that PADPRP, in the absence 
of substrate, blocks DNA strand breaks snd prevents subse-
quent steps leading to religation of the DNA (Satoh and 
Lindhal, 1992; Satoh et 01., 1993). 
PADPRP inhibitors have the potential to act as resistance 
modifiers ,/when used in conjunction with radiation or 
chemoth~~apeutic agents. However, very little in vivo work 
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has been carried out to assess their capacity to increase the 
therapeutic index of anti-cancer drugs, mainly because ben-
zamide and its derivatives lacked sufficient potency and were 
of low solubility. Recently, more potent PADPRP inhibitors 
have been identified (e.g. Suto et at., 1991), but limited work 
has been carried out to establish their biological efficacy. 
We have developed an evaluation system to compare can-
didate compounds with respect to their potency as PADPRP 
inhibitors and their effectiveness as chemopotentiators in 
intact cells. Two 'classical' inhibitors, benzamide (BZ) and 
3AB, have been compared with 3,4-dihydro-5-methoxyiso-
quinolin-I(2H)-one (PD 128763), developed by Warner 
Lambert (Suto et al., 1991), and 8-hydroxy-2-methyl-
quinazolin-4(3H)-one (NUl025). NU1025 was synthesised in 
the Department of Chemistry, University of Newcastle upon 
Tyne (Griffin et al., 1995), as part of an ongoing programme 
to design new PADPRP inhibitors. PD 128763 (100 mg kg-I) 
has been shown to be a highly active radiosensitiser in vivo, 
causing > 50% reduction in tumour burden in mice bearing 
subcutaneous implants of SCC7 cells (Leopold and Sebolt-
Leopold, 1992). The structures of the PADPRP inhibitors are 
shown in Figure I for comparison. 
A chemotherapeutically relevant alkylating agent, 
temozolomide (TM, see Figure 1 for structure; Stevens et aI., 
1987), which has shown promising results in phase I clinical 
trials (Newlands el al., 1992), was used in these studies. TM 
breaks down in biological milieu to. MTIC [5-(3-methyl-
triazen-I-yl)imidazole-4-carboxamide), and thence to the 
methyldiazonium ion, which directly methylates bases in 
DNA (Denny et al., 1994). 
In the body of work described here, we have used TM, in 
conjunction with the PADPRP inhibitors, to investigate the 
PADPRP-mediated repair and survival responses in murine 
leukaemia LI210 cells. The results demonstrate an excellent 
correlation between in vitro potency of the compounds as 
PADPRP inhibitors, and their ability to modulate cellular 
responses induced by DNA damage. 
Materials and methods 
Drugs and chemicals 
3AB was obtained from Pfaltz and Bauer, Phase Separations, 
Deeside, UK; BZ from Sigma, St Louis, MO, USA; TM was 
a gift from MFG Stevens, Cancer Research Laboratories, 
University of Nottingham. The methodology for the syn-
thesis of NUI025 is described elsewhere (RJ Griffin el al., 
1995). PD 128763 was a gift from WR Leopold, Parke-Davis 
Pharmaceutical Division, Warner Lambert, Ann Arbor, MI, 
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Figure I Structures of PADPRP inhibitors and temozolomide. 
USA. Stock solutions of 3AB and BZ were prepared by 
dissolving in complete medium and filter sterilising. NU 1025 
and PD 128763 were dissolved in dimethyl sulphoxide 
(DMSO) and added to cell culture at a final concentration of 
~ 1% DMSO. [32P)NAD (1000 Ci mmol- I), [methyJ-3H)TdR 
(41 Ci mmol- I) and (2-14qTdR (52 mCi mmol- I) were pur-
chased from Amersham International (Amersham, UK). 
Cell culture. growth inhibition and c/onogenic survival assays 
The murine leukaemia L1210 cell line was maintained as a 
suspension culture in RPMI-I640 medium supplemented with 
10% fetal calf serum, glutamine (2 mM) and antibiotics 
(penicillin, 100 U ml- I; streptomycin, 100 Ilg ml- I). Hepes 
and sodium bicarbonate were added at final concentrations 
of 18 mM and II mM respectively. Cell densities were 
routinely maintained between I x 104 and 8 x lOs ml- I. 
Growth inhibition experiments were used to assess the 
cytostatic effects of the compounds. Cells were seeded at 
I x 104 ml- I in triplicate in 24-well multidishes. After 24 h 
drugs were added in the combinations and at the concentra-
tions specified in the figure legends. At this time one set of 
replicates was counted using a Coulter counter (No). After 
48 h the remaining samples were counted (NJ. The percen-
tage growth inhibition of drug-treated samples was estimated 
as Nt - No (drug treated)/Nt - No (control) x 100. In drug 
combination experiments, in which evidence of synergistic 
effects on cell growth or c1onogenicity (see below) was being 
sought, the single, fixed concentration drug sample was taken 
as the control value (Nt control) in the above equation. 
Clonogenic survival assays were used to assess the cytotox-
icity of the compounds. They were performed as previously 
described (Sebolt-Leopold and Scavone, 1992), except that 
colonies were counted by eye on a gridded light box. The 
drug treatment protocols are described in the figure legends, 
and were carried out in suspension culture before plating the 
cells in agar, in the absence of drugs, to estimate survival. 
Survival and growth inhibition curves show the mean of 
three independent experiments ± s.e. Where error bars are 
not displayed in the figures, it is because they are obscured 
by the symbols. 
PADPRP assays 
PADPRP activity was measured in a permeabilised cell assay. 
LI210 cells were rendered permeable to exogenous [32p)NAD 
by exposure to hypotonic buffer and cold shock, as described 
by Halldorsson et at. (1978). In order to reveal total available 
enzyme activity, a palindromic dodecanucleotide, which 
forms a short double-stranded hairpin loop with a blunt end 
demonstrated to activate PADPRP (Grube et at., 1991), was 
included in the assay at a concentration of 20 ILg ml- I. Fol-
lowing incubation of the permeabilised cells with P2p)NAD, 
incorporation of 32p into acid precipitable counts was 
estimated. The results are expressed as percentage activity of 
the drug-treated relative to the control samples, and are the 
mean of quadruplicate samples ± s.e. 
NAD assays 
Cellular NAD levels were determined by a modification of 
the method of Nisselbaum and Green (1969). Cells were 
treated with drugs at the concentrations and for the times 
specified in the figure legends. Approximately 5 x 106 cells 
per sample were harvested at 4°C, washed once with ice-cold 
phosphate-buffered saline (PBS) and repelleted. The pellet 
was resuspended in 1.0 ml of 50% (vjv) ethanol and 
sonicated for 20 s. An aliquot was removed for protein 
estimation (Bradford, 1976), and then the suspension was 
centrifuged for 2 min in a microfuge. The supernatant liquid 
was used for NAD assays as described. Results are expressed 
as pmol NAD mg- I protein, and represent the average of 
three independent samples ± s.e. 
DNA strand break assays , 
DNA strand-break levels were assessed using the technique 
of Kohn et al. (1981). Cells were prelabelled with 
0.4 /lCi ml- I [I4C]TdR for 24 h, followed by a 6 h chase in 
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Figure 1 Effect of inhibitors on PAOPRP activity in a 
penneabilised cell assay. Results are expressed as percentage 
inhibition of enzyme activity in the presence of increasing concen-
. trations of inhibitors. (+) PO 128763; (0) NUl 025; (0) BZ; 
(£) 3AB. 
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non-radioactive medium. Cells were then exposed to drugs at 
the concentrations and for the times specified in the figure 
legends. Internal standards were similarly labelled with 
I/LCi ml- 1 [3H]TdR, exposed to 300 cGy, then loaded on the 
same filters as the drug treated samples, and eluted at 
pH 12.2. To summarise the data obtained, the results were 
expressed using the 'relative elution' (RE) formula of For-
nace and Little (1977). RE represents the amount of DNA 
from the treated samples retained on the filter as a ratio of 
control (untreated). It is calculated using (log RR..mpl.) - (log 
RR.ontrol), where RR (relative retention) is the fraction of 
sample DNA retained on the filter when 50% of the internal 
standard DNA has eluted. Points represent six replicates 
from three individual experiments ± s.e. 
Results 
PADPRP assays 
The relative potencies of the four compounds studied as 
inhibitors of PADPRP are shown in Figure 2, in which 
percentage PADPRP inhibition is plotted against compound 
concentration. The ICso values of PD 128763 and NUI025 in 
this in vitro assay were 0.36 ± 0.01 and 0.44 ± 0.13 /lM 
respectively. 3AB and BZ were more than an order of mag-
b 
100 
1~ ______ ~~ ______ ~~ 
0.0 2.5 5.0 
[Benzamide] (mM) 
d 
100 
1~ ________ ~ ________ ~ __ 
0.0 0.5 1.0 
[PO 1287631 (mM) 
Figure 3 The effect of increasing concentrations of PADPRP inhibitors alone (.) or in conjunction with a fixed (100 I'M) 
concentration of TM (0) on cell growth. (8) 3AB. (b) BZ (c) NUl 025. (d) PO 128763. 
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nitude less potent, with IC50 values of 19.1 ± 5.91lM and 
13.7 ± 6.9IlM. This approximately 50-fold decrease in the 
ICso value of PO 128763 compared with 3AB is in excellent 
agreement with the data of Suto et al. (1991). 
Growth inhibition assays 
The cytostatic effects of PAOPRP inhibitors used alone or in 
conjunction with a fixed concentration (100 IlM) of TM were 
investigated (Figure 3). Exposure of cells to TM alone caused 
inhibition of cell growth, with an ICso value of 361 ± 251lM 
(results not shown). Co-exposure of cells to 100 IlM TM with 
Table I Comparison of the ICso values of the PADPRP inhibitors 
alone or in conjunction with 100 I'M TM estimated from the growth 
inhibition experiments 
Inhibitor 
3-Aminobenzamide 
Benzamide 
NUI025 
PO 128763 
IC50 (mM) ± s.e. 
inhibitor alone 
6.7±0.2 
2.5 ± 0.3 
0.41 ± 0.06 
0.45 ± 0.01 
IC50 (mM) ± s.e. 
inhibitor + 100 I'M TM 
2.5 ± 0.1 
0.84 ± 0.12 
0.04± 0.003 
0.023 ± 0.002 
The IC50 values were derived from the smooth curve analysis of 
GraphPad Inplot. San Diego. CA. USA software and were averaged 
from at least three independent experiments ± s.e. 
a 
100 
10 
increasing concentrations of PADPRP inhibitors caused a 
synergistic increase in growth inhibition (Figure 3). Note that 
for these experiments, the growth of cells in 100 IlM TM, 
which itself reduced growth by about 26%, has been nor-
malised to 100% (see Materials and methods). The ICso 
values for the inhibitors alone or in conjunction with 100 IlM 
TM are summarised in Table I. 
Ten to 20-fold higher concentrations of PO 128763 and 
NU1025 alone were required to inhibit cell growth than were 
required when the compounds were used in conjunction with 
100 IlM TM. For example, the IC50 of NUI025 alone was 
0.41 mM, and this was reduced to 0.04 mM in the presence of 
TM. In comparison. only 2- to 3-fold differences were 
obtained with 3AB and BZ, where there was considerable 
overlap between the growth-inhibitory effects of the com-
pounds per se, and their effects in conjunction with TM. The 
potency of the compounds as PADPRP inhibitors reflected 
their effectiveness as inhibitors of cell growth, although this 
does not constitute proof that PADPRP function is essential 
for cell growth. 
Clonogenic survival assays 
It was necessary to establish that growth inhibition actually 
reflected cytotoxicity. Clonogenic survival assays were per-
formed, where cells were exposed to increasing concentra-
b 
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Figure 4 The effect of a 16 h exposure of cells to increasing concentrations of TM, in the presence or absence of fixed 
concentrations of PADPRP inhibitors, on clonogenic survival (a) ., Control; 0, + I mM 3AB; .6., + 5 mM 3AB. (b) ., control; 
0, + 1 mM BZ; .6., + 3 mM BZ. (c), ., control; 0, + 10 I'M NUl025; fl, + 50 I'M NUI025; +, + 100 I'M NUl 025. (d) •• 
control; 0, + 10 I'M PO 128763; fl, + 50 I'M PO 128763; +, + 100 I'M PO 128763. 
tions of TM for 16 h, either alone or in the presence of fixed 
concentrations of PADPRP inhibitors, before plating for 
survivors in the absence of drugs. The survival curves are 
presented in Figure 4, and the DEFIO values given in Table 
II. (DEFIO is the ratio of the concentration of TM that 
reduces survival to 10% divided by the concentration of TM 
that reduces survival to 10% in the presence of a fixed 
concentration of PADPRP inhibitor). It can be seen that 
there was a reasonable correlation between growth inhibitory 
Table II Comparison of the DEF.o values obtained for a range of 
concentrations of the PADPRP inhibitors derived from the 
clonogenic assays shown in Figure 4 
Inhibitor Concentration DEFJOG 
3-Aminobenzamide I mM 2.4± 0.3 
5mM 4.1 ± 0.4 
Benzamide I mM 4.0± 0.7 
3mM 6.9 ± 0.2 
NUl025 . 10 11M 2.0 ± 0.2 
50 11M 4.0±0.5 
100 11M 5.1 ± 0.7 
PD128763 10 11M 2.0 ± 0.1 
50 11M 6.0 ± 0.5 
100 11M .7.1±0.4 
DeflO values were calculated using the smooth curve analysis 
described in Table I. Each value represents the average ± s.e. derived 
from the averaged 10% survival for TM alone (675 ± 31 11M from 22 
independent survival curves) divided by individual 10% survival 
values from at least three independent survival curves performed in 
the presence of a fixed concentration of inhibitor. 
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Figure 5 The effect of TM and the PADPRP inhibitors on the 
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and cytotoxic effects for TM alone with an ICso value of 
361 JLM ± 25 JLM and a LDso value of 251 ± 13 JLM, respec-
tively, despite the differing exposure times (48 h for growth 
inhibition and 16 h for cytotoxicity). TM has a half-life in 
culture of about 40 min (Tsang et al., 1991), and therefore 
will exert its full effects well before the minimum duration of 
exposure of either experiment. All compounds potentiated 
the cytotoxicity of TM, but PD 128763 and NUI025 pro-
duced about the same DEFIO values at approximately 100-
fold and approximately 60-fold lower concentrations than 
3AB and BZ respectively (Table II). For example, 50 JLM 
NUI025 and 5 mM 3AB gave equivalent DEFIO values of 
approximately 4. For both PD 128763 and NUl025, max-
imal potentiation of cytotoxicity was obtained by concentra-
tions of 50-100 11M, and was significant at doses as low as 
10 I'M. 
The cytotoxic effects of the compounds alone were also 
investigated. The LDso values for a 24 h exposure were 
14 ± 1.0 mM (3AB); 6.0 ± 1.5 mM (BZ); 1.6 ± 0.1 mM 
(NU1025) and 0.99 ± 0.18 mM (PD 128763) (results not 
shown). The LDso values differed by ~ 3-fold from the ICso 
values, and again reflected their' potency as PADPRP 
inhibitors. In agreement with the growth inhibition data 
there was a ~ 10-fold difference between the concentrations 
of PD 128763 and NUl025 required to produce maximal 
potentiation of TM cytotoxicity and the concentrations 
required to produce cytotoxicity per se. 
NAD assays 
Changes in NAD levels are a convenient, albeit indirect, 
assessment of PADPRP activation in TM-treated cells. 
Figure Sa shows a time-dependent depletion of NAD levels 
following treatment with 1 or 2 mM TM. Evidence that the 
NAD depletion is mediated by PADPRP activation is shown 
in Figure 5b. A 4 h incubation with 2 mM TM caused a 50% 
decrease in cellular NAD levels, and this was abrogated in a' 
concentration-dependent manner by PD 128763 and 3AB. 
Note that 10l1M PD 128763 sufficed to prevent approx-
imately 50% of NAD drop, and that NAD depletion was 
completely prevented by 100 I'M. These data correlate with 
the concentration ranges of PD 128763 required to effect 
potentiation of cytotoxicity in the c1onogenic survival 
experiments. In contrast, at least an order of magnitude 
higher concentrations of 3AB were required to exert the same 
effects on NAD levels in TM-treated cells. 
DNA strand break assays 
The effect of the PADPRP inhibitors on DNA strand break 
levels in TM-treated cells was monitored by alkaline elution. 
A 1 h treatment with TM· resulted in a concentration-
dependent increase in the rate of elution (results not shown). 
Changes in DNA strand break levels were detectable at levels 
of TM as low as 150 11M, which reduced survival by about 
30%. All the compounds were tested for their ability to 
produce strand breaks when used alone. A 24 h incubation of 
cells with 1 mM PD 128763 or NUl025 and 20 mM 3AB or 
BZ had no effect on DNA strand-break levels compared with 
untreated cells (results not shown). 
Co-incubation of a fixed concentration of TM (150 11M) 
with increasing concentrations of all PADPRP inhibitors for 
1 h caused a progressive increase in the rate of elution com-
pared with TM alone. A specimen elution profile for the 
effect of increasing concentrations of NUI025 on TM· 
induced DNA strand break levels is shown in Figure 6. The 
results for all four compounds have been summarised by 
plotting RE values vs inhibitor concentration, and are shown 
in Figure 7. Note that the RE values for TM + inhibitor-
tre.ated cells have been calculated using TM alone controls, 
and not untreated cells. For all the compounds, the RE value 
increased linearly with increasing concentration. However, 
RE values started increasing for PD 128763 and NUl025 at 
about 100 11M, whereas concentrations above 3 mM and 5 mM 
were required to increase significantly the RE values for BZ 
853 
854 
Potentiation of temozolomide cytotoxicity 
S Boulton et al 
and 3AB respectively. Again, the potency of the compounds 
in the DNA strand break assay demonstrated an excellent 
correlation with in vitro PADPRP inhibitory potency. 
Finally, the temporal kinetics of TM-induced DNA strand-
break formation and religation was analysed, and the results 
are presented in Figure 8. In cells treated with 200 IlM TM, 
DNA strand-break levels increased rapidly up to 4 hand 
declined thereafter. By 24 h DNA strand break levels had 
returned to almost control levels. Both 3AB (5 mM) and 
NUI025 (300 IlM) increased net levels of DNA strand breaks 
over the entire time period. The time interval during which 
DNA strand break levels were highest (approximately 2-4 h) 
correlated with the reported timing of the peak levels of 
MTIC obtained in culture medium following addition of TM 
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Figure 6 DNA strand-break levels assessed by alkaline elution. 
The effect of co-incubation with increasing concentrations of 
NUl025 in cells treated with a fixed concentration (ISO IlM) of 
TM for 1 h. e, Control (untreated); ., TM alone; 0, 
TM + 0.3 mM NUl 025; , fl., TM + 0.5 mM NUl 025; C,' 
TM + 1.0 mM NUl 025. 
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Figur~ 7., The effect of increasing concentrations 'of PADPRP 
, inhibitors on DNA strand-break frequency in cells treated with 
.ISO 11M TM for 1 h. In this case RE values have been calculated 
· as a ratio of the RR values for PADPRP inhibitor-treated cells 
· over the RR value of TM-treated cells. RE values have been 
· plotted against increasing inhibitor concentration. +, PD 128763; 
0, NUl02S; C, BZ; ., 3AB. ' 
(Tsang et al., 1991). This implies that the breakdown of 
MTIC to the methyl diazonium ion, which directly alkylates 
DNA, is relatively rapid compared to the decomposition of 
TM to MTIC in culture medium. It should be emphasised 
that these data do not differentiate between enhanced 
incision or reduced ligation as a causative mechanism for the 
net increase in DNA strand break levels observed in 
inhibitor-treated cells. 
Discussion 
This is the first report of a comprehensive and quantitative 
analysis comparing the effects of a range of PADPRP 
inhibitors on PADPRP activity and on the biological end 
points associated with the cellular responses to DNA 
damage. Suto et al. (1991) and Sebolt-Leopold and Scavone 
(1992) demonstrated that PD 128763 potentiated the cytotox-
icity of ionising radiation, the monofunctional alkylating 
agent, streptozotocin, and also 2-nitroimidazole. However, 
PD 128763 was only used at a concentration of 500 IlM in 
their experiments, thereby potentially underestimating the 
potency of this compound in intact cells. Here we have 
established that maximal potentiation of TM is obtained at a 
10-fold lower concentration (50 IlM), and is significant at 
concentrations as low as 10 IlM. However, we cannot rule out 
the possibility that the concentration-dependent effects of 
PADPRP inhibitors may vary with different DNA-damaging 
agents, and in different cell lines. 
In phase I trials, following a dose of TM (200 mg m -2), 
peak plasma levels of approximately 50 11M were achieved by 
2 h (Newlands et al., 1992). These levels are of the same 
order of magnitude as the concentration (~ 100 11M) used in 
our experiments, in which potentiation of cytotoxicity by 
PADPRP inhibitors was observed. 
The new compounds are about 50-fold more potent as 
PADPRP inhibitors than 3AB and BZ, and this differential is 
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Figure 8 The effect of 200 11M TM ± PADPRP inhibitors on 
DNA strand-break levels over a 24 h time course. RE values have 
been plotted against time (8) e, 200 11M TM alone; fl., 200 IlM 
TM+5mM 3AB. (b)e, 200IlM TM alone; C, 200llM 
1M + 300 11M NUI025. Single data points' are sho~n .f~om 
representative experiments, where TM ± PADPRP mhlbltor 
treatments were carried out in parallel. ' 
maintained in intact cells' when the cellular responses to 
DNA damage known to be modulated by PADPRP function 
(Le. cytotoxicity and DNA repair) are investigated. Further-
more, there is more than an order of magnitude difference in 
the concentration of PD 128763 and NUl025 (10-50 JlM) 
. required to potentiate TM cytotoxicity compared with the 
concentrations of the compounds alone required to exert 
cytotoxic effects (~ 1 mM). In comparison, considerable over-
lap is evident in the concentrations of 3AB and BZ required 
to exert these two effects. Thus, there is a bigger gap between 
the synergistic enhancement of cytotoxicity and the indepen-
dent toxicity of the new inhibitors compared with 3AB and 
BZ, indicative of improved specificity. 
It has not escaped our notice that the data presented here 
suggest a dissociation between the effect of PADPRP 
inhibitors on cell survival and their effect on DNA strand 
break repair. For example, significant potentiation of TM 
cytotoxicity is obtained with PD 128763 at 10 JlM, and has 
reached its maximum by 50 JlM (see Figure 4). In contrast, 
PD 128763 does not affect TM-induced DNA strand break 
levels significantly until concentrations of ~ 100 JlM are 
reached (Figure 7). A plausible explanation for these obser-
vations is that PADPRP mediates not only DNA repair 
processes, but also independently modulates DNA damage-
inducible responses involved in cell survival (e.g. specific gene 
transcription, p53 stabilisation; Kastan et al., 1991). The 
difference in the concentrations of inhibitors required would 
reflect the degree of inhibition of PADPRP necessary to 
modulate these responses. A more detailed analysis of these 
observations is currently under way. 
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In conclusion, PD 128763 and NUI025 can potentiate the 
cytotoxicity of clinically relevant concentrations of TM, and 
at micromolar compared with millimolar concentrations 
required for BZ and 3AB. These are important considera-
tions if the use of these compounds as potentiators of drug-
induced cytotoxicity is to be extrapolated to the clinic. These 
data provide the groundwork for initiating in vivo studies to 
establish the ability of PADPRP inhibitors, used in conjunc-
tion with chemotherapeutic agents, to enhance tumour 
regression. 
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